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Investigating the structure of proteins and their interactions with other biomolecules or drug 
molecules, coupled with the consideration of conformational change upon binding, is 
essential to better understand their functions. Mass spectrometry (MS) is emerging as a 
powerful tool to study protein and peptide structure and interactions due to the high dynamic 
range, low sample consumption and high sensitivity of this technique, providing insight into 
the stoichiometry, intensity and stability of interactions. The hybrid technique of ion 
mobility-mass spectrometry (IM-MS) can provide insight into the conformations adopted by 
protein and peptide monomers and multimers, in addition to complexes resulting from 
interactions, which when coupled with molecular modelling can suggest candidate 
conformations for these in vacuo species and by inference their conformations in solution 
prior to ionisation and desolvation. The work presented in this thesis considers a number of 
different peptide and protein systems, highlighting how the combination of MS and IM-MS 
based techniques, in conjunction with other biophysical techniques such as circular 
dichroism (CD) spectroscopy, transmission electron microscopy (TEM) and isothermal 
titration calorimetry (ITC) can provide insight into these dynamic systems.  
First a case study into the ability of MS and IM-MS to study disorder-to-order transitions is 
presented. The transcription factor c-MYC can only perform its function upon binding with 
its binding partner MAX; deregulation of c-MYC is, however, implicated in a number of 
human cancers. c-MYC and MAX comprise intrinsically disordered regions which form a 
leucine zipper upon binding. The work presented here focuses on the leucine zipper regions 
of both c-MYC and MAX, their individual conformations and changes upon binding. 
Inhibiting the c-MYC:MAX interaction is a current target for drug therapy and hence the 
inhibition of this interaction with a previously identified small drug-like molecule was also 
examined using these techniques, to determine if such an approach may be appropriate for 
investigation of future therapeutics.  
Next the ability of MS-based techniques to preserve, transmit and distinguish between 
multiple conformations of a metamorphic protein was examined. The chemokine 
lymphotactin has been shown to exist in two distinct conformations in equilibrium in a 
ligand-free state. The existence of such metamorphic proteins has called into question 
whether traditional structural elucidation tools have been inadvertently biased towards 
consideration of single conformations. Here, the potential of gas-phase techniques in the 
study of conformationally dynamic systems is examined through the study of wild type 
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lymphotactin and a number of constructs designed either as a minimum model of fold or to 
mimic one of the distinct folds.  
Interactions between chemokines and glycosaminoglycans (GAGs) are thought to be 
essential for the in vivo activity of these proteins. The interactions between the distinctive 
chemokine lymphotactin and a model GAG were hence probed. As with the structural 
studies, additional protein constructs were considered either to represent the minimum model 
of fold, one distinct fold of the metamorphic protein or designed to diminish its GAG 
binding propensity. The ability of each construct to bind GAGs, the stoichiometry of the 
interactions and conformations adopted by the resulting complexes in addition to aggregation 
occurring upon the introduction of the GAG is considered.  
Finally, the similarities, with respect to structure and function, between the chemokine 
superfamily of proteins and the human β-defensin subfamily of antimicrobial peptides are 
considered. The tendency of human β-defensins 2 and 3 to bind a model GAG is examined; 
the stoichiometry of binding and conformations adopted and aggregation occurring here are 
















Proteins and peptides are essential components of all living organisms which carry out 
specific roles and are crucial for the correct functioning of organisms.  They are composed of 
chains of building blocks known as amino acids; there exist 20 standard natural amino acids, 
however, the sequence of amino acids varies depending on the protein or peptide. Peptides 
and proteins are distinguished based on their size with peptides being smaller, composed of 
fewer than 50 amino acids. The sequence of amino acids enables species to adopt specific 
three-dimensional folds, which can contain regions of order and disorder, and enables 
peptides and proteins to carry out their functions. Proteins are not rigid moieties and instead 
can undergo conformational changes depending on their environment or in response to 
binding with specific partners, often in order to carry out their function. In some cases, the 
so-called metamorphic proteins, proteins can even exist in multiple conformations in 
equilibrium. The study of protein and peptide conformations and conformational changes is, 
therefore, essential in order to better understand their functions.  
In order to carry out their functions proteins and peptides often have to bind other species 
such as proteins, peptides, biomolecules or ligands. The difficulty in studying such systems 
often comes from being able to differentiate between the different components in a 
heterogeneous mixture. For example, to study two peptides that can interact, one has to be 
able to clearly distinguish between the two free peptides and the complexes occurring. The 
work presented in this thesis uses a combination of techniques to study such systems which 
can distinguish different components based on their mass (using a technique known as mass 
spectrometry) and on their mass and conformation (using a technique called ion mobility-
mass spectrometry), and additional characterisation techniques where appropriate. The added 
advantage of such techniques is they require very little sample. The applicability of these 
techniques to study a variety of questions is probed. Shape-changing proteins and peptides 
are first considered to determine if these techniques could distinguish between the different 
conformations and complexes. Two peptides which exist in unstructured forms until they 
bind each other, forming a helical complex, were first studied. Next a protein known to exist 
in two distinct conformations in equilibrium, in a ligand-free state was considered.  
A number of proteins and peptides are known to interact with sugars (glycosaminoglycans) 
which are either present on the surface of cells or in a region between cells, the extracellular 
matrix. Studying the complexes between proteins/peptides and sugars can be difficult, 
however, as in the presence of glycosaminoglycans proteins/peptides can bind the sugar, 
interact with themselves forming multimers or even glycosaminoglycan bound multimers, 
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and hence can result in heterogeneous mixtures. Here, the ability of mass spectrometry to 
distinguish between the different species present, and identify complex formation, is studied 
for both proteins and peptides. Furthermore, the conformations adopted upon binding are 
determined using ion mobility-mass spectrometry, shedding light on this complicated, 
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In the field of protein science it was, until recently, generally accepted that a protein will 
possess a single unique, evolutionary constrained three-dimensional structure. However, 
numerous cases have demonstrated that proteins and peptides undergo conformational 
changes upon binding, display conformational flexibility or even adopt multiple distinct 
conformations in equilibrium. In order to study conformational plasticity in dynamic 
systems, techniques must be capable of considering multiple conformations. Mass 
spectrometry and ion mobility-mass spectrometry, in combination with other biophysical 










 Protein structure  1.1
Proteins are fundamental molecules of life which carry out numerous essential functions; 
providing structure, mediating the immune response, catalysing reactions and transporting 
small molecules, to name only a few
1
. The basic building blocks of proteins are amino acids, 
there are 20 common amino acids which differ only with respect to their side chain, the 
structures of which are shown in Appendix 1 Table A1.1. In proteins and peptides, amino 
acids form long sequences in which the peptide bond is most frequently planar and trans and 
the sequence of amino acids encodes the three-dimensional structure of the protein
2,3
.   
The secondary structure is the local structure adopted by amino acids in the protein, which is 
stabilised through hydrogen bonds between the amino- and carboxy-groups of the peptide 
bonds. Common secondary structural motifs include the α-helix, β-strand, turns and coils
4
.  
The α-helix is a right handed coil, in which each turn is ~5.4 Å and comprises 3.6 amino 
acids which orientate themselves with the side chains pointing outwards
5,6
. The amino acids 
alanine, leucine, methionine, lysine and uncharged glutamate have the highest 
α-helix-forming propensity
7
. The β-strand motif is an extended stretch of amino acids, 
typically 3-10 amino acids, with no hydrogen bonding occurring between carboxy and amino 
groups in neighbouring amino acids, however, strands can lay next to each other, in either a 
parallel or anti-parallel arrangement promoting inter-strand hydrogen bonding and 
stabilisation
3
.  In addition regions of no defined structure can be present such as random coil 
and intrinsically disordered regions
8
, composed of high numbers of polar residues including 
arginine, glycine, glutamine, glutamic acid, serine, proline and lysine
8-10
. Secondary 
structural elements can then be arranged into super secondary structural motifs including 
helix bundles, coiled-coils, β-hairpins, β-barrels or ‘jelly-roll’ topologies
3
. The tertiary or 
global fold of the protein describes all secondary and super secondary structural motifs and 
their interactions. 
For over a century a central tenant in structural biology has been that the function of a 
protein depends upon its well-defined three-dimensional structure
11
. Through the discovery 
of functional disordered proteins
12,13
 and proteins which can undergo conformational 
switching
14-16
 it is apparent that it is necessary to consider the dynamic nature of proteins, the 
possibility of conformational switching and conformational ensembles in conjunction with  
function and therefore studies have to consider conformational flexibility.  
The focus of this thesis is to study both the structure and interactions of biologically relevant 




conformations existing in equilibrium. Here a focus is placed on mass spectrometry (MS) 
and ion mobility mass spectrometry (IM-MS) techniques, assessing the information which 
can be obtained using these experimental approaches. The aim of the studies presented is to 
demonstrate the detail which can be gleaned from these techniques in addition to their 
application to ongoing research challenges. The following sections introduce the systems 
under study considering both their structure and functions (section 1.2-1.4), and the basis of 
the experimental techniques applied (section 1.5).  
 
  MYC 1.2
1.2.1 Classification and structure 
The MYC family of transcription factors contains four members; c-MYC, N-MYC, L-MYC 
and the lesser studied S-MYC. MYC proteins have been described as possessing a number of 
conserved domains including an N-terminal transactivation domain (TAD), regions known 
as MYC boxes which play important roles in binding to co-activators and transcriptional 
activation, a central region and a C-terminal domain (CTD) essential for DNA binding
17
. 
Additionally c-MYC contains a region known as the nuclear localisation signal (NLS), see 
Figure 1.1. The CTD contains a basic helix-loop-helix leucine zipper (b-HLH-Zip) domain 
which is capable of binding a similar region in the specific binding partner of MYC, 
MAX
18,19
, forming a two stranded parallel coiled-coil (Figure 1.1).  
The b-HLH-Zip motif  is particularly common in DNA binding proteins
20
 and can be thought 
of as two connected regions, firstly the basic helix-loop-helix region characterised by two 
α-helices connected by a loop, which is thought to be important for binding to DNA. The 
second region, the leucine zipper forms an extended coiled-coil, with each coil comprising a 
conserved leucine residue at every seventh position. These amino acid sequences fold into an 
α-helical arrangement where the leucine residue side chains extend out from the helix and 
form non-covalent interactions with a corresponding leucine residue on a matching helix in a 
second polypeptide chain (Figure 1.1).  The leucine zipper is further stabilised by 
electrostatic interactions and inter-helical salt bridges, which are thought to confer specificity 
to its formation
21,22
.  These regions are disordered until they bind, forming the two stranded 
parallel α-helical coiled-coil, and are thus an example of coupled folding and binding. It is 
only after interaction with its binding partner that c-MYC is then capable of carrying out its 





Figure 1.1: A) domain structure of c-MYC and MAX, B) helical wheel representation of the leucine 
zipper domain of c-MYC:MAX annotated with the classical abcdef heptad, solid arrows represent 
hydrophobic interactions, modified from reference
19
.  
Interestingly, c-MYC and MAX have also been found to exist as a antiparallel tetramer in 
the crystal structure, which, due to the low dissociation constant, is believed to also exist in 
vivo, however, the function of such a complex remains elusive
23
.   
1.2.2 Function 
The MYC family of proteins are transcription factors, proteins which bind to specific DNA 
sequences controlling information transfer from DNA to messenger RNA, regulating cell 
development, differentiation and cell growth
24
. 
In order to carry out these functions MYC has to bind its binding partner MAX; it is through 
the formation of MYC:MAX heterodimers that MYC proteins can bind to DNA and activate 
transcription
25,26
. Interactions between the b-HLH-LZ domain of MYC and proteins other 
than MAX are also thought to contribute to biological function, to a lesser extent, however, 
monomeric MYC species are inactive
25
. MYC can both activate and repress transcription 
depending on the binding partner and cellular environment
25
.  Recent reports have suggested 
that MYC can bind to ~25,000 sites in the human genome
27-29
 and hence MYC proteins are 






MYC expression is regulated through a number of external signals, including growth factors, 
extracellular matrix contacts and through internal cell cycle control
31
, and can be deregulated 
through several mechanisms which act directly or indirectly to target its expression and/or 
activity
32
. Modifications in MYC expression can result in alterations to the cell apoptotic 
pathway , uncontrolled cell proliferation, transformation or genomic instability
17
. The MYC 
proteins have hence been implicated in a wide range of aggressive human cancers from 
haematological malignancies to solid tumors and often have poor prognosis
17,33
. Oncogenic 
alterations of MYC are induced by point mutations, gene amplification and translocation, 
over-expression and enhanced translation
17




Due to the high number of different human cancers deregulated MYC is implicated in, and 
the increase in rational drug design targeting proteins involved in regulation of cell 
proliferation and/or apoptosis, MYC has become a target for novel cancer therapies. There 
are a number of reported approaches through which MYC can be targeted at different levels 
that can be employed either on their own or in combination with current cancer therapies. 
Strategies to-date include inhibition of myc gene expression at DNA and mRNA levels 
through interaction with the myc promoter and interference with transcription, inhibition of 
MYC expression, disruption of MYC:MAX dimerization, inhibition of the interaction of 
MYC with other binding partners, interference of MYC:MAX binding to DNA, inhibition of 
expression of MYC target genes, and promoting MYC protein degradation
17,36,37
.  
1.2.3 c-MYC and its implication in cancer 
Of the MYC proteins the founding member c-MYC has been implicated in cancer to the 
greatest extent and hence is the most widely studied. Furthermore, mouse models have 
shown that inactivation of c-MYC can result in tumour shrinkage with minimal side effects, 
hence c-MYC inhibitors are potential attractive targets for chemotherapy
38,39
. Targeting 
c-MYC with the aim of disrupting formation of its heterodimeric complex with MAX is 
proving particularly attractive and a number of small molecule inhibitors have been 
reported
40-42
, to-date, however, no anti-MYC drugs exist on the market.  
c-MYC is an interesting target for study from a structural point of view due to its 
conformational plasticity. Furthermore a fast, efficient and reliable method to probe the 
interaction and inhibition of c-MYC:MAX in the presence of potential drug candidates is 




view, c-MYC is an essential target for study. Chapter 3 assesses the potential of mass 
spectrometry and ion mobility mass spectrometry to study c-MYC:MAX. 
 
 Chemokines 1.3
1.3.1 Classification and structure 
Chemokines are a large subset of cytokines
43
. Cytokines are a group of signalling proteins 
which derive their name from the Greek words for cell (cyto) and movement (kinos). 
Chemokines (~8-14 kDa) are so called due to their ability to induce chemotaxis (chemically 
promoted movement). Chemokines generally contain two disulfide bonds and have been 
subdivided into four subclasses based upon the pattern of conserved cysteine residues near 
the N-terminus
44
. The CC, CXC and CX3C subclasses contain two cysteines at the 
N-terminus either side by side, separated by one or three amino acids, respectively. The final 
subclass is the C subclass and is unique in that it contains a single disulfide bond. The genes 
of the different chemokine subclasses have been found clustered in certain chromosomal 
locations. In humans CC chemokines are clustered on chromosome 17, CXC chemokines on 
chromosome 4, the gene of the sole member of the CX3C subfamily is found at chromosome 
16 and the two variants of the C subfamily are found at chromosome 1
45
. Additional minor 
clusters have also been found for CC and CXC subfamilies.  
Chemokines display low amino acid sequence homology, however, their three-dimensional 
structure is highly conserved, as shown by nuclear magnetic resonance spectroscopy (NMR) 
and X-ray crystallography
46-48
. The tertiary fold comprises an extended N-terminal loop 
(important for receptor binding), a central three stranded antiparallel β-sheet (providing a 
stable core), and a C-terminal helix which is thought to confer stability to the overall 
structure by folding over the β-sheet
49,50
. Chemokines have been reported in monomeric, 
dimeric and tetrameric forms. Notably, the dimers display conserved dimerisation motifs 
which depend upon the family to which they belong, either CC or CXC
51
. The monomeric 
form of the protein is, however, thought to be the active form for receptor binding
50
. 
Chemokines can be found in mammals, fish, birds and even some strains of virus and 
bacteria
52
. The work presented in this thesis considers human chemokines and in particular 





Chemokines and chemokine receptors have been referred to as the ‘eyes and ears of the 
immune system’
53
, guiding cells of both the innate and adaptive immune system to specific 
locations, in addition to performing other cellular migratory events involved in organ 
development, wound healing and angiogenesis
54,55
. Chemokines can be broadly classified 
into inflammatory chemokines, which are expressed in response to inflammatory stimuli, or 
homeostatic chemokines which are expressed in the absence of inflammatory stimuli or by 




Chemokines are best known for their role in immune response, where they control the 
migration and activation of leukocytes
50,58
. Chemokines function by activating specific G 
protein-coupled receptors (GPCRs), resulting in signal transduction and the migration of 
inflammatory and non-inflammatory cells to appropriate tissues or compartments
49
. Cellular 
migration results as a consequence of several signalling events and intracellular changes, for 
example cell shape change, actin polymerisation and receptor polarization have been 
implicated
59
. In the case of leukocyte migration in response to inflammation the process 
involves three stages; vascular adhesion, extravasation and chemotaxis. In vascular adhesion, 
leukocytes interact with adhesion molecules on the luminal side of blood vessels
60
. Integrin 
function is up-regulated via chemokine receptor signalling, which results in firm attachment 
of leukocytes to the blood vessel wall. This firm attachment enables leukocytes to migrate 
across the endothelium and, once in the perivascular area, leukocytes are orientated and 
directed through a chemokine gradient. Interactions with glycosaminoglycans are thought to 
play an important role in the localisation of chemokines and development of the 
concentration gradient, perhaps as a method to overcome the effects of vascular flow
61-63
. 
This will be considered in Chapter 5 of this thesis.   
There are ~50 human chemokines, which can activate 19 different transmembrane 
receptors
50
. Many chemokines of the same subfamily bind the same receptor, suggesting 
there is a redundancy to this system
45,64
. It is thought, however, that response specificity may 
be due to expression patterns of individual chemokines or that different combinations of 
activated receptors yields different biological responses
45
. Inappropriate regulation of 
chemokines is associated with a number of pathologies including inflammatory diseases, 







Lymphotactin (Ltn) is a unique chemokine for many reasons. It contains only a single 
disulfide bond and hence is the defining member of the C subclass of chemokines
67
, 
additionally Ltn contains a unique extended C-terminal region and most significantly Ltn is a 
metamorphic protein
68
. Metamorphic proteins can exist in multiple distinct conformations.  
Human Ltn has been shown to adopt two distinct folds, a monomeric and dimeric fold, in 
equilibrium under physiological conditions. The Ltn conformational equilibrium, however, is 
sensitive to changes in ionic strength and temperature which has enabled representative 




Figure 1.2: Ltn conformations, A) Ltn10 (PDB 1J9O) and B) Ltn40 (PDB 2JP1). 
The first fold to be solved was the conserved chemokine conformation consisting of three 
β-strands and an α-helix with the extended C-terminal sequence forming an intrinsically 
disordered (ID) tail. This fold is often referred to as Ltn10 as it was solved at 10 °C (Figure 
1.2). Ltn10 is thought to be responsible for activating the G protein coupled receptor XCR1. 
Interestingly, the sequence of the ID tail is similar across species, with human and mouse Ltn 
exhibiting 68 % sequence identity in the final 25 amino acids, compared with 58 % overall 
sequence identity
72,73
. The conservation of this intrinsically disordered tail implies functional 
importance, however, it has been shown to be completely dispensable for XCR1 activation
74
 
and to-date its function remains unknown. The second distinct fold of Ltn (Ltn40) is a novel 
dimer which is formed from two identical units comprising four β-strands and the ID tail 
(Figure 1.2). This form is thought to be responsible for high-affinity glycosaminoglycan 
binding and hence both forms are believed to be functionally essential in vivo
71
. 
Interconversion between the folds is reversible and involves complete restructuring of all 






Lymphotactin homologs have been found in many species including humans, mice, rats and 
chicken
76
. Ltn (also known as XCL1) can be expressed in many tissues and has been found 
in thymus, spleen, small intestine and peripheral blood lymphocytes and at lower levels in 
the lung, colon, ovary and testis
72,73,77





 T-cells and to a lesser extent through natural killer and γδ T cells
67,78,79
, and 
is known to bind XCR1 to induce T-cell and NK cell chemotaxis
67
. A gene encoding a 
highly related chemokine known as lymphotactin-β or XCL2 has been found in humans 
which differs by only two amino acids at positions seven and eight
80
. The significance of 
XCL2 and extent to which it is produced in vivo remains unknown; therefore, structural and 
functional investigations have focused on XCL1. 
Significantly, Ltn has been used in the development of novel alternative cancer therapies
81-83
 
and Ltn has been implicated in a number T-cell-mediated disease states
68
. Further structural 
and functional studies of this protein are therefore required as future development of 
inhibitors or mimics of Ltn may have therapeutic potential. Human Ltn is an excellent 
example of structural plasticity in proteins and makes an interesting target for evaluation of 
new approaches to consider multiple dynamic conformations of proteins. In Chapter 4 the 
applicability of MS and IM-MS based methods to study Ltn are assessed, and their potential 
to study future mimics or inhibitors considered. Chapter 5 focuses on the use of MS, IM-MS 
to study the interactions of this novel chemokine with other biomolecules, namely 
glycosaminoglycans. 
 
 Human β-defensins 1.4
1.4.1 Classification and structure 
Defensins are a class of small (2-6 kDa) cysteine-rich peptides, which are part of the large 
family of cationic host defence peptides
84







. Mammalian defensins contain six conserved 
cysteine residues which form three disulfide bonds, the connectivites of which can differ and  
hence these peptides are subdivided into three subfamilies (α, β and θ) based upon the 
position and connectivity of the cysteine residues
88


























. The θ-defensins are cyclic peptides which possess the same 






. Despite their differences, the defensin subfamilies are thought to share a 
common ancestry
91
, with the β-defensins being the ancestral gene. 
Genomic studies have predicted the sequences of over 30 human β-defensins (HBDs)
92
, 
however, to-date only the native peptide sequences and structures have been studied for 
HBD1, HBD2 and HBD3. Despite a low sequence homology, X-ray crystallography and 
NMR studies of HBD1-3 display notably similar tertiary folds. These comprise an 
N-terminal α-helix and three anti parallel β-strands stabilised by the three conserved 
disulfide bonds
93-96
, which is strikingly similar to the tertiary fold of β-defensins from 
different species
97,98
.  Studies have demonstrated that the majority of β-defensins exist as 
monomers in solution
94,96,97
, however, the crystal structure of HBD2 shows evidence for 
dimer and octamer formation
93
. Furthermore, HBD3 is thought to be a dimer in solution
96
; 
however, the structure is yet to be solved.  
1.4.2 Function 
Mammalian β-defensins are predominately expressed in epithelial cells and leukocytes
99
. 
The first human β-defensin (HBD1) was identified from purification of hemofiltrate
100
 but 
has subsequently been found to be expressed throughout epithelial cells in the human 
body
101
. HBD1 is expressed constitutively and is thought to act as an initial line of defence 
against microbial infection. HBD2 and HBD3 were first isolated from psoriatic scales
102,103
, 
and have since been found in numerous other tissues including the airway and oral tissue
104
. 
HBD2 has additionally been found in gastrointestinal, female reproductive tract, kidney, ear 
and eye tissues
104
. Both HBD2 and HBD3 expression is induced upon bacterial challenge 
and inflammation
105
.   
β-defensins are thought to play a role in innate and adaptive immunity
88
. The innate immune 
system is characterised by a series of non-specific mechanisms to overcome infection, and it 
is through such interactions HBDs exhibit a wide range of antibacterial, antifungal and 
antiviral activities
106,107
. HBD1 and HBD2 are potent towards Gram-negative bacteria and 
are only weakly active against Gram-positive bacteria
102
 whereas HBD3 has been shown to 
be active against both
103
. Studies have shown that HBD1 has only minor antibiotic activity, 
however, upon reduction of its disulfide bonds, potentially due to increased conformational 
freedom and a corresponding increase in available surface charges, it exhibits potent 
antimicrobial activity against the fungus Candida albicans, whilst under the same conditions 
activity of HBD3 was not improved
108,109
. Structural studies have also shown that incorrect 




against E. coli and a similar observation was made for mouse β-defensin 14
110,111
. 
Consideration of the fold and flexibility with respect to function is therefore important for 
these antimicrobial peptides.   
The mechanism by which defensins kill bacteria is complex and still under investigation. 
The first stage is thought to involve accumulation of the peptides at the microbe surface,  
facilitated through electrostatic interactions between these highly basic peptides and 
negatively-charged components of the outer bacterial cell wall
112
. The antimicrobial 
activities of both HBD1 and HBD2 are reduced by physiological salt concentrations, 
however, HBD3 antimicrobial activity is not affected by salt concentrations
103,113,114
. Salt can 
act to weaken the electrostatic attraction to the membrane, and hence the high net charge of 
HBD3 is thought to overcome the detrimental effects of salt.  
Most antimicrobial peptides kill bacteria by attacking their cell membrane and causing cell 
lysis, however, some antimicrobial peptides have been shown to permeate through the 
membrane and act upon specific targets
115
. There are two widely accepted methods by which 
antimicrobial peptides can cause lysis; the carpet and pore models
112,116-118
. In the carpet 
model peptides cover the membrane, structurally weakening it and at a critical concentration 
the membrane is broken. In the pore model peptides transverse the membrane, to form a pore 
through which the cell cytoplasm can be lost.  To-date, however, the mechanism through 
which β-defensins exert their activity has remained elusive
85
. Studies of HBD3 and S. aureus 
suggested that cell lysis was not the dominant mechanism and instead interference with the 
cell wall synthesis was thought to prevail
119,120
. Shorter peptide model systems of HBD1-3 
suggest that the peptides can interact with negatively charged lipid head groups causing 
membrane destabilisation, which can affect the efficient functioning of cytoplasmic 
membrane proteins in bacteria and results in cell death
121
. The mode of action of HBDs 
hence remains an active area of research.   
More recently β-defensins have been found to display chemotactic behaviour, recruiting 
immune cells to sites of infection through a peptide concentration gradient, and hence play a 
role in adaptive immunity
99,122
. Human β-defensins have been found to be capable of 
recruiting both T-cells and immature dendritic cells, thought to occur through interaction 
between the β-defensin and chemokine receptor-6 (CCR6)
122
. HBD3 has also been shown to 
interact with CCR2 on myeloid cells which can also result in chemoattraction
123,124
. As with 
chemokines, HBD2 has been shown to interact with glycosaminoglycans, an interaction 
which may also prove important with respect to chemotaxis
125
. Interactions with chemokine 




β-defensins and hence are areas of on-going research. Structural studies have shown that the 
connectivity of the six conserved cysteine residues, and the resulting folds, can have 
significant effects on the chemotactic activity of HBD3 through CCR6
110
. More recent 
studies have also highlighted that Cys
v
 and isoleucine/leuince at the N-terminus are essential 
for chemokine activity
126,127
.  Consideration of sequence and fold is therefore once again 
essential for understanding the biological activities of these peptides.  
Converse to their roles in the innate and adaptive immune system, HBDs have also been 
implicated in disease, which has been described as ‘the yin and yang of human 
β-defensins’
128
. Detrimental effects include promotion of tumour growth following 
over-expression of HBD3
123,129
. High levels of HBDs have also been found in psoriasis 
lesions
102,130,131
, however, these high concentrations are thought to provide a level of 
protection against incoming pathogens. Sufferers of the inflammatory skin disease atopic 




In order to better understand the myriad of functions of β-defensins, it is instructive to 
consider not only their interactions but also conformational effects upon binding. The work 
presented in Chapter 6 of this thesis aims to characterise the interactions of β-defensins with 
glycosaminoglycans using biophysical techniques, including isothermal titration calorimetry 
and transmission electron microscopy in combination with mass spectrometry and ion 
mobility mass spectrometry. 
 
 Biophysical techniques for studying protein and peptide structure 1.5
and interactions 
1.5.1 High resolution techniques for structure determination 
X-ray crystallography and NMR spectroscopy are the highest resolution techniques available 
for the study of protein structure, both of which enable detailed models of the three 
dimensional fold to be built. NMR and X-ray crystallography have undoubtedly provided 
some remarkable results
133-137
 with unparalleled resolution, however, these techniques often 
suffer due to the sheer amount of material needed, an inability to produce to high resolution 
crystals and protein aggregation. Furthermore, through the recent discovery of a number of 




has been suggested that traditional techniques have been inadvertently selecting against the 
consideration of proteins that can adopt multiple conformations
14
.  
1.5.2 Relevance of gas-phase techniques in the study of proteins and 
peptides 
Recently gas-phase techniques, including mass spectrometry (MS), ion mobility-mass 
spectrometry (IM-MS) and gas-phase infrared spectroscopy (IR) have been applied to study 
the structure and interactions of peptides and proteins. A central question regarding the use 
of gas-phase techniques to study biological molecules is to what extent, if any, these 
molecules can retain their solution or native-like folds in the gas-phase. 
It has been previously demonstrated that the mass spectrum obtained for a protein from 
electrospray ionisation (ESI) or nano-electrospray ionisation (n-ESI) is highly dependent 
upon the solution conditions and solution state of the protein prior to ionisation and 
desolvation
138-141
. The observed charge states of proteins and peptides depend upon the 
availability of ionisable sites, with multiply charged ions forming due to charge 
accumulation in the droplets. Spectra acquired from buffered ‘native-like’ conditions 
generally present lower charge states and with narrower charge state distributions than 
spectra acquired from solutions containing a high proportion of organic solvents and/or 
lower pH (denaturing conditions) which gives rise to higher charge states and a wider 
distribution of charges than the native-like species, partially due to more unfolded species 
having more available chargeable sites.  
Gas-phase studies have provided evidence for preservation of secondary structural motifs in 
proteins and peptides in the gas-phase, including α-helices
142-144
 and to a lesser extent 
β-sheets which have mainly been studied in small model peptides
145,146
.  Retention of tertiary 
folds of proteins has been supported by ion mobility-mass spectrometry (IM-MS) coupled 
with molecular dynamics simulations
147
 (section 1.5.4). In solution, protein folds can be 
stabilised through non-covalent interactions including hydrogen bonding, electrostatic 
interactions, van der Waals forces and hydrophobic interactions. A report presented by 
Breuker and McLafferty considered to what extent these interactions can be preserved in the 
gas-phase
148
, and highlighted that charged side chains can collapse on the order of 
picoseconds, hydrophobic interactions and dissociation of electrostatic interactions can occur 
over milliseconds, electrostatic interactions such as salt bridges can also strengthen or be 
formed in the solvent-free environment, following which new non-covalent interactions can 




the gas-phase depends in part upon the time ions spend in the gas-phase, which is hence a 
key consideration for structural studies using these techniques. Gas-phase techniques can be 
advantageous, however, as they provide an environment in which intrinsic and extrinsic 
factors governing protein fold and stability can be distinguished and studied.  
The soft ionisation techniques of ESI and n-ESI (see section 1.5.3.1) enable preservation of 
non-covalent complexes
149





, even very large complexes such as virus capsids
155
, as well as protein or 
peptide aggregates particularly of amyloid-forming species
156-158
, with comparison to other 
techniques providing evidence that solution states can be preserved.  Another highly 
influential study was carried out in the laboratory of Graham Cooks and showed that the 
enzymes lysozyme and trypsin could be transmitted through a mass spectrometer before 




Finally, it could also be argued that the gas-phase environment of the mass spectrometer 
where the dielectric constant is 1, is more similar to that which proteins and peptides 
experience in their cellular environment (2-6) than in a dilute aqueous solution
160
. Hence MS 
and IM-MS have promise for the study of biological molecules, enabling consideration of 
isolated molecules. A particularly attractive feature of these gas-phase techniques is that 
successful transmission of biological molecules does not depend on retention or preservation 
of a single constrained fold. Following gentle desolvation, multiple different folded, 
unfolded and partially unfolded species may all be present and selectively studied, enabling 
dynamic conformations and protein unfolding to be studied. Hence these techniques are 
particularly advantageous for the study of dynamic proteins.  
1.5.3 Biological mass spectrometry 
The foundations for mass spectrometry were laid 100 years ago, through the pioneering work 
of Thomson and Aston in the development of the mass spectrograph, as a method to study 
gas-phase atomic structure
161-163
. Since its development and the countless improvements 
made since then, MS has found widespread use across many scientific fields, including the 
analysis of proteins and peptides
164,165
.  
In brief, MS is a technique through which the mass of molecules can be determined, based 
upon the motion of a charged particle in an electric field, which in turn is centred upon the 
molecules mass to charge ratio (m/z). There exist many different types of mass spectrometer, 




introduced into a region of high vacuum where they are subjected to magnetic and/or electric 
fields; next ions are sorted according to their m/z and the abundance of each m/z is 
measured
166
.  This thesis employs the use of both quadrupole time of flight mass 
spectrometers (Q-TOF) and a Fourier transform ion cyclotron mass spectrometer 
(FT ICR-MS), hence the following sections will discuss only these types of instruments (see 
section 1.5.3.2). Detail on other instrumentation and further information on those discussed 
can be found elsewhere
167,168
.  
1.5.3.1 Ionisation methods 
The first stage of any mass spectrometry experiment involves ionising and introducing the 
sample into the mass spectrometer. The development of soft ionisation techniques such as 
matrix-assisted laser desorption ionisation (MALDI) 
169,170
 and electrospray ionisation (ESI) 
were major breakthroughs enabling the analysis of complex biomolecules such as proteins 
and peptides by MS. In MALDI species are generally co-crystallised with organic acids, 
resulting in low pHs hence for all studies reported in this thesis ESI or n-ESI were used. 
 
Figure 1.3: Schematic representation of the ESI in positive mode.  
The origins of electrospray ionisation lie with Dole et al
171-173
 who reported its use as a 
method to generate in vacuo beams of macroions. Fenn et al
174,175
 further developed this 
technique and revolutionised mass spectrometry by enabling the transfer of large 
biomolecules into the gas-phase as multiply charged ions, permitting their molecular weights 
to be determined and ‘giving wings to molecular elephants’
176
. In ESI the sample solution is 
passed through a capillary at atmospheric pressure to which a high electric potential is 
applied. ESI can produce either positive or negative ions depending on the potential applied, 
generally in the range ±2-6 kV. In this thesis ionisation was performed in positive mode in 




the sample capillary and the instrument inlet creates an electric field, causing an 
accumulation of positive charges at the liquid surface at the end of capillary, which then 
breaks to form highly charged droplets. The solution at the tip of the capillary is distorted 
into a Taylor cone, from which a fine mist of droplets is produced
177,178
, assisted by a coaxial 
flow of nitrogen. The droplets emitted experience rapid solvent evaporation, aided by a 
heated source, which causes an increase in charge density until the Rayleigh limit
179
 is 
reached, when surface tension is balanced by Coulombic repulsion. At the Rayleigh limit, 
droplets undergo fission producing smaller charged species. Repeated evaporation and 
fission events yield desolvated ions which are then accelerated into the mass spectrometer 
(Figure 1.3). 
 
Figure 1.4: Summary of ESI mechanisms; ion ejection model (IEM), charge residue model (CRM) 
and chain ejection model (CEM), modified from reference
180
. 
The mechanism occurring in the final stages of gaseous ion formation in ESI is still under 
debate; however, there exist three widely accepted models for the process (Figure 1.4)
180,181
.  
The ion evaporation model was described by Iribarne and Thomson
182
 and proposes that the 
electric field in a Rayleigh-charged nanodroplet would be suitably high to cause ejection of a 
charged analyte ion; this model is suggested to be most appropriate for ions of low molecular 
weight. The charged residue model proposed by Dole et al
171
 suggests that the Rayleigh-
charged nanodroplets which contain a single analyte evaporate to dryness, with the charge 
present on the last solvent shell being transferred to the analyte upon evaporation. The 
charged residue model is widely accepted for large globular species, such as natively folded 
proteins
183,184




polymers and unfolded proteins
185,186
. Here, the hydrophobic nature of the extended species 
makes residing within the interior of the Rayleigh-charge droplet unfavourable causing 
migration to the droplet surface where one terminus gets ejected into the vapour phase 
followed by sequential ejection of the extended chain, leading to high charge states for these 
species.  
Advances in ESI saw the development of a low flow rate version known as nano-
electrospray ionisation (n-ESI), which has the advantage of lower sample rates, hence lower 
volumes and also affords the use of lower concentrations
187,188
. n-ESI is particularly 
advantageous in biological studies where sample is often limited. In n-ESI samples are 
ionised from fine tipped glass capillaries with an internal diameter of ~0.1 mm, to which a 
voltage of ±1-2 kV is applied either via a metal coating on the capillary or through an inert 
metal wire placed within the capillary. The processes occurring in ESI and n-ESI are thought 




1.5.3.2 Mass analysers 
There are many different mass analysers which can be employed individually or in 
combination in hybrid mass spectrometers
167
.  
Quadruple mass analyser 
 
Figure 1.5: Schematic representation of the quadrupole analyser. 
A quadrupole mass analyser consists of four rods of circular or hyperbolic section, which are 




(RF) are applied to the pairs of rods, so that when one pair of rods is in-phase (e.g. positive) 
the other pair is out of phase (e.g. negative) with respect to RF potential, thus creating an 
oscillating electric field as described by Equation 1.1
167
. 
                   [1.1] 
Where,   is the potential applied to the rods, U is the DC voltage, V the zero-peak 
amplitude of the RF potential,   the angular frequency of the RF potential and t is time.  
An ion entering the quadrupole analyser will be attracted to a rod of opposite polarity, 
however, as an alternating RF potential is applied to the pairs of rods their polarity is 
constantly changing and hence if a rod changes polarity before the ion collides with it the 
ions trajectory will change. Ions therefore travel in an oscillating path (Figure 1.5), which is 
dependent on the values of U, V and ω (equal to 2πv, where v is the RF frequency). If the RF 
amplitude (V) is scanned, ions of different m/z can be transmitted through the length of the 
analyser, which is most frequently the mode of operation in MS experiments. For an ion of 
specific m/z, however, there are specific values of U, V and ω which provide a stable 
trajectory and, hence, if these variables are fixed only the ion of interest will pass through the 
quadrupole and all ions of differing m/z will collide with the rods. The quadrupole is 
operated in this mode to act as a mass filter, prior to fragmentation studies, where ions of a 
particular m/z will be transmitted into a collision cell.   
Time-of-flight analyser 
In Q-TOF instruments, after passing thorough the quadrupole and other lens present, ions 
pass into the time-of-flight (TOF) analyser. In its original linear arrangement packets of ions 
enter the analyser where they are accelerated into a field-free flight tube by a potential 
difference. Once in the field-free region their velocity is dependent on their m/z, and hence 
the time taken for an ion to travel to the detector can be used to determine the m/z of the ion, 
as shown in Equations 1.2-1.4.  
   
   
 
       [1.2] 
Where, EK is the kinetic energy of the ion, m is the mass, v is the velocity of the ion entering 













   
)    [1.4] 
The time taken (t) for an ion to travel the length of the drift tube (d) is given by Equation 1.3, 
which when combined with Equation 1.2, demonstrates how the m/z is related to the time 
taken for an ion to traverse the field-free region (Equation 1.4). 
 
Figure 1.6: Schematic representation of the time-of-flight (TOF) analyser.  
The resolution of linear TOFs are limited due to a number of factors including length of the 
drift region, variation in the initial kinetic energy of the ions as well as time and spacial 
distribution effects. In 1973 Mamyrin et al
190
 proposed the use of the reflectron to overcome 
the loss of resolution due to variations in kinetic energy. A reflectron is a series of ring 
electrodes and grids which act as an ion mirror, reflecting ions back up the flight tube. The 
reflectron TOF increases resolution by enabling small differences in kinetic energy to be 
corrected, whilst also increasing the effective drift length. A TOF is frequently coupled to 
the back end of a quadrupole analyser, creating a quadrupole time-of-flight (Q-TOF) mass 
spectrometer. Commercially available Q-TOFs can have a high mass range, which can be 
extended further through modifications
191
. The coupling of Q-TOFs with soft methods of 
ionisation has been instrumental in the study of proteins and large protein complexes
192-194
.     
 Fourier transform ion cyclotron mass spectrometer 
The principles of ion cyclotron mass spectrometry (ICR-MS) lie with the fact that the 
trajectory of ions are curved in a magnetic field; if this field is intense and the velocity of the 
ions are low, the radius of trajectory is small
167
. A balance of the centripetal and centrifugal 




described by Equation 1.5, where z is the charge, v is velocity, m is mass and B is magnetic 
field. 
    
  
 
    [1.5] 
Ions move in a circular trajectory of 2πr with a frequency (f) described by Equation 1.6, and 
the angular velocity (ω) is given by Equation 1.7. Combining Equations 1.5-1.7 it is clear ω 
is related to the m/z of the ion and hence ions of the same m/z have the same ICR frequency. 
  
 
   
     [1.6] 






     [1.7] 
Ions circulate in tight packets in a cyclotron of small radius and can then be excited at their 
resonant cyclotron frequency through a potential applied to parallel plates orthogonal to the 
magnetic field (Figure 1.7), creating a larger ion cyclotron radius. The larger radius causes 
packets of ions of the same m/z to pass close to the detector plate, creating a charge on the 
pair of electrodes which is then digitised. In order to detect ions of a range of m/z at once, a 
broadband excitation can be applied. FT ICR-MS instruments have very high resolution and 
high sensitivity and when coupled with fragmentation techniques have provided great insight 
in proteomic studies and into the post-translational modifications of proteins
195-198
, 
furthermore, coupling with labelling techniques, such as hydrogen-deuterium exchange, has 
provided insight into conformationally dynamic proteins
199
. Another advantage of FT 
ICR-MS instruments is that ions can be isolated in the cell and subjected to electron capture 
dissociation (ECD), see section 1.5.3.4. 
 





Once the beam of ions has passed through the mass analyser it is has to be detected and 
transformed into a usable signal by the detector. There are two main types of detector which 
can be used within a mass spectrometer, those that involve direct measurement of the 
charges reaching the detector and those which involve increasing the intensity of the signal.  
 Microchannel plates 
In TOF mass spectrometers microchannel plates (MCPs) are the most commonly used 
detector, MCPs are well suited to TOF instruments as they allow precise arrival times with 
narrow pulse widths to be obtained. A MCP is a plate comprising parallel channels coated in 
a semiconductor
200
. The ion input side of the detector is held at a negative potential of ~1 kV 
with respect to the output side. When an ion hits one of the semiconductor coated channels 
electrons are released, this process is continuous and results in a cascade of electrons which 





achieved for a single plate while connecting several plates together enable an amplification 
of 10
8
 to be achieved
167
. The cascade of electrons are then measured as current.  
 FT ICR detector 
As described above (section 1.5.2.2), a broad excitation frequency is applied to induce a 
larger cyclotron radius of ions of multiple m/z, which results in multiple signals being 
recorded on the detector plates at once. This signal is known as the free induction decay or 
transient and comprises a superposition of sine waves of different frequencies and 
amplitudes, depending on the ions, and is converted into useable spectra through a Fourier 
transformation.   
1.5.3.4 Electron capture dissociation 
Electron capture dissociation (ECD) is a non-ergodic method of fragmentation developed 
within the McLafferty laboratory
201
, during which bond dissociation occurs much faster than 
typical bond vibration
202
.  In ECD, low energy electrons are introduced to trapped gas-phase 
ions, producing a radical cation, [M + nH]
(n-1)+•
, which can then dissociate forming primarily 
c and z-type fragments
203
; however, b-type fragment ions have also been reported
204
 (Figure 
1.8).  ECD is used with FT ICR-MS instrumentation and offers the advantage of inducing 
more general backbone fragmentation than other methods. ECD is an attractive 
fragmentation technique which can preserve post-translation modifications
167
 and has 







Figure 1.8: Protein fragment nomenclature. 
1.5.4 Ion mobility-mass spectrometry 
Ion mobility-mass spectrometry (IM-MS) is an electrophoretic gas-phase technique, which 
allows ions to be separated based not only on their mass (m) and charge (z) as in 
conventional mass spectrometry but also on their mobility (K) in a given buffer gas, which is 
related to their size and shape. There are three main types of instrumentation which can be 
coupled with mass spectrometry; linear drift tube (DT), travelling wave ion guide (TWIG) 
and field asymmetric ion mobility (FAIMS).    
1.5.4.1 Drift tube ion mobility-mass spectrometry 
Drift tube ion mobility spectrometry (DT IMS) is the traditional and simplest ion mobility 







 investigations of the movement of ions in 
gases, following which McDaniel et al
210,211
 developed a low field drift tube in which 
gaseous ions drifted the length of the tube under the action of a weak field. These 
investigations formed the basis of DT IMS, which involves the measurement of an ion’s 
velocity through a drift region attained under an electric field gradient whilst experiencing 
collisions with a buffer gas. From this measurement it is possible to determine the 
rotationally averaged collision cross section (CCS) of the species, synonymous with its size 
and shape. An ion of larger CCS will undergo a greater number of collisions with the buffer 
gas (usually helium) and hence will travel more slowly, whilst an ion of smaller CCS will 
undergo fewer collisions and reach the end of the drift region faster.  
The behaviour of an ion travelling through a cell filled with buffer gas under the influence of 
an electric field (E) is dependent on ratio of the field strength to buffer gas number (N). At 
high values of E/N ions align in the field and their motion becomes dependent on E. At low 
values of E/N (low field) the motion of ions is more simplistic and ions possess low constant 
velocities proportional to E
212




         [1.8] 
The mobility of an ion (K) depends on its mass, charge (z) and shape, also known as the 
rotationally averaged collision cross section (Ω), and can be described by Equation 1.9, 
where µ is the reduced mass of the analyte and buffer gas, kB is the Boltzman constant, T is 
the temperature reported in Kelvin and N is the density of the buffer gas. 
  
   
   
(
  





    [1.9]  
The mobility of an ion depends upon the temperature and pressure at which the 
measurements were taken and hence it is often reported as the reduced mobility (K0), which 
accounts for temperature and pressure, as shown in Equation 1.10, enabling comparisons to 
be made at ease.  











 are standard pressure (760 torr) and temperature (273.15 K) respectively. 
In the early 1960s, the first reports of coupling ion mobility spectrometry and mass 
spectrometry creating the hybrid technique of DT IM-MS were reported
213-215
. DT IMS has 
subsequently been coupled with many different types of mass spectrometer, with the drift 
cell situated either before or after the mass analyser, the types of instrumentation and their 
subsequent applications have been reviewed elsewhere
216,217
. DT IM-MS has provided 





 and in aggregating systems
158,225,226
. The use of DT IM-MS 
instruments has traditionally been confined to research and development labs in which they 
could be built, however, in 2013 Agilent Technologies (Santa Clara, USA) introduced the 
first commercially available DT IM-MS which will surely prompt an increase in the use and 
applications of DT IM-MS.  
1.5.4.2 Travelling wave ion guide mobility mass spectrometry 
Waters (Manchester, UK) introduced the first commercially available integrated IM-MS 
instrument in 2006, the Synapt HDMS (high definition mass spectrometer) and have since 
introduced two further models. Synapt instruments use a technique known as travelling wave 
ion guide (TWIG) ion mobility, incorporating a travelling voltage wave into a RF 
guide
227,228
. In Synapt instruments, ions are first stored in a region known as the ion guide 




through an additional ion guide which transfers ions into the TOF. The mobility cell is filled 
with nitrogen buffer gas and comprises a series of planar electrodes arranged orthogonally to 
the ion beam, ions are radially confined within the cell due to an RF field applied to 
consecutive electrodes. Ions traverse the length of the cell due to a travelling wave, 
comprising a series of transient DC voltages which are superimposed on top of the RF 
voltage. Ions with the highest mobility travel on the crest of the wave whilst lower mobility 
ions will fall behind successive wave fronts before finally reaching the end of the ion guide. 
Unlike DT IM-MS, the time taken for an ion to traverse the mobility cell is not directly 
related to the CCS of that ion; however, is proportional to tD
X
, where X is an experimentally 
determined parameter dependent on instrumental settings. In order to obtain CCS using 
TWIG IM-MS one has to first measure the drift time for a calibration set of standards for 
comparison to drift times recorded previously on a DT IM-MS instrument, after which the 
CCS of the system under investigation can be calculated
229,230
. The commercial availability 
of TWIG IM-MS has provided access to a wide range of research groups and hence the 
applications of TWIG IM-MS to biological studies is varied, including the study of dynamic 
protein conformations
231
 and protein:protein complexes
153,155,232
 as well as in imaging
233
, to 
name only a few. A recent report has, however, shown that for conformational or structural 
studies careful control over instrumental parameters must be taken to avoid thermal 
unfolding of ions
234
.   
1.5.4.3 Field asymmetric ion mobility-mass spectrometry 
The final type of ion mobility instrumentation to be successfully coupled with MS is field 
asymmetric ion mobility (FAIMS). FAIMS was first reported in the late 1990s by Purves et 
al
235,236
 and here ions are passed between a pair of electrodes under the influence of an 
opposing gas flow. An asymmetric waveform is applied to the upper electrode, comprising a 
high-voltage component and a longer low-voltage component of opposite polarity, whilst the 
lower electrode is held at ground potential.  In order for ions to pass through the electrodes 
without collision, a DC ‘compensation voltage’ which reflects the difference in the high and 
low field mobility of the ion is applied, this compensation voltage can be thought of as a 
separation parameter. In FAIMS the velocity with which ions traverse the mobility region is 
not directly proportional to applied field and is instead dependent upon it. CCS cannot be 
directly determined from this IMS technique. Separation in FAIMS occurs at room 
temperature and at atmospheric pressure and hence is often coupled to the front end of a 
mass spectrometer. FAIMS devices are commercially available from Thermo Scientific (San 




collaboration with Owlstone (Cambridge, UK). The heating of ions in the high field of the 
FAIMS device makes it unsuitable for conformational studies; however, it has found use in 
the separation of complex mixtures and post-translationally modified peptides
237,238
. 
1.5.4.4 Estimation of theoretical collision cross sections 
One particularly valuable feature of IM-MS for conformational studies is that it is often 
possible to determine a theoretical CCS to compare with experimental CCS. For protein and 
peptide studies this is most frequently achieved using structures obtained from NMR, X-ray 
crystallography or molecular modelling. Structures solved by NMR and X-ray 
crystallography are available online from the Protein Data Bank (PDB) which is run by the 
Research Collaboratory for Structural Bioinformatics
239
. Most frequently, coordinates either 
from PDB files or molecular modelling are input into a Fortran program developed by 
Shvartsburg and Jarrold known as MOBCAL (a program to CALculate MOBilities)
240-242
, 
which can determine the rotationally averaged collision cross section for molecule. There are 
four different models for the ion-buffer gas collisions; projection approximation (PA), exact 
hard sphere scattering (EHSS), trajectory method (TM) and the projection superposition 
approximation (PSA) method. 
In PA, the rotationally averaged CCS is calculated considering each possible orientation of 
the molecule
243
. The ion is modelled using a collection of overlapping hard spheres, whose 
radii are equal to the hard sphere collision distances. Buffer gas collisions are also 
considered purely as hard-sphere collisions and PA does not consider multiple collision 
events or long range interactions, which simplifies this model greatly; however, CCS 
determined from PA are often significantly underestimated
244
. The EHSS is similar to the PA 
model; however, it accounts for multiple collision processes as well as scattering
240
. The 
trajectory method was further developed to consider the ion as a collection of atoms and 
accounts for long-range interactions and close collisions between the ion and the buffer gas 
atoms  as well as multiple collision events and is considered the most reliable method to 
determine CCS for large ions
241
. All theoretical CCS presented in this thesis were determined 
using the trajectory method.  The TM method is computationally expensive and can 
therefore be slow, especially for large proteins and protein complexes, which prompted the 
development of the projection superposition approximation (PSA) model. In PSA CCS are 
determined in a similar fashion to that used in PA; however, collective shape and size effects 
are accounted for
245-248
. PSA is therefore more accurate than PA, in addition to being much 




1.5.5 Circular dichroism spectroscopy  
Circular dichroism spectroscopy (CD) is a low resolution solution-phase spectroscopic 
technique, which can be used to estimate the secondary structural contents of peptides and 
proteins
249,250
. CD is based upon the differential absorption of left and right circularly 
polarised light by chiral chromophores. Proteins and peptides can contain a number of chiral 
chromophores, indeed in the far ultra violet (UV) region (280-180 nm) CD shows a number 
of characteristic features, including peptide bond absorption with a weak, broad n→π
*
 
transition (centred around 210 nm) and a more intense π →π
*
 transition (centred around 190 
nm). β-sheets, α-helices, turns and disordered regions all present distinctive spectra and 
hence the secondary structural content can be determined, using algorithms which compare 
the CD spectra obtained to structures solved by X-ray crystallography
250,251
. 
1.5.6 Transmission electron microscopy 
Transmission electron microscopy (TEM) is a method of microscopy in which a beam of 
electrons is transmitted through a thin sample. TEM has the advantage of much higher 
resolving power (defined as half the wavelength of the illuminating beam) than traditional 
microscopic techniques due to the small wavelength of the electron beam
252
. In TEM a high 
voltage is applied to a tungsten filament (the cathode) creating electrons, which are 
accelerated towards a metal plate with a central aperture (the anode), some electrons pass 
through the aperture creating the electron beam. The electron beam is subsequently focused 
by a magnetic lens before passing through the sample. The majority of electrons will pass 
through the specimen without deviation, however, some will be scattered by heavy atoms 
within the sample
252
. The scattering causes a pattern to be formed in the emerging beam, 
which is refocused and magnified by post-sample lenses and is then viewed on the detector, 
typically a fluorescent screen or charge-coupled camera. 
The higher the atomic number of the atoms within the sample, the more electrons are 
scattered and provide a higher contrast in the TEM images. As biological samples are 
generally composed of low atomic number atoms, heavy metal salts are often used as stains 
to enhance the contrast
253
. A commonly used stain for biological samples is uranyl acetate, 
which has been shown to cross-link and stabilise fragile macromolecular assemblies
253
. 
Uranyl acetate (UA) is a negative stain, meaning the stain dries around the molecules 
resulting in the area around the species of interest appearing dark whilst molecules 
themselves appear light. UA, however, can chemically react with biomolecules causing 




incredibly useful in the study of aggregating proteins
254
, particularly those which form 
amyloid fibrils
255
, afforded through the application of protein solutions to coated carbon 
grids which can be inserted into the electron microscope.   
1.5.7 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is a biophysical technique used to characterise the 
thermodynamics of binding interactions
256
. An isothermal titration calorimeter is most 
commonly based on a feedback network, which constantly measures the temperature change 
between a sample cell and a reference cell. A constant power is applied to the reference cell 
to activate the feedback loop which applies a variable power to the sample cell, in order to 
keep the temperature difference between the two cells small. If a reaction occurs within the 
sample cell, the temperature in the cell will change resulting in a change in the feedback loop 
to compensate for this, in an exothermic reaction the feedback power will decrease and in an 
endothermic reaction the feedback power will increase. Measurement of the deviation from 
baseline allows reaction characteristics to be determined. Strict controls are required to 
discount heat of change due to protein and ligand dilution and heat of mixing. 
In a typical ITC experiment to study ligand binding to a peptide or protein, a cell is filled 
with the peptide/protein solution and a syringe is filled with the ligand at a high 
concentration. The ligand is then titrated in to the cell and the calorimeter measures the heat 
flow resulting from the heat effect induced by the change in composition at constant 
temperature. ITC experiments can be used to determine the association constant (Ka), 









analysis and equations through which these can be determined can be found in Appendix 1.2. 
  Summary 1.6
MS and IM-MS based methods have great promise for the study of multiple dynamic 
conformations of proteins and peptides, overcoming some of the major challenges of 
traditional techniques. This thesis investigates the ability of MS and DT IM-MS in 
combination with other biophysical methods such as CD, TEM and ITC to study the 
structure and interactions of peptides and proteins. Firstly, conformationally dynamic 
systems are investigated considering a peptide system which undergoes a disorder-order 
transition upon binding its partner (c-MYC:MAX) and a metamorphic protein  
(lymphotactin),  (Chapters 3 and 4, respectively). The interactions occurring between a 




(Chapter 5). Finally, the interactions occurring between the model glycosaminoglycan and 
two members of the human β-defensin sub class of antimicrobial peptides are considered 
(Chapter 6). The ability of this combination of techniques to report on structure and 
interactions, and their future applicability to other dynamic systems are discussed. 
 References  1.7
(1) Buxbaum, E. Fundamentals of protein structure and function; Springer, 2007. 
(2) Pauling, L. The Nature of the Chemical Bond and the Structure of Molecules and Crystals: 
An Introduction to Modern Structural Chemistry; Cornell University Press, 1960; Vol. 18. 
(3) Fersht, A. Structure and mechanism in protein science: a guide to enzyme catalysis and 
protein folding; Macmillan, 1999. 
(4) Richardson, J. S., Adv. Protein Chem, 1981, 34, 339. 
(5) Bragg, L.; Kendrew, J. C.; Perutz, M. F., Proc. R. Soc. Lond., A, 1950, 203, 321-357. 
(6) Pauling, L.; Corey, R. B.; Branson, H. R., Proc. Natl. Acad. Sci. U. S. A., 1951, 37, 205-211. 
(7) Pace, N. C.; Scholtz, M. J., Biophys. J., 1998, 75, 422-427. 
(8) Dunker, A. K.; Lawson, J. D.; Brown, C. J.; Williams, R. M.; Romero, P.; Oh, J. S.; Oldfield, 
C. J.; Campen, A. M.; Ratliff, C. M.; Hipps, K. W.; Ausio, J.; Nissen, M. S.; Reeves, R.; Kang, C.; 
Kissinger, C. R.; Bailey, R. W.; Griswold, M. D.; Chiu, W.; Garner, E. C.; Obradovic, Z., J. Mol. 
Graph. Model., 2001, 19, 26-59. 
(9) Radivojac, P.; Iakoucheva, L. M.; Oldfield, C. J.; Obradovic, Z.; Uversky, V. N.; Dunker, A. 
K., Biophys. J., 2007, 92, 1439-1456. 
(10) Williams, R. M.; Obradovi, Z.; Mathura, V.; Braun, W.; Garner, E. C.; Young, J.; Takayama, 
S.; Brown, C. J.; Dunker, A. K., Pac. Symp. Biocomput., 2001, 89-100. 
(11) Fischer, E., Ber. Dtsch. Chem. Ges., 1894, 27, 2985-2993. 
(12) Wright, P. E.; Dyson, H. J., J. Mol. Biol., 1999, 293, 321-331. 
(13) Dyson, H. J.; Wright, P. E., Nat. Rev. Mol. Cell. Biol., 2005, 6, 197-208. 
(14) Murzin, A. G., Science, 2008, 320, 1725-1726. 
(15) Goodchild, S.; Curmi, P. G.; Brown, L., Biophys Rev, 2011, 3, 143-153. 
(16) Ha, J.-H.; Loh, S. N., Chem. Euro. J., 2012, 18, 7984-7999. 
(17) Vita, M.; Henriksson, M. In Semin Cancer Biol; Elsevier: 2006; Vol. 16, p 318-330. 
(18) Blackwood, E. M.; Eisenman, R. N., Science, 1991, 251, 1211-1217. 
(19) Lavigne, P.; Crump, M. P.; Gagne, S. M.; Hodges, R. S.; Kay, C. M.; Sykes, B. D., J. Mol. 
Biol., 1998, 281, 165-181. 
(20) Landschulz, W. H.; Johnson, P. F.; McKnight, S. L., Science, 1988, 240, 1759-1764. 
(21) Lavigne, P.; Kondejewski, L. H.; Houston Jr, M. E.; Sönnichsen, F. D.; Lix, B.; Sykes, B. D.; 
Hodges, R. S.; Kay, C. M., J. Mol. Biol., 1995, 254, 505-520. 
(22) Muhle-Goll, C.; Gibson, T.; Schuck, P.; Schubert, D.; Nalis, D.; Nilges, M.; Pastore, A., 
Biochemistry, 1994, 33, 11296-11306. 
(23) Nair, S. K.; Burley, S. K., Cell, 2003, 112, 193-205. 
(24) Pabo, C. O.; Sauer, R. T., Annu. Rev. Biochem., 1992, 61, 1053-1095. 
(25) Adhikary, S.; Eilers, M., Nat. Rev. Mol. Cell. Biol., 2005, 6, 635 - 645. 
(26) Blackwood, E. M.; Lüscher, B.; Eisenman, R. N., Genes Dev., 1992, 6, 71-80. 
(27) Li, Z.; Van Calcar, S.; Qu, C.; Cavenee, W. K.; Zhang, M. Q.; Ren, B., Proc. Natl. Acad. Sci. 
U. S. A., 2003, 100, 8164-8169. 
(28) Fernandez, P. C.; Frank, S. R.; Wang, L.; Schroeder, M.; Liu, S.; Greene, J.; Cocito, A.; 
Amati, B., Genes Dev., 2003, 17, 1115-1129. 
(29) Cawley, S.; Bekiranov, S.; Ng, H. H.; Kapranov, P.; Sekinger, E. A.; Kampa, D.; Piccolboni, 
A.; Sementchenko, V.; Cheng, J.; Williams, A. J., Cell, 2004, 116, 499-509. 
(30) Gearhart, J.; Pashos, E. E.; Prasad, M. K., N. Engl. J. Med., 2007, 357, 1469-1472. 
(31) Eisenman, R. N. The Myc/Max/Mad Transcription Factor Network; Springer, 2006; Vol. 
302. 
(32) Meyer, N.; Penn, L. Z., Nat. Rev. Cancer, 2008, 8, 976-990. 
(33) Field, J. K.; Spandidos, D., Anticancer Res., 1990, 10, 1. 




(35) Nesbit, C. E.; Tersak, J. M.; Prochownik, E. V., Oncogene, 1999, 18, 3004-3016. 
(36) Ponzielli, R.; Katz, S.; Barsyte-Lovejoy, D.; Penn, L. Z., Eur. J. Cancer, 2005, 41, 2485-
2501. 
(37) Hermeking, H., Curr. Cancer Drug Targets, 2003, 3, 163-175. 
(38) Sodir, N.; Evan, G., J. Biol., 2009, 8, 77. 
(39) Soucek, L.; Whitfield, J.; Martins, C.; Finch, A.; Murphy, D.; Sodir, N.; Karnezis, A.; 
Swigart, L.; Nasi, S.; Evan, G., Nature, 2008, 455, 679 - 683. 
(40) Hammoudeh, D. I.; Follis, A. V.; Prochownik, E. V.; Metallo, S. J., J. Am. Chem. Soc., 2009, 
131, 7390-7401. 
(41) Wang, H.; Hammoudeh, D. I.; Follis, A. V.; Reese, B. E.; Lazo, J. S.; Metallo, S. J.; 
Prochownik, E. V., Mol. Cancer Ther., 2007, 6, 2399-2408. 
(42) Wang, H.; Chauhan, J.; Hu, A.; Pendleton, K.; Yap, J. L.; Sabato, P. E.; Jones, J. W.; Perri, 
M.; Yu, J.; Cione, E., Oncotarget, 2013, 4, 936. 
(43) Baggiolini, M.; Dewald, B.; Moser, B., Annu. Rev. Immunol., 1997, 15, 675-705. 
(44) Dammann, O.; OShea, T., J. Interferon Chytokine Res., 2002, 22, 1067-1068. 
(45) Zlotnik, A.; Yoshie, O., Immunity, 2000, 12, 121-127. 
(46) Kim, K.-S.; Rajarathnam, K.; Clark-Lewis, I.; Sykes, B. D., FEBS Lett., 1996, 395, 277-282. 
(47) Mizoue, L. S.; Bazan, J. F.; Johnson, E. C.; Handel, T. M., Biochemistry, 1999, 38, 1402-
1414. 
(48) Lodi, P. J.; Garrett, D. S.; Kuszewski, J.; Tsang, M.-w.; Weatherbee, J. A.; Leonard, W. J.; 
Gronenborn, A. M.; Clore, G., Science, 1994, 263, 1762-1767. 
(49) Fernandez, E. J.; Lolis, E., Annu. Rev. Pharmacol. Toxicol., 2002, 42, 469-499. 
(50) Allen, S. J.; Crown, S. E.; Handel, T. M., Annu. Rev. Immunol., 2007, 25, 787-820. 
(51) Rollins, B. J., Blood, 1997, 90, 909-928. 
(52) Laing, K. J.; Secombes, C. J., Dev. Comp. Immunol., 2004, 28, 443-460. 
(53) Handel, T.; Hamel, D. Chemokines, Part A; Access Online via Elsevier, 2009. 
(54) Rot, A.; von Andrian, U. H., Annu. Rev. Immunol., 2004, 22, 891-928. 
(55) Luster, A. D., Curr. Opin. Imunol., 2002, 14, 129-135. 
(56) Rossi, D.; Zlotnik, A., Annu. Rev. Immunol., 2000, 18, 217-242. 
(57) Baggiolini, M.; Loetscher, P., Immunol. Today, 2000, 21, 418-420. 
(58) Baggiolini, M., Nature, 1998, 392, 565-568. 
(59) Proudfoot, A. E.; Buser, R.; Borlat, F.; Alouani, S.; Soler, D.; Offord, R. E.; Schröder, J.-M.; 
Power, C. A.; Wells, T. N., J. Biol. Chem., 1999, 274, 32478-32485. 
(60) Moser, B., Eur. Cytokine Netw., 2003, 14, 204-210. 
(61) Hoogewerf, A. J.; Kuschert, G. S.; Proudfoot, A. E.; Borlat, F.; Clark-Lewis, I.; Power, C. 
A.; Wells, T. N., Biochemistry, 1997, 36, 13570-13578. 
(62) Proudfoot, A. E. I.; Handel, T. M.; Johnson, Z.; Lau, E. K.; LiWang, P.; Clark-Lewis, I.; 
Borlat, F.; Wells, T. N. C.; Kosco-Vilbois, M. H., Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 1885-
1890. 
(63) Handel, T. M.; Johnson, Z.; Crown, S. E.; Lau, E. K.; Proudfoot, A. E., Annu. Rev. Biochem., 
2005, 74, 385-410. 
(64) Murphy, P. M.; Baggiolini, M.; Charo, I. F.; Hebert, C. A.; Horuk, R.; Matsushima, K.; 
Miller, L. H.; Oppenheim, J. J.; Power, C. A., Pharmacol. Rev., 2000, 52, 145-176. 
(65) Charo, I. F.; Taubman, M. B., Circ. Res., 2004, 95, 858-866. 
(66) Gerard, C.; Rollins, B. J., Nat. Immunol., 2001, 2, 108-115. 
(67) Kelner, G.; Kennedy, J.; Bacon, K.; Kleyensteuber, S.; Largaespada, D.; Jenkins, N.; 
Copeland, N.; Bazan, J.; Moore, K.; Schall, T., Science, 1994, 266, 1395-1399. 
(68) Volkman, B. F.; Liu, T. Y.; Peterson, F. C., Methods Enzymol., 2009, 461, 51-70. 
(69) Kuloglu, E. S.; McCaslin, D. R.; Kitabwalla, M.; Pauza, C. D.; Markley, J. L.; Volkman, B. 
F., Biochemistry, 2001, 40, 12486-12496. 
(70) Kuloglu, E. S.; McCaslin, D. R.; Markley, J. L.; Volkman, B. F., J. Biol. Chem., 2002, 277, 
17863-17870. 
(71) Tuinstra, R. L.; Peterson, F. C.; Kutlesa, S.; Elgin, E. S.; Kron, M. A.; Volkman, B. F., Proc. 
Natl. Acad. Sci. U. S. A., 2008, 105, 5057-5062. 
(72) Yoshida, T.; Imai, T.; Kakizaki, M.; Nishimura, M.; Yoshie, O., FEBS Lett., 1995, 360, 155-
159. 
(73) Kennedy, J.; Kelner, G. S.; Kleyensteuber, S.; Schall, T. J.; Weiss, M. C.; Yssel, H.; 




(74) Tuinstra, R. L.; Peterson, F. C.; Elgin, E. S.; Pelzek, A. J.; Volkman, B. F., Biochemistry, 
2007, 46, 2564-2573. 
(75) Tyler, R. C.; Murray, N. J.; Peterson, F. C.; Volkman, B. F., Biochemistry, 2011, 50, 7077-
7079. 
(76) Hedrick, J. A.; Zlotnik, A. In Methods Enzymol.; Richard, H., Ed.; Academic Press: 1997; 
Vol. Volume 287, p 206-215. 
(77) Müller, S.; Dorner, B.; Korthäuer, U.; Mages, H. W.; D'Apuzzo, M.; Senger, G.; Kroczek, R. 
A., Eur. J. Immunol., 1995, 25, 1744-1748. 
(78) Boismenu, R.; Feng, L.; Xia, Y. Y.; Chang, J.; Havran, W. L., J. Immunol., 1996, 157, 985-
992. 
(79) Tikhonov, I.; Kitabwalla, M.; Wallace, M.; Malkovsky, M.; Volkman, B.; Pauza, C. D., 
Cytokine, 2001, 16, 73-78. 
(80) Yoshida, T.; Imai, T.; Takagi, S.; Nishimura, M.; Ishikawa, I.; Yaoi, T.; Yoshie, O., FEBS 
Lett., 1996, 395, 82-88. 
(81) Dilloo, D.; Bacon, K.; Holden, W.; Zhong, W.; Burdach, S.; Zlotnik, A.; Brenner, M., Nat. 
Med., 1996, 2, 1090-1095. 
(82) Huang, H.; Bi, X.; Yuan, J.; Xu, S.; Guo, X.; Xiang, J., Gene Ther., 2005, 12, 999-1010. 
(83) Rousseau, R. F.; Haight, A. E.; Hirschmann-Jax, C.; Yvon, E. S.; Rill, D. R.; Mei, Z.; Smith, 
S. C.; Inman, S.; Cooper, K.; Alcoser, P., Blood, 2003, 101, 1718-1726. 
(84) Taylor, K.; Barran, P. E.; Dorin, J. R., Biopolymers, 2008, 90, 1-7. 
(85) Sahl, H.-G.; Pag, U.; Bonness, S.; Wagner, S.; Antcheva, N.; Tossi, A., J. Leukoc. Biol., 
2005, 77, 466-475. 
(86) Hoffmann, J. A.; Hetru, C., Immunol. Today, 1992, 13, 411-415. 
(87) Broekaert, W. F.; Terras, F.; Cammue, B.; Osborn, R. W., Plant Physiol., 1995, 108, 1353. 
(88) Raj, P. A.; Dentino, A. R., FEMS Microbiol. Lett., 2002, 206, 9-18. 
(89) Tang, Y.-Q.; Yuan, J.; Ösapay, G.; Ösapay, K.; Tran, D.; Miller, C. J.; Ouellette, A. J.; 
Selsted, M. E., Science, 1999, 286, 498-502. 
(90) Selsted, M. E., Curr. Protein. Pept. Sci., 2004, 5, 365-371. 
(91) Linzmeier, R. M.; Ganz, T., Genomics, 2005, 86, 423-430. 
(92) Schutte, B. C.; Mitros, J. P.; Bartlett, J. A.; Walters, J. D.; Jia, H. P.; Welsh, M. J.; Casavant, 
T. L.; McCray, P. B., Jr., Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 2129-2133. 
(93) Hoover, D. M.; Rajashankar, K. R.; Blumenthal, R.; Puri, A.; Oppenheim, J. J.; Chertov, O.; 
Lubkowski, J., J. Biol. Chem., 2000, 275, 32911-32918. 
(94) Sawai, M. V.; Jia, H. P.; Liu, L.; Aseyev, V.; Wiencek, J. M.; McCray, P. B.; Ganz, T.; 
Kearney, W. R.; Tack, B. F., Biochemistry, 2001, 40, 3810-3816. 
(95) Hoover, D. M.; Chertov, O.; Lubkowski, J., J. Biol. Chem., 2001, 276, 39021-39026. 
(96) Schibli, D. J.; Hunter, H. N.; Aseyev, V.; Starner, T. D.; Wiencek, J. M.; McCray, P. B., Jr.; 
Tack, B. F.; Vogel, H. J., J. Biol. Chem., 2002, 277, 8279-8289. 
(97) Bauer, F.; Schweimer, K.; Klüver, E.; Conejo-Garcia, J.-R.; Forssmann, W.-G.; Rösch, P.; 
Adermann, K.; Sticht, H., Protein Sci., 2001, 10, 2470-2479. 
(98) Landon, C.; Thouzeau, C.; Labbé, H.; Bulet, P.; Vovelle, F., J. Biol. Chem., 2004, 279, 
30433-30439. 
(99) Selsted, M. E.; Ouellette, A. J., Nat. Immunol., 2005, 6, 551-557. 
(100) Bensch, K. W.; Raida, M.; Mägert, H.-J.; Schulz-Knappe, P.; Forssmann, W.-G., FEBS Lett., 
1995, 368, 331-335. 
(101) Zhao, C.; Wang, I.; Lehrer, R. I., FEBS Lett., 1996, 396, 319-322. 
(102) Harder, J.; Bartels, J.; Christophers, E.; Schroder, J., Nature, 1997, 387, 861-861. 
(103) Harder, J.; Bartels, J.; Christophers, E.; Schröder, J.-M., J. Biol. Chem., 2001, 276, 5707-
5713. 
(104) Devine, D. A.; Hancock, R. E. W. Mammalian Host Defense Peptides; Cambridge university 
press: Cambridge, 2004. 
(105) Lehrer, R. I., Nat. Rev. Microbiol., 2004, 2, 727-738. 
(106) Ganz, T., Science, 1999, 286, 420-421. 
(107) Weinberg, A.; Krisanaprakornkit, S.; Dale, B., Crit. Rev. Oral Biol. Med., 1998, 9, 399-414. 
(108) Schroeder, B. O.; Wu, Z.; Nuding, S.; Groscurth, S.; Marcinowski, M.; Beisner, J.; Buchner, 
J.; Schaller, M.; Stange, E. F.; Wehkamp, J., Nature, 2011, 469, 419-423. 
(109) Lehrer, R. I., Nature, 2011, 469, 309-310. 




(111) Campopiano, D. J.; Clarke, D. J.; Polfer, N. C.; Barran, P. E.; Langley, R. J.; Govan, J. R. 
W.; Maxwell, A.; Dorin, J. R., J. Biol. Chem., 2004, 279, 48671-48679. 
(112) Brogden, K. A., Nat. Rev. Microbiol., 2005, 3, 238-250. 
(113) Goldman, M. J.; Anderson, G. M.; Stolzenberg, E. D.; Kari, U. P.; Zasloff, M.; Wilson, J. M., 
Cell, 1997, 88, 553-560. 
(114) Bals, R.; Wang, X.; Wu, Z.; Freeman, T.; Bafna, V.; Zasloff, M.; Wilson, J. M., J. Clin. 
Invest., 1998, 102, 874. 
(115) Shafer, W. M. Antimicrobial peptides and human disease; Springer, 2006. 
(116) Shai, Y., Trends Biochem. Sci., 1995, 20, 460-464. 
(117) Oren, Z.; Shai, Y., Eur. J. Biochem., 1996, 237, 303-310. 
(118) Oren, Z.; Shai, Y., Pept. Sci., 1998, 47, 451-463. 
(119) Sass, V.; Pag, U.; Tossi, A.; Bierbaum, G.; Sahl, H.-G., Int. J. Med. Microbiol., 2008, 298, 
619-633. 
(120) Sass, V.; Schneider, T.; Wilmes, M.; Körner, C.; Tossi, A.; Novikova, N.; Shamova, O.; 
Sahl, H.-G., Infect. Immun., 2010, 78, 2793-2800. 
(121) Krishnakumari, V.; Nagaraj, R., Biochim. Biophys. Acta. Biomembranes., 2012, 1818, 1386-
1394. 
(122) Yang, D.; Chertov, O.; Bykovskaia, S.; Chen, Q.; Buffo, M.; Shogan, J.; Anderson, M.; 
Schröder, J.; Wang, J.; Howard, O., Science, 1999, 286, 525-528. 
(123) Jin, G.; Kawsar, H. I.; Hirsch, S. A.; Zeng, C.; Jia, X.; Feng, Z.; Ghosh, S. K.; Zheng, Q. Y.; 
Zhou, A.; McIntyre, T. M., PLoS ONE, 2010, 5, e10993. 
(124) Röhrl, J.; Yang, D.; Oppenheim, J. J.; Hehlgans, T., J. Immunol., 2010, 184, 6688-6694. 
(125) Seo, E. S.; Blaum, B. S.; Vargues, T.; De Cecco, M.; Deakin, J. A.; Lyon, M.; Barran, P. E.; 
Campopiano, D. J.; Uhrin, D., Biochemistry, 2010, 49, 10486-10495. 
(126) Taylor, K.; Clarke, D. J.; McCullough, B.; Chin, W.; Seo, E.; Yang, D.; Oppenheim, J.; 
Uhrin, D.; Govan, J. R. W.; Campopiano, D. J.; MacMillan, D.; Barran, P.; Dorin, J. R., J. Biol. 
Chem., 2008, 283, 6631-6639. 
(127) Tyrrell, C.; De Cecco, M.; Reynolds, N. L.; Kilanowski, F.; Campopiano, D.; Barran, P.; 
Macmillan, D.; Dorin, J. R., Mol. Immunol., 2010, 47, 1378-1382. 
(128) Weinberg, A.; Jin, G.; Sieg, S.; McCormick, T. S., Front. Immunol., 2012, 3. 
(129) Kawsar, H. I.; Weinberg, A.; Hirsch, S. A.; Venizelos, A.; Howell, S.; Jiang, B.; Jin, G., Oral 
Oncol., 2009, 45, 696-702. 
(130) Schröder, J.-M.; Harder, J., Int. J. Biochem. Cell Biol., 1999, 31, 645-651. 
(131) Sørensen, O. E.; Thapa, D. R.; Roupé, K. M.; Valore, E. V.; Sjöbring, U.; Roberts, A. A.; 
Schmidtchen, A.; Ganz, T., J. Clin. Invest., 2006, 116, 1878-1885. 
(132) Nomura, I.; Goleva, E.; Howell, M. D.; Hamid, Q. A.; Ong, P. Y.; Hall, C. F.; Darst, M. A.; 
Gao, B.; Boguniewicz, M.; Travers, J. B., J. Immunol., 2003, 171, 3262-3269. 
(133) Dyson, H. J.; Wright, P. E., Chem. Rev., 2004, 104, 3607-3622. 
(134) Ishima, R.; Torchia, D. A., Nat. Struct. Mol. Biol., 2000, 7, 740-743. 
(135) Clore, G. M.; Gronenborn, A. M., Trends Biotechnol., 1998, 16, 22-34. 
(136) Mesters, J. Principles of protein X-ray crystallography; Springer, 2007. 
(137) Usón, I.; Sheldrick, G. M., Curr. Opin. Struct. Biol., 1999, 9, 643-648. 
(138) Chowdhury, S. K.; Katta, V.; Chait, B. T., J. Am. Chem. Soc., 1990, 112, 9012-9013. 
(139) Konermann, L.; Douglas, D. J., Biochemistry, 1997, 36, 12296-12302. 
(140) Dobo, A.; Kaltashov, I. A., Anal. Chem., 2001, 73, 4763-4773. 
(141) Kuprowski, M. C.; Konermann, L., Anal. Chem., 2007, 79, 2499-2506. 
(142) Boyarkin, O. V.; Mercier, S. R.; Kamariotis, A.; Rizzo, T. R., J. Am. Chem. Soc., 2006, 128, 
2816-2817. 
(143) Stearns, J. A.; Boyarkin, O. V.; Rizzo, T. R., J. Am. Chem. Soc., 2007, 129, 13820-13821. 
(144) Stearns, J. A.; Seaiby, C.; Boyarkin, O. V.; Rizzo, T. R., Phys. Chem. Chem. Phys., 2009, 11, 
125-132. 
(145) Pagel, K.; Kupser, P.; Bierau, F.; Polfer, N. C.; Steill, J. D.; Oomens, J.; Meijer, G.; Koksch, 
B.; von Helden, G., Int. J. Mass. Spectrom., 2009, 283, 161-168. 
(146) Dugourd, P.; Antoine, R.; Breaux, G.; Broyer, M.; Jarrold, M. F., J. Am. Chem. Soc., 2005, 
127, 4675-4679. 
(147) Jurneczko, E.; Barran, P. E., Analyst, 2011. 
(148) Breuker, K.; McLafferty, F. W., Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 18145-18152. 




(150) Pacholarz, K. J.; Garlish, R. A.; Taylor, R. J.; Barran, P. E., Chem. Soc. Rev., 2012, 41, 4335-
4355. 
(151) Kitova, E. N.; El-Hawiet, A.; Schnier, P. D.; Klassen, J. S., J. Am. Soc. Mass Spectrom., 
2012, 23, 431-441. 
(152) Hopper, J. T. S.; Oldham, N. J., J. Am. Soc. Mass Spectrom., 2009, 20, 1851-1858. 
(153) Ruotolo, B. T.; Benesch, J. L.; Sandercock, A. M.; Hyung, S.-J.; Robinson, C. V., Nat. 
Protoc., 2008, 3, 1139-1152. 
(154) Barrera, N. P.; Di Bartolo, N.; Booth, P. J.; Robinson, C. V., Science, 2008, 321, 243-246. 
(155) Uetrecht, C.; Barbu, I. M.; Shoemaker, G. K.; van Duijn, E.; Heck, A. J., Nat. Chem., 2010, 
3, 126-132. 
(156) Bleiholder, C.; Dupuis, N. F.; Wyttenbach, T.; Bowers, M. T., Nat. Chem., 2011, 3, 172-177. 
(157) Bernstein, S. L.; Wyttenbach, T.; Baumketner, A.; Shea, J.-E.; Bitan, G.; Teplow, D. B.; 
Bowers, M. T., J. Am. Chem. Soc., 2005, 127, 2075-2084. 
(158) Cole, H. L.; Kalapothakis, J. M. D.; Bennett, G.; Barran, P. E.; MacPhee, C. E., Angew. 
Chem., 2010, 122, 9638-9641. 
(159) Ouyang, Z.; Takáts, Z.; Blake, T. A.; Gologan, B.; Guymon, A. J.; Wiseman, J. M.; Oliver, J. 
C.; Davisson, V. J.; Cooks, R. G., Science, 2003, 301, 1351-1354. 
(160) Barran, P. E.; Polfer, N. C.; Campopiano, D. J.; Clarke, D. J.; Langridge-Smith, P. R. R.; 
Langley, R. J.; Govan, J. R. W.; Maxwell, A.; Dorin, J. R.; Millar, R. P.; Bowers, M. T., Int. J. Mass. 
Spectrom., 2005, 240, 273-284. 
(161) Thomson, J. J., Proc. R. Soc. Lond., A, 1913, 89, 1-20. 
(162) Aston, F. W., Philos. Mag., 1919, 38, 707-714. 
(163) Squires, G., J. Chem. Soc. Dalton Trans., 1998, 3893-3900. 
(164) Heck, A. J. R., Nat Meth, 2008, 5, 927-933. 
(165) Wysocki, V. H.; Resing, K. A.; Zhang, Q.; Cheng, G., Methods, 2005, 35, 211-222. 
(166) Dinh, G. G. a. T. V. Handbook of Spectroscopy; Wiley VCH, 2003; Vol. 1. 
(167) Edmond de Hoffmann; Stroobant, V. Mass Spectrometry: Principles and Applications; 3 ed.; 
John Wiley and Sons: Chichester, 2007. 
(168) Dass, C. Fundamentals of contemporary mass spectrometry; Wiley. com, 2007; Vol. 16. 
(169) Karas, M.; Bachmann, D.; Hillenkamp, F., Anal. Chem., 1985, 57, 2935-2939. 
(170) Tanaka, K.; Waki, H.; Ido, Y.; Akita, S.; Yoshida, Y.; Yoshida, T.; Matsuo, T., Rapid 
Commun. Mass Spectrom., 1988, 2, 151-153. 
(171) Dole, M.; Mack, L. L.; Hines, R. L.; Mobley, R. C.; Ferguson, L. D.; Alice, M. B., J. Chem. 
Phys., 1968, 49, 2240-2249. 
(172) Clegg, G.; Dole, M., Biopolymers, 1971, 10, 821-826. 
(173) Dole, M.; Cox Jr, H.; Gieniec, J., Adv. Chem. Ser, 1973, 125, 73-84. 
(174) Yamashita, M.; Fenn, J. B., J. Phys. Chem., 1984, 88, 4451-4459. 
(175) Fenn, J.; Mann, M.; Meng, C.; Wong, S.; Whitehouse, C., Science, 1989, 246, 64-71. 
(176) Fenn, J. B., Angew. Chem., 2003, 42, 3871-3894. 
(177) Kebarle, P.; Tang, L., Anal. Chem., 1993, 65, 972A-986A. 
(178) Wu, X.; Oleschuk, R. D.; Cann, N. M., Analyst, 2012, 137, 4150-4161. 
(179) Rayleigh, L., Philosophical Magazine Series 5, 1882, 14, 184-186. 
(180) Konermann, L.; Ahadi, E.; Rodriguez, A. D.; Vahidi, S., Anal. Chem., 2012, 85, 2-9. 
(181) Nguyen, S.; Fenn, J. B., Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 1111-1117. 
(182) Iribarne, J.; Thomson, B., J. Chem. Phys., 1976, 64, 2287. 
(183) Kebarle, P.; Verkerk, U. H., Mass Spectrom. Rev., 2009, 28, 898-917. 
(184) Iavarone, A. T.; Williams, E. R., J. Am. Chem. Soc., 2003, 125, 2319-2327. 
(185) Ahadi, E.; Konermann, L., J. Phys. Chem. B, 2012, 116, 104-112. 
(186) Konermann, L.; Rodriguez, A. D.; Liu, J., Anal. Chem., 2012, 84, 6798-6804. 
(187) Wilm, M. S.; Mann, M., Int. J. Mass. Spectrom. Ion. Proc., 1994, 136, 167-180. 
(188) Wilm, M.; Mann, M., Anal. Chem., 1996, 68, 1-8. 
(189) Juraschek, R.; Dülcks, T.; Karas, M., J. Am. Soc. Mass Spectrom., 1999, 10, 300-308. 
(190) Mamyrin, B.; Karataev, V.; Shmikk, D.; Zagulin, V., Zh Eksp Teor Fiz, 1973, 64, 82-89. 
(191) van den Heuvel, R. H.; van Duijn, E.; Mazon, H.; Synowsky, S. A.; Lorenzen, K.; Versluis, 
C.; Brouns, S. J.; Langridge, D.; van der Oost, J.; Hoyes, J., Anal. Chem., 2006, 78, 7473-7483. 
(192) Van Berkel, W. J. H.; Van Den Heuvel, R. H. H.; Versluis, C.; Heck, A. J. R., Protein Sci., 




(193) Benesch, J. L. P.; Ruotolo, B.; Simmons, D. A.; Robinson, C. V., Chem. Rev., 2007, 107, 
3544-3567. 
(194) Chamot-Rooke, J.; Mikaty, G.; Malosse, C.; Soyer, M.; Dumont, A.; Gault, J.; Imhaus, A.-F.; 
Martin, P.; Trellet, M.; Clary, G.; Chafey, P.; Camoin, L.; Nilges, M.; Nassif, X.; Duménil, G., 
Science, 2011, 331, 778-782. 
(195) Cooper, H. J.; Heath, J. K.; Jaffray, E.; Hay, R. T.; Lam, T. T.; Marshall, A. G., Anal. Chem., 
2004, 76, 6982-6988. 
(196) Renfrow, M. B.; Cooper, H. J.; Tomana, M.; Kulhavy, R.; Hiki, Y.; Toma, K.; Emmett, M. 
R.; Mestecky, J.; Marshall, A. G.; Novak, J., J. Biol. Chem., 2005, 280, 19136-19145. 
(197) André, M.; Le Caer, J.-P.; Greco, C.; Planchon, S.; El Nemer, W.; Boucheix, C.; Rubinstein, 
E.; Chamot-Rooke, J.; Le Naour, F., Proteomics, 2006, 6, 1437-1449. 
(198) Chamot-Rooke, J.; Rousseau, B.; Lanternier, F.; Mikaty, G.; Mairey, E.; Malosse, C.; 
Bouchoux, G.; Pelicic, V.; Camoin, L.; Nassif, X.; Duménil, G., Proc. Natl. Acad. Sci. U. S. A., 2007, 
104, 14783-14788. 
(199) Bou-Assaf, G. M.; Chamoun, J. E.; Emmett, M. R.; Fajer, P. G.; Marshall, A. G., Int. J. 
Mass. Spectrom., 2011, 302, 116-124. 
(200) Ladislas Wiza, J., Nucl. Instrum. Methods, 1979, 162, 587-601. 
(201) Zubarev, R. A.; Kelleher, N. L.; McLafferty, F. W., J. Am. Chem. Soc., 1998, 120, 3265-
3266. 
(202) Breuker, K.; Oh, H. B.; Lin, C.; Carpenter, B. K.; McLafferty, F. W., Proc. Natl. Acad. Sci. 
U. S. A., 2004, 101, 14011-14016. 
(203) Roepstorff, P.; Fohlman, J., Biomed. Mass Spectrom., 1984, 11, 601. 
(204) Cooper, H. J., J. Am. Soc. Mass Spectrom., 2005, 16, 1932-1940. 
(205) Oh, H.; Breuker, K.; Sze, S. K.; Ge, Y.; Carpenter, B. K.; McLafferty, F. W., Proc. Natl. 
Acad. Sci. U. S. A., 2002, 99, 15863-15868. 
(206) Breuker, K.; Oh, H. B.; Horn, D. M.; Cerda, B. A.; McLafferty, F. W., J. Am. Chem. Soc., 
2002, 124, 6407-6420. 
(207) Erikson, H. A., Physical Review, 1927, 30, 339-348. 
(208) Bradbury, N. E., Physical Review, 1932, 40, 508-523. 
(209) Langevin, P., Annales De Chimie Et De Physique, 1903, 28, 433-530. 
(210) Barnes, W. S.; Martin, D. W.; McDaniel, E. W., Phys. Rev. Lett., 1961, 6, 110-111. 
(211) McDaniel, E. W.; Martin, D. W.; Barnes, W. S., Rev. Sci. Instrum., 1962, 33, 2-7. 
(212) Mason, E. A.; McDaniel, E. W. Transport Properties of Ions in Gases; Wiley-VCH Verlag 
GmbH & Co. KGaA, 2005. 
(213) K. B. McAfee, J.; Edelson, D., Proc. Phys. Soc., 1963, 81, 382. 
(214) Hogg, A. M.; Kebarle, P., J. Chem. Phys., 1965, 43, 449-456. 
(215) Kebarle, P.; Hogg, A. M., J. Chem. Phys., 1965, 42, 668-674. 
(216) Kanu, A. B.; Dwivedi, P.; Tam, M.; Matz, L.; Hill, H. H., J. Mass. Spectrom., 2008, 43, 1-22. 
(217) Harvey, S. R.; MacPhee, C. E.; Barran, P. E., Methods, 2011, 54, 454-461. 
(218) Myung, S.; Badman, E. R.; Lee, Y. J.; Clemmer, D. E., J. Phys. Chem. A, 2002, 106, 9976-
9982. 
(219) Clemmer, D. E.; Hudgins, R. R.; Jarrold, M. F., J. Am. Chem. Soc., 1995, 117, 10141-10142. 
(220) Pierson, N. A.; Valentine, S. J.; Clemmer, D. E., J. Phys. Chem. B, 2010, 114, 7777-7783. 
(221) Kalapothakis, J. M. D.; Berezovskaya, Y.; Zampronio, C. G.; Faull, P. A.; Barran, P. E.; 
Cooper, H. J., Chem. Comm., 2014. 
(222) Faull, P. A.; Korkeila, K. E.; Kalapothakis, J. M.; Gray, A.; McCullough, B. J.; Barran, P. E., 
Int. J. Mass. Spectrom., 2009, 283, 140-148. 
(223) Glover, M. S.; Dilger, J. M.; Zhu, F.; Clemmer, D. E., Int. J. Mass. Spectrom., 2013, 354, 
318-325. 
(224) Grabenauer, M.; Bernstein, S. L.; Lee, J. C.; Wyttenbach, T.; Dupuis, N. F.; Gray, H. B.; 
Winkler, J. R.; Bowers, M. T., J. Phys. Chem. B, 2008, 112, 11147-11154. 
(225) Gessel, M. M.; Bernstein, S.; Kemper, M.; Teplow, D. B.; Bowers, M. T., ACS Chem. 
Neurosci., 2012. 
(226) Gessel, M. M.; Wu, C.; Li, H.; Bitan, G.; Shea, J.-E.; Bowers, M. T., Biochemistry, 2011, 51, 
108-117. 
(227) Giles, K.; Pringle, S. D.; Worthington, K. R.; Little, D.; Wildgoose, J. L.; Bateman, R. H., 




(228) Pringle, S.; Giles, K.; Wildgoose, J.; Williams, J.; Slade, S.; Thalassinos, K.; Bateman, R.; 
Bowers, M.; Scrivens, J., Int. J. Mass. Spectrom., 2007, 261, 1-12. 
(229) Ruotolo, B. T.; Benesch, J. L. P.; Sandercock, A. M.; Hyung, S.-J.; Robinson, C. V., Nat. 
Protoc., 2008, 3, 1139-1152. 
(230) Leary, J. A.; Schenauer, M. R.; Stefanescu, R.; Andaya, A.; Ruotolo, B. T.; Robinson, C. V.; 
Thalassinos, K.; Scrivens, J. H.; Sokabe, M.; Hershey, J. W. B., J. Am. Soc. Mass Spectrom., 2009, 
20, 1699-1706. 
(231) Jenner, M.; Ellis, J.; Huang, W. C.; Lloyd Raven, E.; Roberts, G. C.; Oldham, N. J., Angew. 
Chem., 2011, 50, 8291-8294. 
(232) Smith, D. P.; Radford, S. E.; Ashcroft, A. E., Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 
6794-6798. 
(233) Stauber, J.; MacAleese, L.; Franck, J.; Claude, E.; Snel, M.; Kaletas, B. K.; Wiel, I. M. V. 
D.; Wisztorski, M.; Fournier, I.; Heeren, R. M. A., J. Am. Soc. Mass Spectrom., 2010, 21, 338-347. 
(234) Merenbloom, S. I.; Flick, T. G.; Williams, E. R., J. Am. Soc. Mass Spectrom., 2012, 23, 553-
562. 
(235) Purves, R. W.; Guevremont, R.; Day, S.; Pipich, C. W.; Matyjaszczyk, M. S., Rev. Sci. 
Instrum., 1998, 69, 4094-4105. 
(236) Purves, R. W.; Guevremont, R., Anal. Chem., 1999, 71, 2346-2357. 
(237) Xuan, Y.; Creese, A. J.; Horner, J. A.; Cooper, H. J., Rapid Commun. Mass Spectrom., 2009, 
23, 1963-1969. 
(238) Saba, J.; Bonneil, E.; Pomiles, C.; Eng, K.; Thibault, P., J. Proteome Res., 2009, 8, 3355-
3366. 
(239) Berman, H.; Henrick, K.; Nakamura, H.; Markley, J. L., Nucleic Acids Res., 2007, 35, D301-
D303. 
(240) Shvartsburg, A. A.; Jarrold, M. F., Chem. Phys. Lett., 1996, 261, 86-91. 
(241) Mesleh, M. F.; Hunter, J. M.; Shvartsburg, A. A.; Schatz, G. C.; Jarrold, M. F., J. Phys. 
Chem. A, 1996, 100, 16082-16086. 
(242) Shvartsburg, A. A.; Schatz, G. C.; Jarrold, M. F., J. Chem. Phys., 1998, 108, 2416-2423. 
(243) Wyttenbach, T.; Helden, G. v.; Batka Jr, J. J.; Carlat, D.; Bowers, M. T., J. Am. Soc. Mass 
Spectrom., 1997, 8, 275-282. 
(244) Clemmer, D. E.; Jarrold, M. F., J. Mass. Spectrom., 1997, 32, 577-592. 
(245) Bleiholder, C.; Contreras, S.; Bowers, M. T., Int. J. Mass. Spectrom., 2013, 354–355, 275-
280. 
(246) Bleiholder, C.; Wyttenbach, T.; Bowers, M. T., Int. J. Mass. Spectrom., 2011, 308, 1-10. 
(247) Anderson, S. E.; Bleiholder, C.; Brocker, E. R.; Stang, P. J.; Bowers, M. T., Int. J. Mass. 
Spectrom., 2012. 
(248) Bleiholder, C.; Contreras, S.; Do, T. D.; Bowers, M. T., Int. J. Mass. Spectrom., 2013, 345–
347, 89-96. 
(249) Kelly, S. M.; Price, N. C., Curr. Protein. Pept. Sci., 2000, 1, 349-384. 
(250) Whitmore, L.; Wallace, B. A., Biopolymers, 2008, 89, 392-400. 
(251) Whitmore, L.; Wallace, B. A., Nucleic Acids Res., 2004, 32, W668-W673. 
(252) Weakley, B. S. Biological transmission electron microscopy; Second edition ed.; Churchill 
Livingstone: Edinburgh, 1981. 
(253) Jan K. G. Dhont; Gerhard Gompper; Peter R. Lang; Dieter Richter; Marisol Ripoll; Dieter 
Willbold; Zorn, R. Lecture notes of the 42nd IFF Spring School 2011; Macromolecular Systems in 
Soft and Living Matter; Forschungszentrum Julich GmbH: Julich, 2011; Vol. 20. 
(254) Cohlberg, J. A.; Li, J.; Uversky, V. N.; Fink, A. L., Biochemistry, 2002, 41, 1502-1511. 
(255) Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; 
Ramponi, G.; Dobson, C. M.; Stefani, M., Nature, 2002, 416, 507-511. 








This chapter contains descriptions of the instrumentation used for data collection, including 
typical instrumental operating conditions and schematic representations. An example of data 
acquisition and analysis for a drift tube ion mobility mass spectrometry experiment is also 













Liquid chromatography-mass spectrometry grade methanol and acetonitrile were purchased 
from Sigma Aldrich Company Ltd (Dorset, UK).  High purity water, in the resistivity range 
of 18.0-18.2 MΩ·cm, was obtained from an Arium 611 water purification system (Satorius, 
Göttingen, Germany). Ammonium acetate used for buffers and ammonia solution used for 
pH adjustment were purchased from Fisher Scientific (Loughborough, UK). Formic acid and 
hydrochloric acid used for pH adjustment were purchased from VWR International Ltd 
(Leicestershire, UK). Sodium hydroxide used for pH adjustment was purchased from Sigma 
Aldrich Company Ltd (Dorset, UK). Meta-nitrobenzyl alcohol (m-NBA) used in 
‘supercharging’ experiments was purchased from Sigma Aldrich Company Ltd (Dorset, 
UK).  Sodium iodide, used in calibration of the Q-TOF instruments was purchased from 
Sigma Aldrich Company Ltd (Dorset, UK) and prepared in 50:50 methanol:water. All 
peptide and protein sample sources and preparation are discussed in the relevant chapters. 
Solution pH measurements were taken using a Jenway 2505 pH meter (Jenway scientific 
equipment, Essex, UK), reading to 0.01 units. All sample solids were weighed to an accuracy 
of ± 0.0001 g on either a AC100 (Mettler Toledoscales, Columbus, OH, USA) or a AZ 124 
(Satorius, Göttingen, Germany) balance.   
 
 Mass Spectrometry  2.2
All mass spectrometry (MS) experiments, excluding electron capture dissociation (ECD) 
experiments (see Section 2.5), were performed on quadruple time-of-flight (Q-TOF) mass 
spectrometers using nano-electrospray ionisation (n-ESI). Two Q-TOF instruments were 
utilised for the experiments presented in the following chapters, a Q-TOF II (Figure 2.1) and 
a Q-TOF Ultima API, both manufactured by Waters (Manchester, UK). The principles and 
operation of both instruments are similar and hence will be discussed as one in the following 
sections.  
2.2.1 Nano electrospray ionisation 
Samples were ionised using n-ESI in positive ionisation mode. The n-ESI tips were made in-
house from thin-walled glass capillaries with an internal diameter of 0.5-0.9 mm (World 
Precision Instruments, Sarasota, FL, USA) using a Flaming/Brown micropipette puller 




in the range of 10-30 µm. The n-ESI tips were filled with sample using gel micro-loading 
tips (Eppendorf, Hamburg, Germany). The positive voltage required to ionise the sample was 
applied via a thin (0.125 mm diameter) platinum wire (Goodfellow, Huntingdon, UK). The 
voltage applied to the sample was typically in the range 1.2-2.0 kV, with the precise voltage 
applied depending on the sample solution composition, and often in the case of the 
glycosaminoglycan (GAG) binding studies the extent of aggregation observed. However, 
unless otherwise stated a capillary voltage of 1.6 kV was applied in all studies presented 
here. 
2.2.2 An ion’s journey in a Q-ToF: ion transfer, mass analysis and detection 
In this section the journey of the ions from generation to detection in a Q-TOF mass 
spectrometer is described, Figure 2.1 highlights all major components of the Q-TOF II.  
 
Figure 2.1: Schematic representation of the Waters Q-TOF II instrument. All major components are 
labelled and the ion path in the TOF is shown with an arrow. 
The pressure of both Q-TOF instruments used here is controlled and maintained via a 250 or 
255 L/s turbomolecular pump (Edwards, West Sussex, UK) in each of the differential 
pumping regions labelled as source, analyser and TOF in Figure 2.1. Source pumping and 
backing of the turbomolecular pumps is through two rotary pumps (Edwards, West Sussex, 




(Edwards, West Sussex, UK) placed in the source pumping line between the source block 
and backing rotary pump. This is advantageous because an elevated source pressure can aid 
desolvation of protein complexes or aggregates, such as those observed in the GAG binding 
studies (Chapters 5 and 6). The source pressure was optimised for each system studied and 
typical values for each are shown in Table 2.1.  
After generation by n-ESI, ions enter the mass spectrometer via a ‘Z-spray’ source. In this 
geometry the plume of ions formed is directed perpendicularly through the first sampling 
orifice (sample cone), and then through the second orifice (extractor cone) which is 
perpendicular to the first. The orientation of the Z-spray source allows greater sensitivity to 
be achieved, as ions, guided by decreasing voltages, enter the instrument, whilst limiting 
transmission of neutral species such as uncharged proteins and contaminants.  In order to aid 
desolvation, and hence increase transmission, the source block was held at an elevated 
temperature, 80 °C unless otherwise stated.  
Once ions have passed through the extractor cone they are then guided through an RF lens 
(transfer hexapole) to the analyser region. The typical pressure in this region was tuned for 
each system studied and is shown in Table 2.1. 





c-MYC:MAX Q-TOF II ~1.8 2.3-3.5 x 10-5 
Lymphotactin Q-TOF Ultima ~2.8-4.2 x 10-1 4.3-5.2 x 10-5 
Human β-defensins Q-TOF Ultima ~2.7-4.0 x 10-1 4.3-5.2 x 10-5 
Table 2.1: Typical source and analyser pressure ranges used for each system studied and the 
instrument used.  
Upon reaching the analyser region, the ions first pass through a quadrupole analyser, which 
can be operated in MS or MS/MS mode. In MS mode the quadrupole acts as a mass filter to 
allow all ions of a given m/z range to pass through and continue travelling the length of the 
instrument, through the hexapole collision cell and transfer lens to the TOF, whilst in 
MS/MS mode the quadrupole is used to select and isolate ions of a given m/z for subsequent 
analysis by collision induced dissociation (CID). In CID, ions of a preselected m/z are 
isolated in the quadrupole and transferred into the collision cell, which is filled with argon 
(BOC Speciality Gases Ltd, Guildford, UK). The kinetic energy with which these ions enter 
the collision cell can be increased, typically from 4-10 eV up to a maximum of 200 eV. 




Hence, increasing the kinetic energy with which ions enter the cell increases the energy of 
these collisions and facilitates ion fragmentation. After ions have exited the collision cell, 
either after fragmentation in MS/MS mode or passing straight through in MS mode, they 
travel through a final hexapole transfer lens before entering the TOF. 
Ions enter the TOF through a number of lenses designed to focus and accelerate the ion beam 
into the time-of-flight analyser. The pusher then accelerates the beam orthogonally into the 
TOF tube until it reaches the retarding field of the reflectron, where ions are refocused and 
reflected back to the microchannel plate (MCP) detector. Each ion enters the TOF with the 
same kinetic energy and hence the time an ion takes to reach the detector is proportional only 
to its m/z and inversely proportional to its velocity. The signals detected by the MCP detector 
are transferred to a 4 GHz time-to-digitial convertor (TDC) which generates a mass spectrum 
by storing the arrival times of ions in a histogram memory. The output of the TDC is then 
processed and viewed as a mass spectrum in MassLynxTM version 4.1 software, (Waters, 
Manchester, UK).  
2.2.3 Calibration 
The Q-TOF mass spectrometers were calibrated at the start of each day of experiments, 
through external mass calibration, using a calibration solution of 2 mg/mL sodium iodide 
prepared in 50:50 methanol:water. Sodium iodide solution produces a series of salt cluster 
ions of the type Nan+1In where n≥0, which span the range of m/z used throughout the 
experiments.  
2.2.4 Typical Q-ToF II Settings  
All c-MYC:MAX MS studies (Chapter 3) were performed on the Q-TOF II (Waters, 
Manchester, UK), typical operating settings of which are shown in Table 2.2. 
2.2.5 Typical Q-ToF Ultima Settings 
Ltn equilibria (Chapter 4), Ltn GAG binding (Chapter 5) studies and defensin GAG biding 
(Chapter 6) studies were performed on a Q-TOF Ultima API (Waters, Manchester, UK), the 







Instrument parameter Experimental Setting 
Capillary (kV) 1.6 - 1.8 
Cone 23 - 25 
Extractor 1 
RF Lens 0.55 
Source Temp (°C) 80 
LM Resolution 5 
HM Resolution 5 
Collision Energy 4.9 












TOF (kV) 9.1 
Reflectron 34.66 
Pusher Cycle Time (µs) 100 - 125 
Multiplier 650 
MCP 2000 
Table 2.2: Typical experimental operating settings used for all experiments performed on the 
Q-TOF II. All values are in volts unless otherwise stated. 
2.2.6 Q-TOF Ultima high-mass upgrade 
A number of modifications were made to the Q-TOF Ultima by MS Vision (Almere, 
Netherlands) to enable the more efficient transmission of high mass species.  The main 
modifications made are highlighted in this section and include an additional Speedivalve 
(SP10K, Edwards, West Sussex, UK) placed in the source backing line, enabling fine 
adjustment of the source pressure. Typical source pressure used post-modification was in the 
range 2.7-4.3 x 10-1 mbar. A pressure sleeve was fitted around the first few inches of the 
hexapole, increasing the pressure of this region, and the quadrupole mass range was 
increased to 30, 734 m/z.  The apertures on the collision cell were reduced from 2.25 mm to 
1.5 mm and the capillary supplying the collision gas was changed from one with an internal 
diameter of 75 µm to one with an internal diameter of 100 µm, the combination of these two 




typical collision cell pressure used for experiments reported here was ~2.0 x 10-2 mbar.  
Additionally, the maximum collision energy was increased from 200 eV to 400 eV. Finally, 
the TOF pusher pulse was increased from 9 to 18 µs. 
Instrument parameter Experimental Setting 




Capillary (kV) 1.6 – 1.8 1.6 
Cone 60 – 100 60 
RF Lens1 Energy 1.7 2 
Aperture 1 1 – 2.2 2 
RF Lens2 Energy 0 0 
Source Temp (°C) 80 80 
LM Resolution 5 5 
HM Resolution 5 5 
Collision Energy 10 10 
Ion Energy 1.7 1 
Steering 0 -1.1 
Entrance 75 65 
Pre-filter 5.6 4 
Transport 2.4 5 
Aperture3 15.1 15 
Acceleration 200 200 
Focus 0 0 
Tube Lens 90 60 
Offset1 -0.7 0 
Offset2 0 0 
Pusher 975 980 
TOF (kV) 9.1 9.1 
Reflectron 35.52 35 
Pusher Cycle Time (µs) 90 – 100 100 – 180 
Multiplier 650 650 
MCP 1800 – 2400 2400 
Table 2.3: Typical experimental operating settings used for all experiments performed on the Q-TOF 
Ultima API, pre and post high mass upgrade. All values are in volts unless otherwise stated.  
2.2.7 Typical Q-ToF Ultima Settings post high-mass upgrade 
A number of experiments presented in this thesis were performed post high-mass upgrade 
including experiments to study lymphotactin and glycosaminoglycan binding (see Chapter 5 
section 5.2) and a number of experiments to study the interactions of human β-defensins with 
glycosaminoglycans and each other (see Chapter 6 section 6.2). Typically instrumental 




 Ion mobility-mass spectrometry 2.3
All ion mobility experiments were performed on an in-house modified Q-TOF (Micromass 
UK Ltd, Manchester, UK), adapted in order to carry out separations based on an ion’s 
mobility, and to enable the temperature-dependent collision cross sections (CCS) to be 
determined. The Q-TOF is similar to those described in detail in section 2.2.2. The main 
modifications made to this instrument, and its operation, are described in the following 
sections. In all experiments data was acquired using positive ionisation mode via n-ESI, as 
described in section 2.2.1. For details on sample preparation for all drift tube ion mobility-
mass spectrometry (DT IM-MS) experiments please see the relevant chapters. 
2.3.1 Instrument description: drift tube ion mobility-mass spectrometer 
The main modification made to the Q-TOF instrument to enable the determination of an ions 
CCS was the inclusion of a 5.1 cm copper drift cell, and supplementary ion optics1. The drift 
cell is situated post-source, before the quadrupole analyser (Figure 2.2). For use the cell is 
filled with high purity (99.999 %) helium (BOC Speciality Gases Ltd, Guildford, UK), to a 
pressure of 3.8-4.0 Torr  at a temperature of ~300 K (27 °C).  The drift cell is situated within 
the drift chamber to which a 500 L/s TMH520 turbomolecular pump (Pfeiffer Vacuum Ltd, 
Newport Pagenll, UK) is fitted, which is backed by an dual-stage rotary pump (Edwards 
Vacuum, Crawley, UK), to address the extra load conferred by this chamber and by the 
buffer gas. The DT IM-MS instrument also contains the three 250 L/s turbomolecular pumps 
present on a standard Q-TOF; situated at the source, analyser and TOF differential pumping 
regions.  
In order to have increased control over the pressure in the source region and to allow higher 
source pressures to be achieved, the DT IM-MS instrument was modified to include a 
speedivalve (Edwards, West Sussex, UK) placed in the source pumping line between the 
source block and the backing rotary pump, and an argon inlet into the source block (Figure 
2.2). The pressure of the source was tuned for each sample, every day, to enable maximum 
ion transmission. Typical operating pressures for the DT IM-MS instrument are as follows; 
source ~1.3-4.2 x 10-1 mbar, drift chamber ~4.1-5.0 10-3 mbar, analyser ~2.0-3.1 x 10-6 mbar 





Figure 2.2: Schematic representation of the drift tube ion mobility mass spectrometer. Components of 
the Q-TOF are identical to those in Figure 2.1. 
The DT IM-MS instrument can be operated either in MS or IM-MS mode. When operated in 
MS mode, the continuous beam of ions generated by n-ESI passes into the drift cell before 
travelling through the rest of the instrument. In IM-MS mode, ions are introduced into the 
drift cell as discrete pulses to enable the separation of analytes by their mobility. In order to 
create these pulses of ions the potential on the top hat lens is raised, causing accumulation of 
ions in the pre-cell hexapole. This trapping voltage is then lowered at regular intervals, for 
40 µs, to inject a discrete pulse of ions into the drift cell.  
The pulse of ions into the drift cell is synchronised with the TOF pulse, to allow recording of 
the mobility measurements, with one pulse into the drift cell (i.e one mobility separation) 
being sampled over 200 TOF pulses. In order to synchronise these pulses the frequency at 
which ions are pulsed into the drift cell is set, dependent on the TOF pusher period, whilst 
the TOF pusher period is itself dependent on the m/z range considered and hence sample 
being studied. The TOF pusher cycle time was in the range of 90-130 µs for all experiments 
reported here. The frequency (f) of drift cell pulse is calculated by f = 1/t, where time is the 




separation (200). For example when a TOF pusher time of 130 µs is used, f = 1/(200*130 µs) 
= 38.5 Hz. This frequency is set and applied using a DG 535 digital delay/pulse generator 
(Stanford research systems, Sunnyvale, CA, USA). 
Once the pulse of ions has been introduced, ions traverse the length of the drift cell due to a 
weak, static electric field applied to the cell, known as the drift voltage. The potential of this 
drift voltage is varied over the acquisition procedure, as discussed in more detail in Sections 
2.3.2 and 2.3.3. 
Upon exiting the drift cell ions are refocused by passing through a short post-cell hexapole, 
before travelling through the rest of the instrument to be detected by the MCPs, enabling the 
output of the ion mobility experiment to be recorded; this is known as the ion arrival time 
distribution (ATD). As the drift and TOF pulses are synchronised, such that one pulse into 
the drift cell is sampled over 200 TOF pulses, this means one ATD is generated for every 
200 MS scans. A typical experiment will collect 11 ATDs and sum these to yield greater 
signal intensity. For samples with particularly low signal intensity, such as highly aggregated 
samples in GAG binding studies, 20 ATDs were acquired and summed for analysis.  
2.3.2 Typical DT IM-MS settings 
Tuning of the DT IM-MS instrument is controlled in two ways; Q-TOF mass spectrometer 
settings are controlled through a modified version of MassLynxTM version 4.1 (Waters, 
Manchester, UK), whilst the drift cell and additional ion optics are controlled by an external 
power supply. The typical operating settings as controlled by MassLynxTM for the modified 
Q-TOF used for all DT IM-MS experiments presented in the following chapters are shown in 
Table 2.4.  
As mentioned above, the DT IM-MS instrument contains additional ion optics before and 
after the drift cell (Figure 2.3), these are controlled by an external power supply constructed 
in-house. The drift voltage (i.e the difference between C1 and C2, see Figure 2.3B) is altered 
stepwise to perform measurements at different drift fields,  typically from 60 to 20 V. 
Voltages supplied to the pre and post cell lens are tuned to enable maximum transmission of 
ions.  The ranges of settings for these lenses for all experiments shown here are given in 
Table 2.5. It is important to note that C1, C2, H2 and TH2 float upon the hexapole collision 
cell voltage, set in MassLynxTM. Additionally, the pre-cell lens (H1, TH1 and L1-L3) are 





Instrument parameter Experimental settings 
Capillary (kV) 1.6 – 1.8 
Cone 35 – 120 
Extractor 130 – 110* 
RF Lens 2 – 2.43 
Source Temp (°C) 80‡ 
LM Resolution 4.4 – 5 
HM Resolution 4.3 – 5 
Collision Energy 0.9 – 4 
Ion Energy 0.5 – 2.1 
Steering (-0.64) – (-2) 
Entrance 40.8 – 49.3 
Pre-filter 5 – 8.8 
Transport 2.9 – 3 
Aperture2 3.4 – 12.6 
Acceleration 200 
Focus 0 – 3 
Tube Lens 90 – 100 
Guard 44.1 – 50.2 
TOF (kV) 7.2 
Reflectron 35 
Pusher Cycle Time (µs) 90 – 130 
Multiplier 650 
MCP 2400-3000 
Table 2.4: Typical experimental operating settings used for all experiments on the DT IM-MS 
instrument. All values are in volts unless otherwise stated. *Extractor voltage is given when the drift 
voltage is set to 60 V, during DT IM-MS acquisition extractor is lowered by the same value as the 
drift voltage. ‡ For Ltn:GAG binding studies a source temperature of 100 °C was used to aid 
desolvation of these highly aggregating systems.  
 
Figure 2.3: A) Photograph of the drift cell in the DT IM-MS instrument B) Schematic representation 
of the drift cell and lens stack, with lens labelled. H1 and H2 are the pre and post-cell hexapoles 
respectively. TH1 and TH2 are the pre and post-cell top hat lenses. Pre-cell lens (L1-L3) and post-cell 




Lens Applied voltage range / 
V 
Output voltage 
TH1 0 – 33 C1 + CV +TH1 
H1 33 – 41 C1 + CV + H1 
L1 (-1) – (-276) C1 + CV + L1 
L2 0 – (-112) C1 + CV + L2 
L3 3 – 32 C1 + CV + L3 
C1 70 – 30* C1 + CV 
C2 10 C2 + CV 
L4 0 – (-25) C2 + CV + L4 
H2 0 H2 + CV 
Table 2.5: The drift cell lens applied voltage range used in experiments presented here and the 
corresponding output voltages. *The voltage applied to C1 is altered throughout the course of the 
mobility experiments, affording the different drift voltages.  
2.3.3 The experimental workflow: an example 
In order to demonstrate the typical acquisition and analysis procedure for a DT IM-MS 
experiment an example is given here for a plant cyclotide known as kalata B1, see Figure 
2.4.  
 
Figure 2.4: Kalata B1 A) Structure solved by NMR (PDB 1JJZ), B) Cartoon representation showing 
sequence of amino acids, with disulfide bonds shown by red lines. Cyclic kalata B1 used in this study 
was prepared by the MacMillan research group using bacterial expression followed by cyclisation2. 
The first stage of any DT IM-MS experiment involves the tuning of the source pressure and 
drift cell optics for the sample of interest. This is performed with the instrument in MS mode 
and following tuning a MS spectrum is acquired for reference. Then in IM-MS mode, at a 
drift voltage of 60 V, the total arrival time distribution is collected. Typically 11 ATDs are 
collected (Figure 2.5A) and summed for analysis; however, as discussed in section 2.3.1 the 
number of ATDs collected can be increased for samples of weak intensity. The potential 
applied to C1 is then lowered, lowering the drift voltage, and the ATDs are collected again at 




60, 50, 45, 40, 35, 30, 25 and 20 V.  The temperature and pressure at the start and end of 
each acquisition is recorded. These values are then averaged and reported as the temperature 
and pressure for each drift voltage acquisition.   
 
Figure 2.5: DT IM-MS experimental workflow, an example using kalata B1. A) The 11 total ATDs 
obtained at a drift voltage of 45 V, B) The region highlighted in A magnified, to show a single total 
ATD at a drift voltage of 45 V C) Full mass spectrum of all ions arriving in the single mobility 
separation shown in B, where M represents a single Kalata B1 peptide, and D) the extracted ion ATD 
for the peak highlighted in C, at m/z 1447 at a drift voltage of 45 V.  
Using MassLynxTM version 4.1, the full mass spectrum of all ions arriving at the detector 
following a single ion mobility experiment (Figure 2.5B) can be generated by combining 
over all scans under the peak (Figure 2.5C).  The mass spectrum of cyclic oxidised peptide 
kalata B1 obtained in this way shows that this peptide exists in a number of oligomeric states 
presenting from monomeric (M) species up to pentameric (5M) species. The MassLynxTM 
software enables an extracted ion ATD to be obtained for each peak in the mass spectrum, 
achieved by combining over the m/z range of interest. For the purpose of this example 
analysis will focus on the peak at m/z 1447, which could be due to two mass-coincident 
species namely the [M+2H]2+ and [2M+4H]4+. The dimeric species [2M+4H]4+ has double 




monomeric species, [M+2H]2+. The extracted ion ATD of the peak at m/z 1447 (Figure 2.5D) 
does indeed show two distinct peaks, indicating the presence of two species.  
In an extracted ion ATD the presence of two peaks can be due to either species of the same 
m/z but of different oligomeric orders or the presence of multiple conformations, both of 
which can be separated out based on their mobility. These two phenomena can be 
distinguished from each other by considering the relative ratio of the two species in the 
extracted ion ATD at multiple drift voltages. The relative ratio between the two can remain 
constant, suggesting it is two conformers of a species. Alternatively, the relative ratio may 
change with drift voltage with the earlier arriving conformer increasing in relative intensity 
with decreasing drift voltage, which suggests that the two species are due to ions of differing 
oligomeric orders.  In this case the increase in the relative proportion of the higher order 
oligomer is due to the fact that it is more highly charged, with higher charged species being 
better focused by the confining voltages applied and less susceptible to radial diffusion. 
These effects become more pronounced at lower drift voltages as ions spend longer 
travelling the length of the drift cell, due to the decreased electric potential. In the case of the 
ion at m/z 1447 for kalata B1, these two species are due to a monomeric and dimeric species, 
as determined from the extracted ion ATDs over the eight drift voltages and from the mass 
spectrum, in which we can clearly see the presence of dimeric species, namely the 
[2M+3H]3+ species at m/z 1929.  
Once the extracted ion ATDs are generated, the intensity is summed over the total number of 
pulses in a Microsoft Excel (Microsoft, Redmond, WA, USA) spreadsheet.  The summed 
extracted ion ATDs are then input into Origin 8.5.1 or Origin 9 (OriginLab, Northampton, 
MA, USA), which is used to determine the average arrival scan number. Peaks in the ATD 
were fitted using an iterative Gaussian function in Origin (Figure 2.6A), which considers the 
following parameters; peak centre, width, area and y-offset. In all cases a y-offset of zero 
was applied and all other parameters were determined through iterative fitting for each 
extracted ion ATD, at each drift voltage. The Gaussian function enables the centre of the 
peak to be determined, which is used as the average scan number for each discrete peak.  
The same procedure is applied to extracted ion ATDs containing only a single resolvable 
conformational family, in this case with only one Guassian peak being considered and its 
centre used as the average scan number. The number of conformational families and hence 
number of peaks fitted for each ATD was determined by first visually considering the ATD 
at each drift voltage, in addition to attention to the quality of fit in all cases where an R
2
 




time ions spend traveling in the drift region increases and hence distinct conformational 
families or oligomers can become resolvable; presenting either as distinct peaks,  shoulders 
or tails. If multiple conformational families are observed and an average arrival scan number 
determined over five or more drift voltages then the CCS is reported. In cases where multiple 
conformational families are observed, but not resolvable, the presence of an additional 
conformational family is noted and reported, however, CCS cannot be accurately 
determined. For all samples studied in this thesis, where multiple conformations were 
observed, both species were clearly resolvable in one or more repeats and such species are 
clearly identified in the relevant Chapters and Appendices.   
In all cases the minimum number of peaks to obtain a fit of good quality, were considered. It 
is important to note that due to the resolution of the instrument in some cases similar 
conformational families will not be resolvable, in such cases the width of the ATD also 
provides information on the conformational diversity of the species of interest. A protein 
may exist in a wide range of similar conformations which, if there is a small variance in the 
different CCS, may not be resolvable on this instrumentation. The width of the ATD is 
therefore considered for each protein over all charge states and drift voltages, as a measure 
of conformational diversity. For all samples studied in this thesis, the width of the ATD 
either indicated a single conformational family, in which case a single average CCS is 
reported for each charge state; or multiple resolvable conformations, in which case the CCS 
of each conformational family is reported.  
 
Figure 2.6: DT IM-MS analysis for cyclic oxidised kalata b1 peak at m/z 1447 A) Extracted ion ATD 
at drift voltage of 45 V, peaks fitted using the Guassian function in Origin 9 with average scan number 
as determined from the centre of each peak labelled. B) Plot of arrival time versus P/V for each of the 
eight drift voltages for monomeric species (black) and dimeric (grey), fitted with a line of best fit. 
Corresponding R2 values are shown. 
For CCS determination the Guassian fitting procedure is repeated for each ion at each drift 




by multiplication with the MS pusher time. The average arrival time (ta) of a particular ion 
corresponds to the length of time an ion spends travelling through the drift cell, the drift time 
(td), combined with the length of time the ion spends travelling through the rest of the mass 
spectrometer, known as the dead time (t0), i.e ta = td + t0.  
The principles of drift tube ion mobility-mass spectrometry are well established and it is 
known that the low field mobility (K) of an ion in a drift cell is inversely proportional to its 
drift time and the drift voltage (V) (Equation 2.1), where L is the length of the drift region. 
The low field region is defined as having a low ratio of electric field strength (E) to buffer 
gas number density (N). At low fields, ions have low velocities, which are independent of 
the field strength and therefore the motion of the ions can be described in more simplistic 
terms. 
   
  
   
    [2.1] 
The mobility of an ion, however, is also dependent on the temperature (T) and pressure (P) at 
which the experiment is carried out, hence in order to normalise for differences in 
temperature and pressure the reduced mobility is most often reported (K0), see Equation 2.2.  
    
   
   
    [2.2] 
Where P0 and T0 are the reduced temperature (273.15 K) and pressure (760 Torr) 
respectively.  
By combining Equation 2.1 and 2.2 (Equation 2.3) it is clear that a plot of average arrival 
time versus (P/V) for each ion will yield a linear plot with a gradient which is inversely 
proportional to the reduced mobility of that ion (Figure 2.6B) where P is the average 
measured experimental pressure for each drift voltage. The R2 value of this line is used to 
determine the quality of the experimental data, with a value of ≥0.9990 equating to good 
quality, usable data and indicative of the fact that the experiments were performed within the 
low field region, which is imperative for the relationships described above to hold. 
Furthermore, the y-intercept of this plot is equal to the deadtime (t0).  
          
     
      
     [2.3] 
Therefore, once the average scan numbers and corresponding arrival times have been 




and determine both the reduced mobility (K0) and the dead time (t0) of the ion. The 
rotationally averaged collision cross section (Ω) of the ion can then be determined from 
Equation 2.4.  
   
   
   
(
  





    [2.4] 
Where, z is the nominal  ion charge state, e is the elementary charge, N is the buffer gas 
density, µ is the reduced mass of the ion-neutral pair, T is the gas temperature and kB is the 
Boltzmann constant.   
In all samples studied, this process is repeated on three different days, yielding CCS 
measurements in triplicate. The average value is then reported and the error reported as the 
standard deviation between these three values. For kalata B1 the CCS of the [M +2H]2+  and 
[2M +4H]4+ ions were calculated, using the procedure outlined above, as 452 ± 4 and 686 ± 
5 Å2 respectively. Kalata B1 was chosen as an example here to highlight not only the data 
acquisition and analysis procedure for a DT IM-MS experiment but also the intrinsic ability 
of IM-MS to separate out ions of the same m/z but differing oligomeric orders. This feature 
of ion mobility mass spectrometry is particularly useful in the study of highly aggregating 
systems, as these species would not be distinguishable in a typical mass spectrometry 
experiment unless extremely high resolution instruments were used which, due to their often 
limited m/z transmission range, are not always applicable to the study of large proteins or 
protein complexes.  
Another elegant feature of DT IM-MS is its ability to distinguish between different 
conformations of an ion. For example the Kalata B1 peptide can be produced in a cyclic 
oxidised or reduced form and a linear form, which is typically reduced. Although these 
species would have slightly differing masses we can distinguish them further based on their 
conformations using DT IM-MS, as has been shown previously for other cyclic and linear 
peptide systems3. The CCS of  [M+2H]2+ for cyclic oxidised, cyclic reduced and linear 
Kalata B1 were experimentally determined to be as follows; 452 ± 4, 463 ± 4 and 474 ± 4 Å2 
respectively. The cyclic oxidised form presents with the smallest CCS suggesting it is the 
most structurally constrained, as expected since this form contains three disulfide bonds. The 
cyclic reduced form is slightly larger, suggesting the absence of the disulfide bond enables it 
to adopt a larger conformation, and the linear form, as expected, adopts the largest 
conformation and hence largest CCS, as it is the least structurally constrained, containing no 




 Molecular modelling 2.4
DT IM-MS experiments provide information on the global fold of a protein or peptide at any 
given charge state, through determination of experimental CCS. In order to gain more 
detailed insight into the conformations adopted by a species it is possible to compare 
experimental CCS obtained to theoretical CCS obtained from molecular modelling. This is 
afforded either through the comparison from solved structure coordinates (from NMR or X-
ray crystallography experiments) or from molecular dynamics (MD) simulations. In the 
following chapters, comparisons are made using both methods. The theoretical CCS of a 
structure, both from NMR coordinates or MD simulations, is determined using the program 
MOBCAL4,5 which provides algorithms to determine the mobility or momentum transfer 
integral (rotationally averaged collision cross section). MOBCAL provides four methods to 
determine CCS; projection approximation (PA), exact hard sphere scattering model (EHSS), 
trajectory method (TM) and projection super approximation (PSA), as discussed in Chapter 1 
section 1.5.4.4. In the work presented here only the TM values were used and reported. All 
molecular modelling was performed by Dr Massimiliano Porrini and brief details of the 
procedures used to determine the theoretical CCS are given in the relevant chapters. Unless 
otherwise stated, the ionisation state of the protein or peptide used for calculations was 
assigned using the tleap module in Amber, which uses an algorithm to automate assignment 
of protonated side chains, computing pK values of ionisable groups and adds in any missing 
hydrogen atoms to the structure in use6,7. 
 
 Fourier transform ion cyclotron resonance mass spectrometry  2.5
All high resolution mass spectrometry and electron capture dissociation (ECD) experiments 
were performed on a 12 T Apex Ultra Qh FT-ICR mass spectrometer (Bruker Daltonik 
Gmbh, Bremen, Germany). The Fourier transform ion cyclotron resonance mass 
spectrometer (FT-ICR MS) instrument was calibrated for each day of experiments using 
ESI-L, a low concentration tune mix from Agilent Technologies (Santa Clara, CA, USA).  
This hybrid mass spectrometer contains a series of ion optics post-source and pre-ICR cell to 
guide ions into the high vacuum analyser cell. After sample ionisation, using either ESI or 
n-ESI, the ions are guided through a capillary and a series of ion funnels before passing 
through a multipole. The ions then pass through a series of focusing lenses before entering 




second series of focusing lens which guides the ions into the collision cell, where CID can be 
employed. Finally, ions pass through the last set of ion focusing lens before travelling along 
the transfer line into the ICR cell, in which ECD fragmentation occurs.  
For analysis of monomeric wild type (WT) Lymphotactin (Ltn), sample ionisation was via 
ESI, with a capillary voltage of 4 kV. For all other studies n-ESI was performed using a 
NanoMate (Advion Biosciences, Ithaca, NY, USA) running in infusion mode and equipped 
with a HD_A_0 ESI chip (Advion biosciences, Ithaca, NY, USA) using a capillary voltage 
of 1.6 kV. For sample preparation details please see the relevant chapters (Chapters 4-6).  
2.5.1 Electron capture dissociation 
For ECD experiments the ECD current was 1.7 A, the ECD cathode was turned on and 
allowed to warm up for at least one hour before acquisition began. In order to maximise ion 
signal during isolation, for each peptide, protein or complex studied, each charge state was 


























60–65 50–90 40– 75 50 – 85 80–120 60 65–70 60 
Time of 
flight / ms 




1–10 1–4 0.2–10 0.5–8 5–10 0.1–0.6 2.0–6.0 0.8–1.2 
Total scans 
 
300 300 200 200 200 300 200 300 
Table 2.6: Typical FT ICR MS operating parameters optimised for ECD studies and their settings for 
each system studied. 
All data was reprocessed in DataAnalysis 4.0 (Bruker Daltonik Gmbh, Bremen, Germany). 
Peaks were identified and charge states and molecular weight determined using the SNAP 
algorithm in the DataAnalysis software with the following parameters; signal-to-noise ratio 
0.0001, relative intensity threshold 0.0001 and quality factor threshold 0.001. ProSight PTM 
(Kelleher research group, Northwestern University, Evanston, IL, USA) was used to identify 
c' and z•-type fragments with a fragment tolerance set up to 50 ppm. Conventional ECD 
results in complementary c' and z• fragment ion pairs (see Chapter 1 section 1.5.3.4), 




formation8,9 and is an important consideration for compact protein species10, such as those 
studied here. To enable consideration of species formed following hydrogen transfer all data 
was manually inspected following analysis by ProSight PTM. Internal (zIc) fragments were 
also identified manually. 
Site specific fragment yields were calculated for monomeric fragmentation species as 
percentage values, considering that backbone cleavage to form c and z fragments can give a 
pair of complementary ions and internal cleavage can yield a complementary triad of ions. 
Considering this, 100% yield= 0.5[c] + 0.5[z] + 0.33[internal fragments] + [other products], 
where other products are reduced molecular ions and products from loss of small neutral 
species from the later. For fragmentation of dimeric species, site specific fragment yields 
were calculated as such 100% yield= 0.5[c] + 0.5[z] + 0.17[internal fragments] + [other 
products]. For fragments formed by dissociation of dimer to monomer followed by ECD 
fragmentation the site specific yields were calculated as such 100% yield= 0.25[c] + 0.25[z] 
+ 0.17[internal fragments] + [other products], where other products also involves monomeric 
species arising from dimer dissociation. Low backbone fragmentation yields are observed, in 
all cases, due to the nature of ECD where the dominate species observed are due to electron 
capture, and charge reduction, without cleavage. In order to overcome the low fragmentation 
efficiency in ECD, and to increase fragmentation yields, ‘activated ion’ ECD is often 
implemented11-13, which involves either infra-red irradiation or collisional activation. 
Activated ion ECD has the advantage of enabling higher fragmentation yields and greater 
sequence coverage to be obtained, however, can also promote unfolding of ions13. In all 
studies reported here ions were not activated prior to the introduction of electrons in ECD.  
 Circular dichroism spectroscopy 2.6
The secondary structure of the c-MYC-Zip, c-MYC-ZipΔDT and MAX-Zip peptides was 
assessed using circular dichrosim  (CD) spectroscopy. The secondary structure present in 
mixed peptide solutions containing either c-MYC-Zip plus MAX or c-MYC-ZipΔDT plus 
MAX were also assessed, in the absence and presence of the ligand 10058-F4. Information 
on the sample preparation, including buffer strength, pH and concentrations used can be 
found in Chapter 3 section 3.2. 
All CD spectra were recorded using a quartz cuvette with a 1 mm path-length (Hellma, 
Essex, UK) on a J-810 spectropolarimeter (Jasco, Essex, UK). Spectra were recorded at 
25 °C, over the range 190-290 nm, at a rate of 10 nm min-1. Five scans were acquired for 




absence of peptide were used as reference, and the background was subtracted for such. The 
spectra were smoothed using the Savitzky-Golay algorithm, with a convolution width of 25. 
The secondary structure content was estimated using the CDSSTR algorithm on the 
DICHROWEB server14-16.  
 Transmission electron microscopy: preparation of grids 2.7
All transmission electron microscopy (TEM) experiments were performed on a Philips 
CM120 Biotin transmission electron microscope (Philips, Eindhoven, Netherlands) with an 
operating voltage of -80 kV. TEM studies were performed on solutions of WT, WT 1-72, 
CC3 and W55D Ltn in the presence of Fondaparinux (Fx) and WT in the absence of Fx, for 
information on sample preparation see Chapter 5 section 5.2. Defensin TEM studies were 
performed on individual solutions of HBD2 and HBD3 in the presence of Fx and HBD3 in 
the absence of Fx. Further studies on HBD2 plus HBD3 in the presence of Fx were also 
performed. For information on defensin sample preparation for TEM see Chapter 6 section 
6.2. 
The preparation of TEM grids for analysis was as follows; 3 µL of sample was spotted onto 
a 3.05 mm, 200 mesh copper grid (Taab, Aldermaston, UK) coated with formvar and carbon 
and left for five minutes. The grid was then dried and rinsed once with 10 µL high purity 
water, after which the excess water was wicked off. The sample was then stained using 4 µL 
1 % uranyl acetate (w/v) and left for 30 seconds before the excess stain was wicked off.  The 
grid was then left to dry overnight.  
 
 Isothermal Titration Calorimtery 2.8
Isothermal titration calorimetry (ITC) experiments were performed on HBD2 plus Fx, to 
study the solution phase interaction of these systems. All ITC experiments were performed 
using a MicroCal Auto-ITC200 (GE Healthcare and Life Sciences, Little Chalfont, UK).  For 
all ITC experiments the reference cell was filled with water and a reference voltage of 5 V 
was applied whilst the sample cell contained the HBD2 solution and Fx was automatically 
titrated in using the pipette. Samples were stored at 25 °C for at least 30 minutes prior to 
analysis and all ITC experiments were performed with the instrument set to 25 °C. The 
sample cell was stirred at a constant speed of 1000 revolutions per minute (RPM). For all 




to allow the system to re-equilibrate, the first injection was 0.5 µL and all subsequent 
injections were 2.49 µL in volume.  
Two experiments were performed injecting the Fx into a HBD2 sample solution at different 
concentrations and two control experiments were performed, Fx was injected into a cell 
filled with buffer and buffer was injected into a cell containing HBD2. For all ITC 
experiments the buffer was 20 mM ammonium acetate, for sample preparation details see 
Chapter 6 section 6.2. Between each ITC experiment the pipette used to inject the Fx or 
buffer into the cell was cleaned with methanol and DeconTM ContradTM detergent (Decon 
Laboratories, East Sussex, UK). All data was analysed in Origin 9.  
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Investigating disorder-to-order transitions: 
c-MYC:MAX  
Understanding the disorder-to-order transition that can occur upon the binding of a protein 
to its partner is essential for better understanding of both protein structure and function. 
This is particularly important for an aggressive oncoprotein such as c-MYC, which contains 
a disordered region that forms a leucine zipper upon binding its partner protein MAX, 
enabling it to carry out its function.  In order to understand and potentially inhibit this 
interaction in initial studies it is more feasible to look at the regions directly involved in the 
interaction. The leucine zipper regions of c-MYC and MAX and the formation of their homo- 
and heterodimers have been examined using CD, MS and DT IM-MS. The effect on the 
heterodimer formation of adding a previously identified inhibitor (10058-F4) was also 
studied. Experimental DT IM-MS results were compared to results from MD studies in order 





Intrinsically disordered proteins (IDPs) are promiscuous proteins which have been shown to 
be functionally important whilst being notoriously difficult to study using traditional protein 
characterisation techniques
1-3
.  Disorder-to-order transitions or coupled binding and folding 
are thought to be important pathways of IDPs, frequently associated with signalling events in 
the cell and mediating protein:protein interactions
4-6
. Interactions of IDPs with their targets 
facilitate binding with moderate affinities (as part of the binding free energy is expended 
upon folding of the IDP on binding) but high specificity, which is thought to be critically 
important for regulation and signal transduction
7
. Furthermore, IDPs have the ability to bind 
multiple partners, often adopting different folded forms upon binding
8
. Hence there are a 
number of different disorder-to-order transitions possible for such systems; a particularly 
common transition, however, is from disordered to helical
9
. Studying the conformations 
adopted upon disorder-to-order transitions and the mechanisms by which they occur is 
incredibly important for the understanding of these pathways. An elegant study by Keppel et 
al
10
 presented the use of hydrogen/deuterium exchange and trypsin digest mass spectrometry 
to study the coupled folding and binding of two IDPs in a protein complex. 
Hydrogen/deuterium exchange is a method which can probe backbone flexibility by studying 
how quickly amide hydrogens can exchange with deuteriums when the protein is diluted in 
an excess of D2O. Their study considered the IDP ACTR (activator of thyroid and retinoid 
receptors, NCOA3_HUMAN, residues 1018-1088) and its binding partner CBP, which is a 
molten globular protein. The results highlighted that regions involved in binding and/or 
folding could be readily identified due to increased protection in the complex, as compared 
to the individual species, and elegantly demonstrated the emerging power of mass 
spectrometry to study these disordered systems and their interactions.  
IDPs are known to play crucial roles in many important diseases such as Parkinson’s, 
Alzheimer’s and many others, in addition to being implicated in cancer initiation, 
progression and metastasis
11,12
. Drug discovery efforts aimed at these highly dynamic 
systems have, however, been limited and they are still often considered  ‘undruggable’ due 
to the difficulty in applying traditional drug discovery techniques, i.e. the design of a 
molecule that can ‘fit’ to a well-defined target site. Approaches to design drugs to target 
these important, flexible proteins are, however, on the rise, and have generally been aimed at 
regulating the protein:protein interactions; nonetheless the rational design of IDP ligands 
remains a challenging task
13-15
. Previous studies have suggested that binding of a small 




disordered system to prevent target binding
16
, as has been shown for the intrinsically 
disordered transcription factor c-MYC
17
. 
c-MYC is an oncoprotein and transcription factor, which can only carry out its full function 
following binding with its obligatory co-factor MAX
18,19
 (see Chapter 1 section 1.2). 
Heterodimerisation occurs through the binding of a basic helix-loop-helix leucine zipper 
(b-HLH-Zip) domain in MYC to a similar region on MAX. The b-HLH-Zip regions of MYC 
and MAX are intrinsically disordered until they dimerise, when they form a parallel left-




MYC is highly deregulated in an incredibly broad range of human cancers (Chapter 1 section 
1.2.3), hence making it an attractive target for novel tumour specific cancer treatments
21
. 
Despite numerous different studies (targeting MYC at various levels
21
) to date no anti-MYC 
drugs are clinically available. One approach to targeting c-MYC is by preventing 
c-MYC:MAX heterodimerisation to form the leucine zipper complex (Figure 3.1A). The 
Prochownik and Metallo research groups have reported previously a number of c-MYC 
inhibitors with low µM affinity aimed at stabilizing the c-MYC disordered state and 
preventing heterodimerisation
17,22,23
. These initial studies have focused on peptide sequences 
of c-MYC and MAX as opposed to full length protein. One such report by Hammoudeh et 
al
17
 identified three possible binding sites for a number of these ligands two of which lie 
within the b-HLH-Zip region, with the most potent c-MYC:MAX inhibitor 10058-F4, 
(Figure 3.1B) binding to a 7 amino acid stretch of c-MYC that overlaps with the leucine 
zipper region.  
 
Figure 3.1: A) The NMR structure of the c-MYC:MAX leucine zipper (PDB file 1A93). B) Proposed 
c-MYC inhibitor 10058-F4. C) Peptides synthesized for this study: the leucine zipper region of MAX 





In this chapter, in order to study the interaction of 10058-F4 with c-MYC and any disruption 
in the formation of the c-MYC:MAX heterodimer, the leucine zipper regions of both 
proteins were synthesised, in addition a shorter c-MYC peptide which consists of the c-MYC 
leucine zipper region but does not contain the additional amino acids which make up the full 




Due to the flexibility of IDPs, experimental approaches for characterising their structures and 
interactions with ligands are limited
25,8
. Traditional techniques for the study of protein 
structure, such as NMR spectroscopy or X-ray crystallography have produced some 
undoubtedly remarkable findings for structured proteins
26,27
, however, their application to 
IDPs is often limited due to the large quantities of material needed, difficulties in 
distinguishing between species with extensive conformational heterogeneity and difficulty in 
producing high quality crystals.  Due to its ability to study dynamic systems presenting with 
multiple conformations, coupled with the low sample quantities required, mass spectrometry 
is becoming an increasingly popular tool to study IDPs
28-30
. Furthermore unlike many other 
biophysical techniques, MS is well suited to the analysis of complex mixtures. 
The ability of mass spectrometry to distinguish changes in the tertiary fold of a protein based 
on the number of charges a protein ion can accept during the electrospray process has been 
long established, with more unfolded species generally presenting to the gas-phase with a 
greater numbers of charges
31,32
. Hence it is inherently well suited to the study of IDPs which 
are often conformationally heterogeneous. A study by Frimpong et al
33
 into the IDP 
α-synuclein showed that by charge deconvolution of the mass spectra, different 
conformational families could be observed for this disordered system. Furthermore, by 
altering solution conditions such as pH and solvent composition the relative intensities of 
these overlapping families could be altered. This demonstrates that different conformational 
states of a heterogeneous IDP such as α-synuclein could be preserved and studied in the 
gas-phase. Studies by Iakoucheva et al
34
 showed that using proteolytic digest methods 
coupled with MS, it is actually possible to predict which regions of a protein are likely to be 
ordered or disordered, with disordered cleavage sites being favourably and commonly 
cleaved, whereas cleavage in sites of structural order in a protein are less favourable. The 
results of their study compared favourably to areas predicted by the neural network program 
predictor of natural disordered regions to be disordered.  Furthermore, the combination of 
ion mobility with mass spectrometry has proved incredibly useful as a tool to study the 
conformations of intrinsically disordered proteins
35-37




extremely valuable in studying binding of IDPs to ligands or other binding partners, 
providing information on stoichiometry of binding and conformations adopted by bound 
species
38-42
. These studies have suggested that gas-phase, mass spectrometry-based 
techniques have the potential to be a useful tool for studying disordered, dynamic systems. 
This proof-of-concept study has focused on the leucine zipper regions of c-MYC (c-MYC-
ZipΔDT) and MAX (MAX-Zip), and a longer c-MYC peptide containing the full previously 
identified drug binding region (c-MYC-Zip), Figure 3.1C. CD is employed in combination 
with MS and DT IM-MS to study their interactions, in the absence and presence of the 
inhibitor 10058-F4. The aim of the study was to determine if this is a feasible method for the 
study of interactions of c-MYC with future ligands, designed to be more potent, and with 
further development aimed at studying the full length proteins.  
 Experimental 3.2
3.2.1 Peptide and ligand samples 
Peptides of the leucine zipper regions of c-MYC (with and without the drug target region) 
and MAX where synthesised by the MacMillan research group (University College London, 
London, UK). The sequences of the peptides synthesised are shown in Figure 3.1C. Details 
of the synthetic procedure implemented by the MacMillan research group has been published 
elsewhere
43
, brief details are given in Appendix 2 section A2.1. Peptides were supplied as 
lyophilised samples and stored at -20 °C until use.  
Stock solutions of peptides were typically prepared at 350 or 400 μM concentration in 20 
mM ammonium acetate (AmAc), pH 6.8. Ammonium acetate salt was purchased from 
Fischer scientific (Loughborough, UK) and prepared in high purity water, in the resistivity 
range of 18.0-18.2 MΩ•cm, obtained from an Arium 611 water purification system (Satorius, 
Göttingen, Germany). Peptide concentrations were checked using the Pierce BCA 
concentration assay (Thermo Fischer Scientific, Wilmington, DE, USA) following the 
manufacturer’s instructions but using volumes 10 times lower than stated in the manual, 
afforded through the use of low volume UV cuvettes. Peptides were stored at 4 °C and 
diluted to the desired concentration before use.  
The ligand 10058-F4, used in c-MYC:MAX studies was purchased from Sigma-Aldrich 
Company Ltd (Dorset, UK),  1 and 0.1 mg/mL stock solutions were prepared in acetonitrile 




3.2.2 Sample preparation for CD studies 
For circular dichrosim spectroscopy (CD) studies single peptide solutions were prepared at 
25 µM in 10 mM AmAc buffer, pH 6.8. The mixed peptide solutions were prepared at a 1:1 
ratio with a total protein concentration of 25 µM in 10 mM AmAc buffer, and incubated for 
1 hour at 37 °C before analysis.  Mixed peptide plus 10058-F4 ligand samples were prepared 
at a 1:1:1 ratio in which each component was present at 12.5 μM, and incubated for one hour 
at 37 °C before analysis. In order to study the effect of pH on the observed CD spectra of 
c-MYC-Zip plus MAX-Zip, with and without the ligand (10058-F4), samples were prepared 
at 1:1 or 1:1:1 ratios in 10 mM AmAc, buffer pH was adjusted to 9.8 or 2.8 through the 
drop-wise addition of either sodium hydroxide (NaOH) solution (Sigma Aldrich Company 
Ltd, Dorset, UK) or formic acid (VWR International Ltd, Leicestershire, UK).  
3.2.3 Sample preparation for MS studies 
MS studies were performed on c-MYC-Zip plus MAX-Zip and c-MYC-ZipΔDT plus 
MAX-Zip, prepared in 20 mM AmAc with 20 % acetonitrile at a 1:1 ratio, with each peptide 
present at a concentration of 125 μM. 10058-F4 was prepared in acetonitrile hence addition 
of acetonitrile to the mixed peptide solutions enables any effect of the solvent to be 
distinguished from ligand affects. Mixed peptide plus 10058-F4 samples were prepared at 
equimolar concentrations in 20 mM AmAc, with all components present at 125 μM. All 
samples were incubated at 37 °C in a digital dry bath (Jencons-PLS, East Grinstead, UK) and 
analysed after 15 minutes, one or three hours. For c-MYC-Zip plus MAX-Zip plus 10058-F4 
two additional incubation times were studied, after six and 24 hours at 37 °C. For 
c-MYC-Zip plus MAX-Zip plus 10058-F4 the effect of altering buffer strength over the 
range 10-100 mM AmAc was determined. In addition at 20 mM AmAc the effect of altering 
the pH over the range 9.8 to 2.8 was studied. Finally, this mixed peptide solution was 
prepared at 1:1:5 (c-MYC-Zip:MAX-Zip:10058-F4) ratio in 20 mM AmAc pH 6.8. All MS 
studies presented in this chapter were performed on a Q-TOF II mass spectrometer (Waters. 
Manchester, UK) as described in Chapter 2 section 2.2. 
3.2.4 Sample preparation for DT IM-MS studies 
For determination of collision cross sections (CCS), single peptide solutions were prepared 
at a concentration of 125 μM. Mixed peptide solutions were prepared at 1:1 ratios with each 
peptide present at 125 μM. In the presence of ligand, samples were prepared at equimolar 
concentrations with each component at a concentration of 125 μM. In all cases samples were 




added. Samples were incubated at 37 °C before analysis, in the absence of ligand all samples 
were incubated for 1 hour and in the presence of the ligand samples were incubated for 3 
hours. Furthermore CCS of c-MYC-Zip:MAX-Zip in the presence of 10058-F4 was studied 
at an additional time point, after 1 hour incubation. All DT IM-MS measurements were 
performed on an in-house modified Q-TOF (Micromass Uk Ltd.), adapted in order to carry 
out separations based on an ion’s mobility, and to enable the temperature-dependent CCS to 
be determined, as described in Chapter 2 section 2.3. 
3.2.5 Molecular dynamics simulations 
All molecular dynamics simulations and theoretical calculations discussed in this chapter 
were performed by Dr Massimilano Porrini. Details of the procedure can be found 
elsewhere
43
 and are given in brief in Appendix 2 section A2.2. Molecular dynamics 
simulations were run to enable the theoretical CCS to be determined for the 
c-MYC-ZipΔDT:MAX-Zip hetero-dimeric leucine zipper complex (PDB code 1A93). The 
disordered monomeric and dimeric species CCS were calculated following simulated 
annealing of the monomers or heterodimer. 
 
 Results and discussion 3.3
3.3.1 Solution-phase secondary structure analysis: circular dichroism 
spectroscopy 
CD spectroscopy was utilised in order to study the secondary structure content of the 
individual peptides and peptide mixes before and after ligand addition (Figure 3.2). For each 
individual peptide solutions the observed CD spectrum is consistent with that of a system 
containing a proportion of α-helical and coiled regions (Figure 3.2A and Table 3.1). This is 
in contrast to the reports of Hammoudeh et al
17
 on similar peptide regions of c-MYC in 
which they only saw an α-helical signature upon addition of c-MYCs binding partner MAX; 
however, slightly differing peptide regions of the c-MYC:MAX interaction domain were 
studied here
17,22
. It is not possible, however, to determine from CD if this helicity is due to 
monomers or homodimers. Homodimers of c-MYC are thought to be rare, but they have 
been previously reported
44
. Previous studies have reported the use of CD to study 
homodimers of c-MYC
24,45
, these studies have focused on peptides of the leucine zipper 
region but have often covalently attached the monomeric chains to enable the dimeric 
structure to be studied in this way
24




α-helical, sometimes coiled-coil, structures and that even monomeric c-MYC has some 
helicity.
 
MAX homodimers are, however, known to be more favourable and functional, 
being capable of binding DNA. Furthermore their structure has been solved using high 
resolution techniques and shown to be consistent with that of the helical b-HLH-Zip 
structure, hence homodimers could account for the helical signature observed here for 
MAX
45,46
. It is therefore plausible that the helical signature seen here for all individual 
peptides could be due to monomeric species or dimeric species or a combination of both; 
however, from CD alone it is impossible to determine which species the solution spectra 
are dominated by. 
 
Figure 3.2: CD spectra obtained for A) individual peptide solutions of c-MYC-zip (black), MAX-Zip 
(green) and c-MYC-ZipΔDT (purple). B) c-MYC-ZipΔDT plus MAX in the absence of 10058-F4 
(grey) and after one hour incubation (red) with 10058-F4. C)  c-MYC-Zip plus MAX in the absence 
of 10058-F4 (grey) and after one hour incubation (red) with 10058-F4. MRE was determined in 
individual peptide mixes based on peptides being monomeric and in peptide mix solutions assuming 
all peptides were in the heterodimeric form. 
c-MYC-ZipΔDT plus MAX (Figure 3.2B and Table 3.1) and c-MYC-Zip plus MAX-Zip 
(Figure 3.2C and Table 3.1) mixtures  provide similar α-helical signatures, as expected for 
the heterodimeric complexes. Interestingly, this helical signature is calculated to be lower 
than that observed for the single peptide solutions and for c-MYC-Zip:MAX is seen to 
increase in the presence of the ligand 10058-F4. For both mixes the percentage of disordered 




a certain amount of disorder or that the unbound peptides are substantially disordered in this 
mixed peptide solution. It is important to note that in the case of the mixed peptide solutions, 
the mean residue ellipticity (MRE) was calculated based on all peptides in the solution 
forming a heterodimeric complex; however, it is likely that the process is more complicated 
than this with some proportion of unbound monomer or perhaps even homodimers being 
present in the solution.  
Solution Helical 
content / % 
Sheet 
content / % 
Coil 
content / % 
Disordered 
content / % 
c-MYC-Zip 20 29 12 37 
c-MYC-ZipΔDT 44 11 15 3 
MAX-Zip 22 27 13 37 
c-Myc-ZipΔDT plus Max 8 37 11 43 
c-Myc-ZipΔDT plus Max 
plus 10058-F4 (1 hr) 
9 36 11 43 
c-Myc-Zip plus Max 5 41 12 41 
c-Myc-Zip plus Max plus 
10058-F4 (1 hr) 
20 29 14 36 
Table 3.1: The secondary structure content as determined from the CD spectra shown in Figure 3.1, 
calculated from DICHROWEB server using the CDSSTR algorithm
47-49
. A representative example of 
the quality of fitting is given in Appendix 2 Figure A2.1. In all cases data was input as normalised to 
MRE and single peptide solutions were considered to be monomeric species and mixed peptide 
solutions were considered as heterodimers.  
Further CD experiments were performed on the c-MYC-Zip:MAX-Zip peptide mixture at 
pH 9.8 and pH 2, in the absence and presence of the ligand 10058-F4, (Appendix 2 Figure 
A2.2). At both pHs in the absence and presence of the ligand, the helical content is found to 
be higher than at pH 6.8. This is unsurprising as the sodium hydroxide used for pH 
adjustment (pH 9.8) can help stabilise salt bridges in a helical form, furthermore 
dimerization is thought to be promoted under acidic conditions
50
. 
Interestingly, although in all cases the CD spectra visually appear to be mostly helical, 
secondary structural analysis using the CDSSTR algorithm in DICHROWEB reveals a 
substantial proportion of disorder and sheet content in these peptides, both in the individual 
solutions and the mixed peptide solutions. It is clear from the CD experiments performed 
here that CD provides ambiguous results for a complex multicomponent, conformationally 
dynamic system and in order to probe the species present in such samples a technique which 
can distinguish between species of different oligomeric orders and different conformations is 




studied by MS and DT IM-MS, which are intrinsically well suited to study conformationally 
dynamic systems.  
3.3.2 Investigating ligand binding: a mass spectrometry approach 
The mass spectra for the individual peptides were first acquired and show mostly monomeric 





for each of the peptides (Figure 3.3). 
 
Figure 3.3: Mass spectra obtained from 125 µM peptide solutions in 20 mM AmAc. A) c-MYC-Zip 
B) c-MYC-ZipΔDT and C) MAX-Zip. All major peptide peaks are labelled with charge states and a 
sphere represents one monomeric unit. 
Theoretical PI values for c-MYC-Zip, c-MYC-ZipΔDT and MAX are as follows; 6.79, 6.76 
and 8.36, and correspond to net charges of 0, 0, and +2 respectively at pH 7. Here 
experiments were performed at pH 6.8 and it is observed that the ions typically populate 
lower charge states than the total number of protonatable sites, suggesting all potential sites 




during ionisation. Furthermore it is clear that all peptides studied here are capable of 
homodimerisation, with homodimers (D) of c-MYC-Zip, c-MYC-ZipΔDT and MAX-Zip, 




 species. Homodimerisation 
accounts for approximately 10, 24 and 8 % of the total intensity of the peptide species 
observed by MS for c-MYC, c-MYC-ZipΔDT and MAX-Zip respectively. In all cases the 
[D+4H]
4+ 
could also be due to the monomeric species [M+2H]
2+
, as they have the same 
mass-to-charge ratio, however, the isotope distribution for these peaks shows, for all 
peptides, they are primarily due to the dimer and hence have been identified as such. 
Additionally a number of lower intensity peaks are present in all spectra due to contaminants 
carried over from the synthetic procedure.  
The peptide mixtures c-MYC-Zip plus MAX-Zip and c-MYC-ZipΔDT plus MAX-Zip were 
examined to determine if the heterodimeric complex could be formed, preserved and 
transmitted into the gas-phase. Samples were mixed and incubated for 15 minutes, one or 
three hours before analysis. For both peptides, at each incubation time, the spectra obtained 





, Figure 3.4 shows spectra obtained after three hours incubation. The increase in 




, for the monomeric species in 
the mixed peptide solutions is attributed to the addition of 20% acetonitrile to the solution in 
these studies. Acetonitrile was used here to replicate the solvent conditions employed for 
ligand binding studies where 10058-F4 was prepared in acetonitrile and this increase in 
charge state distribution is observed for both the c-MYC-Zip and c-MYC-ZipΔDT individual 
peptide solutions plus 10058-F4 (Appendix 2 Figure A2.3), attributed to the acetonitrile used 
to prepare the ligand. 
The c-MYC-Zip:MAX-Zip and c-MYC-ZipΔDT:MAX-Zip  heterodimeric complexes (C), 




. Upon the addition of stoichiometric 
amounts of 10058-F4 (1:1:1), no ligand:peptide or ligand:complex species were observed for 
either c-MYC peptide. Furthermore, the single c-MYC peptide solutions were also studied in 
the presence of the ligand 10058-F4 at a 1:1 ratio and again no ligand:peptide complexes 
were observed for either c-MYC peptide, with (c-MYC-Zip) or without (c-MYC-ZipΔDT)  
the drug target binding region (Appendix 2 Figure A2.3). A dissociation constant (Kd) of 
5.3 µM
17
 has been reported for the 10058-F4 ligand to c-MYC and additional work 
highlighted that truncated peptide regions containing the DT region bind with a similar 
affinity
22







Figure 3.4: Mass spectra recorded after 3 hours incubation at 37 °C, peptide mixtures were prepared at 
a 1:1 ratio at 125 µM of A) c-MYC-Zip plus MAX-Zip. Insert: magnified region of the spectra 
showing the c-MYC:MAX-Zip complexes in the absence and presence of 10058-F4 B)  
c-MYC-ZipΔDT plus MAX-Zip Insert: magnified region of the spectra showing the 
c-MYC-ZipΔDT:MAX-Zip complex in the absence and presence of 10058-F4. In both cases peaks 
due to c-MYC peptides are in black and peaks due to MAX-Zip are in grey, green peaks are 
heterodimeric species.   
In order to try to observe the peptide:ligand or complex:ligand species a number of different 
solution and desolvation conditions were employed for MAX-Zip plus c-MYC-Zip, the 
peptide which contains the previously identified drug target binding region. Firstly, samples 
were incubated at room temperature for 15 minutes, one hour or three hours but again no 
ligand complexes were observed following these experiments (Appendix 2 Figure A2.4).   
The effect of varying the solution conditions was then probed by changing both the 
concentration of the ammonium acetate buffer, over the range of 10-100 mM, and the pH of 




Figures A2.5 and A2.6 respectively). Under all solution conditions studied here no 
10058-F4:c-MYC-Zip complex or 10058-F4:c-MYC-Zip:MAX-Zip complexes were 
observed. The addition of the ligand itself does not cause any significant shift in the pH of 
the sample, however, it is less soluble at low pH, crashing out of solution below pH 2.8 at 
concentrations of 125 µM.  
Next a number of desolvation and ionisation conditions were probed including the effect of 
capillary voltage, the potential applied in order to ionise and desolvate the sample. Typically 
a capillary voltage of 1.6 kV was used in the studies reported here for c-MYC-Zip plus 
MAX-Zip, however, this applied voltage was varied over the range 1.3-2.0 kV to determine 
if the applied voltage could influence the ability to preserve and transmit any ligand-bound 
complexes (Appendix 2 Figure A2.7). At all applied capillary voltages no ligand-bound 
species were observed, however. Furthermore, the effect of cone voltage was investigated 
over the range 10-40 V, but even with the gentlest conditions no ligand complex could be 
observed (Appendix 2 Figure A2.8).  
The final technique employed in an attempt to preserve any ligand-bound complexes was 
solvent vapour exposure, a technique which has previously proved successful in stabilising 
weak gas-phase protein:ligand interactions
52
. Solvent vapour exposure involves inserting a 
small open container of solvent into the source region of the mass spectrometer, in this case 
solvent was held in the lid of a falcon tube inserted below the source cone.  The falcon tube 
lid was filled with acetonitrile but again no peptide:ligand complexes were observed 
(Appendix 2 Figure A2.9). 
The fact that no c-MYC-Zip:10058-F4 or c-MYC-Zip:MAX-Zip:10058-F4 complexes were 
observed under any of the numerous conditions employed here is significant. The ligand is 
thought to bind c-MYC through hydrophobic interactions between the aromatic ring of 
10058-F4 and hydrophobic residues in the drug target (DT) region of c-MYC-Zip
22
 and 
previous work has shown the preservation of hydrophobic protein:ligand interactions is 
indeed possible in the gas-phase
53,54
. Hence it can be inferred that the Kd of the ligand may 
be greater than quoted in earlier studies, and any ligand binding in solution is too weak to be 
preserved during desolvation and ionisation even under very gentle source conditions, a 
finding which is consistent with recent metadynamics simulations which suggested the 
binding of 10058-F4 to a c-MYC peptide of the Zip region is driven by weak, non-specific 






For both c-MYC peptides a notable decrease in the intensity of the [C+5H]
5+
 complex 
species was, however, observed in the presence of the ligand, with the largest decrease in 
complex signal observed for the c-MYC-Zip:MAX-Zip complex being after three hours 
incubation at 37 °C, (Figure 3.4 insert and Table 3.2). An increase in the [C+4H]
4+
 species, 
however, is also observed (Figure 3.4 insert and Table 3.2). Similar observations are made 
for both c-MYC-Zip:MAX-Zip and c-MYC-ZipΔDT:MAX-Zip, despite the latter not 
containing the full drug target region, again suggesting interactions between 10058-F4 and 
c-MYC are not as specific as initially described. From MS experiments alone it appears that 
10058-F4 does not significantly perturb the total equilibrium between free peptide and 
heterodimeric complex but it does affect the charge state distribution of the complex. This 
shift in charge state could be indicative of a shift in the conformational equilibrium of this 
peptide complex, which can be probed directly utilising DT IM-MS.  
 c-MYC-Zip:MAX c-MYC-ZipΔDT:MAX 
Incubation No 10058-F4 Plus 10058-F4 No 10058-F4 Plus 10058-F4 
time 5+ 4+ 5+ 4+ 5+ 4+ 5+ 4+ 
15 minutes 11.4 3.1 10.1 5.5 23.2 6.4 8.3 3.9 
1 hour 16.0 2.4 8.9 6.1 18.0 7.8 10.6 12.5 
3 hours 18.7 2.7 5.21 5.2 15.7 9.3 12.1 9.9 
Table 3.2: The relative intensities of the c-Myc-Zip:MAX-Zip and c-Myc-ZipΔDT:MAX-Zip 4+ and 
5+ complexes, after incubation at 37 °C for 15 minutes, 1 hour and 3 hours, in the absence and 
presence of the ligand 10058-F4. 
3.3.3 Studying conformational change utilising ion mobility-mass 
spectrometry 
The conformations adopted by the individual peptides, homo- and heterodimers were studied 
using DT IM-MS both in the absence and presence of 10058-F4. Table 3.3 contains the 
calculated experimental CCS determined in the absence of the ligand. Experimental CCS 
were determined for all observed species and compared to theoretical CCS obtained either 
from the NMR structure (PDB 1A93)
20
 or from a simulated annealing (SA) procedure. The 
theoretical values obtained from both procedures are also shown in Table 3.3. 
From DT IM-MS experiments, for all species studied, an increase in CCS with charge is 
observed, as expected, as more unfolded species will be able to accept larger numbers of 
charges. Furthermore, for small peptide systems like those studied here an increase in charge 
is likely to increase the CCS due to Columbic repulsion of proximal charges, which is more 
probable to have a significant effect on small peptide systems where charges are likely to be 













 711 ± 2 
 [M+3H]
3+
 649 ± 3 
 [M+2H]
2+
 479 ± 8 
 [D+5H]
5+
 1131 ± 5 
c-Myc-ZipΔDT M  592* 
 [M+4H]
4+
 629 ± 4 
 [M+3H]
3+
 595 ± 5 
 [M+2H]
2+ 
453 ± 11 
 [D+5H]
5+
 941 ± 8  
Max-Zip [M+2H]
2+
  560* 
 [M+4H]
4+
 565 ± 2 
 [M+3H]
3+
 554 ± 6 
 [D+4H]
4+













 982 ± 7  
  1164 ± 9  
 [C+4H]
4+











 947 ± 3  
  1136 ± 12  
 [C+4H]
4+
 906 ± 3  
Table 3.3: Experimental and theoretical CCS for c-MYC-Zip, c-MYC-ZipΔDT and MAX-Zip 
monomers (M) and homodimers (D) in addition to the heterodimeric complexes (C); c-MYC-
Zip:MAX-Zip and c-MYC-ZipΔDT:MAX-Zip. Experimental CCS listed here were determined from 
single peptide, and mixed peptide solutions in the absence of the ligand. Theoretical CCSs were 
determined either from simulated annealing (*) or from NMR coordinates (‡). 
For the individual monomeric peptides it is observed that c-MYC-Zip adopts the largest 
conformations with CCS of ~479-711 Å
2





It would be expected that this peptide would adopt the largest CCS out of the three 
individual peptides as it has the longest chain length, consisting of 33 amino acids whilst 
c-MYC-ZipΔDT and MAX-Zip are both composed of 29 amino acids. c-MYC-ZipΔDT 
exists in a similar CCS range over the same charge state range observed for c-MYC-Zip, 
being only marginally smaller (~453-629 Å
2
) and is attributed to a similar conformational 
family to that adopted by c-MYC-Zip. The slightly smaller CCS observed are ascribed to the 





, and are slightly more compact (~554-565 Å
2
) than those observed for the 




of existing in more compact forms. The conformations adopted by these monomeric peptides 
in the mixed peptide samples in the presence of 10058-F4, was also studied and CCS of all 
monomeric species remain the same within experimental error (Appendix 2 Table A2.1). 
 
Figure 3.5: A) c-MYC-Zip B) c-MYC-ZipΔDT and C) MAX-Zip. Top: Theoretically predicted 
structures obtained through SA. In the SA procedure for each stored minimised structure the 
rotationally averaged CCS was determined and the representative structures were chosen selecting the 
lowest energy species among those having a CCS “close” to the peak position of the distributions. The 
CCS of each representative structure is shown below the structure. The colours refer to the secondary 
structure as follows; green, white, orange, blue and cyan refer to turn, coil, isolated bridge, 310-helix 
and α-helix respectively. Bottom: Secondary structure contents in percentage determined considering 
a window of 10.0 Å
2
 centred at the CCS distributions peak position, ensembles of structures (~100 
structures), using the DSSP algorithm.  
Experimental CCS obtained for the monomeric peptides were compared to theoretical CCS 
obtained from a SA molecular modelling procedure. From Table 3.3 it is clear that the 
experimentally obtained conformations adopted by these peptides are very similar to those 
predicted from the SA procedure, representative structures obtained are shown in Figure 3.5 
and visually appear very disordered in nature.  It is possible, however, to determine the 





The DSSP algorithm enables the secondary structure of amino 
acids in a peptide or protein to be assigned based on the atomic-resolution coordinates of the 
species. The resulting trends for ~100 structures in a 10 Å
2
 window centred at the peak of the 
CCS distribution as determined by the SA procedure are shown for the three peptides in 
Figure 3.5. These monomeric peptides are primarily disordered as would be expected for 
these species, which have been shown to undergo a disorder-to-order transition upon 




species contain residues implicated in the formation of 310-helices, which could account 
towards the helical signature observed in CD for all individual peptide solutions studied.  
Considering next the heterodimers, Figure 3.6 presents the CCS distributions obtained for 
[C+5H]
5+ 
of both c-MYC-Zip:MAX-Zip (Figure 3.6A) and c-MYC-ZipΔDT:MAX-Zip 
(Figure 3.6B), in the absence (top) and presence (bottom) of the ligand. For both c-MYC 
peptides similar observations are made, with striking differences detected by DT IM-MS in 
the absence and presence of the ligand. Considering first the heterodimeric complexes 
([C+5H]
5+ 
) in the absence of ligand, two conformations are observed (Table 3.1 and Figure 
3.6 top), with average CCS of 982 and 1164 Å
2 
for c-MYC-Zip:MAX-Zip and 906 and 1136 
Å
2 
for c-MYC-ZipΔDT:MAX-Zip. Comparison of these experimental CCS with theoretical 
calculations can provide candidate conformations. Considering the more extended 
conformation of both heterodimeric complexes, close agreement to the theoretical CCS 
calculated for the leucine zipper dimer derived from the NMR co-ordinates is observed 
(represented by black dotted lines and corresponding structures in Figure 3.6). For c-MYC-
ZipΔDT:MAX the theoretical CCS is calculated as 1162 Å
2
, highlighting that this extended 
conformation is likely to be the leucine zipper type conformation.  
 
Figure 3.6: A) c-MYC-zip:MAX-Zip B) c-MYC-ZipΔDT:MAX-Zip. CCS distributions derived from 
arrival time distributions at a drift voltage of 45 V for [C+5H]
5+ 
. Results in absence of ligand (after 1 
hour incubation at 37 °C) and in the presence of the ligand, 10058-F4 (after 3 hours incubation at 37 
°C) are shown in the top and bottom panel respectively. Profiles for the predicted conformation from 
SA (solid black lines) and from NMR structures (vertical black dotted line) are displayed together 
with experimental fitted curves (dashed lines), CCS obtained from additional SA procedure is shown 




For c-MYC-Zip:MAX the theoretical CCS for the leucine zipper dimer was calculated as 
1247 Å
2
 (represented by black dotted line in Figure 3.6A) however, in order to create the 
c-MYC-Zip:MAX leucine zipper complex an additional four amino acids (YILS) had to be 
added to the NMR structure to account for the DT region. Therefore to ensure that this 
slightly altered structure was still stable in this conformation at 300 K and to allow the 
structure to relax and equilibrate an additional MD simulation was run (see Appendix 2 
section 2.2). The MD simulation consisted of thermalizing and equilibrating the leucine 
zipper in explicit water, following which a 10 ns simulation was carried out and 100 sample 
structures were stored (1 every 100 ps) along the obtained trajectory. These structures were 
then stripped of water and minimised in vacuo, the CCS of each resulting structure was 
calculated and the average was determined to be 1124 Å
2
 (represented by grey dashed line in 
Figure 3.6A). More compact than the value obtained prior to relaxation (1247 Å
2
), however, 
both are in very close agreement with the experimental value of 1164 Å
2
. This highlights that 
this helix:helix interaction, in c-MYC-Zip:MAX, is stable in vacuo at the temperature 
employed during the experimental procedure and is indeed most likely the more extended 
conformation observed experimentally. This fully helical complex could account for a 
proportion of the helical signature observed for mixed peptide samples in CD studies.  
The earlier arriving conformer observed for both heterodimeric complexes in the absence of 
the ligand for [C+5H]
5+
 corresponds to a more compact complex (Figure 3.6 top), with a 
CCS similar to the most visited CCS value of the low energy candidates determined through 
the SA approach, representative structures are given in Figure 3.6 and CCS distribution 
obtained are represented by solid black lines. The difference in width observed for the ATDs 
obtained experimentally as opposed to the distribution obtained through the SA procedure is 
likely due to both experimental diffusion and conformational heterogeneity, that is to say the 
structures will exist in a conformational family of similar structures. As with the monomeric 
structures determined by SA the secondary structure of the heterodimeric structures can be 
assessed using the DSSP algorithm in Amber10 in this case considering ~160 structures 
(Figure 3.7). Despite their largely disordered conformation it is clear the heterodimeric 
complexes predicted through SA contain some regions of 310-helix and turns, where a turn is 
a secondary structural element where the polypeptide chain reverses its overall direction and 





Figure 3.7: A) c-MYC-Zip:MAX-Zip B) c-MYC-ZipΔDT:MAX-Zip. Secondary structure contents in 
percentage of the disordered dimer complexes predicted from SA, determined considering a window 
of 10.0 Å
2
 centred at the CCS distributions peak position, ensembles of structures (~160 structures) 
and using the DSSP algorithm. Where, a turn is a secondary structural element where the polypeptide 
chain reverses its overall direction and comprises stabilising hydrogen bonds typical of helices. 
Experimental conditions including pressure in the drift cell, energy with which ions are 
injected into the cell and time ions spend in the gas-phase are tuned in these DT IM-MS 
studies, to enable gentle transfer of ions and to cause minimal disruption to solution-phase 
topologies
57-59
. Therefore, combining experimental results with theoretical CCS determined 
from SA and from the NMR structure it is surmised that the complex exists in solution as 
both a structured leucine zipper conformation and a disordered conformation; these 
disordered conformations could potentially be the encounter complex en route to the 
formation of the highly ordered form. Both conformations can be preserved and transferred 
into the gas-phase, where DT IM-MS can distinguish between them, highlighting the 
elegance of this technique to differentiate between conformations in a complex dynamic 
system. Furthermore, both the fully helical leucine zipper and the disordered complex would 
contribute to the helical signature seen in the CD spectra for the peptide mixtures adding to 
the complexity of these spectra.  
Upon addition of the ligand 10058-F4 and incubation at 37 °C for three hours the ATDs for 
[C+5H]
5+  
in both peptide mixtures (Figure 3.6 bottom) appears  notably different to those 
obtained in the absence of the ligand. For both heterodimeric complexes at this charge state 
in the presence of 10058-F4 only a single conformation is observed, consistent with the 
compact disordered species observed in the absence of the ligand. The leucine zipper 
conformation however is no longer observed. This provides persuasive evidence for the 




could not have been determined by MS or CD alone. The mechanism by which this complex 
is inhibited is unclear, however, the striking differences in the absence and presence of 
10058-F4 suggest that the ligand is interacting either with the c-MYC peptides or the 
heterodimer in solution presumably stabilising the disordered complex and inhibiting 
formation of the helical coiled-coiled conformation. These interactions are too weak, or 
perhaps non-specific, to enable any ligand-bound species to be detected by MS, however, the 
conformational consequences can be distinguished by DT IM-MS. The fact that similar 
observations are made for c-MYC-Zip and c-MYC-ZipΔDT peptide, despite the latter not 
having the DT region, suggests that this ligand 10058-F4, is not as specific as previously 
reported.  
The ATDs shown in the top and bottom panels of Figure 3.6 were, however, obtained after 
different incubation times, in both cases incubation was at 37 °C. The mixed peptide samples 
were incubated for one hour before analysis; however, in the presence of the ligand the 
samples were incubated for three hours prior to analysis, as MS studies showed the greatest 
decrease in the [C+5H]
5+
 heterodimeric complex at this time point. Therefore in order to 
confirm that the leucine zipper complex is inhibited due to the presence of the ligand and this 
observation is not an artefact of increased incubation time, the c-MYC-Zip plus MAX-Zip 
plus 10058-F4 mixed peptide solution was studied after one hour incubation at 37 °C. In this 
case the extended species was again absent and only the compact disordered species was 
observed confirming that that inhibition of this leucine zipper complex is due to the presence 
of 10058-F4 (Figure 3.8).  
 










Figure 3.9: A) c-MYC-zip:MAX-Zip B) c-MYC-ZipΔDT:MAX-Zip. CCS distributions derived from 




 ions. Results in absence 
of the ligand (after 1 hour incubation at 37 °C) and in the presence of the ligand, 10058-F4 (after 3 
hours incubation at 37 °C) are shown in the top and bottom panel respectively. Profiles for the 
predicted conformation from SA (solid black lines) and from NMR structures (vertical black dotted 
line) are shown.  
The heterodimeric complex is also observed at the 4+ charge state, DT IM-MS experiments 
show that this ion presents in a single conformational family with a CCS similar to that of 
the disordered complexes predicted through SA. For both c-MYC peptides the shape of the 
ATD for this complex does not alter in the presence of ligand (Figure 3.9). The 
c-MYC-Zip:MAX-Zip [C+4H]
4+
 complex does, however, shift to a slightly lower CCS, this 
further supports the theory that the 10058-F4 ligand promotes more compact forms of the 
complex to be favoured in solution, consistent with the findings for [C+5H]
5+
 in which a 
shift to the more compact, disordered conformation of the complex upon ligand addition is 
observed. This observation further suggests that 10058-F4 is indeed interacting either with 
the c-MYC peptide or the heterodimer in solution, causing a conformational change to be 
observed despite no ligand-bound species being detected by MS. The more compact form 
may favour a lower charge state in the gas-phase since less protonatable sites will be 
accessible, and in part this observation explains the relative increase of the [C+4H]
4+
 species 
in the presence of the ligand. As with c-MYC-Zip:MAX-Zip, the c-MYC-ZipΔDT:MAX 
[C+4H]
4+
 complex exists as a single compact conformation (Figure 3.9). In this case, 
however, the CCS of the heterodimer is not influenced upon the addition of 10058-F4, with 
no compaction observed for the complex in this case, perhaps due to the already more 




most compressed form or perhaps that it is a more stable species and therefore this 
disordered complex experiences less stabilisation upon ligand addition and hence no 
compaction is observed.  
 
The consistent differences in the conformations observed for the complex ions at the two 
charge states observed is interesting to consider, with the complex being observed as a single 
conformational family for [C+4H]
4+
 and as two distinctive conformational families for 
[C+5H]
5+
. Both charge states exist in a compact conformation which compares extremely 
well with the disordered complex assigned through the SA simulations. The [C+5H]
5+
 
species, however, also exists in a more extended conformation, similar to that of a 
coiled-coiled leucine zipper complex. The fact that this leucine zipper like conformation is 
only observed at the higher charge state is unsurprising as helical structures with their side 




 The inherent 
flexibility of the disordered complex would allow it to exist in a wider range of charge states 
and also, due to self-solvation of the peptides, potentially lower charge states. Furthermore, 
visual examination of the disordered complex highlights that the chargeable residues reside 
mostly in the core of the complex and hence this conformation is likely to present at lower 
charge states (Figure 3.10).  In contrast, the leucine zipper is unable to undergo the same 
self-solvation of charges and is therefore less likely to be observed at lower charge states.  
 
Figure 3.10: c-MYC-Zip:MAX-zip complex structures from A) simulated annealing B) based on 
NMR structure (PDB 1A93). Colour coded by residue type where non-polar, basic, acidic and polar 




The CCS of the homodimers of c-MYC-Zip, c-MYC-ZipΔDT and MAX-Zip were also 
determined (Table 3.3) and follow the same trend as the monomeric peptides with the 
MAX-Zip homodimer being the most compact (857 Å
2
) and the c-MYC-Zip homodimer 
being the most extended (1131 Å
2
). The c-MYC-Zip and MAX-Zip homodimers are similar 
in CCS whilst the c-MYC-Zip homodimer is significantly larger suggesting that the 
conformation adopted by the homodimer of c-MYC-Zip is significantly different to those 
adopted by the other homodimers. Comparing the experimental CCS obtained from the 
homodimers to the theoretical CCS obtained for the heterodimers, it appears that 
c-MYC-ZipΔDT and MAX both most likely exist in a disordered conformation whilst the 
c-MYC-Zip homodimer appears to be in the leucine zipper conformation. It would be 
expected of all the homodimers that MAX would be the one most likely to exist in a leucine 
zipper conformation due to its propensity to form homodimers
45,46
. However, perhaps the 
longer chain length of c-MYC-Zip allows this complex to form as a homodimer and it is 
limited by chain length for other homodimers, an effect which is overcome with the specific 
binding of the heterodimeric complex, as observed for the [C+5H]
5+
 species. Alternatively, it 
is possible that the pH of the solutions (pH 6.8) is more conducive for the disordered 
complex to form for MAX-Zip homodimers and alteration of the pH or addition of limited 
amounts of salt to the solutions may result in MAX-Zip leucine zipper homodimers being 
observed by DT IM-MS. In all cases the conformations adopted by the homodimers are not 
observed to change upon the addition of 10058-F4 (Appendix 2 Table A2.1) suggesting this 
ligand selectively inhibits the c-MYC:MAX leucine zipper dimers whilst having no effect on 
the homodimer formation over the time scale considered here, supporting the specificity of 
this ligand to the disordered heterodimer. 
 
 Conclusions 3.4
The studies presented here focused on the leucine zipper regions of c-MYC and MAX, their 
binding and inhibition by the ligand 10058-F4. Two different length c-MYC peptides were 
synthesised for this study, both containing the leucine zipper region but the peptide 
c-MYC-Zip also contained the previously identified 10058-F4 binding site. The studies 
presented here, however, show no significant differences in complex formation, inhibition or 
binding of 10058-F4, between the c-MYC-Zip and c-MYC-ZipΔDT peptides despite the lack 
of the full proposed binding site in the latter. The MS and DT IM-MS results here therefore 




ligand-bound species are observed, that the ligand has a Kd higher than that previously 
reported. Supported by a recent study utilising metadynamics simulations on a 10 amino acid 
stretch of c-MYC containing the identified drug target region (c-MYC402-412) which 
suggested that the ligand binding to c-MYC is driven primarily by weak, non-specific 
interactions with hydrophobic patches
55
. If these binding interactions are indeed primarily 
non-specific it would explain why there are no significant observed differences between the 
c-MYC-ZipΔDT and c-MYC-Zip peptides, with respect to inhibition of the leucine zipper 
conformation. For both heterodimers we observe a loss of the leucine zipper conformation 
upon the addition of 10058-F4; however, for c-MYC-Zip we also see a compaction of the 
[C+4H]
4+
 charge state. This is coupled with a shift in charge state, a decrease in the [C+5H]
5+ 
species, paired with an increase in the [C+4H]
4+
 state, observed for both c-MYC peptides, 
and suggests that the more loose form seen in the absence of the ligand and as the  [C+5H]
5+ 
species may be en route to zipper formation. 
The results presented here highlight that solution-based methods such as CD, for quantifying 
small changes in secondary structure for complex, dynamic, principally disordered systems 
provides ambiguous results and cannot provide the clear distinction between components 
that MS and DT IM-MS has achieved here. In addition to separating out ions of different m/z 
enabling monomers, homodimers and heterodimers to be clearly distinguished the 
conformational families of each can be individually determined.  
These results show that the c-MYC:MAX heterodimer comprising the leucine zipper peptide 
regions can exist in two distinct conformations, one of which is compact and hence likely 
disordered and a second which corresponds to an extended and potentially ‘coiled-coil’ 
structure. Using DT IM-MS these different conformational families can be identified and 
both distinct forms studied simultaneously. The formation of this leucine zipper coiled-coil 
type structure is inhibited by the ligand 10058-F4, pushing the equilibrium towards the 
disordered and supposedly inactive form, supporting that this ligand stabilises the disordered 
form. This proof of concept study has provided clear evidence that the combination of MS 
and DT IM-MS could provide a useful ligand screening method in the development of 
compounds designed to disrupt formation of the c-MYC:MAX leucine zipper. Furthermore, 
DT IM-MS is a powerful tool to distinguish between multiple conformations of dynamic 
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Investigating conformational equilibrium: 
Lymphotactin 
The theory that a protein will exist in a single, unique, evolutionary constrained 
conformation has been called into question by the characterisation of metamorphic proteins, 
which exist in multiple functional folds. Successful transmission of proteins into the gas-
phase does not depend on protein fold and therefore mass spectrometry is inherently well 
suited to study conformationally dynamic systems. This chapter presents the combination of 
MS, DT IM-MS and ECD as a tool to study proteins which are dynamic with respect to 
conformation, considering the metamorphic protein lymphotactin and specific mutants 








Lymphotactin (Ltn) is a unique chemokine for many reasons, for example, it contains an 
extended C-terminal sequence which forms an intrinsically disordered (ID) tail; it also 
contains a single disulfide bond as opposed to the two normally found in chemokines
1,2
. 
Most significantly Ltn is a metamorphic protein capable of adopting two distinct folds, for 
the same sequence of amino acids
3
, existing in a monomeric and dimeric fold (Chapter 1 
section 1.3.3). Lymphotactin exists in equilibrium between a monomeric conserved 
chemokine fold (Ltn10) and a dimeric fold (Ltn40) unique amongst the chemokine subclass 
(Figure 4.1).  
 
Figure 4.1: A) Monomeric Ltn10 (PDB 1J9O), B) Dimeric Ltn40 (PDB 2JP1). Green spheres 
highlight position of the disulfide bond. 
A number of proteins which can adopt multiple, distinct conformations have been previously 
identified, however, these proteins were initially considered ‘special cases’ with 
conformational switching often being observed to be triggered by environmental factors such 
as pH-induced transitions, redox-controlled transitions and disulfide isomerisation
4-7
.  The 
discovery of the metamorphic proteins Mad2 and Ltn, which can adopt distinct 
conformations in equilibrium in a ligand-free state, however, called in to question not only 
the theory that a protein will exist in a single unique conformation but also if traditional 




Ltn is a well-studied metamorphic protein; both conformations adopted have been solved, 
conditions under which the conformational equilibrium can be shifted are known and 
biological functions of both folds are under study
1,3
. Ltn is therefore an ideal model 
metamorphic protein to study in order to determine if both distinct folds of such a protein 
can be preserved, transmitted and distinguished in the gas-phase
9
. Such a study would help 
determine if a mass spectrometric framework would be a suitable alternative to traditional 
structure elucidation techniques. Furthermore, Ltn10 is an excellent model system to probe 




containing an α-helix and three β-strands stabilised by a disulfide bond, as well as possessing 
an ID region. 
The ability of MS-based techniques to study both structured and unstructured proteins, 
combined with the ability of IM-MS to distinguish between multiple conformations, even 
when they present at the same charge state, suggests that a MS-based approach could 
overcome the (unintentional) bias associated with many traditional techniques that consider 
and solve for only a single conformation. One particular advantage of MS-based techniques 
is they provide an opportunity to distinguish between intrinsic and extrinsic factors 
contributing to protein fold stability. Prior to performing gas-phase structural studies, 
however, one has to consider the effect of ionising and desolvating protein structures. It 
appears probable that protein ions generally undergo some structural collapse of side-chain 
groups within picoseconds of dehydration
10
, however, onset of gross structural 
rearrangements can require tens of milliseconds to seconds, therefore one could propose that 
as long as experimental trapping times are kept short the solution fold may be retained
10-12
.  
MS-based techniques can be used to sample dynamic conformations as well as to take 
‘snapshots’ of protein folding and unfolding, using labelling or label-free methods. Labelling 
methods can involve hydrogen/deuterium exchange or more recently a technique known as 
fast photochemical oxidation of proteins, both of which have produced some elegant studies 
of protein folding and dynamics in addition to distinguishing between protein 
conformations
13-19
. These techniques, however, generally involve digesting the sample prior 
to MS analysis and therefore conformational information obtained is an average of all 
species present in solution. Label-free MS-based methods can be used to consider all 
conformations present in solution individually, and generally have been focused on studying 
unfolding either via increasing the time ions spend in the gas-phase or through consideration 
of multiple charge states, and most frequently in combination with IM-MS studies
20-22
.   
IM-MS has been used to distinguish between distinct conformations of proteins and 
aggregating peptide systems which can undergo conformational switching, highlighting its 
applicability to investigate conformationally dynamic systems
23,24
. One such study presented 
by Jenner et al
25
, studied NADPH-cytochrome p450 reductase (CPR), using MS and IM-MS. 
CPR exists in an ‘open’ and ‘closed’ conformation, where in its ‘closed’ conformation it is 
inaccessible to the large cytochrome p450 molecule and hence movement of domains is 
functionally essential. The IM-MS studies presented in this study not only highlighted that 
the two distinct conformations could be preserved into the gas-phase but also the population 




Furthermore, careful consideration of conformations, along with elegant mutagenesis 
studies, identified two key salt bridges essential for the compact conformations to form. 
Their findings highlighted that these stabilising interactions could be preserved in the gas-
phase over the time scale of these experiments and that IM-MS can be a useful tool to study 
conformationally dynamic systems, allowing multiple conformations to be studied in each 
experiment.  
Recently a study was presented by Skinner et al
26
 which compared structural analysis from 
electron capture dissociation (ECD) experiments, to previously obtained results from 




 groups. This study focused on the 
unfolding of ubiquitin [M+7H]
7+
 and highlighted that comparison of ECD and DT IM-MS 
has great promise to gain insight into unfolding of protein ions as a function of time spent in 
the gas-phase.  
Although many MS fragmentation techniques exist, ECD is particularly advantageous for 
protein structural studies. This is due to the fast, non-ergodic, fragmentation process which 





ECD is therefore thought not to perturb the higher order structure 
of proteins, enabling examination of the conformations adopted by a single protein over 
multiple charge states. Over the last couple of decades ECD has been used in a number of 
elegant studies of protein fold providing further information on protein conformations and 
their stabilities in the gas-phase
30-34
. 
Despite the obvious promise in the combination of these techniques
35,36
, to-date a study 
combining these techniques to explore protein unfolding as a function of charge has not yet 
been presented. Furthermore, the applicability of such a combination of techniques to 
distinguish between multiple conformations of the same protein has not been addressed.  The 
combination of these techniques would allow the study of fold and unfolding by IM-MS, 
with amino acid detail provided by ECD analysis, and could be used to delineate the stability 
of various regions of protein fold. This chapter focuses on the application of these techniques 
to differentiate between two distinct folds of wild type (WT) Ltn. Studies are performed on 
mutants of Ltn designed to stabilise each distinct conformation, in order to further probe 






4.2.1 Protein samples 
All recombinant human lympohactin (Ltn) samples were expressed and purified by the 
Volkman Research Group (Medical College of Wisconsin, Milwaukee, USA) as previously 
described
1,37,38
. Due to differences in expression and purification systems used for WT Ltn 
and the mutants CC3 and W55D, residues M63 and M73 were mutated to valine and alanine 
respectively in both CC3 and W55D. These mutations cause no distinguishable difference in 
structure or function
3,38
. Protein samples were received as lyophilised samples and stored 
at -20 °C for subsequent study.  Stock solutions were typically prepared at 100, 150 or 
200 μM in high purity water or 20 mM ammonium acetate (AmAc) and stored in aliquots at 
-20 °C until use. Concentrations of protein solutions were verified using the Pierce BCA 
concentration assay (Thermo Fischer Scientific, Wilmington, DE, USA) following 
manufacturer’s instructions, using volumes 10 times lower than stated in the manual, 
afforded through use of low volume UV cuvettes.  
4.2.2 Sample preparation for MS studies 
All MS studies into the effect of solution conditions on the monomer-dimer equilibrium of 
wild type (WT) and W55D Ltn constructs were performed on 50 μM protein solutions, 
prepared in high purity water or AmAc at 20, 50, 100 or 150 mM concentration.  
To study the effect of pH on the equilibrium of WT Ltn 20 mM AmAc was used as buffer, 
the pH of which was altered over the range 5.8 to 2.8 through drop-wise addition of formic 
acid (VWR International Ltd, UK). The effect on the WT Ltn monomer:dimer equilibrium of 
adding NaCl (Sigma Aldrich Ltd, UK) was studied using 20 mM AmAc plus either 1 or 
5 mM NaCl.  W55D pH studies were performed in 20 mM AmAc buffer, over the pH range 
9.8-2.8, buffer pH was adjusted through drop-wise addition of either ammonia (Fisher 
Scientific, UK) or formic acid. Monomer-dimer equilibrium for CC3 and WT 1-72 were 
studied using 50 μM protein solutions in 20 mM AmAc at pH 6.8. 
The ability of the structural core to bind the ID tail was probed using a sample solution 
containing a 1:1 mixture of WT 1-72 plus WT 72-93 each at a concentration of 50 μM in 




All MS experiments were performed on a Q-TOF Ultima (Waters, Manchester, UK), for 
typical operating conditions see Chapter 2 section 2.2. All studies, except those involving 
WT 72-93, were performed on the Q-TOF Ultima prior to the high mass upgrade.   
4.2.3 Sample preparation for DT IM-MS studies 
For CCS determination all Ltn samples were prepared at 100 μM in 20 mM AmAc. 
Additionally, CC3 supercharged samples were prepared at 100 μM in 20 mM AmAc plus 
1 % meta-nitrobenzyl alcohol (m-NBA), purchased from Sigma Aldrich Company Ltd 
(Dorset, UK). DT IM-MS measurements were performed on an in-house modified Q-TOF 
(Micromass UK Ltd.), as described in Chapter 2 Section 2.3. 
4.2.4 Sample preparation for ECD studies 
Electron capture dissociation (ECD) fragmentation studies for monomeric WT Ltn and 
WT 1-72 were performed on solutions of 5 μM protein in 100 mM AmAc. ECD studies for 
CC3, W55D and dimeric WT Ltn, were performed on 30 μM protein in 100 mM AmAc. 
CC3 supercharged samples were prepared at 30 μM in 20 mM AmAc plus 1 % m-NBA. 
All ECD studies were performed on a 12T Apex Ultra Qh FT-ICR mass spectrometer 
(Bruker Daltonik Gmbh, Bremen, Germany), instrumental details can be found in Chapter 2 
section 2.5. 
4.2.5 Molecular modelling 
Ltn molecular modelling was performed by Dr Massimiliano Porrini. In brief, theoretical 
CCS were determined for Ltn10, Ltn40 and CC3 Ltn from the NMR structures (PDB 
identifiers 1J9O, 2JP1 and 2HDM respectively) plus Ltn10 1-72. The structures were 
minimised in vacuo using the sander engine of Amber11
39
 and implementing Amber99SB-
ILDN
40
 prior to determining their CCS using the trajectory method of MOBCAL
41
. For 
Ltn40, the PDB file (2JP1) contains 20 candidate structures and theoretical CCS were 
determined for each using the above procedure and the average value reported as the 
theoretical CCS. Details on additional molecular dynamics simulations performed on WT 





 Results and discussion 4.3
4.3.1 Studying the conformational equilibria of WT lymphotactin using MS  
The initial stage of investigation into this metamorphic protein focused on determining if 
both distinct forms, ie monomer (Ltn10) and dimer (Ltn40), could be preserved and 
transferred into the gas-phase.  
The mass spectrum for wild type (WT) Ltn was acquired in 20 mM ammonium acetate 
(AmAc), Figure 4.2. Both monomeric (MWT) and dimeric (DWT) species are observed in the 
spectrum, with monomeric species being more intense.  Monomeric WT Ltn presents over a 




, this suggests the protein is 





which are particularly intense suggesting the conformations of Ltn which can accept either 
six or seven net protons are particularly favourable. Dimeric WT Ltn is also observed, over 




, at lower intensity than the monomer. 
This indicates both distinct forms of WT Ltn can be preserved and transmitted into the gas-
phase, however, here the equilibrium between the two is pushed strongly towards monomer.  
 
Figure 4.2: The mass spectrum obtained for 50 μM WT Ltn in 20 mM AmAc pH 6.8.  
NMR studies have shown that the solution equilibrium can be altered through the choice of 
specific solvent conditions; Ltn10 was found to be favoured in 20 mM phosphate buffer with 
200 mM NaCl (pH 6) and Ltn40 was solved in 20 mM sodium phosphate (pH 6).  It has been 




chemokine (Ltn10) fold and promotes formation of the dimeric (Ltn40) fold
2
. This repulsion 
can be overcome by binding a chloride which will stabilise Ltn10 by neutralising the 
repulsive effect, hence high salt content pushes the equilibrium towards Ltn10. High 
concentrations of salts such as NaCl, however, are not compatible with MS-based studies, as 
they ionise readily and are transmitted easily, generally suppressing protein signal. In 
addition, salts can bind to protein and depending on their volatility can be retained after 
ionisation and desolvation. This causes an apparent diminished intensity for the protein 
signal as the observed signal is split over several different species, containing different 
numbers of salts adducted to protein, as shown in Appendix 3 Figure A3.1 for WT Ltn in 20 
mM AmAc plus 5 mM NaCl. Therefore it is not feasible to directly copy the solution 
conditions employed in NMR studies of Ltn to MS studies. 
There are solvent conditions that can be altered whilst remaining compatible with n-ESI-MS 
studies; for example the strength of volatile buffer as well as solution pH. The effect of 
altering both of these and their influence on Ltn monomer-dimer equilibrium were 
considered. Figure 4.3A illustrates the effect of altering buffer concentration from 0 mM 
AmAc to 100 mM AmAc. For WT Ltn in water (Figure 4.3A top) only monomeric species 
are observed and a major shift in the charge-state distribution (CSD) to higher charge states 
is observed, as compared with WT Ltn in 10-100 mM AmAc. These low m/z values are 
expected, as water, often in combination with organic solvents, promotes high charge states, 
whilst addition of volatile buffer salts is known to lower the charge states observed
42
. The 
difference between water and 10 mM AmAc is dramatic and highlights that for Ltn the 
obtained spectra can be strongly influenced by solvent conditions. Furthermore water is not a 
suitable solvent to probe the Ltn10 and Ltn40 folds and further studies require buffered 
‘near-native’ solutions. 
The mass spectra obtained for Ltn in 10-100 mM AmAc highlight that under all buffered 
conditions studied here monomeric and dimeric forms of WT Ltn are preserved. It is clear 
that as buffer strength is increased the CSD narrows and shifts to lower charge states, as 
expected. The shift in charge state over this range of buffer conditions is, however, very 
small, suggesting that Ltn adopts similar states under all AmAc buffer strengths studied. At 
high buffer strengths it is possible to slightly increase the relative proportion of dimer, 
however, a major shift in the equilibrium is not observed and monomer is always more 
intense. The mass spectrum obtained in 20 mM AmAc presents a wide range of charge states 




other studies of WT Ltn (except ECD studies, see section 4.2.4) were carried out at this 
buffer strength. 
 
Figure 4.3: WT Ltn mass spectra for 50 μM Ltn A) Buffer strength, 0-100 mM AmAc, B) Buffer pH, 
6.8-2.8, altered through addition of formic acid to 20 mM AmAc. For top panels all major species are 
labelled, in all other panels the highest and lowest charge states of monomer and dimer are labelled.  
All NMR studies on this metamorphic protein were performed at pH 6, however, 20 mM 
AmAc with no additional additives is pH 6.8. Therefore in order to determine if studies 
would be better performed at a lower pH, in addition to probing the effect of pH on 
monomer-dimer equilibrium, the pH of 20 mM AmAc buffer was lowered through addition 
of formic acid (Figure 4.3B). Ltn is extremely pH stable, with no observed change in the 
CSD of both monomer and dimer between pH 6.8 and 4.8. At pH 3.8 a slight shift in the 
CSD is observed for monomeric Ltn. [MWT+6H]
6+




species, however, there is a marginal increase in the intensity of higher charge states. At pH 
2.8 an additional shift in the CSD is detected with [MWT+7H]
7+
 now being the most intense 
species. Furthermore, at pH 2.8 the intensity of dimeric species decreases. The changes 
observed in the CSDs, however, are much less dramatic than would be expected for a typical 
protein
43
, highlighting the stability of WT Ltn, enabling MS experiments to proceed at pH 
6.8, which simplifies the solution conditions.  
Interestingly under all MS compatible solution conditions studied here monomeric Ltn is 
consistently observed to be the dominant form, suggesting under these conditions it is more 
stable than the dimer, or under these conditions a proportion of the dimer is dissociating to 
monomer increasing the observed monomeric signal, a hypothesis which can be explored 
using DT IM-MS.  
4.3.2 Examining the metamorphic conformations of WT Ltn by DT IM-MS and 
ECD 
4.3.2.1 DT IM-MS of monomeric WT Ltn 





 (Figure 4.4 and Appendix 3 Table A3.1). As the charge increases, the CCS 
increase can be attributed to increased access to protonatable sites in solution for the more 
unfolded forms and to Coulombic effects. The lowest charged species observed 
([MWT+4H]
4+
) is present at low intensity with a CCS significantly smaller than that of 
[MWT+5H]
5+
; which is assigned to a significantly collapsed species, as has been reported 
previously for gas-phase monomeric proteins
11,20
, suggesting that this form is not structurally 
stable.  
MS indicated the most significantly populated species observed under these conditions 
presented with between five and seven net protons (Figure 4.2). Interestingly from 
DT IM-MS it is observed that these species all present with exceptionally similar CCS 
(~1000 Å
2
), establishing that there is a compact, stable conformational family in solution, 
which can accept between five and seven net protons without a major unfolding transition. 
The slight increase in CCS observed over this charge state range can be ascribed to 
Coulombic effects.  A significant increase (up to 42 % larger than [MWT+7H]
7+










Figure 4.4: Average CCS from three repeats determined for WT Ltn, error bars show standard 
deviation between repeats. WT monomer species are represented by black dots and dimer species by 
grey squares. WT 1-72 monomeric CCS are represented by open circles. Theoretical CCS for WT 
Ltn10 (PDB 1J9O) and Ltn40 (PDB 2JP1) are shown by dashed black and grey lines respectively. 
Dotted line represents the theoretical CCS obtained for the clipped structure of PDB file 1J9O, 
removing residues 73-93.  
From DT IM-MS it is clear that here monomeric WT Ltn exists in three distinct 











). In order to determine if any of these 
conformational families could be due to WT Ltn in its solution-phase conformation (Ltn10) a 
comparison between experimental CCS and predicted CCS from the solved structure (PDB 
1J9O) was made (Figure 4.4). The theoretical CCS determined from the NMR structure was 
1694 Å
2




 species but 
compares favourably with the CCS determined for extended conformational family. PDB 
1J9O contains the ID tail extended from the structural core, resulting in a large theoretical 
CCS and suggesting that the extended conformational family retains the Ltn10 fold, with the 
ID tail unfolded from the structural core. It is important to note that [MWT+9H]
9+
 is observed 
experimentally to exist in two conformations the second of which is even more extended (up 
to 50 % larger than [MWT+7H]
7+
) and corresponds to a conformer further along an unfolding 
pathway, a point discussed in more detail below. 
The theoretical CCS for Ltn10 is significantly larger than the compact conformational 




core of Ltn without the ID tail, achieved by clipping the NMR structure (PDB 1J9O) 
removing residues 73-93. When the tail is removed a theoretical CCS of 1176 Å
2
 is obtained, 
which is in agreement with the experimental CCS obtained for full length WT Ltn in the 




, suggesting that these species retain the 
Ltn10 fold with the tail associated or wrapped around the structural core.  
To study this hypothesis an Ltn construct was considered which consists only of the 
N-terminus and structural core (residues 1-72) known as WT 1-72. Experimental CCS were 
determined for monomeric WT 1-72 (M1-72) (Figure 4.4 open circles and Appendix 3 Table 
3.2), and compare exceptionally favourably with full length MWT Ltn in its compact 
conformation. It was therefore surmised that in its compact conformational ensemble full 
length MWT Ltn exists in the Ltn10 fold with the ID tail wrapped around or associated with 
the core. Interestingly, WT 1-72 also contains an extended conformational family, with a 
second larger conformation observed for [M1-72+7H]
7+
 in addition to an extended 
[M1-72+8H]
8+ 
species, a point which is discussed in detail in section 4.3.2.4.  
Finally, the ability of the structural core (WT 1-72) to bind the ID tail was studied 
experimentally by MS through the addition of a peptide consisting of the tail residues (WT 
72-93) to a solution of WT 1-72. The spectra obtained from a 1:1 mixture confirm that the 
tail can bind the structural core (Appendix 3 Figure A3.2). Hence, from the studies of 





) monomeric full length WT Ltn is most likely in the Ltn10 fold with the tail 
wrapped around the structural core. The tail unfolds to form the extended conformational 
family causing a dramatic increase in CCS at charge states 8 and 9+. 
4.3.2.2 DT IM-MS of dimeric WT Ltn 









 have very similar CCS ~1778-1902 Å
2
. These experimental 
values are compared to a theoretical CCS obtained from the NMR structure of Ltn40 and are 
found to be in good agreement but marginally larger than the predicted CCS (1610 Å
2
). The 
PDB file (2JP1) used to determine the theoretical CCS, however, does not contain the full ID 
tail sequence, which would explain the slightly smaller predicted size. In fact this PDB file 
omits 33 amino acids from each chain, yet the difference between this theoretical value and 




dimeric species are in the Ltn40 conformation but once again the ID tail is wrapped around 
or associated with the structural core, as observed for Ltn10. 
The CCS for the lowest charge states, [DWT+8H]
8+
  and  [DWT+9H]
9+
  are significantly 
smaller  than the other dimer charge states (up to 29 % smaller than [DWT+10H]
10+
)  and up 
to 15 % smaller than the predicted CCS, suggesting these species are either the product of 
‘gas-phase collapse’ or a less structured solution-phase encounter complex between the 
unfolded monomeric chains. Additionally, two conformations are observed for [DWT+9H]
9+
, 
suggesting that this may be a transition species between a collapsed and structurally more 
stable form. 
4.3.2.3 ECD of monomeric WT Ltn, Ltn10 
From DT IM-MS experiments of WT Ltn, information on the fold and unfolding can be 
obtained. In order to further probe the fold, ECD fragmentation studies were then performed.  
In these studies higher buffer strength (100 mM AmAc) was implemented due to the harsher 
desolvation conditions of the FT ICR-MS instrument used here. The use of higher buffer 
strength enables a spectrum to be obtained (Appendix 3 Figure A3.3) which is similar to that 
of WT Ltn prepared in 20 mM AmAc and studied on the MS and DT IM-MS instruments; 
although a slightly higher range of charge states are observed here. 
 
Figure 4.5: Schematic representation of zIc, c- and z-type fragments.  




 were observed at 
high enough intensity and each charge state was studied in turn. Fragments formed during 
this process are identified by considering fragmentation producing c- and z-type fragments
44
 
(Chapter 1 section 1.5.3.4), as well as internal fragments which are formed by multiple 
backbone cleavages resulting in internal stretches of amino acids being observed (Figure 




C-terminus are denoted as ‘zIc’ fragments. Once all fragments had been identified their 
percentage yields were determined as a function of cleavage site (see Chapter 2 section 
2.5.1) and are shown mapped onto the Ltn10 fold in Figure 4.6. In Figure 4.6 the 
fragmentation occurring for each individual charge state studied is plotted as percentage 
yield versus the fragmentation site, amino acid at which fragmentation occurs, and 
identifying the species as a zIc c- or z-type fragment, obtaining a fragmentation map for a 
single charge state. The stacking of the fragmentation maps for each charge state enable 
trends across charge states to be identified, as shown in Figure 4.6. 
 
Figure 4.6: Percentage yields calculated for zIc, c- and z- type fragments as a function of cleavage site 




. A y-axis scale break is used here to show low level 




From the fragmentation map it is clear that as charge state increases there is a simultaneous 
increase in both the extent of backbone fragmentation and percentage yield of the fragment 
ions. This is expected due to a combination of effects, firstly ECD efficiency is known to be 
higher at higher charge states
45
 and secondly at higher charge states species are more likely 
to be more unfolded, hence there are more available sites of cleavage.  For all charge states 
the fragmentation yields are low, consistent with previous ECD studies
26,30
, due to the high 
intensity of charge reduced species, which have undergone electron capture with no 
dissociation. Furthermore, Ltn contains a disulfide bond and disulfide bonds have been 





would also result in a lower backbone fragmentation efficiency and, therefore, is an 
important consideration in such studies. Despite the low fragmentation yield insight into the 
protein fold and unfolding can be gleaned as fragmentation does not occur uniformly and 
observed fragments can be attributed to the presence (or absence) of stabilising non-covalent 
interactions present within the solution fold.  




) exhibit very little 
fragmentation, apart from at the N- and C-termini, consistent with a compact structured 
conformational family stabilised by non-covalent interactions. As the charge state increases 
both the number of fragmentation sites and the fragmentation yield increases. This is most 
evident in the region which forms the α-helix in solution, in addition to the N- and C-
terminus, consistent with these regions unfolding and hence being more amenable to 
cleavage, and in agreement with DT IM-MS results. Increased fragmentation is also 
observed in the regions between the β-sheet core and α-helix in addition to the region 
between the α-helix and the ID tail. Interestingly, at all charge states studied here very little 
fragmentation is observed within the intrinsically disordered tail region; attributed to the lack 
of backbone interactions in these regions, which are thought to be important for the ECD 
fragmentation mechanism
47
. For the [MWT+10H]
10+ 
additional sites of fragmentation are 
observed along the ID tail, suggesting it may have undergone a reordering or restructuring 
event to enable fragmentation to occur.  
For all charge states, the extent of backbone fragmentation and intensity of the fragmentation 
is low in the β-sheet core, often being observed only as zIc fragments as opposed to c- and z-
type fragments. The low efficiency of fragmentation in this region is expected as the β-sheet 
core is stabilised by the disulfide bond, which would limit fragmentation in this region. 
Hence, when considering the fold and unfolding of a protein using gas-phase techniques it 




potential to be retained in the gas-phase. The disulfide bond between residues 10-47 
covalently bonds and stabilises these regions and several fragments are observed with this 
bridge intact (Figure 4.6 and Figure 4.7). Disulfide reduced fragments are also observed and 
increase in intensity with charge state, suggesting that this bond becomes more accessible to 
electron capture as Ltn unfolds. The disulfide bond would help to stabilise the β-sheet core 
and at all charge states minimal fragmentation occurs within this region. It is not until the 
highest charge state that fragmentation is observed in the β1 and β2 strands, suggesting 
Ltn10 has to be far along its unfolding pathways before these regions become destabilised. 
Indeed even at the highest charge state, in which the most extensive fragmentation is 
observed across the protein, only 25 % of the total fragments observed occurred due to 
fragmentation in the β-strands. When fragmentation does occur here it is of low intensity, 
only 17 % of the overall summed intensity of all observed fragments.  Furthermore, cleavage 
in this region is most frequently a result of zIc fragmentation, with the zIc fragments 
generally consisting of more than one β-strand and suggesting these fragments partially 
retain some of the stabilising interactions present in the solution fold, attributed in part to the 
disulfide bond as well as non-covalent interactions.  
Non-covalent interactions such as salt-bridges can be retained in the gas-phase and may 
strengthen in the solvent free environment
10
. In order to consider such interactions for Ltn 
molecular dynamics simulations (MD) were performed (Appendix 3 section A3.1). Firstly 
two separate 150 ns MD trajectories were run in explicit solvent to identify potential salt 
bridges in solution (Appendix 3 Table A3.4). An occupancy cut-off of 20 % was applied to 
identify the most likely salt bridges and pooling the two simulations resulted in identification 
of the following interactions; Glu3-Arg8, Asp6-Arg8, Glu30-Arg56, Asp57-Arg17 and 
Asp57-Arg60. In order to determine if these salt bridges can be retained in the gas-phase, in 
vacuo simulations were then run. In MS and DT IM-MS charge states 5-7+ are observed to 
be most intense hence these charge states are the most desirable targets for MD simulations, 
however, only charge states 7-10+ could be observed at high enough intensity to be 
subjected to ECD and therefore the 7+ charge state was chosen for MD studies. An in vacuo 
simulation of [MWT+7H]
7+
 determined the salt bridges between Glu3-Arg8, Asp57-Arg17 
and Asp57-Arg64 all increase in occupancy in the gas-phase (Appendix 3 Table A3.5), 
furthermore, an additional salt bridge is formed between Asp63-Arg60. Both the 
Asp57-Arg60 and Asp63-Arg60 can act to stabilise the α-helix whilst Asp57-Arg17 would 





Figure 4.7: A) WT Ltn10 (PDB 1J9O) with residues implicated in salt bridge formation labelled 
acidic (red) and basic (blue), created in VMD. B) zIc fragmentation map for monomeric WT Ltn, with  





 little fragmentation is observed within the structural core, 
an exception to this is in the loop region between the end of the β-strand core and start of the 
α-helix (Ala52) where low intensity fragmentation is observed, which causes loss of residues 
53-91 in a single z-type
 
fragment, suggesting the α-helix is separable from the core. In 
solution the α-helix is positioned with respect to the β-sheets via a number of hydrophobic 
interactions
1
. Hydrophobic interactions can be lost in the gas-phase
10
, which would explain 
separation of the α-helix from the β-sheet core. The salt bridges between Asp57-Arg60 and 
Arg60-Asp63 can provide intra-helix stabilisation enabling it to be lost in a single stable 







observed. Loss of the α-helix is at a relatively 
low intensity and this could be due to the (lesser occupied) salt bridge between β1 and 
α-helix (Asp57-Arg17) which would limit α-helix dissociation and help to overcome the loss 
of hydrophobic interactions. 




) significant fragmentation is 
observed along the α-helical region in addition to more extensive termini fragmentation. This 
suggests that the higher charge states are most likely due to a form of Ltn10 where unfolding 
in the C-terminus and partial unravelling of the α-helix has occurred, and could indicate a 
loss of the influence of Asp57-Arg17 and intra-helix (Asp57-Arg60 and Asp63-Arg60) 
interactions, allowing cleavage to be accompanied by dissociation. When considering 
[MWT+9H]
9+
 it is important to note that in DT IM-MS experiments two conformations were 
observed. The more extended conformation has a CCS of 1685 Å
2
 and has been considered 






and the most extended [MWT+9H]
9+
), in combination with the 
ECD fragmentation maps highlight that between charge states 8 and 9+ the α-helical region 
becomes unravelled and more amenable to cleavage. For [M+10H]
10+
 fragmentation within 
the α-helical region and now along the ID tail indicates that loss of the α-helix disrupts the 
tails interaction with the core further accompanied by substantial reordering of the 
C-terminal region. 
For all charge states, fragmentation within the β-sheet region is limited, which as discussed 
above is attributed in part to the disulfide bond. Considering the solution-phase structure, 
visual examination of the PDB file identifies a potential classical salt bridge comprising 
Glu30-Arg34 and Arg34-Asp49, positioned across the top of the triple stranded β-sheet. MD 
simulations for Ltn10 in water suggest these interactions can occur (Appendix 3 Figure 
A3.6A) at low occupancy (lower than those listed in Appendix 3 Table A3.4). In vacuo 
simulations demonstrate that this bridge would strengthen significantly within the gas-phase 
(Appendix 3 Figure A3.6B). If present this salt bridge could provide an intriguing 
explanation for the gas-phase stability of the β-sheet region, in combination with the 
disulfide bond.  
For [MWT+8H]
8+ 
a single, low yield, c-type fragment ion is observed at residue 68, the region 
between the α-helix and start of the tail, which results in cleavage of the ID tail. 
Fragmentation in this region increases in percentage yield and number of fragmentation sites 
as charge state increases, suggesting fragmentation of the ID tail becomes more favourable 
as the charge state increases, consistent with DT IM-MS experiments which attributed the 
unfolding event occurring between charge states seven and eight to tail unfolding. 
Furthermore, the MD simulations of [MWT+7H]
7+
 also provide evidence for the ID tail 
folding in towards the structural core in solution (Appendix 3 Figure A3.4), and the tail 
remaining associated in the gas-phase resulting in a compact CCS ~1250 Å
2
 (Appendix 3 
Figure A3.5) providing further support to the interpretation of the DT IM-MS data. 
Fragmentation in the region between the α-helix and ID tail is, however, of low yield with 
fragmentation occurring along the α-helix consistently observed at higher yield, highlighting 
that the α-helix is more amenable to cleavage than the region between the α-helix and ID tail 
in these studies. 
Due to the low efficiency of ECD fragmentation, in order to carry out these studies a 
sufficiently high number of ions have to be trapped in the ICR cell prior to fragmentation. As 
all charge states of a protein are not observed at the same intensity and in order to trap a 




tuned for each charge state, employing the minimum trapping time in all cases (all on the 
order of seconds).  The possibility of ions unfolding further due to increased trapping time 
can therefore not be discounted and it is likely that the observed unfolding is due to a 
combination of both charge and trapping time in the ECD studies. In order to test this 
[MWT+10H]
10+ 
was analysed after trapping for one and seven seconds (Appendix 3 
Figure A3.7). The fragmentation maps obtained display similar trends however slightly more 
fragmentation in the β-sheet core is observed in the species trapped for seven seconds. This 
observation suggests that Ltn ions can undergo limited unfolding over the timescales of the 
ECD experiments. Unfolding as a function of time is an unavoidable consequence of such 
studies considering multiple charge states, as in addition to various other instrumental 
parameters the trapping time has to be tuned for each individual species, leading to increased 
trapping times for low intensity charge states. Matching the trapping times for all ions by 
increasing the time for higher intensity charge states would also have detrimental effects, 
namely oversaturation and signal ringing. The differences observed for increasing trapping 
time are much smaller, however, than the differences observed for increasing charge state, 




 (Figure 4.6) which were 
both trapped for the same length of time prior to ECD analysis but show significant 
differences in fragmentation. Therefore, in the remaining analysis of Ltn and its mutants 
unfolding as a function of trapping time is considered a minor contributor to this process and 
not discussed further. The major contribution to differences in ECD fragmentation maps and 
unfolding is attributed to charge state and hence the solution conformation prior to 
ionisation. In order to apply this technique to future protein systems, however, the effect of 
trapping time on unfolding for each protein would need to be assessed, as it may be expected 
to have a larger effect on less structurally stable proteins or proteins lacking any constriction 
due to disulfide bonds.  
Comparison between the structural elements of Ltn10, gas-phase fragmentation maps and 
DT IM-MS bears up remarkably well for monomeric Ltn, and further careful consideration 
can yield additional information. The NMR studies on Ltn10 found that residues 1-10 have 
less NOE restraints and higher RMSD values
38
, corresponding to a dynamic terminal region, 
and a region in which extensive backbone fragmentation was observed during ECD studies. 
In contrast residues 11-23 were found to be more ordered, with long-range NOEs and 
backbone RMSDs below 0.5 Å which has in part been attributed to the disulfide bond
38
 and 
in ECD studies less fragmentation is observed in this region. Hence, both the core structure 
and different extents of disorder in both termini are distinguished in ECD fragmentation 




structural region with respect to unfolding, highlighting that for Ltn10 the order of stability 
of each region is as follows C-terminus<N-terminus<α-helix<β3<β2<β1. Additionally, 
considering CCS in combination with the cleavage sites and fragmentation maps of the 
monomer over all charge states, insights into fold stability can be obtained (Figure 4.8). 
 





. Orange ‘lightning bolts’ indicate sites where ECD fragmentation is 
most significant. 
4.3.2.4 ECD of monomeric Ltn WT 1-72 
To further probe the fold and unfolding of Ltn10, monomeric WT 1-72 (M1-72) was also 
subjected to ECD fragmentation studies. WT 1-72 can be thought of as the minimum model 
of structured fold for Ltn10. This construct is mostly monomeric, however, a small 
proportion of dimer is also observed (Appendix 3 Figure A3.2), which due to its low 
intensity is not discussed here.  
For the lowest charge states of WT Ltn10 the ID tail is observed to be wrapped around or 
associated with the core, perhaps providing structural stability to the core, a hypothesis 





, were observed at high enough intensity to be trapped and 
subjected to ECD fragmentation. The resulting zIc, c- and z-type fragment ions were 
identified and percentage yields calculated, shown in the fragmentation map below (Figure 




 an increase in both the yield and extent 
of backbone fragmentation is observed with increasing charge states. For [M1-72+8H]
8+
 the 
extent of fragmentation occurring in the α-helix decreases in comparison to [M1-72+7H]
7+
, 
this is attributed to the lower signal intensity of the [M1-72+8H]
8+ 
species, leading to fewer 
ions being trapped and subjected to ECD and highlights the difficulties of performing such 
ECD studies on multiple charge states. Despite the high sensitivity of the FT ICR-MS 
instruments, the low efficiency of ECD requires a signal intensity of greater than 1 x 10
6 
ions 
for each scan, which can be overcome in many instances by increasing the trapping time 
allowing greater signal accumulation prior to ECD. For [M1-72+8H]
8+
 despite a trapping time 
of 10 seconds the signal intensity was on threshold, and lower than that of [M1-72+7H]
7+
, 





Figure 4.9: A) Percentage yields calculated for zIc, c- and z-type fragments as a function of cleavage 




. B) Sequence of WT 1-72 labelled with 




Information on the fold and unfolding can be gleaned through the consideration of the 
fragmentation maps, as with WT Ltn10 fragmentation does not occur uniformly and can be 
mapped onto the secondary structural elements, enabling trends in unfolding to be discerned. 
As the charge state increases both the extent and intensity of fragmentation observed 
increases in the N-terminal region suggesting it is beginning to unfold from the structural 




 fragmentation in the α-helical region is 
observed suggesting this region is also beginning to unravel and is hence more amenable to 
fragmentation. It is interesting to note that two distinct conformations are observed for 
[M1-72+7H]
7+





 and a more extended conformation (>40 % larger than [M1-72+4H]
4+
). This 
more extended conformation is similar in CCS to that of [M1-72+8H]
8+
, which when 
combined with the results of ECD fragmentation, suggests that here the increase in CCS is 
due to unfolding of the α-helix. 
As with full length WT Ltn10 very little fragmentation is observed in the β-sheet core, 
ascribed to greater stability in this region than the α-helix due to the disulfide bond and 
stability provided through gas-phase salt bridge formation, discussed above for full length 
WT Ltn. The fragmentation maps obtained from WT 1-72 and resulting trends are similar to 
those observed for WT Ltn10 with the protein unfolding via the C-terminus, and suggests 
that in the absence of the ID tail the fold is still stable and preserved in the gas-phase. One 
notable difference is that in full-length Ltn10 significant unravelling of the α-helix is not 
observed until [MWT+9H]
9+
 whereas in WT 1-72 this unravelling is observed from 
[M1-72+7H]
7+
. At lower charge states the ID tail is believed to be associated with the 
structural core of full-length WT protein and thought to unfold before the α-helix unravels. 
The fact that the α-helix is observed to unravel at lower charge states in WT 1-72 suggests 
that the ID tail may confer some form of structural stability and protection to WT Ltn10 fold 
and absence of the tail in WT 1-72 causes the α-helix to unfold at a lower charge states. 
Previous reports have shown that the ID tail of Ltn is entirely dispensable for receptor 
binding
38
, questioning the importance of this region. If the tail is conferring stability or 
protection to the core it could help explain why this region is conserved. Alternatively, WT 
1-72 may be observed to unfold at lower charge states due to its smaller size, as the charges 
are likely to occupy sites closer to one and other than in the full length protein at the same 
charge state, causing the protein to unfold to greater extents at lower charge states due to 
Coulombic repulsion. It is also possible that unfolding occurs due to a combination of both 
decreased stability due to the absence of the tail and greater Coulombic repulsion due to the 




combination of DT IM-MS and ECD experiments highlighting vulnerable regions in the 
unfolding pathway (Figure 4.10).  
 





. β-strands are represented by arrows and the α-helix is represented by a 
spiral, dashed spiral represents a loss of defined structure.  Orange ‘lightning bolts’ indicate sites 
where ECD fragmentation is most significant. 
4.3.2.5 ECD of dimeric WT Lymphotactin, Ltn40 
To probe Ltn40, only the charge states of dimer where net charge is an odd number and 







. As for the monomer, zIc, c- and z-type fragments were 
considered; however, since both monomeric units are identical in sequence these 
experiments do not distinguish between the two chains and therefore the total fragment 
percentage yields are mapped onto a single monomeric unit (Figure 4.11 and Figure 4.12). 
There are two main fragmentation pathways for this non-covalent complex; dimer can 
remain intact and fragment, or dimer can dissociate to monomer and then fragment. Both 
were considered during analysis, shown in Figure 4.11 where above axis histograms 
represent dimer fragmentation and below axis chromatograms represent dissociation to 
monomer followed by fragmentation.  
For [DWT+9H]
9+
 ECD mainly leads to dissociation from dimer to monomer followed by 
extensive fragmentation along the backbone, which suggests that the dimer interface is not 
stable in this form. The instability of the dimer at this charge state can be attributed to either 
collapse upon ionisation and transfer or to a less stable encounter species, and is entirely 
consistent with the findings from DT IM-MS, in which the CCS for the lowest charge states 
of dimeric WT Ltn are smaller than that of the predicted CCS, a phenomena which has been 
reported previously
11,48
.   





greater stability as dimers, with a much lower proportion of dimer dissociating to monomer 




fragmentation maps are striking, showing almost complete retention of the dimer within the 
β-sheet interface, residues 11-51. The majority of fragments arise from cleavage either side 
of this structural core, residues 1-10 and 47-61 indicating that this β-sheet region remains 
stable within the gas-phase. The results suggest that the ID tails are wrapped around the 
structural core, and that the less dynamic part of this tail (residues 52-60) is more closely 
associated. 
  
Figure 4.11: Percentage yield calculated for zIc, c-and z-type fragments as a function of cleavage site 






. Above axis histograms represent 
fragments formed while retaining the dimer interface. Below axis histograms represent fragments 




As with Ltn10 possible interactions which could serve to stabilise Ltn40 within the gas-





. MD simulations were performed in solution and in vacuo to identify any 
potential salt bridges, which would act to stabilise the gas-phase structure. A number of salt 
bridges were identified in the two solution runs (Appendix 3 Table A3.6) and the in vacuo 
run (Appendix 3 Table A3.7).  As with Ltn10 the occupancy of some identified salt bridges 
increased for Ltn40 in vacuo in comparison with in solution, characteristic of electrostatic 
interactions, and analysis will focus on salt bridges retained in the gas-phase. In vacuo MD 
simulations identified a number of intra-chain salt bridges between residues Asp49-Arg8, 
Asp49-Arg34 for Chain A and interactions between Asp6-Lys7, Asp49-Arg8, Asp49-Arg34 
and Asp57-Arg56 for Chain B. A higher number of salt bridges are identified in Chain B due 
to the asymmetric distribution of charges in the 11+ species, where Chain A contains an 
additional charge. All identified intra-chain salt bridges lie on the edges of the β-sheet core 
and hence if these interactions are preserved in the gas-phase, they would stabilise this 
structural region. Furthermore, in Ltn40 the disulfide bond covalently links β0 to β3 
providing further intra-chain stability.   
A high number of possible inter-chain salt bridges were also identified; Arg22-Glu30, 
Glu30-Lys24, Arg22-Asp57, Asp57-Arg17, Arg42-Glu3, Arg17-Glu3, Glu30-Arg61, and 
Glu30-Arg22 (denoted ChainA-ChainB). Significantly all of these potential salt bridges lie 
on the edges of the β-strands and could therefore strengthen the dimer interface (Figure 
4.12). These stabilising interactions could serve to retain aspects of the Ltn40 fold in the gas-
phase, which is supported by the finding that these residues are retained at high frequency in 
zIc fragments (Figure 4.12).  
 
Figure 4.12: A) Ltn40 (PDB 2JP1) with inter-chain salt bridges labelled, acidic residues (red) and 
basic (blue), created in VMD. B) WT sequence with disulfide bond (solid line). All stretches of 









The CCS of [D+11H]
11+
 as a function of time during the 200 ns MD simulation  is centred at 
~1550 Å
2
, smaller than the experimental value (1802 Å
2
) for this species as determined by 
DT IM-MS (Appendix 3 Figure A3.8). Differences here can be attributed to the C-terminal 
tail which is not present in the starting structure (PDB 2JP1) and would certainly increase the 
CCS. Careful comparison of the results from the combination of gas-phase techniques 
presented enables the unfolding pathway of this protein to be mapped (Figure 4.13).  
 











 the dimer is represented here 
by a single monomeric unit with β-strands being represented by arrows. Orange ‘lightning bolts’ 
indicate sites where ECD fragmentation is most significant for the dimer. For [D+9H]
9+
 where 
fragments only map to a monomer unit with no secondary structure, the extensive fragmentation is 
depicted by a large lightning bolt and dashed lines represent a lack of defined structural elements.  
In order to determine if dimeric Ltn is present in the Ltn40 conformation as opposed to a less 
specific form such as a dimer of Ltn10, comparisons between the two fragmentation maps 
are made (Figure 4.6 and Figure 4.11). The residues 10-25 in Ltn10 have little structure and 
hence fragmentation is observed along the backbone here. In Ltn40, however, these residues 
have formed the β0 strand and loop to β1, and subsequently in dimeric WT Ltn very little 
fragmentation is observed in this region, consistent with increased structural stability.  Next 
considering the residues which form the α-helical region in Ltn10 (residues 54-66), ECD 
fragmentation maps of the higher charge states of monomeric Ltn show sequencing along the 
entire backbone of this region, consistent with an α-helical region unravelling. In dimeric 
Ltn, fragmentation is not observed along this region and instead fragmentation is observed to 
branch out from the β-sheet core, with the most favourable fragmentation site observed as 
residue 53, demonstrating that retention of the structural core and loss of residues 52-93, 
which contain very little secondary structure in Ltn40, is preferential. Additional 
fragmentation in the nine amino acids which form the first part of the ID tail (residues 52-60) 
is observed in Ltn40 suggesting this region is associated with the protein core and hence 




which allowed this region to be solved. Fragmentation maps of monomeric and dimeric Ltn 
show prominent differences between the two, providing compelling evidence for retention of 
both the Ltn10 and Ltn40 conformations in the absence of solvent, and the power of this 
technique to report on folded forms and unfolding intermediates. These significant 
differences in the ECD fragmentation of the two WT Ltn species, highlight that here it is 
probable that both distinct folds of this metamorphic protein have been preserved and can be 
differentiated in an unsolvated form.  
4.3.3 Probing the Ltn10 and Ltn40 folds through specific site mutations 
The Volkman research group previously designed two specific site mutants CC3 and W55D, 
intended to mimic each distinct fold of Ltn whilst limiting interconversion to the other
3,38
. 
CC3 and W55D are studied here to further probe the Ltn10 and Ltn40 folds in the gas-phase 
and are compared to WT Ltn. All experimental conditions for both CC3 and W55D, were 
kept as similar to WT Ltn as possible to enable direct comparisons to be made, enabling each 
distinct fold to be further probed and the effectiveness of these mutations to stabilise each 
fold to be determined. 
4.3.3.1 Probing the Ltn10 fold, consideration of the CC3 mutant 
CC3 is designed to mimic Ltn10 and contains an additional disulfide bond based on the third 
disulfide in the CC chemokine, HCC-2
38
. CC3 was engineered by introducing two extra 
cysteines in positions 21 and 59, with the aim that addition of an extra disulfide bond, based 
on a chemokine fold, would structurally constrain Ltn stopping structural rearrangement to 
Ltn40. The spectrum obtained for CC3, highlights that this mutant exists primarily in a 
monomeric (MCC3) form with very little dimer signal as expected (Figure 4.14A). The CC3 





species which accept either six or seven protons being the most favourable and hence most 
intense.  
The global fold of CC3 was assessed by DT IM-MS and the CCS determined are consistent 
with a structurally constrained species presenting over a narrow range of conformations 
(Figure 4.14B and Appendix 3 Table A3.8) increasing by only 23 %, a stark contrast to WT 
Ltn which was observed to increase by up to 50 %. This decrease in flexibility is expected 
considering CC3 contains a second disulfide bond. The NMR structure for CC3 has been 
solved (PDB 2HDM) enabling direct comparisons between experimental and theoretical 
values for this construct to be made, and are found to be in extremely good agreement. The 




in the ID tail. As experimental values for the full length protein match extremely well with 
this theoretical value it is surmised that, as with WT Ltn, the ID tail is wrapped around or 
associated with the structural core. In the case of CC3, however, the ID tail is associated with 
the core at all charge states studied, attributed in part to the disulfide bond placement which 
pins the α-helix to the structural core and may therefore also encourage tail association 
increasing the stability of this compact form and limiting unfolding. 
 
Figure 4.14: CC3 Ltn in 20 mM AmAc A) Mass spectra obtained for 50 μM protein B) Experimental 
CCS, reported values are an average of three different day repeats. Error bars fall within the symbol 
size and represent standard deviation of the three repeats. Theoretical CCS of the CC3 mutant was 
determined from the NMR structure (PDB 2HDM) and is shown by dashed line. 
To probe the stabilising effect of the additional disulfide bond on the Ltn10 fold and 





were observed at high enough intensity to be subjected to ECD fragmentation 
and the resulting fragmentation maps are shown in Figure 4.15. For all species studied very 
little fragmentation is observed, as expected due to their relatively low charge states and 




 only minor fragmentation is observed in 
both termini, with a marginal increase in backbone fragmentation observed for the two 




). The fragmentation maps highlight, 
at all charge states, CC3 is present in compact stable conformations which cannot undergo 
extensive fragmentation, an observation which is entirely consistent with findings from DT 
IM-MS. It is important to note that fragmentation would also be limited due to the two 













species formed are identified as zIc, c- and z-type fragments. B) CC3 sequence labelled with disulfide 








, zIc fragments corresponding to complete loss of the 
ID tail are observed, suggesting at these higher charge states the tail is more loosely 
associated with the structural core and hence can be lost during ECD fragmentation. For 
[MCC3+8H]
8+
 low intensity fragmentation in the α-helix is also observed suggesting this is the 
first secondary structural element to unfold, consistent with WT Ltn10. Complete sequencing 
along the backbone of this region is however not observed suggesting it has not unravelled 
and unfolded fully an observation consistent with DT IM-MS experiments in which 
[MCC3+8H]
8+ 
is only 23 % larger than the most compact species.  
As with WT Ltn, minimal fragmentation occurs within the β-sheet core, with fragmentation 
in this region forming low intensity zIc fragments (Figure 4.15); 19 % of the total fragments 
for this species are due to fragmentation here, corresponding to only 6 % of the total 
intensity. Indeed considering the stabilising interactions present it is anticipated that very 
little fragmentation would occur within the core, as CC3 contains two disulfide bonds 
between residues 11-48 and residues 21-59, which would act to stabilise this core region 
substantially. Furthermore, as with Ltn10 there are likely to be a number of stabilising salt 
bridges conferring stability to the structure, within the α-helix and perhaps due to the 
compact nature of these species within the structural core. In-depth salt bridge analysis was, 
however, not performed here.  
Considering DT IM-MS and ECD data, and the fact that this mutant is mostly observed at 
low charge states, it is clear that this construct is more compact and less prone to tail 
unfolding than WT Ltn and hence CC3 is an effective, stable construct to mimic the Ltn10 
fold. 
4.3.3.2 Probing the unfolding landscape of Ltn10: supercharged CC3  
To probe the fold and stability of CC3 at higher charge states and potentially further along 
the unfolding pathway CC3 was studied under similar instrumental conditions but after the 
addition of a ‘supercharging’ reagent, meta-nitrobenzyl alcohol (m-NBA). m-NBA causes an 
increase in charging due to an increase of surface tension in the n-ESI droplets
49
, and due to 
charge repulsion the increase in charge can promote more extended species. The addition of 
1 % m-NBA to 20 mM ammonium acetate enabled the highest observed charge state in the 




 (Figure 4.16A). The CCS for all 
species were determined by DT IM-MS (Figure 4.16B and Appendix 3 Table A3.8). For 
charge states observed in both buffered and supercharged conditions, an increase in CCS of 




extended structures at all charge states. This is most evident for the highest charged species 
observed under both solution conditions, which show the greatest increase in CCS in the 
presence of m-NBA. The difference in CCS after addition of m-NBA suggests that the 
conformations are somewhat altered upon addition of this supercharging reagent. Indeed 
previous studies have shown that addition of supercharging reagents can disrupt the native 
conformation of protein complexes
50
. The promotion of higher charge states, however, 
enables the unfolding of CC3 to be further explored, which could not be afforded through 
consideration of only buffered conditions.  
 
Figure 4.16: CC3 Ltn in 20 mM AmAc plus 1 % m-NBA A) Mass spectra obtained for 50 μM protein 
B) Experimental CCS, reported values are an average of three different day repeats. Error bars fall 
within the symbol size and represent standard deviation of the three repeats. Theoretical CCS of CC3 
and WT Ltn were determined from the NMR structures (PDB 2HDM and 1J9O) and are shown by 
dashed and dotted lines respectively. 
From Figure 4.16B it is evident that under these supercharged conditions, there is no major 
conformational shift or key unfolding transitional state, characterised by a significant shift in 
CCS observed at a single charge state. For WT Ltn a major conformational switch was 
observed between charge states 7+ and 8+, which was attributed to α-helix unravelling 
attributed to a loss of salt bridge stabilisation, however, for CC3 due to the placement of the 
additional disulfide bond (Figure 4.17) this unfolding pathway is limited. Instead CCS 
increases steadily (~1023-1824 Å
2
) highlighting that under these conditions unfolding of 
CC3 is a continuous process consisting of small incremental increases in CCS. CCS obtained 
for supercharged CC3 Ltn are compared both to the theoretical CCS obtained from the NMR 
coordinates for this mutant (PDB 2HDM) and those obtained for WT Ltn10 (PDB 1J9O), 
with the ID tail extended out from the structural core of the protein (Figure 4.16B). The 
theoretical CCS determined for  CC3 compares well with the lowest charge states observed 








addition of m-NBA they are most likely still folded with the ID tail associated with the 
structural core. Whereas, the theoretical CCS obtained from WT Ltn10 compares well with 




. As the α-helix in CC3 can be 
thought of as being stapled to the core and as comparisons between the highest charge states 
of CC3 bear up remarkably well with WT Ltn, the increase in experimental CCS is attributed 
to tail unfolding.  
 














 were subjected to ECD fragmentation (Figure 4.17). It is interesting to first 
consider the [MCC3+8H]
8+
 species, which was studied under both buffered and supercharged 
conditions. Under supercharged conditions more extensive fragmentation is observed along 
the backbone particularly in the α-helical region, suggesting this region is more unfolded 
under these solution conditions, consistent with the observed increase in CCS which 
suggested unfolding was promoted in the presence of m-NBA. 
 
Figure 4.18: CC3 sequence labelled with disulfide bond (solid line) and secondary structural elements, 
annotated with all zIc fragments observed for CC3 under supercharged conditions.  
As charge state increases more extensive fragmentation is observed in both the α-helix and 
along the ID tail, emphasising that these regions are the first to unfold from the core of the 
protein. At all charge states studied under supercharged conditions zIc fragments are 
observed which correspond to the complete loss of the tail and regions of the N-termini, 
retaining the structural core (Figure 4.18). Thus under these conditions, the disordered 
regions are more weakly associated with the structural core and hence are more available for 
fragmentation. Additionally, for [MCC3+11H]
11+ 
greater fragmentation in the α-helix is 
observed highlighting this region is becoming more unfolded and beginning to unravel from 
the structural core. An increase in fragmentation along the C-terminus is also observed for 
this charge state suggesting it has undergone a reordering event. For [MCC3+11H]
11+
 
fragmentation within the β-sheet region is observed, at lower intensity than that observed for 
the α-helix and consistent with a compact, perhaps structured region which is stabilised by 




occurs in the β-sheet region it is mostly in the form of zIc fragments (Figure 4.17) thought to 
retain at least some of the stabilising interactions present in solution. 
It is important to note that due to the conformational constriction implemented in this mutant 
by the addition of the second disulfide bridge, the unfolding pathway of WT Ltn10 involving 
complete loss of the α-helix and disordered tail in a single fragment is not observed until the 
most extended species ([MCC3+11H]
11+
) and is facilitated through ECD disulfide reduction, 
which emphasises that the additional disulfide structurally constrains the Ltn10 fold 
inhibiting the unfolding as expected. Combining ECD and DT IM-MS results for buffered 
and supercharged CC3 Ltn a more extensive picture of the unfolding of this mutant can be 
afforded, than that allowed by studying this protein only in buffered conditions. Even in the 
most extended species observed there is evidence that the structural core remains relatively 
intact and the observed fragments map extremely well to the Ltn10 fold, stressing that the 
fold and secondary structural elements comprising it are not significantly perturbed through 
addition of m-NBA. Addition of m-NBA clearly can promote extended structures, however, 
this could still be a useful reagent for use in the study of protein fold, particularly for 
proteins containing multiple disulfide bonds such as CC3. 
4.3.3.3 Probing the Ltn40 fold through specific site mutation  
The final mutant studied is a single point mutation (W55D), designed to push the equilibrium 
towards the dimeric Ltn40. The amino acid replacement is located in the beginning of the 
α-helix in the Ltn10 conformation and is designed to destabilise this conformation, with loss 
of the tryptophan side chain disrupting the Ltn10 hydrophobic core. In order to determine to 
what extent the W55D mutant mimics the Ltn40 fold, W55D was prepared under the same 
solution conditions (20 mM AmAc) and studied under the same instrumental conditions 
applied for all other Ltn species. Under these conditions the most intense species is 





 (Figure 4.19A). The dimeric species (DW55D) is also observed, at somewhat 





 (Figure 4.19A), wider by two charge states than WT Ltn dimer.   
In order to determine if the equilibrium could be shifted towards the dimeric form a number 
of solution conditions were studied, including increasing buffer strength and alteration of the 
pH (Appendix 3 Figure A3.9), however, no significant increase in dimer was observed. The 




monomer prevailed as the most intense species under all conditions, a significant point 
which is discussed in more detail below.  
 
Figure 4.19: W55D Ltn. A) Mass spectra acquired in 20 mM AmAc pH 6.8 B) Average experimental 
CCS obtained from three different day repeats, error bars are calculated from the standard deviation 
and lie within symbol size. A wider charge state range of dimer is observed in B due to differences in 
the instrumentation used. Dashed line represents theoretical CCS of WT Ltn40 obtained from the 
NMR structure (PDB 2JP1).  
From DT IM-MS it is clear that the monomeric global unfolding signature is different for 
W55D than for all other monomeric forms of Ltn studied previously under buffered 
conditions, with CCS increasing almost uniformly with charge from ~778 to 1407 Å
2
 (Figure 
4.19B and Appendix 3 Table A3.9). There are a number of plausible conformations that 
MW55D could exist in, including the Ltn10 conformation, a single unit of Ltn40 or a yet 
unknown conformation. Consideration of CCS alone cannot provide an answer to this 
problem, as experimental CCS are observed to lie over a wide range encompassing both the 
theoretical CCS of a single Ltn40 chain without the ID tail (1141 Å
2
) and that determined for 
Ltn 1-72 (1228 Å
2
), which is thought to represent the Ltn10 fold with the tail wrapped 
around or associated with the structural core. Therefore, these species present an interesting 
challenge in identifying and studying protein fold; can this combination of DT IM-MS and 





 were subjected to ECD and observed fragment ions 
were subsequently mapped onto both folds (Figure 4.20). As expected, fragmentation 
increases as a function of charge, however, this does not occur uniformly and therefore 
trends observed reveal conformational information. The most extended, highest charged 
species ([MW55D+10H]
10+
), displays extensive fragmentation into the core residues of both 
folds suggesting that this species is far along the unfolding pathway resulting in many 




therefore more appropriate to consider the intermediate charge states, in which the protein 
ions are beginning to unfold but are not yet highly extended and unfolded. 
Beginning with [MW55D+8H]
8+
 fragmentation is observed in residues 52-65. This 
fragmentation pattern does not appear to be consistent with unravelling and unfolding of an 
α-helix present in the Ltn10 form as has been observed for WT Ltn10, which is characterised 
by cleavage along the backbone in this region (Figure 4.20A and Figure 4.21). Instead 
starting from [MW55D+8H]
8+ 
fragmentation is observed to branch out from the core residues 
comprising the β-sheet core in the Ltn40 fold, with low intensity fragments also being 
observed within the core (Figure 4.20B and Figure 4.21). This observation is consistent with 
that of the WT Ltn in the Ltn40 fold, in which fragmentation is observed to branch out from 
the β-sheet core with higher intensity fragments in the first nine amino acids after the β3 
strand, consistent with the NMR structure which shows that these regions are associated with 
the protein core allowing them to be solved. Indeed at all charge states, fragmentation is 
observed to branch out from the structural core of Ltn40 with minor fragmentation observed 
between strands suggesting MW55D is perhaps existing as a single chain of Ltn40. 
 
Figure 4.20: Monomeric W55D  ECD analysis:  Percentage yields calculated for c type, z type and zIc 





. Fragments are mapped onto A) Ltn10 fold and B) Ltn40 fold. A y-axis scale break is 




Furthermore, the distinct differences in DT IM-MS and ECD studies of this monomeric 
system in comparison to WT, WT 1-72 and CC3 Ltn, all of which appear extremely similar 
suggest these species are not in the Ltn10 fold. Similarities between the fragmentation maps 
obtained here with those previously obtained for Ltn40 (Figure 4.11) in combination with the 
NMR studies (which show a primarily dimeric species in the Ltn40 conformation) suggest it 
is conceivable that MW55D could be a single chain of Ltn40, however, it is impossible to 
definitively determine which fold MW55D is existing in from these studies. A monomeric form 
of Ltn40 could be a result of dissociation of the dimer upon the ionisation and transfer of the 
protein, suggesting that under our experimental conditions the dimer interface is not as stable 
as the WT Ltn40 interface. Alternatively a proportion of W55D could exist in a monomeric 
form in solution under these conditions. Both of these possible explanations suggest that this 
mutant is not a stable, constrained mimic of Ltn40 advising that the design of a more stable 
dimeric mutant is essential.  
 
Figure 4.21: W55D sequence labelled with disulfide bond (solid line), the secondary structural 
elements of Ltn40 (above) and Ltn10 (below) folds, annotated with all zIc fragments observed for 
monomeric W55D.   
DT IM-MS highlights dimeric W55D (DW55D) (Figure 4.16B and Appendix 3 Table A3.9) is 
considerably different to DWT (Figure 4.4). Dimeric W55D Ltn presents over a CCS range of 
~1509 to 2519 Å
2
, with the most extended form ([DW55D+16H]
16+
) being  32 % larger than 
the most extended species of WT Ltn40 ([DWT+13H]
13+




for W55D dimer, so direct comparisons cannot be made and instead comparisons are made 
with WT dimer (PDB 2JP1), which as discussed before omits 33 amino acids from the ID 
tail of each chain. Comparison of this theoretical CCS to the experimental CCS demonstrates 
that DW55D populates a wide range of conformations more compact and extended than this 
theoretical value. The majority of observed species are more extended than the theoretical 
value, suggesting either the ID tail is extended out from the structural core and/or the whole 
structure is more flexible and therefore more capable of existing in a larger range of 
conformations where for some there will be a smaller interface region stabilising the dimer. 
The fact that this mutant occupies a wider range of charge states is also indicative of a more 
flexible system. Significantly, less dimer signal is observed for W55D in comparison to the 
WT Ltn and analysis of MW55D suggests that these species are due to dissociated dimer and 
therefore DW55D is considered less stable than DWT. The likelihood of this would be increased 
if the dimer interface is indeed smaller and less stable in the W55D mutant.  It is probable 
that the wide range of experimental CCS is due to both tail unfolding and increased 
flexibility in DW55D. 
In order to probe this hypothesis ECD studies were performed, as with WT dimer only the 







.  Analysis was performed considering zIc, c and z-type 
fragments as a product of dimer fragmentation (above axis histograms) or dissociation of 
dimer to monomer followed by fragmentation (below axis histograms).  Both monomeric 
units are identical in sequence and therefore fragmentation maps are plotted onto a single 
chain (Figure 4.22 and Figure 4.23). 
ECD of the lowest charge state ([Dw55D+9H]
9+
) leads to extensive dissociation of dimer to 
monomer followed by extensive fragmentation along the backbone (Figure 4.22). A 
tendency for the lowest dimer charge state to dissociate to monomer was also observed for 
WT Ltn and attributed to either an encounter complex or a less stable, perhaps collapsed 
form of the dimer. Unlike WT Ltn, dissociation of dimer to monomer upon ECD 
fragmentation is observed for all charge states of W55D and again suggests that the dimer 
interface is not as strong in W55D, consistent with the studies of MW55D which suggested that 
the dimer interface had been weakened and the high proportion of monomer observed is 
likely due to dissociation of dimer to monomer. These results highlight the significant 
structural influence point mutations can have, considering the position of the amino acid 





Figure 4.22: Percentage yields calculated for zIc, c- and z-type fragments as a function of cleavage 






. Above axis histograms 
represent fragments formed while retaining the dimer interface. Below axis histograms represent 
fragments formed following dimer dissociation to monomer. For figure clarity the % yield scale is 
altered between charge states.  
 
Figure 4.23: W55D sequence labelled with disulfide bond (solid line) and the secondary structural 
elements of Ltn40, annotated with all zIc fragments observed for dimeric W55D, where the dimer 





Figure 4.24: Structure of WT Ltn40 (PDB 1JP1) with residue W55 shown in purple, generated in 
VMD.  
Interestingly, the highest intensity of fragmentation is observed for [DW55D+9H]
9+
, suggesting 
this species is the most structurally unstable conformation and can therefore undergo the 
greatest extent of fragmentation, consistent with the results of  DT IM-MS experiments 
which suggest it is a collapsed form. For [DW55D+11H]
11+
 dimer fragmentation  maps better 
with the Ltn40 fold, with the majority of fragmentation occurring at the termini and in 
flexible regions just before the β-sheet core (Figure 4.22 and Figure 4.23), suggesting that 
the dimeric species which survive the desolvation process are likely to be present in the 
Ltn40 fold. This finding is consistent with the studies of other Ltn constructs here, which 
highlighted that the solution folds of this metamorphic protein are retained in the gas-phase 
and can be probed using these techniques. For [DW55D+11H]
11+
 fragmentation is observed 
within the β0 strand, which increases in intensity for  [DW55D+13H]
13+
. The increase in 
fragmentation along this region suggests it is the least stable of the β-strands and is the first 
to unfold from the structural core. It is therefore surmised here that the structural core of 
W55D in the Ltn40-like conformation unfolds from the N-terminus, interestingly the 
converse of Ltn10 which unfolds first from the C-terminus. ECD fragmentation maps allow 
the stability of each region to be ranked from least to most stable (β0<β1< β3< β2), which 
could help in the design of future mutants aimed to mimic this fold but with increased 
stability and decreased unfolding. For W55D clearly a lower proportion of dimer is present 
than for WT Ltn and therefore a more stable dimer mutant is required.  
4.3.3.4 Visualising protein unfolding 
By combining DT IM-MS results with ECD fragmentation maps for CC3 and W55D a 
detailed picture of the unfolding of both Ltn10 and Ltn40 can be built, giving insight into 
fold stability as a function of increased charge (Figure 4.25).  
Using the methodology presented here, the secondary and tertiary structure of the mutants 




protein. It is observed that CC3 is more structurally constrained than WT Ltn, as expected 
for a protein with an additional disulfide bond, and most likely retains in the Ltn10 fold in 
the gas-phase. The positioning of the additional disulfide bond pins the α-helix to the 
structural core and blocks the first unfolding pathway of Ltn10.  For W55D the results 
suggest that the dimer interface is less stable in this mutant than in WT Ltn, leading to 
dissociation of dimer to monomer both upon ionisation and transfer and as a result of ECD 
fragmentation. The fragmentation maps of this mutant also suggest that for Ltn40 the first 
unfolding pathway involves unfolding of the β0 strand and N-terminus. The combination of 
these gas-phase techniques and their application to mutagenesis studies has potential to 
further the design of mutants with stabilised folds by highlighting susceptible regions. 
 
Figure 4.25: Cartoon representation of the unfolding of Ltn10 and Ltn40 folds as shown by 
DT IM-MS and ECD,  probed through specific mutants, A) buffered CC3 B) supercharged CC3 C) 
monomeric W55D and D) dimeric W55D, where the dimer is represented here by a single monomeric 
unit.  Yellow arrows represent β-sheet regions and purple spirals represent α-helical regions. Orange 
‘lightning bolts’ indicate sites where ECD fragmentation is most significant, extensive fragmentation 






The combination of DT IM-MS and ECD fragmentation can provide detailed insight into the 
fold and unfolding of proteins, with no constriction due to buffers or additives enabling 
multiple, dynamic conformations of a metamorphic protein to be studied simultaneously.  
Results suggest that for WT Ltn in both its monomeric and dimeric forms the solution folds 
can be preserved in the gas-phase, over the time scales of the experiments present here (up to 
seconds), suggesting this combination of DT IM-MS and ECD has the potential to enable the 
study of multiple conformations of structurally dynamic proteins and has the opportunity to 
overcome many of the challenges associated with traditional structure elucidation tools. In 
both Ltn10 and Ltn40, the CCS in combination with ECD maps suggest that β-sheet regions 
may be preserved, with increased stability of these regions being observed. Further in-depth 
studies would be required to conclusively prove that these regions are indeed preserved, 
however, the results here suggest it is conceivable. Ltn would therefore be an excellent 
candidate for further gas-phase protein structural studies, to further study β-sheets in the gas-
phase.  
The analysis of the mutants CC3 and W55D provided further details on the distinct folds of 
Ltn. The results presented here confirm that CC3 is a suitable mimic for Ltn10, with the 
extra disulfide bond constricting and stabilising the fold. W55D, however, appears less stable 
as a dimer than WT Ltn and suggests the dimeric interface is weakened for this construct as 
compared with WT protein and signifying that future studies should consider the creation of 
a Ltn40 mutant with increased stability.  
The ability of this combination of techniques to distinguish significant effects of point 
mutations on protein fold and unfolding highlights the wealth of information that can be 
obtained in this way. Information can be acquired on the relative stabilities of mutants in 
comparison to WT protein, and therefore has potential to be highly influential in the analysis 
of possible protein mimics of therapeutic potential. The power of using such techniques 
becomes evident when you consider the small sample volumes required for such studies, 
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Investigating interactions with GAGs: 
Lymphotactin 
Glycosaminoglycan (GAG) binding is essential for chemokine activity. Chemokine:GAG 
interactions mediate binding of the chemokine to the vasculature and enable a chemokine 
concentration gradient to be established, a process important for cell migration. 
Understanding more about this intricate biological process, the complexes formed and their 
conformations is vital for a better understanding of chemotaxis. This chapter focuses on the 
chemokine lymphotactin and its ability to bind a model GAG (fondparinux). A number of 
specific mutants, designed either to stabilise one of the distinct folds of lymphotactin or to 
destabilise lymphotactin:GAG binding, are also considered. In this chapter MS, DT IM-MS 
and ECD are utilised to identify the lymphotactin:GAG complexes formed. Extensive 
aggregation was observed upon addition of fondparinux to lymphotactin solutions and TEM 






5.1.1 Chemokine:GAG binding 
Proteins involved in immune modulation, such as cytokines and growth factors, fulfil their 
biological function through high-affinity interactions with cell-surface receptors
1
. Recent 
studies, however, have shown that many of these proteins also exhibit low-affinity 
interactions with glycosaminoglycans (GAGs) or proteoglycans, proteins to which GAG 
chains are attached
2
. GAGs are long unbranched polysaccharide chains which consist of 
repeating disaccharide units and are extremely variable in nature, with sequences which 
differ in the basic composition of the saccharide, linkage, chain length, acetylation and N- 
and O-sulfonation
3
. They can, however, be divided into six major families; heparin, heparin 
sulphate, chondroitin sulphate, dermatan sulphate, keratin sulphate and hyaluronic acid
4
, 
based on the disaccharide linkage. Heparin sulfate is the most ubiquitous, being expressed on 
virtually every cell in the body and comprising 50 % to 90 % of endothelial proteoglycans
5
. 
In recent years it has become apparent that in order to fulfil their biological function 
chemokines are required to interact both with their G protein coupled receptor (GPCR) and 
to GAGs on cell surfaces or in the extracellular matrix
2,6
. The ability of GAGs to bind 
chemokines is anticipated from a simple electrostatic point of view, with GAGs being highly 
acidic and chemokines generally being basic
7
. There exist, however, two acidic chemokines 
of the CC subfamily, both of which have been shown to bind GAGs, signifying that 
chemokine:GAG interactions display specificity and are not solely dominated by non-
specific electrostatic interactions
8
. Chemokines have been shown to bind GAGs as a 
localisation mechanism, in order to act as a directional signal for migrating cells. The 
absence of such interactions could cause rapid diffusion of chemokines to levels below the 
threshold for receptor activation, particularly in the presence of vascular flow. Moreover, it 
has been suggested that interactions with GAGs confer specificity to this complex regulatory 
system and it has been proposed that chemokines could be directed to different locations 
based on varying affinities for different GAGs; an important point to consider in 




The functional importance of such interactions was solidified through an influential study 
into the CC class of chemokines by Proudfoot et al
8
, in which site-specific mutations were 
implemented in order to inhibit GAG binding and were shown in vitro to minimally perturb 




in comparison to the WT chemokine, attributed to the necessity of chemokine:GAG 
interactions. Studies into viral mechanisms of immunomodulation have also highlighted the 
importance of chemokine:GAG interactions through the discovery that a number of viruses 




Chemokine:GAG binding is an intricate process and understanding more about these 
pathways, complexes formed and their conformations is essential. Such studies are 
challenging due to the extreme heterogeneity of GAGs and difficulties in producing them 
recombinantly, hence most studies initially focus on model GAGs, generally of the 
heparin/heparin sulphate subfamilies due to their commercial availability. A number of 
approaches have been presented to-date to gain insight into these important interactions 
including: heparin affinity chromatography, titrated heparin binding assays, surface plasmon 
resonance, in vivo cellular recruitment and NMR studies
16
. A small number of particularly 
sophisticated and detailed studies have been presented to solve the structures of complexes 
formed between chemokines and GAGs and to identify key residues involved in binding
17,18
. 
Furthermore, the common sequence motif BBXB has been identified as responsible for GAG 
binding, where B is a basic amino acid
19
. 
Chemokines generally exist in solution as monomers or dimers and occasionally tetramers
2
; 
however, upon GAG binding they have been found, and predicted, to exist in primarily 
dimeric or tetrameric GAG-bound forms, although in some cases monomer:GAG complexes 
have been observed
20,21
. Detailed structural studies of such complexes have allowed two 
chemokine:GAG crystal structures to be solved; CCL5 and  CXCL2, both in complexes with 
a heparin-derived disaccharide and both of which form GAG bound dimers
22,23
. In these 
studies attempts were also made to crystalize these proteins with longer oligosaccharides; 
however, they were unsuccessful due to problems associated with aggregation and a 
corresponding inability to produce high quality crystals. Heparin has been shown in vitro to 
induce higher-order aggregates in solution
11
.  This ability to produce higher order oligomers 
in the presence of GAGs is deemed essential for the activity of particular chemokines in 
vivo
8
 and thought to help over-come issues associated with vascular flow
24
. 
Recently mass spectrometry (MS) has emerged as an alternative and valuable method to 
study these interactions; MS does not require labels and allows low intensity bound species 
to be separated and identified. Furthermore MS is well suited to the study of aggregating 
systems
25-28
. MS can be used to determine the stoichiometry of chemokine:GAG interactions 
or in combination with proteolytic digests to identify binding sites
29




application of MS to study chemokine:GAG interactions has been pioneered through 
research from Julie Learys’ group, who have produced a number of sophisticated studies in 
this field
30-33
. One such study used MS to determine the stoichiometry of GAG-bound 
complexes of a number of chemokines from the CC subfamily (CCL2, CCL8, CCL7, 
CCL11, CCL13 and CCL27), finding that members of this subclass could be differentiated 
by their GAG binding, with complexes presenting as either monomers or dimers
34
. More 
recently the application of ion mobility-mass spectrometry (IM-MS) in combination with 
collision induced dissociation (CID) studies has been presented to study the conformations 
and corresponding stabilities of chemokine:GAG complexes. Results of such studies 
demonstrated a stabilising effect upon GAG binding to CCL2, the extent of which can differ 
with the sulfonation pattern of the GAG
35,36
. Furthermore, these investigations have shown 
that complexes formed and their relative stabilities can differ depending on the class of 
chemokine studied, with the CC and CXC families of chemokine exhibiting different 
behaviour
36
. This work highlights the detail such studies can provide, particularly in 
combination with other techniques.  
5.1.2 Ltn:GAG binding 
The metamorphic chemokine lymphotactin (Ltn) is thought to segregate the two functional 
roles of chemokines through a conformational barrier. The conserved chemokine fold 
(Ltn10) has been found to be responsible for binding the relevant GPCR, namely XCR1
37
, 
whilst the dimeric fold (Ltn40) is thought to be inactive against XCR1
38
. The GAG binding 
functionality of Ltn has been assessed via elution from a heparin-sepharose column with a 
sodium chloride gradient
38,39
. WT Ltn was found to elute in two broad fractions in ~450 and 
700 mM NaCl which were assigned as the two conformations (Ltn10 and Ltn40 
respectively) of WT Ltn, having significantly different binding affinities. This hypothesis 
was confirmed through the study of Ltn10 and Ltn40 mutants (CC3 and W55D 
respectively)
1,38
. These findings suggest that although both folds can bind heparin, Ltn40 
encodes for high affinity GAG binding. Furthermore, the addition of heparin to a solution of 
Ltn can shift the equilibrium towards Ltn40
39
.  
Despite the higher GAG binding affinity of the Ltn40 conformation, to-date detailed studies 
have focused on Ltn10 binding. This is principally due to the fact that such studies were 
carried out prior to the dimeric structure of Ltn being solved
38
 and hence were performed 
under conditions in which the equilibrium is strongly shifted towards the monomeric 
form
40,41
. Considering the propensity of GAGs to bind to basic amino acids, Peterson et al
41
 




alanine to identify key amino acids for GAG binding.  The studies showed that the greatest 
decrease in heparin binding affinities occurred for substitutions at R23A and R43A, with a 
maximum decrease in affinity determined for the double point mutant. It is important to note 
that in WT Ltn, charge repulsion between R23 and R43 is thought to destabilise the Ltn10 
fold, an effect which is overcome through addition of salt. Substitution for alanine at either 
R23 or R43 reduces charge repulsion, stabilising Ltn10, and pushing the equilibrium towards 
the monomeric fold. The Ltn10 and Ltn40 three-dimensional folds are, however, 
unperturbed by these substitutions.  
This chapter focuses on the use of MS in combination with DT IM-MS and transmission 
electron microscopy (TEM) to study the interactions of a model GAG, fondaparinux (Fx), 
with WT Ltn and mutants designed to stabilise Ltn10 (CC3) and Ltn40 (W55D). 
Fondaparinux (also known as Atrixia) is a pentameric GAG (Figure 5.1) chemically related 
to heparin, which has been marketed by GlaxoSmithKline as an anticoagulant and has been 
used as a treatment for deep vein thrombosis
42
.  It serves as an excellent model GAG due to 
its availability in an extremely pure form with a well characterised and controlled sulfonation 
pattern and hence has been used in previous studies of chemokine:GAG binding
43
. Previous 
NMR-based GAG binding studies of Ltn highlighted that pentameric GAGs can bind Ltn10 
with low affinity (Kd ~100 μM), however, upon addition of longer chain length GAGs Ltn 
solutions exhibit greater aggregation and form insoluble complexes
41
 making Fx an attractive 
model for initial studies. Additional MS and TEM studies were performed to study 
interactions of Fx with single (R23A and R43A) and double (R23/R43A) point mutants 
designed to have lower affinity towards GAGs. The studies presented here aim to provide 
insight into the interactions of Ltn with a model GAG, in order to definitively determine the 
stoichiometry of interactions and to gain understanding into the conformations of these 
complexes. Such information would provide insight into this complicated, biologically 
important pathway.  
 





5.2.1 Protein and glycosaminoglycan samples 
All recombinant human lympohactin (Ltn) samples were expressed and purified by the 
Volkman Research Group (Medical College of Wisconsin, Milwaukee, USA) as previously 
described
37,40,41
. It is important to note due to differences in the expression and purification 
systems used for WT Ltn and the mutants CC3 and W55D, residues M63 and M73 were 
mutated to valine and alanine respectively in both CC3 and W55D. Proteins were received as 
lyopholised samples and stored at -20 °C for subsequent study.  Stock solutions of 
lymphotactin samples were typically prepared at 100, 150 or 200 μM in 20 mM ammonium 
acetate (AmAc) and stored in aliquots at -20 °C until use. Concentrations were checked 
using the Pierce BCA concentration assay (Thermo Fischer Scientific, Wilmington, DE, 
USA) following the manufacturer’s instructions but using volumes 10 times lower than 
stated in the manual, afforded through the use of low volume UV cuvettes. 
The pentameric glycosaminoglycan (GAG) foundaparinux sodium was a gift from 
GlaxoSmithKline (Brentford, UK). Foundaparinux was prepared at a stock concentration of 
587 μM in water. Aliquots of which were dialysed overnight versus water using a 1,000 
molecular weight cut-off Micro DispoDialyzer (Harvard Apparatus, MA, USA),  and stored 
at  -20 °C until use.  
5.2.2 Sample preparation for MS studies 
In all cases samples were prepared in 20 mM AmAc, at pH 6.8 and analysed immediately 
after sample preparation.  
For all Ltn samples individual protein plus Fx solutions were prepared at 50 μM protein 
concentration at a 1:1 ratio of Ltn:Fx. WT Ltn was additionally studied at a 1:1 ratio at 25 
and 10 μM, and at a 2:1 ratio (Ltn:Fx) at a 25 μM Ltn concentration. WT 1-72 was also 
studied at 1:1 and 2:1 ratios (Ltn:Fx) at a 25 μM protein concentration.  
The interactions of WT 72-93 plus WT 1-72 with Fx were also considered using MS. Here 
sample solutions were prepared WT 1-72: WT 72-93: Fx ratios of 1:1:1 (50 μM), 2:2:1 
(50:50:25 μM), 2:2:1 (50:50:25 μM) and 4:4:1 (25:25:6.25 μM).  
All MS studies were performed on a Q-TOF Ultima (Waters, Manchester, UK), for details 




dissociation studies, experiments involving Ltn 72-93 and all experiments on R23A, R43A 
and R23A/R43A were performed post high mass upgrade.  
5.2.3 Sample preparation for DT IM-MS studies 
For determination of CCS for Ltn:Fx species WT, CC3 (monomer mutant) and W55D 
(dimer mutant) constructs were prepared at 100 μM  protein concentration in 20 mM AmAc 
at a 1:1 (Ltn:Fx) ratio. WT 1-72 was studied at 50 μM in 20 mM AmAc at a 2:1 ratio with 
fondparinux. 
All DT IM-MS measurements were performed on an in-house modified Q-TOF (Micromass 
UK Ltd.), described in Chapter 2 section 2.3. For all DT IM-MS studies the source was held 
at 100 °C to aid desolvation.  
5.2.4 Sample preparation for ECD studies 
For WT:Fx binding interface studies by ECD, samples were prepared at a 1:1 ratio at 30  μM 
in 100 mM AmAc, pH 6.8. All ECD studies were performed on a 12T Apex Ultra Qh 
FT-ICR mass spectrometer (Bruker Daltonik Gmbh, Bremen, Germany), details on the 
instrument and its operation can be found in Chapter 2 section 2.5. 
5.2.5 Sample preparation for TEM studies 
For transmission electron microscopy (TEM) studies WT, CC3, W55D, WT 1-72, 
WT 72-93, R23A, R43A and R23A/R43A samples were prepared at 50 μM protein 
concentration at a 1:1 ratio of Ltn:Fx. WT Ltn was additionally studied at 10 μM protein 
concentration at a 1:1 ratio of Ltn:Fx. Furthermore, a sample containing WT 1-72 plus WT 
72-93 plus Fx present at a 1:1:1 ratio (50:50:50 μM) was also studied.  In all cases samples 
were prepared in 20 mM AmAc at pH 6.8 and left to incubate for 30 minutes before grid 
preparation. In addition individual solutions of WT Ltn and Fx, at 50 μM in 20 mM AmAc 
were studied as controls. For details on TEM grid preparation see Chapter 2 section 2.7. 
All TEM experiments were performed on a Philips CM120 Biotin transmission electron 
microscope (Philips, Eindhoven, Netherlands), details on the instrument and its operation 






 Results and discussion 5.3
5.3.1 Interactions with WT Ltn 
Firstly the interactions between Fx and WT Ltn were considered. This was of interest due to 
the metamorphic nature of WT Ltn, which exists in equilibrium between the conformational 
and functional forms, each of which is thought to have different affinity for GAGs. 
5.3.1.1 Stoichiometry of binding: insights from MS 
The spectrum obtained from a 1:1 mixture at 50 μM (Figure 5.2B) contains a number of 
peaks due to Fx bound to Ltn over a range of charge states. Fx binds to both the monomeric 
form of Ltn (MWT+Fx) and the dimeric form; dimeric WT Ltn is capable of binding either 
one (DWT+Fx) or two (DWT+2Fx) Fx chains, with expected and observed masses of all 
species being in good agreement (Appendix 4 Table A4.1). Previous heparin-sepharose 
column binding studies of WT Ltn showed that Ltn eluted in two fractions with significantly 
different affinities for heparin, assigned to monomer and dimer interactions, with the dimer 
fraction being larger. It was therefore hypothesised that here WT Ltn would be observed to 
bind Fx as a monomer to a lesser extent than the dimer. Surprisingly, the intensity of 
MWT+Fx is higher than anticipated, with [MWT+Fx+6H]
6+
 the most intense Fx-bound species. 
It is possible that this species is formed faster or is an encounter species en route to a 
dimer-bound species. It is not possible, however, to test this theory with MS, as upon 
addition of Fx to WT Ltn extensive aggregation occurs, with large aggregates visible in the 
n-ESI tip (example images are shown in Appendix 4 Figure A4.1). The solution changes 
from clear to cloudy in appearance and is accompanied by a significant reduction in signal 
intensity. The higher order aggregation induced upon addition of Fx is studied further using 
transmission electron microscopy (TEM) in section 5.3.1.4. This extremely rapid and 
extensive aggregation means it is not possible to perform any MS time course experiments to 
determine how bound and unbound species vary as a function of time.  
High concentrations of binding partners can lead to non-specific interactions, therefore the 
specificity of Ltn to form monomeric and dimeric Fx-bound species is assessed as a function 
of concentration. In order to achieve this, sample solutions were prepared at a protein 
concentration of 25 and 10 μM at 1:1 ratio with Fx (Figure 5.2C and D). In all cases 
monomeric and dimeric Ltn are observed to bind to Fx and even more significantly the 
monomeric species is the most intense in all cases. The spectra obtained for the 1:1 mixtures 




aggregation occurring for all samples. The lower concentration of unaggregated material in 
these samples leads to spectra of low signal-to-noise and hence raised baselines.  
 
Figure 5.2: Spectra obtained for WT Ltn A) 50 μM B) 50 μM plus 50 μM Fx (1:1, Ltn:Fx) C) 25 μM 
plus 25 μM Fx (1:1) D) 10 μM plus 10 μM Fx (1:1) and E) 25 μM plus 12.5 μM Fx (2:1)  * denotes a 
species observed in all spectra presumably a contaminant left over after purification. In panel A all 




The presence of MWT+Fx species at even the lowest concentration suggests these complexes 
are not just a product of non-specific, high concentration interactions and instead there is 
specificity to their formation. To explore this further, a sample was prepared at a 2:1 at 25 
μM Ltn concentration (Figure 5.2E). This shows a lower but still significant proportion of 
MWT+Fx species, highlighting that although formation of monomeric Fx bound complexes 
can be limited by increasing Ltn concentration relative to Fx concentration, under all 
conditions and concentrations employed here the monomeric Fx bound species persists. 
Furthermore, in all cases the 7+ and 6+ charge states are the most intense unbound Ltn 
species, consistent with the findings in the absence of Fx (Figure 5.2A) and demonstrating 
Fx is not significantly perturbing the equilibrium or charge state distribution. Additional 
peaks at low m/z are observed in all cases due to contaminants and salts present in the 
samples.  




 were probed through collision 
induced dissociation (CID) experiments, with the first and highest intensity fragmentation 
pathway being loss of SO3 from Fx (a common fragmentation pathway of Fx in isolation
44
), 
with the MWT+Fx interaction remaining intact (Appendix 4 Figure A4.2). The fact that Fx 
fragments before the non-covalent complex dissociates reinforces the fact that strong, stable 
interactions are occurring here and suggests that MWT+Fx species are indeed stable, specific 
complexes. 
The propensity of Fx to bind specifically to monomeric Ltn in addition to dimeric Ltn 
suggests that despite its structural plasticity, when considering GAG binding the functions of 
the two distinct folds are not as separate and defined as previously thought. Dimeric Ltn was 
previously considered to be responsible for high affinity binding; however, here, monomeric 
Ltn clearly binds with high intensity.  Other chemokines are known to bind GAGs as both  
monomers and dimers
43
, suggesting that Ltn could behave in a similar fashion to the 
‘traditional’ structurally constrained chemokines, capable of binding GAGs in a number of 
oligomeric states.   
5.3.1.2 Conformations of WT:Fx complexes: DT IM-MS studies 
Due to the weak signal obtained for the Ltn plus Fx samples, due to aggregation of a 
significant proportion of the material into large unresolvable complexes, the source pressure 
and voltages on the DT IM-MS instrument were tuned to preserve Fx-bound species. This in 
turn led to a reduction in signal for unbound protein and an inability to observe some 




CCS for the unbound species (Figure 5.3) were determined in the absence of Fx, and are as 
reported in Chapter 4.   
To determine if the presence of Fx can affect the conformations of unbound protein, the 
charge states observed in the presence of Fx were analysed in all cases. CCS determined for 
all unbound WT Ltn species determined in the absence and presence of Fx are shown in 
Table 5.1, and were found to remain the same within experimental error, suggesting that Fx 
does not affect the conformation of unbound WT Ltn in solution (in contrast to the findings 
of c-MYC:MAX upon addition of the ligand 10058-F4 in Chapter 3).  
Species CCS/ Å2 
 Absence of Fx Presence of Fx 
[MWT+6H]
6+ 
1021 ± 27 1034 ± 47 
[MWT+7H]
7+
 1100 ± 63 1077 ± 34 
[DWT+12H]
12+
 1894*   1893 ± 21 
Table 5.1: Experimentally determined average CCS for all unbound WT species observed in the 
absence and presence of Fx, the error is reported as the standard deviation between repeats. *species 
observed in all repeats but only resolvable in one. 





 were the highest intensity bound species, 
suggesting that formation of these species is favourable. DT IM-MS experiments show that 
despite the additional mass from Fx, [MWT+Fx+5H]
5+ 
 adopts a conformation which has a 
smaller CCS than the unbound species at the same charge state and [MWT+Fx+6H]
6+
 is 
within error of the unbound species. This suggests that there has been a conformational 
tightening upon Fx binding, supporting the idea that these species are due to stable, specific 
binding.  
The CCS of [MWT+Fx+7H]
7+
, however, is significantly larger than the CCS of both its 
corresponding unbound counterpart ([MWT+7H]
7+
) and the bound species of lower charge 
states, with a ~50 % increase in CCS for [MWT+Fx+7H]
7+
 compared with [MWT+Fx+5H]
5+
 
(1247 vs 845 Å
2
). This large increase in CCS across the charge states suggests either that the 
7+ bound complex is non-specific and/or that binding of Fx can produce flexible species 
capable of adopting a wide range of conformations. Considering the inherent flexibility of 
Ltn, it is likely that this protein could form complexes with different structures.  
Binding of either one or two units of Fx to a dimeric form of Ltn produces compact 
complexes with CCS within error or smaller than those of the unbound dimer. Due to the 
additional mass from Fx, larger CCS could be expected, however, CCS here suggest that 




and DWT+2Fx, CCS of the different charge states remain fairly constant increasing by only 
5 % and 16 %, respectively. In both cases therefore a stable conformational family is formed 
upon binding of Fx, which is not significantly affected by charge. Furthermore, CCS 
obtained for  DWT+Fx and DWT+2Fx are very similar, with the dimer bound to two Fx chains 
being only marginally larger than the dimer bound to a single Fx at the same charge state.  
Taken together, these results suggest that WT Ltn can bind Fx specifically, producing stable 
compact conformations in both monomeric and dimeric forms, with the dimer capable of 
binding one or two Fx chains specifically and with monomeric conformations appearing 
more flexible than dimeric conformations. 
 
Figure 5.3: Average CCS of WT Ltn and Fx bound Ltn, dimeric (top) and monomeric (bottom) 
species, calculated from three repeats, error bars represent standard deviation between these values. 
Unbound species were determined in the absence of Fx (hollow symbols). Filled symbols represent Fx 




5.3.1.3 Investigating the WT:Fx binding interface through ECD 
fragmentation.  
In order to further examine the binding of Fx to WT Ltn, both the MWT +Fx and the DWT+Fx 
species were subjected to ECD fragmentation.  
Considering MWT+Fx first, charge states 5-7+ were examined, all of which exhibit very little 
fragmentation, with the 5+ charge state showing no visible fragment ions, further 
emphasising the stability of these monomeric bound species.  [MWT+Fx+6H]
6+
 remains 
mostly intact and fragments only at the last two amino acids of the C-terminus following 
ECD. Both the 5+ and 6+ unbound species could not be isolated at high enough intensity for 
ECD fragmentation and hence comparisons with unbound species cannot be made here. 
[MWT+Fx+7H]
7+ 
undergoes greater fragmentation, consistent with this species having a 
larger CCS and suggesting that it is more open and would have more potential sites of 
cleavage available. Indeed after being subjected to ECD, dissociation of [MWT+Fx+7H]
7+ 
to 
form MWT and fragments corresponding to MWT with cleavage at the N-terminus are 
observed, suggesting Fx binding at this charge state is not as strong. A number of fragments 
are observed corresponding to retention of the MWT+Fx complex, with the most intense 
being due to fragmentation of the first amino acid at the N-terminus or final amino acid at 
the C-terminus. When subjected to ECD [MWT+7H]
7+
 showed limited fragmentation, 





suggesting these regions are more stabilised or less available for 
cleavage. Additionally, there are a number of low intensity, low molecular weight fragments 
which could not be attributed to c- or z-type fragments of monomer but could, however, be 
due to internal fragments of WT Ltn or Fx bound to internal fragments of WT Ltn. No single 
species of unique molecular weight that could be conclusively identified as either were 
observed.  
The limited fragmentation along the sequence of WT Ltn coupled with no observable loss of 
the ID tail suggests that the tail is most likely involved in stabilising the complex, consistent 
with findings from DT IM-MS which show compact species. Additionally all species show a 
number of peaks due to electron capture with no dissociation resulting in charge reduction of 
MWT+Fx and lower intensity peaks due to charge reduction of the m/z coincident DWT+2Fx 
species. Accurate mass measurements and the presence of these species show that for all 
peaks assigned as MWT+Fx and studied here a small proportion of DWT+2Fx exists as well, 




Due to their high stability and limited fragmentation, the precise binding site cannot be 
mapped for the MWT+Fx species using ECD fragmentation. This could, however, also be an 
indication that Fx binds to a basic patch across the surface of monomeric Ltn, creating an 
extended binding interface, stabilised through multiple interactions. Figure 5.4A highlights 
all basic amino acids in Ltn10, the surface of monomeric Ltn contains large basic patches 
which, if Fx does bind here, would explain the lack of fragmentation along the backbone.  
The unbound species in ECD experiments [MWT+7H]
7+
 fragmented, resulting in a complete 
loss of the α-helix and ID tail (Chapter 4 section 4.3.2), however, the main basic patch on 
Ltn10 encompasses both the β-sheet core and α-helix, and if Fx binding does occur over this 
region would prevent this fragmentation pathway, consistent with experimental observations. 
In contrast to the unbound WT Ltn, the ID tail is not lost in MWT+Fx suggesting it may also 
be involved in binding or complex formation.  
 
Figure 5.4: A) Ltn10 and B)Ltn40 with all basic residues labelled in blue with Van der Waals model, 
created in VMD from PDB files 1J9O and 2JP1 respectively.  





 were transmitted at high enough intensity to be 
examined here.  At both charge states, however, no c- or z-type fragmentation was observed. 
A number of low intensity, low molecular weight fragments were detected and attributed to 
internal fragments occurring either from the dimer in a bound or unbound state; however, 
these fragments could not be assigned as any unique sequence and therefore cannot be 
unambiguously identified. The lack of significant, high intensity fragmentation demonstrates 
the stability of the complex and strength and specificity of binding. As with the monomeric 
bound form there is no observable loss of the ID tail in its entirety which is in contrast to the 
unbound  dimer (Chapter 4 section 4.3.2), suggesting the ID tail is involved either in 
stabilising the complex or directly with binding. Furthermore, no significant fragmentation 




patches are again present on the surface of the protein which would provide a plausible 
region for Fx to bind (Figure 5.4), providing multiple interactions along the backbone 
explaining the lack of any high intensity fragmentation.  
5.3.1.4 Assessing WT aggregation: transmission electron microscopy 
As noted in section 5.3.1.1, WT Ltn samples aggregate upon addition of equimolar 
concentrations of Fx. TEM studies were then performed on these insoluble aggregates 
(Figure 5.5). 
GAGs have been found to promote aggregation not only for chemokines but also for amyloid 
fibril-forming proteins, including  α-synuclein
45
 and β-amyloid protein
46,47
. Indeed GAGs are 
routinely found associated with, and incorporated within, amyloid deposits. Furthermore, 
heparin-induced aggregation of a number of the amyloid fibril forming proteins has been 
studied in vitro using TEM; however, to-date such studies have not been performed on 
chemokines. To better understand the aggregation process and species being formed such 
studies into chemokine:GAG aggregation is necessary.  
 
Figure 5.5: Representative TEM images obtained for 1:1 mixtures of Fx and A) WT Ltn (50 μM) B) 
WT Ltn (10 μM).  
Considering WT Ltn in the presence of Fx at 50 µM  protein concentration it is clear large 
aggregates are formed, which tend to form large clusters (Figure 5.5A). The morphology of 
the species formed is interesting, with ribbon-like structures appearing to twist around one 
and other. These observed species appear to have a degree of order or structure but are not 
consistent with the long straight protofilament structures frequently formed by amyloidgenic 
proteins, suggesting aggregation is different here. Heparin has, however, been observed to 






, suggesting heparin can act as a template for fibril formation and 
hence its presence can also affect the morphology of the species formed.  
Due to the overlapping nature of the species it is impossible to obtain an accurate length 
distribution under these conditions; visually species appear variable in length with a wide 
range of sizes typically observed in all images, normally on the order of µm. The size of both 
the individual structures and corresponding clusters of species is remarkable when 
considering samples were incubated for only 30 minutes prior to TEM grid preparation. 
When the concentration of the WT plus Fx sample is reduced (10 μM Ltn plus 10 μM Fx) 
(Figure 5.5B), the species formed are of a similar morphology, however, they appear shorter 
in length. The apparent shift in length distribution is ascribed to the lower concentration used 
here, limiting and slowing the aggregation process. It is clear, however, that even at low 
concentrations, for this type of in vitro study, significant aggregation occurs for WT Ltn 
upon addition of Fx.  
A control study was undertaken to consider the individual solutions of WT Ltn and Fx 
(Appendix 4 Figure A4.3). For WT Ltn some small aggregates were present, whilst Fx 
exhibited limited signs of aggregation but of a different morphology than the species 
observed for Ltn plus Fx solutions, therefore it is important to note that Fx has a propensity 
for self-aggregation and hence is most likely promoting Ltn aggregation here.   
5.3.2 Interactions with WT core and intrinsically disordered tail. 
DT IM-MS and ECD studies into WT Ltn suggested that in all bound complexes the tail was 
most likely associated with or involved in binding, leading to tight conformations and no 
observable cleavage of the ID tail in ECD studies. In order to further probe this theory, the 
core of Ltn (WT 1-72) and the ID tail (WT 72-93) were then studied.  
5.3.2.1 Ability of WT core and tail to bind Fx: MS studies 
The WT 1-72 construct was first studied, this construct contains the full structural core of 
Ltn10 but does not contain the ID tail and therefore could be considered more similar to the 
traditional conserved chemokine structure than full length WT Ltn. Interestingly WT 1-72 
aggregates much more extensively in the presence of Fx than the full length protein, with the 
spectra obtained at a 1:1 ratio at 50 μM protein concentration showing substantial 
aggregation, producing a spectrum of low quality (Appendix 4 Figure A4.4).  In order to 
acquire a cleaner, clearer spectrum the sample was then prepared at a 2:1 (Ltn:Fx) ratio at a 




D1-72+2Fx species are formed, with observed and expected masses of all species being in 
good agreement (Appendix 4 Table A4.3). The considerable increase in aggregation 
observed for WT 1-72 in comparison with WT Ltn suggests that the presence of the ID tail 
inhibits GAG binding and aggregation, this could either be via direct interaction between the 
GAG and the tail or the tail may affect the specificity of binding and the corresponding 
complex conformations, with formation of aggregation-prone non-specific complexes in the 
absence of the tail. 
 
Figure 5.6: Spectra obtained for A) WT 1-72 (50 µM concentration) B) WT 1-72 plus Fx acquired at a 
2:1 ratio at 25 μM Ltn concentration. 
In order to further probe these interactions the ability of the ID tail (WT 72-93) to bind Fx 
was then considered. This peptide contains an additional two amino acids at its N-terminus 
as a product of his-tag cleavage and therefore does not fully represent the native tail but will 
indicate if this ID sequence of amino acids (which contains one basic amino acid, lysine in 
position 77) can bind Fx. The spectra obtained from a 1:1 mixture of WT 72-93 and Fx 
highlights that the tail itself is not responsible for GAG binding (Figure 5.7B) with no 




(~5 mins), TEM studies, however, show that aggregation can occur when incubated for 30 
minutes (section 5.3.2.3). Therefore it is proposed instead that the ID tail affects the 
conformations of complexes adopted and the specificity of binding without directly 
interacting with Fx, a hypothesis which can be further probed by studying the conformations 
adopted by WT 1-72 upon binding to Fx. 
 
Figure 5.7: Spectra obtained for A) WT 72-93 B) WT 72-93 plus Fx prepared at 1:1 Ltn:Fx ratio. In 
both cases WT 72-93 was prepared at 50 µM concentration. 
5.3.2.2 Conformations of WT 1-72:Fx complexes: DT IM-MS studies 
Due to the inability of WT 72-93 to bind Fx, no DT IM-MS studies were performed on this 
construct. Instead, CCS of the WT 1-72:Fx species were determined. As with WT Ltn, 
comparisons were initially made between all observed unbound species in the absence and 
presence of Fx, Table 5.2.  





) are found to be within experimental error of values 
determined in the absence of Fx. An additional, more extended [M1-72+6H]
6+ 
species is, 
however, also identified in the presence of Fx, with a CCS of 1209 ± 13 Å
2




extended species is of similar CCS to the extended conformation of [M1-72+7H]
7+
, suggesting 
it is most likely due to a species of the same conformational family and that the presence of 
Fx is causing WT 1-72 to unfold at lower charge states. Additionally, the more compact 
conformation of unbound [M1-72+7H]
7+ 
 is seen to increase in CCS in the presence of Fx, 
again consistent with Fx promoting unfolding. Fx clearly effects the conformations of 
unbound WT 1-72. There are a number of mechanisms through which this could occur, 
either Fx could be transiently, or non-specifically, interacting with WT 1-72 promoting 
unfolding of these species, alternatively, these species may be an encounter species en route 
to stable binding for which the initial interaction with Fx promotes extension and unfolding 
of the monomer following which stronger binding occurs forming the M1-72+Fx species. 
Promotion of these extended conformations could explain the rapid aggregation observed by 
MS for this Ltn construct. No unbound dimeric WT 1-72 species are detected in the presence 
of Fx therefore the unbound species plotted in Figure 5.8 are those determined in the absence 





 in the presence of Fx are plotted in Figure 5.8. 
Species CCS/ Å2 
 Absence of Fx Presence of Fx 
[M1-72+5H]
5+
 916 ± 8 909 ± 13 
[M1-72+6H]
6+
 950 ± 9 973 ± 20 
[M1-72+6H]
6+
 -- 1209 ± 13 
[M1-72+7H]
7+
 1037* 1142 ± 18 
[M1-72+7H]
7+
 1229 ± 12 1211 ± 3 
Table 5.2: Experimentally determined average CCS for all unbound WT 1-72 species observed in the 
absence and presence of Fx, the error is reported as the standard deviation between repeats. *species 
observed in all repeats but only resolvable in one. 
DT IM-MS findings for Fx-bound WT 1-72 (Figure 5.8 and Appendix 4 Table A4.4) tell a 
dramatically different story to the full length WT Ltn. For this mutant, multiple 
conformations, both for the M1-72+Fx and the D1-72+Fx species, are present. For species of 
both oligomeric orders CCS are larger than their unbound counterparts. Interestingly, the 
more extended conformation of [M+Fx+6H]
6+
 is of similar CCS to that of the larger unbound 
6+ species in the presence of Fx, suggesting the more extended unbound species may be en 
route to complex formation.  
The observation of multiple conformations, which are often extended in nature, in 
combination with the extensive aggregation occurring during MS studies suggests that for 
this construct binding is less specific than for the full length WT Ltn. This suggests a 




Fx. It is plausible that the tail is needed to mediate specific binding and in doing so, also 
confers a conformational stability to the complexes.  
 
 
Figure 5.8: Average CCS of WT 1-72 Ltn and Fx bound Ltn dimeric (top) and monomeric (bottom) 
species, calculated from three repeats, error bars represent standard deviation between these values. 
Unbound species were determined in the absence of Fx (hollow symbols), extended species observed 




 are represented by hollow right triangles.  




5.3.2.3 Assessing core and tail aggregation: transmission electron 
microscopy 
MS and DT IM-MS results suggest that Fx binding and the corresponding aggregation 
process occurring for WT 1-72 are significantly different than that of WT Ltn, a finding 
further emphasised by the TEM images for this sample (Figure 5.9A). TEM images show 
larger globular aggregates forming, strikingly different in appearance to the ribbon-like 
species formed for WT Ltn.  This finding supports the assertion that the ID tail is essential 
for formation of the structures observed for WT Ltn samples; it is conceivable that in WT 
Ltn the presence of this ID tail controls or limits the extent of aggregation. To-date no in 
vitro TEM studies into the aggregation process of chemokines in presence of GAGs have 
been reported. It would be interesting to compare the complexes formed by classical 
chemokines, in the presence of Fx, to Ltn, to determine if they demonstrate the ribbon or 
globular morphology, as there is a clear correlation between the two morphologies and the 
presence or absence of the ID tail for Ltn. 
 
Figure 5.9: Representative TEM images obtained for A) WT 1-72 plus Fx (1:1 ratio at 50 μM) B) WT 
72-93 (50 μM) C) WT 72-93 plus Fx (1:1 ratio at 50 μM) D) WT 1-72 plus WT 72-93 plus Fx (1:1:1 




In order to further study this effect, TEM images were acquired for the tail (WT 72-93) in 
the absence (Figure 5.9B) and presence (Figure 5.9C) of Fx. It is clear that the ID tail itself 
can aggregate forming clusters of interesting morphology, containing some straight species 
and overall appearing net-like in appearance. In the presence of Fx, however, this 
morphology changes, with primarily straight, short fibres which can align and twist around 
each other being observed. These appear more similar to the ribbon structures of the full 
length protein plus Fx than the species formed for WT 72-93 the absence of Fx, suggesting 
once again that this ID tail has a key role in the complexes formed for full length protein in 
the presence of Fx, despite no binding or aggregation being detected by MS. A WT 1-72 plus 
WT 72-93 plus Fx (1:1:1) solution was also studied (Figure 5.9D), with TEM images 
showing both the globular species formed for WT 1-72 plus Fx and the ribbon-like species 
observed for WT 72-93 plus Fx (Figure 5.9C). The TEM grid is, however, dominated by the 
globular species, illustrating that either these aggregates have a higher affinity for the grid or 
that aggregation of WT 1-72 occurs faster than WT 72-93 in the presence of Fx and hence 
the solution is dominated by these globular species. The latter is supported by further MS 
studies (Appendix 4 Figures 4.5 and 4.6) and suggests that non-covalent interactions 
between the tail peptide and the structural core, are not sufficient to inhibit this aggregation 
process. The combination of studies presented here illustrate that the ID tail plays a 
significant role in both the binding of Fx and the aggregation pathways of Ltn, proposing a 
functional role in GAG binding. These results could help explain why such a sequence 
would be preserved in nature.  
5.3.3 Interactions of CC3 and Fx. 
Due to the clear ability of WT Ltn to bind Fx as both a monomer and dimer the Ltn 
monomer mutant (CC3), which contains a second disulfide bond limiting its interconversion 
to Ltn40, was also studied to further probe these interactions.  
5.3.3.1 Stoichiometry of binding: insights from MS 
The spectrum for CC3 highlights that despite its conformational constriction it can bind Fx, 
mostly binding as a monomer; however, some low level dimeric bound species are also 
observed (Figure 5.10), with the observed and expected masses of all species being in good 
agreement (Appendix 4 Table A4.5). This observation is consistent with other chemokines, 
almost all of which contain two disulfide bonds and those studied have been shown to bind 






As with WT Ltn, dimeric CC3 species can bind either one or two Fx chains and their 
presence for this monomeric mutant is significant, suggesting that Fx is facilitating dimer 
formation. Whether dimeric CC3 is in the Ltn10, Ltn40 or a yet unknown conformation 
cannot be discerned here. The formation of dimeric CC3 Fx-bound species, has not been 
previously reported, most likely due to their low population. This work underlines the 
sensitivity of MS, for the study of these intricate and complex binding processes and 
highlights dimeric bound CC3 as an interesting target for future study to better understand 
how Fx is promoting dimerisation.   
As with WT Ltn and WT 1-72 Ltn, CC3 appears to aggregate upon addition of Fx at 
equimolar concentrations, however, considering the baseline, signal intensity and visible 
aggregates observed in the tip it appears to aggregate to a lesser extent than WT Ltn.   
 
Figure 5.10 Spectra obtained for A) CC3 and B) CC3 plus Fx, 1:1 mixture. In both cases CC3 was 
prepared at 50 µM concentration. 
5.3.3.2 Conformations of CC3:Fx complexes: DT IM-MS studies 
For CC3, CCS of the two monomeric unbound species observed both in the presence and 
absence of Fx were found to be within experimental error (Table 5.3). This suggests that Fx 
does not significantly influence the conformations adopted by monomeric CC3. No unbound 
dimeric species were detected for CC3 in the presence of Fx due to their naturally low 




charge state range of CC3 in the presence of Fx, on the DT IM-MS instrument, comparisons 
in Figure 5.11, were made with unbound CC3 in the absence of Fx (Appendix 3 Table A3.8).  
Species CCS/ Å2 
 Absence of Fx Presence of Fx 
[MCC3+6H]
6+ 
1014 ± 3 1030 ± 28 
[MCC3+7H]
7+
 1163 ± 4 1181 ± 23 
Table 5.3: Experimentally determined average CCS for all unbound CC3 species observed in the 
absence and presence of Fx, the error is reported as the standard deviation between repeats. 
 
Figure 5.11: Average CCS of CC3 Ltn and Fx bound Ltn dimeric (top) and monomeric (bottom) 
species, calculated from three repeats, error bars represent standard deviation between these values. 
Unbound species were determined in the absence of Fx (hollow symbols). Filled symbols represent Fx 
bound species.  
Conformations adopted by CC3 upon Fx binding were considered (Figure 5.11 and 




compact than unbound CC3 at the same charge state. The remaining two charge states 
([MCC3+Fx+6H]
6+
 and  [MCC3+Fx+7H]
7+
) are extremely similar in CCS, with 
[MCC3+Fx+6H]
6+
 being marginally larger than the unbound species at this charge state and  
[MCC3+Fx+7H]
7+
 being slightly more compact than its unbound counterpart, despite the 
additional mass due to Fx (1508 Da). These CCS suggest a stable, relatively compact 
conformational family is being formed upon Fx binding to monomeric CC3, a finding further 
supported by CID studies (Appendix 4 Figure A4.7). The variance in CCS for MCC3+Fx is 
lower than that of the WT, changing only by ~30 % over the three charge states (as opposed 
to ~50% for  MWT+Fx), which is most likely due to the conformational constriction imposed 
on this mutant by the addition of the second disulfide bond.  
The dimeric Fx bound species for CC3 follow a similar trend to that of WT Ltn, with both 
the DCC3+Fx and DCC3+2Fx presenting over a relatively narrow and similar range of CCS, 
with the DCC3+2Fx species being slightly larger. The variance in CCS over the charge state 
range is again low ~20 % in each case, suggesting that these species are present in a stable 
conformational ensemble over which the addition of charge does not significantly affect the 
CCS. For both dimeric bound species it is interesting to note that CCS of the lowest charge 
states compare extremely favourably with the WT Fx-bound species of the same charge 
state, however as charge state is increased the CC3 species become larger than WT Ltn. The 
CCS obtained here for DCC3+Fx and DCC3+2Fx species suggests that these complexes are 
most likely stable and specific species, with Fx promoting the dimerization of this 
structurally constrained mutant. 
5.3.3.3 Assessing CC3 aggregation: transmission electron microscopy 
The aggregation occurring for CC3 in the presence of Fx was next considered (Figure 5.12), 
with species formed appearing visually extremely similar to those formed in the WT sample 
at the same concentration: large, twisted ribbon structures. CC3 plus Fx aggregation does not 
appear to form as numerous or extensive clusters as WT Ltn plus Fx suggesting that either 
these species have a significantly lower affinity for the TEM grid or CC3 aggregates to a 
lesser extent. The latter is consistent with observations made during, and findings from, MS 
studies which show evidence for lower aggregation levels; with a higher signal-to-noise and 
fewer visible aggregates observed in the n-ESI capillary. These smaller clusters formed for 
CC3 in the presence of Fx and viewed in the TEM images enable clearer and, therefore, 
more detailed images to be obtained on individual species and clearly show species twisting 





Figure 5.12: Representative TEM images obtained for CC3 plus Fx prepared at a 1:1 ratio at 50 µM 
concentration.  
5.3.4 Interactions of W55D and Fx. 
5.3.4.1 Stoichiometry of binding: insights from MS 
The final Ltn mutant studied in detail here is W55D, which by MS is found to interact with 
Fx in a similar fashion to WT Ltn and CC3, forming MW55D+Fx, DW55D+Fx and DW55D+2Fx 
species over a range of charge states (Figure 5.13), with observed and expected masses of all 
species being in good agreement (Appendix 4 Table A4.7). Fx-bound W55D species present 
over a wider charge state range than those of the WT Ltn or CC3 bound species, consistent 
with this highly flexible mutant presenting over a wider charge state and CCS range in its 
unbound form (see Chapter 4). 
Interestingly, based on the relative intensity of the ions, W55D appears to bind Fx as a 
monomer to a lesser extent than WT Ltn, consistent with this mutant being mostly dimeric in 
solution; however, under these experimental conditions, in which extensive aggregation is 
observed, it is impossible to quantify the extent of binding. The fact that any Fx bound 
monomeric W55D  is observed is significant, as NMR studies have shown this mutant to be 
mainly dimeric in solution and previous gas-phase structural studies into this mutant 
(Chapter 4 section 4.4.3) have suggested that monomeric signals in the spectra are due to 
dissociated dimer, occurring upon ionisation and desolvation. The occurrence of MW55D+Fx 
species here, suggests either that there is a small proportion of monomer in solution which is 
capable of binding Fx or that the dimeric Fx-bound species, as with the unbound W55D 
dimer, are relatively fragile and can be broken apart upon ionisation and desolvation.  CID 
experiments were performed on the highest intensity dimeric bound species, 
[DW55D+Fx+9H]
9+
, and showed dissociation to  monomer and MW55D+Fx, suggesting that 
MW55D+Fx could indeed be a product of dissociation (Appendix 4 Figure A4.8). MW55D+Fx 
were also subjected to CID fragmentation studies and similar observations were made to that 
of WT Ltn, with Fx fragmenting before complex dissociation; however, a greater proportion 
of monomer dissociation occurs for W55D (Appendix 4 Figure A4.9). Therefore it is not 




depth studies would need to be performed. Indeed it is possible that the MW55D+Fx species 
observed are due to both possibilities described here, namely a small proportion of monomer 
being present in solution along with dissociation on desolvation.  
 
Figure 5.13: Spectra obtained for A) W55D and B) W55D plus Fx, 1:1 mixture. In both cases W55D 
was prepared at 50 µM concentration. 
Comparison between the charge state distribution and intensity of the unbound W55D 
monomer in the absence (Figure 5.13A) and presence (Figure 5.13B) of Fx show clear 
differences. In the presence of Fx the signal intensity of the unbound species is greatly 
reduced, particularly for the species which accept either six or seven protons. This decrease 
in unbound monomer signal in the presence of Fx could be due to a number of factors: either 
Fx is binding a large proportion of dimeric protein in solution stabilising the dimer and 
limiting dissociation to monomer; the presence of Fx shifts the monomer:dimer equilibrium 
in solution reducing the intensity of any monomer present; or this unbound signal reduction 
could be due to W55D rapidly binding and aggregating, causing a significant decrease in all 
unbound protein signal in the presence of Fx. Indeed it is likely that this observation is due to 
a combination of these effects. It is clear that W55D is aggregating in the presence of Fx, due 




observation which is further probed using TEM (see section 5.3.4.3). It is, however, also 
possible that binding of Fx is stabilising dimeric W55D and limiting dissociation to 
monomer upon ionisation and desolvation.  
5.3.4.2 Conformations of W55D:Fx complexes: DT IM-MS studies 
For W55D CCS of all charge states of unbound dimeric species in the absence and presence 
of Fx are within experimental error, confirming that Fx does not affect the conformations of 
unbound dimeric W55D (Table 5.4).  
The lowest charge states (4 and 5+) of unbound MW55D were not observed in the presence of 
Fx and therefore in Figure 5.14 the CCS of these species are those determined in the absence 
of Fx. Unbound monomeric W55D species observed in the presence of Fx are, however, 
present in two conformational families, one of which is within experimental error to the 
species observed in the absence of Fx and whilst the other is more extended (Table 5.4). The 
more extended conformational family could be due to Fx affecting the conformations of any 
solution phase unbound monomeric species, promoting extension or unfolding. 
Alternatively, these more extended conformations could be due to dissociation of Fx-bound 
species during desolvation yielding monomeric species with a larger CCS. It is indeed likely 
that if dissociation of bound species was occurring upon desolvation that this would yield 
monomeric species of altered CCS. This observation coupled with significantly decreased 
monomeric signal in the presence of Fx (Figure 5.13) suggests that Fx binding is stabilising 
the W55D dimer, leading to decreased dissociation upon ionisation and desolvation, hence a 
lower unbound signal. Furthermore, when dissociation does occur it yields monomers of 
different CCS due to the structure of the precursor complex. It is therefore speculated that 
monomeric species of extended CCS are due to dissociation from dimeric W55D:Fx 
complexes.  
Species CCS/ Å2 
 Absence of Fx Presence of Fx 
[MW55D+6H]
6+
 1057 ±12 1075 ± 20 
[MW55D+6H]
6+
 -- 1238 
[MW55D+7H]
7+
 1150 ± 26 1165 ± 34 
[MW55D+7H]
7+
 -- 1480 ± 26 
[MW55D+8H]
8+
 1401 ± 6 1408 
[MW55D+8H]
8+
 -- 1717 
[DW55D+10H]
10+
 1704 ± 6 1687 
[DW55D+11H]
11+
 2020 1998 
[DW55D+12H]
12+
 2062 ± 8 2059 
[DW55D+13H]
13+
 2103 ± 67 2171 
Table 5.4: Experimentally determined average CCS for all unbound W55D species determined in the 





Figure 5.14: Average CCS of W55D and Fx bound W55D dimeric (top) and monomeric (bottom) 
species, calculated from three repeats, error bars represent standard deviation between these values. 
Unbound species were determined in the absence of Fx (hollow symbols), extended species observed 




 are represented by hollow right triangles.  
Filled symbols represent Fx bound species. 
Considering the W55D:Fx complexes (Appendix 4 Table A4.8), CCS determined for  
monomeric bound species of W55D (Figure 5.14) lie between the two conformational 
families of unbound monomeric W55D. Interestingly these MW55D+Fx species present over a 
much narrower range of CCS than determined for M+Fx of both WT and CC3 Ltn, 
increasing by only ~10 % over the charge state range. This finding is in contrast to the trends 
for the unbound species, which highlighted that W55D in both its monomeric and dimeric 




effect on the monomeric form of W55D causing a decrease in flexibility. This is consistent 
with the monomeric form of W55D being different to that of the conserved chemokine fold, 
as highlighted in Chapter 4 Section 4.4.3, and suggests that the MW55D
 
and MW55D+Fx species 
could be a product of dissociation, possibly from a dimeric bound form. In-depth studies 
outside of the scope of this initial binding study would, however, be needed to determine the 
likely conformations MW55D+Fx has adopted. Even without knowing the precise 
conformation these species are adopting, useful comparisons are made between the different 
constructs and between monomeric and dimeric bound species. This observation also 
strongly reinforces a point raised from Chapter 4, that a more stable mutant is required to 
properly mimic the Ltn40 fold. 
DW55D+Fx present with CCS both smaller (charge states 9+ and 12+) and larger (charge 
states 10+ and 11+) than the unbound W55D dimer, however, CCS increase by only ~20 % 
over this charge state range, suggesting a stable conformational family is formed. These 
W55D bound dimers are significantly larger than the WT and CC3 D+Fx species, consistent 
with unbound W55D generally being larger. 
DW55D+2Fx species present over a similar CCS range as the DW55D+Fx species, with 
conformations both smaller and larger than DW55D+Fx at the same charge state and larger 
than the unbound dimeric species at all charge states. CCS of DW55D+2Fx increase by only 
~20 % over the charge state range, again consistent with a stable conformational family of 
the Fx bound form and highlighting the specificity and stabilising effect of Fx binding.  It is 
therefore surmised that as for WT and CC3 Ltn, W55D forms specific stable dimeric Fx 
bound complexes. 
5.3.4.3 Assessing W55D aggregation: transmission electron microscopy 
The species formed in the W55D plus Fx mixed sample (Figure 5.15) appear by TEM much 
shorter in length than those formed for WT Ltn and CC3 at the same concentration, although 
the morphology appears similar, forming ribbon-like species. It is notable that a single point 
mutation can cause such a difference in the length of these large aggregate species. 
 





The single point mutation in W55D is thought to push the solution phase equilibrium 
towards the dimeric structure, whereas WT and CC3 have a substantial proportion of 
monomer in solution. DT IM-MS experiments of WT and CC3 show that the M+Fx species 
are highly flexible in nature, with a wide range of CCS determined. It is therefore feasible to 
speculate that in the case of CC3 and WT Ltn, the flexibility of these M+Fx bound species 
may lead to the large twisted ribbon-like species formed for these two constructs. In contrast 
the W55D with a lower proportion of monomer, if any, in solution leads to less flexible 
MW55D+Fx species  being formed, potentially from dimeric bound structures in solution, 
which due to their rigidity cannot form the same long, flexible aggregates observed for WT 
and CC3, consistent with the decreased flexibility of the MW55D+Fx species. If this is the case 
it would suggest that, in this set of experiments, the species detected by DT IM-MS could be 
on-pathway to the large aggregate species in the TEM studies, especially when considering 
the short time scales of these experiments, and hence such approaches could be useful in 
future in-depth analysis of this aggregation mechanism and pathway.  
5.3.5 Probing the GAG binding function through further specific site 
mutations  
  
Figure 5.16: Arginine residues 23 and 43 labelled in purple and cyan respectively, on A) Ltn10 and B) 
Ltn40, both chains labelled. Figure created in VMD from PDB files 1J9O and 2JP1 respectively 
The Volkman group
41
 have identified that residues R23 and R43 are key for GAG binding, 
with binding affected by a factor of 40, as measured in surface plasmon resonance (SPR) 
sensograms for R23A and R43A compared to WT Ltn. Furthermore, the same study 
highlighted that the R23A/R43A double point mutant showed a further decrease in binding, 
by a factor of 300.  The position of these residues are shown mapped on to the Ltn10 (Figure 
5.16A) and Ltn40 folds (Figure 5.16B). This study was performed prior to the Ltn40 
conformation being solved and, therefore, solely considered the Ltn10 fold. The point 




heparin-sepharose column binding studies, during which the proteins eluted in the following 
order: WT, R23A, R43A and R23A/R43A (Table 5.5). Therefore in order to further probe 
the interactions between Fx and Ltn, preliminary MS and TEM studies were performed on 
these mutants of reduced affinity. The spectra of all three arginine mutants can be found in 
Appendix 4 Figure 4.10. 
Ltn mutant Peak 1 elution 
(mM NaCl) 
Peak 2 elution 
(mM NaCl) 
WT 452 694 
R23A 382 557 
R43A 376 458 
R23A/R43A 309 344 
Table 5.5: Elution from heparin-sepharose column for WT, R23A, R43A and R23A/R43A
39
. Peak 1 is 
assigned as Ltn10 and peak 2 as Ltn40 based on studies of WT, CC3 and W55D.  
5.3.5.1 Insights in to interactions: MS studies. 
R23A Ltn was the first of this series of mutants to be studied, as by heparin-sepharose 
column binding studies this mutation was shown to have the smallest effect on heparin 
binding both in its monomeric (peak 1) and dimeric (peak 2) form, see Table 5.5. Compared 
to the mass spectra acquired for WT Ltn, in the presence of Fx under similar conditions 
(Figure 5.17A) R23A appears to favour a dimeric Fx-bound form (Figure 5.17B), with these 
species having a higher relative intensity than for WT Ltn.  A significant observation 
considering this mutation has been shown to shift the unbound equilibrium slightly towards 
the monomeric fold
39
. Direct comparisons between these spectra, however, cannot be made 
as these proteins could be, and most likely are, aggregating to different extents which would 
affect the spectra acquired and intensity of all species within the spectra. Visually, it does 
appear as if R23A is aggregating to a lesser extent than WT Ltn in the presence of Fx; 
however, TEM studies enable this to be probed in detail (see section 5.3.5.2). From the 
spectra obtained it is clear that R23A is capable of binding Fx, and can bind in both a 
monomeric and dimeric form and hence this mutation does not completely diminish GAG 
binding.  
Considering next the R43A Ltn mutant, the spectrum obtained (Figure 5.17C) shows a 
decrease in intensity of dimeric Ltn binding Fx with respect to R23A. This observation is 
consistent with this mutant binding GAGs with lower affinity than R23A and WT Ltn, hence 
solidifying that this residue is of importance with respect to GAG binding. Furthermore, 
R43A appears to aggregate to a lesser extent than previous Ltn constructs studied, indicative 
of a lower GAG binding affinity. As with R23A, R43A can, however, still bind Fx in both a 




binding, mutation of this residue to an alanine does not completely diminish the Ltn GAG 
binding propensity. 
 
Figure 5.17: Spectra obtained for Ltn plus Fx for A)WT, B) R23A , C) R43A and D) R23A/R43A. In 
all cases spectra were obtained from 1:1 mixtures of Ltn:Fx at 50 μM protein concetration. Expected 
and observed masses of all species can be found in Appendix 4 Table A4.9. 
The final arginine/alanine mutant studied was the double point mutation R23A/R43A which 
was shown by both SPR and heparin-sepharose column binding studies to have the most 
significant decrease in binding for both the monomeric and dimeric forms. Mutation of either 




amino acids present on both folds of Ltn (Figure 5.4), reducing the GAG binding affinity of 
both monomeric and dimeric Ltn. The spectra obtained for R23A/R43A plus Fx (Figure 
5.17D) shows a reduction in both monomeric and dimeric binding of Ltn, with these species 
present at a much lower intensity, consistent with heparin-sepharose column binding studies 
which revealed a significant decrease in Ltn10 and Ltn40 binding for R23A/R43A. The 
R23A/R43A construct was also visually observed to aggregate to a lesser extent than 
previous samples studied, such as WT Ltn.  
Intriguingly, a number of additional species are present in this spectrum, assigned as 
Fx-bound trimers and tetramers of R23A/R43A (Figure 5.18).  The expected and observed 
masses of all species for R23A/R43A, and the two single point mutants, are in good 
agreement (Appendix 4 Table A4.9). These higher order oligomers were not observed for 
any other Ltn construct studied here and could be unique, favoured complexes for 
R23A/R43A, or could be attributable to slower aggregation. For this system it may be 
feasible to capture oligomeric species on pathway to higher order aggregates. If this were the 
case, however, it would be expected that a number of species of increasing oligomeric orders 
would have been observed for the lower concentration WT samples or for the other Ltn 
arginine mutants which aggregate to a lesser extent. Therefore, it is thought that the 
identification of these species is not due to the slower aggregation occurring here and instead 
formation of these species is specifically promoted via the mutations made to R23A/R43A 
Ltn.  
 
Figure 5.18: Enlarged region of m/z 2100-3500 for spectrum shown in Figure 5.17E for R23A/R43A 




R23A/R43A Ltn does not form trimers or tetramers in the absence of Fx (Appendix 4 Figure 
A4.10). Furthermore, no unbound trimers or tetramers are observed in the presence of Fx, 
emphasising that formation of these species is induced by Fx to enable binding to occur. The 
chemokines CCL2 and CXCL4 have been shown to bind GAGs as tetramers, with detailed 
structural studies highlighting that tetramerisation of these chemokines results in a structure 
containing continuous basic patches providing a GAG binding surface
18,21
. This provides a 
possible explanation for the observation of Fx bound trimers and tetramers for R23A/R43A. 
These two residues have proved key for the GAG binding of WT Ltn and fall in the centre of 
the large basic patch of amino acids on both Ltn10 and Ltn40, however, WT Ltn contains a 
further 13 basic residues; seven arginine residues and six lysine residues. It is therefore 
speculated here that to overcome the detrimental effect, with respect to GAG binding, of 
removing two basic residues R23A/R43A oligomerises, with the packing of the subunits 
creating a basic surface to which the GAG can bind. Here, it is thought that oligomerisation 
occurs prior to stable R23A/R43A:Fx complex formation, most likely through transient 
interactions with Fx, after which stable species can form. DT IM-MS in combination with 
detailed MD studies has the potential to shed light on the conformations of these species and 
further work should involve such studies. The intensity of all Fx-bound species is low, 
accentuating the fact that GAG binding affinity is significantly reduced in this construct and 
this cannot be completely overcome through the rapid formation of higher order oligomers.   
5.3.5.2 Assessing aggregation: TEM studies 
The three arginine mutants were also studied using TEM, to assess the extent to which they 
were aggregating in the presence of Fx and if the morphology of the species was similar to 
that observed for the other Ltn constructs studied here.  
As with all other constructs, samples were allowed to incubate for 30 minutes prior to TEM 
grid preparation. R23A forms aligned structures of a ribbon-like morphology (Figure 5.19A), 
similar to those for WT (Figure 5.5), CC3 (Figure 5.12) and W55D (Figure 5.15) Ltn 
constructs and the Ltn ID tail (Figure 5.9B), in the presence of Fx. The sample, however, is 
not observed to aggregate to the same extent as the other Ltn mutants studied here and 
reiterates that GAG binding and hence GAG induced aggregation is reduced for this mutant.  
R43A Ltn produces ribbon-like structures (Figure 5.19B), shorter in length than those of WT 
and CC3 Ltn plus Fx, attributed to the lower GAG binding affinity and hence slower GAG 
induced aggregated for this mutant. It is interesting, however, to note that both the R23A and 
R43A single point mutations do not significantly alter the morphology of the large 






Figure 5.19: Representative TEM images obtained for 1:1 mixtures of Fx and A) R23A B) R43A C) 
R23A/R43A.  
The R23A/R43A mutant displays very little aggregation, with the majority of images 
showing either dye aggregation or low level protein aggregation (Figure 5.19C). The 
aggregates observed for R23A/R43A appear less structurally defined than other Ltn species, 
and form much smaller clusters consistent with this mutant binding Fx with the lowest 
affinity and undergoing minor GAG induced aggregation.  
 
 Conclusions 5.4
The studies presented here focused on one of the functions of the metamorphic chemokine 
Ltn, namely to bind glycosaminoglycans, using a combination of MS-based techniques to 
provide details on stoichiometry of binding and conformations adopted by bound species, in 
addition to TEM studies enabling the visualisation of aggregation occurring upon the 
addition of GAGs.  
In the main this work focused on the interactions of WT Ltn, mutants designed to mimic the 
Ltn10 (CC3) or Ltn40 (W55D) folds in addition to the ability of the structural core 




results highlight that, despite its metamorphic nature, the functions of WT Ltn are not 
completely separate and defined in vitro, and Ltn is capable of binding Fx as both a 
monomer and a dimer. WT Ltn forms monomeric complexes capable of binding one Fx 
chain and dimeric complexes capable of binding one or two Fx chains, with DT IM-MS 
experiments indicating stable, specific complexes are being formed in all cases. The 
monomeric bound species are inherently flexible and present over a wide range of CCS 
(increasing in CCS by up to 50 %); this flexibility is thought, in part, to enable the formation 
of large flexible, twisted ribbon-like structures to be formed during the GAG induced 
aggregation process.   
Of all Ltn constructs studied in detail, CC3 appears most similar to WT Ltn, with respect to 
stoichiometry of binding, conformations of monomeric and dimeric bound species and 
significantly the larger aggregates visualised through TEM studies, despite the more 
conformationally confined nature of this construct. Even after pushing the equilibrium 
strongly towards the monomeric form of Ltn (through addition of an extra disulfide bond) 
the nature of GAG binding is not perturbed.  
The dimeric mutant W55D provides more complex results and points to its inadequacy as a 
dimeric mutant. Binding of Fx does reduce the conformational flexibility of dimeric W55D, 
with Fx bound species presenting over a much narrower range of CCS than its unbound 
counterparts. Monomeric bound species of W55D also appear more structurally constrained 
than both the unbound monomer and the other constructs studied here, which infers that 
these species are of a different nature than the other mutants studied, consistent with the 
earlier structural studies of W55D (Chapter 4). Interestingly, by TEM W55D is observed to 
form aggregates of a similar morphology but of much shorter length than WT and CC3 in the 
presence of Fx, an observation which has been attributed to the decreased flexibility of the 
W55D bound species.  
Significantly, WT 1-72 has substantially different behaviour in the presence of Fx, with 
extensive aggregation occurring, forming species of an altered, globular morphology. In 
addition the GAG-bound complexes adopt multiple, highly extended conformations 
suggesting binding is less specific for this mutant. The ID tail (WT 72-93) itself does not 
bind Fx (as viewed by MS), however, based on the results for WT 1-72 in comparison to all 
full length constructs, the ID tail is essential for specific, stable GAG-bound conformers to 




In addition a series of arginine mutants (R23A, R43A and R23A/R43A) which had been 
previously reported to exhibit decreased GAG binding
39,41
 were studied. For all three 
mutants, a decrease in intensity of binding and GAG-induced aggregation is observed. For 
the single point mutants this effect is more pronounced for R43A, than for R23A, indicating 
that the R43 residue is more significant with respect to GAG binding and particularly for 
dimeric GAG binding. Both the R23 and R43 residues lie within a large basic patch, in both 
the monomeric and dimeric folds and hence mutation of either of these residues disrupts this 
basic region, which then inhibits binding. Mutation of both the R23 and R43 residues to form 
R23A/R43A reduces the intensity of GAG binding further attributed to greater disruption of 
the basic region. R23A/R43A, however, shows by MS, higher order oligomers binding Fx, 
with trimers and tertramers being detected. These species were not present in the spectra of 
the protein itself or in any other Ltn mutant spectra, in the absence or presence of Fx. It is 
therefore hypothesised that R23A/R43A oligomerises forming trimers and tetramers in order 
to create a larger basic patch of amino acids to which Fx can then bind, in order to overcome 
the disruption to this region caused via the mutations. It is speculated here that weak, 
transient interactions between R23A/R43A and Fx promote oligomerisation of R23A/R43A 
enabling stronger, more specific interactions between the oligomers and Fx to occur. Future 
studies into these mutants should involve DT IM-MS experiments to obtain information on 
the conformations of these species.  
Clearly, GAG binding is a complicated and intricate process; however, the in vitro work 
presented here probes this in detail. It is surmised that Fx binds to a basic patch of amino 
acids on both the Ltn10 and Ltn40 folds. Interactions between GAGs and a basic region of a 
protein would enable multiple interactions to occur, strengthening and stabilising binding 
and corresponding complexes formed. Mutation of basic amino acids within this accessible 
region decreases the GAG binding propensity of Ltn. Furthermore, complexes formed 
between Ltn and Fx appear to be stabilised by the ID tail, suggesting this preserved 
disordered region is functionaly important with respect to GAG binding, despite not being 
needed for receptor activation
37
. Finally, this combination of biophysical tools clearly can be 
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Investigating interactions with GAGs: 
Human β-defensins 
Human β-defensins (HBDs) share several structural and functional similarities with 
chemokines. Previous studies have demonstrated that HBDs can bind glycosaminoglycans 
(GAGs) and activate some chemokine receptors. This chapter focuses on the binding of 
human β-defensin-2 (HBD2) and human β-defensin-3 (HBD3) to the model pentameric 
GAG, fondaparinux (Fx).  The work presented here aims to study and characterise the 
HBD:GAG interactions and aggregation using a combination of biophysical techniques 
including MS, DT IM-MS, ECD, TEM and isothermal titration calorimetry, to better 
understand these interactions and determine how they compare to chemokines. In addition 





6.1.1 Chemokines and defensins: similarities in structure and function 
The β-defensin subclass of antimicrobial peptides shares a number of structural and 
functional similarities with the chemokine superfamily of proteins. Defensins are small 
cationic, cysteine-rich peptides which are divided into three main subfamilies based on the 
positioning of their disulfide bonds, as discussed in Chapter 1 section 1.4. In β-defensins the 












. The positioning of 
disulfide bonds helps to stabilise the conserved tertiary fold of the β-defensins, which 
comprises an α-helix and three antiparallel β-strands
1-4
. This tertiary fold is reminiscent of 
the highly conserved chemokine fold
5,6
, however, in chemokines the fold is stabilised most 
frequently by two disulfide bonds.  
 
Figure 6.1: Tertiary folds of a HBD and representatives from three major chemokine classes, solved 
by NMR A) human β-defensin-3 (PDB 1JK6) B) CC chemokine CCL20 (PDB 2JYO) C) CXC 
chemokine CXCL8, stabilised monomer structure (PDB 1IKL)  D) C chemokine lymphotactin, 
monomeric (PDB 1J9O). 
Interestingly, in addition to sharing similar tertiary folds (Figure 6.1), the functions of 
chemokines and defensins have recently been recognised to overlap. The most well 
characterised function of defensins is their role within the innate immune system, in which 
they display antimicrobial properties with broad-spectrum activity towards viruses, fungi, 
Gram-positive and Gram-negative bacteria
7-9
. In 2000 Krijgsveld et al
10
 reported the first 
chemokine displaying antimicrobial activity, following which the majority of human 
chemokines have since been studied and numerous examples of broad-spectrum 
antimicrobials have been reported
11-14
.   
In addition to the recent discovery of antimicrobial properties, chemokines are most well 
known as signalling proteins in both the innate and acquired immune system
15,16
, within 
which they often interact with G-protein coupled receptors (GPCRs)
5,17
. This is another 
function which β-defensins share, with human β-defensin-2 (HBD2) and human β-defensin-3 
(HBD3) reportedly binding CC-type chemokine receptor-2
18









chemokine proteins and β-defensin peptides overlap significantly; however, due in-part to 
the smaller size of β-defensins (2-6 kDa compared with 8-10 kDa for chemokines) and their 
third disulfide bond, these peptides are not classified as chemokines.  
6.1.2 GAG binding 
In order to fulfil their full function in vivo it is essential for certain chemokines to interact 
both with their GPCR and with glycosaminoglycans on endothelial cells and in the 
extracellular matrix
9,22,23
, as discussed in Chapter 5. GAG binding is thought to provide a 
necessary method of localisation and concentration of chemokines and is essential in order to 
establish a concentration gradient along which cells can migrate during chemotaxis
9
.  





. Investigations into defensin:GAG binding are, however, in their 
infancy in comparison to those carried out on the chemokine superfamily. To-date most 
studies considering GAG binding have focused on the implications with respect to 
antimicrobial activity, with few considering chemotaxis
28
, despite overlapping properties of 
these two families. One such study demonstrated that a member of the α-subclass of 
defensins can bind the GAG dermatan  sulfate, which subsequently reduced the antibacterial 
effect of the defensin
25
. McCullough et al
26
 studied interactions between a heparin-derived 
sulfated disaccharide and a series of β-defensin related peptides using mass spectrometry 
(MS) and ion mobility-mass spectrometry (IM-MS). A number of monomeric defensin plus 
GAG complexes were observed here which were found to adopt compact collision cross 
sections (CCS), suggesting tight specific binding. Furthermore, as with the α-defensins, 
GAG binding decreased the antimicrobial activity of these β-defensin related peptides.  
In 2010 Seo et al
29
 presented the first detailed structural study into the GAG binding ability 
of human β-defensins. Here investigation focused on interactions between HBD2 and a 
series of GAGs using a combination of biophysical techniques, including gel mobility shift 
assays, mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy.  The 
results highlighted that HBD2 was capable of binding GAGs of a chain length greater than 
two; however, above six units extensive aggregation was observed. Both MS and NMR 
studies highlighted that HBD2 forms a dimer upon binding with the pentameric GAG 
fondaparinux (Fx), consistent with observations made for chemokines which have been 
reported to bind GAGs most frequently in monomeric or dimeric forms
30-33





Interactions between GAGs and the remaining human-β-defensins have been under-reported. 
The investigations presented here aim to address this through studying the interactions of 
both HBD2 and HBD3 with the model GAG Fx, using a combination of biophysical 
techniques. The interactions between HBD2 and Fx are further characterised using drift tube 
ion mobility-mass spectrometry (DT IM-MS), electron capture dissociation (ECD) and 
isothermal titration calorimetry (ITC). The ability of HBD3 to bind Fx and stoichiometry of 
the interactions is discerned from MS. The conformations of the resulting HBD3+Fx 
complexes are explored using DT IM-MS. The extent of GAG-induced aggregation of HBDs 
has not to-date been investigated and hence the aggregation occurring upon Fx addition to 
both of these β-defensins is studied using transmission electron microscopy (TEM). The 
combination of techniques presented here aims to shed light on this intricate biological 
process and further understand these interactions, enabling any similarities or differences in 
comparison to chemokine:GAG binding to be discerned.  
6.1.3 Heterodimerisation of chemokines and implications for HBDs 
Many chemokines form dimers via distinct, defined dimerization motifs generally 
represented by either the CC or CXC chemokine dimer interface; however, novel dimers are 
also known
34,35
. In general chemokines of the CC subclass dimerise through formation of a 
two-stranded antiparallel β-sheet near the N-termini, whilst chemokines of the CXC subclass 
dimerise through the first strand of the monomeric β-sheet
36
. The characterisation of defined 
dimerization motifs for the CC and CXC classes of chemokines suggested that chemokines 
of the same subclass could heterodimerise using these motifs and indeed heterochemokine 
dimers have been observed
37
, in some cases having higher affinity over homodimers
38,39
. 
Furthermore, it has been suggested that heterodimeric chemokine complexes could have 
functional consequences, adding another layer of complexity to these intricate biological 
pathways and potentially providing an additional mechanism for in vivo modulation
38,40-42
. 
Studies have shown a correlation between GAG binding and chemokine homodimerisation 
and oligomerisation
33,43
; hence, recent studies have considered the possibility of GAG 
modulation of heterodimerisation
44
. Crown et al
44
 investigated a number of CC chemokines 
and their propensity for heterodimerisation by MS and NMR, reporting several CC 
heterodimers, which in the case of CCL2 and CCL8 reduced the homodimer intensity, 
highlighting that these heterodimeric complexes can be highly favoured. By NMR it was 
found that CCL2+CCL8 dimerised through formation of a CC dimer interface, signifying the 
specificity of this heterodimeric chemokine. Significantly, heterochemokine complexes were 




of Fx were observed to form both CCL8+CCL11 and CCL8+CCL11+Fx complexes in the 
presence of Fx, implicating GAGs in the regulation of chemokine heterodimerisation and 





 have been found to form homodimers, although the dimeric 
structure of HBD3 has not to-date been solved. The ability of different members of the 
β-defensin subfamily to form heterodimeric complexes has not yet been reported.  The 
propensity of  HBD2 and HBD3 to form homodimers, coupled with the fact that they interact 
with the same CCRs
18
 and can be found in the same regions
7,8,45-47
 makes them attractive 
targets to investigate the possibility of heterodefensin complex formation. In order to 
consider heterodefensin complex formation MS and DT IM-MS studies are performed in the 
absence and presence of Fx. 
 
 Experimental 6.2
6.2.1 Peptide and glycosaminoglycan samples 
HBD2 and HBD3 produced by solid phase synthesis were purchased from the Peptide 
Institute (Osaka, Japan). Stock solutions of 200 μM peptide in 20 mM AmAc were prepared 
and aliquots were stored at -20 °C until use.  Ammonium acetate salt was purchased from 
Fischer Scientific (Loughborough, UK) and prepared in high purity water, in the resistivity 
range of 18.0-18.2 MΩ•cm obtained from an Arium 611 water purification system (Satorius, 
Göttingen, Germany). 
Bovine pancreatic trypsin inhibitor (BPTI) was purchased from Sigma-Aldrich Company Ltd 
(Dorset, UK). A stock solution at 1 mM protein concentration was prepared in deionised 
water and stored in aliquots at -20 °C until use.  
Concentrations were verified using the Pierce BCA concentration assay (Thermo Fischer 
Scientific, Wilmington, DE, USA) following manufacturer’s instructions but using volumes 
10 times lower than stated in the manual, afforded through the use of low volume UV 
cuvettes. 
Foundaparinux sodium was a gift from GlaxoSmithKline (Brentford, UK). The 
foundaparinux solution was prepared at a stock concentration of 587 μM in water. Aliquots 
of which were dialysed overnight versus water using a 1,000 molecular weight cut-off Micro 




6.2.2 Sample preparation for MS studies  
In all cases samples were prepared in 20 mM AmAc at pH 6.8. 
Individual HBD2 and HBD3 samples were prepared at 50 μM peptide concentration. HBD2 
plus Fx and HBD3 plus Fx solutions were prepared at 1:1 molar ratios at 50 μM peptide 
concentration.  HBD3 plus Fx was additionally studied at a 2:1 defensin:GAG ratio at  
50 μM HBD3 concentration.  
For HBD2 plus HBD3 MS binding studies 1:1 mixtures were prepared at 50 μM total 
peptide concentration and for MS binding studies of HBD2 plus HBD3 plus Fx, mixtures 
were prepared at a 1:1:1 ratio with each component being present at 25 μM. 
For MS studies BPTI was prepared at 50 μM. BPTI plus Fx samples were prepared at a 1:1 
ratio at 50 μM BPTI concentration. HBD2 plus BPTI was prepared at a 1:1 ratio at 50 μM 
total protein concentration. HBD2 plus BPTI plus Fx was prepared at a 1:1:2 ratio at a 
50 μM total protein concentration plus 50 μM Fx.  
All MS studies were performed on a Q-TOF Ultima (Waters, Manchester, UK), for operating 
conditions see Chapter 2 section 2.2. Collision induced dissociation experiments, HBD2 plus 
HBD3 and HBD2 plus BPTI studies were performed post-high mass upgrade and all other 
experiments were performed prior to the high mass upgrade.  
6.2.3 Sample preparation for DT IM-MS studies 
For determination of CCS for all HBD2 and HBD2+Fx species, 50 μM sample solutions of 
HBD2 plus Fx at a 1:1 ratio was prepared. In addition a ‘supercharged’ sample was also 
studied prepared at the same concentration, however, in this case the buffer was 20 mM 
AmAc plus 1 % m-NBA. For determination of CCS of HBD3 and HBD3+Fx species to limit 
aggregation sample solutions were prepared at a 2:1 HBD3:Fx ratio, with HBD3 at 50 μM 
concentration. Additionally, one repeat of HBD2 and HBD3 prepared as individual peptide 
solutions at concentrations of 50 μM were acquired as a control. 
For HBD2+HBD3 complexes CCS were determined using 1:1 mixtures at 100 μM total 
peptide concentration.  For HBD2+HBD3+Fx complex CCS determination, mixtures were 
prepared at a 2:2:1 ratio (HBD2:HBD3:Fx) at a total peptide concentration of 100 μM. 
All DT IM-MS measurements were performed on an in-house modified Q-TOF (Micromass 




6.2.4 Sample preparation for ECD studies 
For HBD2+Fx ECD studies, samples were prepared at a 1:1 ratio at 30 μM peptide 
concentration in 20 mM AmAc. In addition a ‘supercharged’ sample was also studied 
prepared at the same concentrations, however, in this case the buffer was 20 mM AmAc plus 
1 % m-NBA. Finally, a HBD2 sample was prepared at 25 µM concentration in 20 mM 
AmAc. 
All ECD studies were performed on a 12T Apex Ultra Qh FT-ICR mass spectrometer 
(Bruker Daltonik Gmbh, Bremen, Germany), details on the instrument and its operation can 
be found in Chapter 2 section 2.5. 
6.2.5 Sample preparation for isothermal titration calorimetry studies  
For isothermal titration calorimetry (ITC) experiments on HBD2 plus Fx, HBD2 was 
prepared either at 10 or 15 μM (cell solution) and Fx solutions prepared at 175 or 88 μM 
(syringe solution) in 20 mM AmAc. To ensure buffer composition was identical for each 
sample and to limit any buffer dilution effects in the ITC experiments Fx was dialysed for 
four hours against 12 L of 20 mM AmAc, an aliquot of dialysis buffer was then used to 
prepare the HBD2 sample. Control experiments were carried out in which Fx (88 µM) was 
injected into a cell filled with buffer and buffer was injected into a cell containing HBD2 (10 
µM). 
All ITC experiments were performed using a MicroCal Auto-ITC200 (GE Healthcare and Life 
Sciences, Little Chalfont, UK), details on the instrument and its operation can be found in 
Chapter 2 section 2.8. 
6.2.6 Sample preparation for TEM studies 
For TEM studies HBD2 plus Fx and HBD3 plus Fx sample solutions were prepared at 1:1 
ratios at a peptide concentration of 50 μM. HBD3 plus Fx was additionally studied at a 2:1 
(HBD3:GAG) ratio, at 50 μM peptide concentration. The HBD2 plus HBD3 plus Fx sample 
was prepared at a 1:1:1 ratio with each component present at 50 μM concentration. 
Additionally, HBD3 prepared at 65 μM was studied as a control. All TEM samples were 





All TEM experiments were performed on a Philips CM120 Biotin transmission electron 
microscope (Philips, Eindhoven, Netherlands), details on the instrument and its operation 
can be found in Chapter 2 section 2.7. 
6.2.7 Molecular dynamics simulations 
All molecular dynamics simulations and theoretical calculations discussed in this chapter 
were performed by Dr Massimilano Porrini. Details on the procedure can be found in brief in 
Appendix 5 section A5.1. Theoretical CCS were determined for in vacuo minimised 
monomer and dimer+Fx of HBD2. The structure of Fx was taken from the PDB file of its 
complex with Antithrombin-S195A factor Xa (PDB 2GD4). Initial coordinates for HBD2 
were taken from the crystal structure of the dimer (PDB 1FD3). 
 
 Results and discussion 6.3
6.3.1 Ability of HBD2 to bind Fx 
6.3.1.1 Stoichiometry of binding: MS studies  
Previous MS studies from the Barran group highlighted that HBD2 can bind Fx, with 
dimeric HBD2 binding a single Fx chain
28,29
. These studies were, however, performed at 
relatively high concentration with samples prepared at a 1:1 ratio at 135 µM HBD2 
concentration in 20 mM ammonium acetate (AmAc). The studies presented in this chapter 
aim to further probe and characterise these interactions and the complexes formed. Initial 
studies into HBD2 binding reported here focused on reproducing the MS binding studies on 
different instrumentation using a lower concentration of both HBD2 and Fx, samples were 
therefore prepared at a 1:1 ratio at 50 µM peptide concentration in 20 mM AmAc. In 
addition, n-ESI capillaries, source voltages and pressure were tuned to enable maximum 
signal transmission, enabling the spectra shown in Figure 6.2 to be acquired. 
The spectrum acquired for HBD2 (Figure 6.2A) establishes that HBD2 presents mostly in a 
monomeric form, consistent with the findings from solution-phase NMR studies
3
, and is 
capable of accepting between three and five protons. In addition some lower intensity 
dimeric (charge states 4+ and 5+) and trimeric (charge states 6-8+) species are also detected, 
attributed to HBD2 oligomerising in solution at this concentration and all observed masses 
are in good agreement with the expected masses (Appendix 5 Table A5.1). Dimeric HBD2 
has been previously reported in X-ray crystallography studies
1




concentrations than those used here; furthermore, a trimeric HBD2 structure has not been 
reported. The results suggest that either conditions used here enable low intensity species to 
be preserved, transmitted and detected, or alternatively conditions here are promoting their 
formation.  
 
Figure 6.2: Mass spectra of HBD2 A) 50 µM HBD2 B) HBD2 plus Fx prepared at a 1:1 ratio at 50 
µM peptide concentration.  
Upon addition of stoichiometric concentrations of Fx, two high intensity GAG-bound 
complexes are observed (Figure 6.2B), both of which are consistent with dimeric HBD2 
binding a single chain of Fx (DHBD2+Fx), presenting in charge states 5+ and 6+. The 
observed masses are in good agreement with the expected masses (Appendix 5 Table 5.1). It 
is interesting to note that in its Fx-bound form, HBD2 exclusively forms dimers with no 
other Fx-bound species being observed. It has been suggested previously for chemokines that 
the GAG chain length is an important factor in the consideration of complexes formed, with 
shorter GAGs often giving rise to monomeric complexes which have been attributed to the 
shorter length being insufficient to bridge the interface
30,31
. It appears the pentameric GAG 
Fx is sufficient to bridge the dimeric interface of HBD2, consistent with previous studies
28,29
. 




proposing that Fx preferentially stabilises the dimeric interface between these two highly 
cationic peptides. It is important to note that upon addition of Fx there was evidence of 
aggregation with visible aggregates observed in the n-ESI capillaries and blocking with time, 
similar to observations made for the chemokine Ltn upon addition of Fx (Chapter 5).  
Interestingly, upon addition of Fx, the distribution of unbound HBD2 is altered with respect 
to oligomer population, with no unbound dimers or trimers present, signifying Fx is shifting 
this equilibrium.  Alternatively, their absence in the spectrum could be due to the lower 
signal intensity here, due to the aggregating HBD2 plus Fx sample, which may cause these 
lower intensity peaks to no longer be observed. The charge state distribution of monomer is 
also affected upon addition of Fx, the population of [MHBD2+3H]
3+
 is considerably 
diminished and [MHBD2+4H]
4+
 is observed to be the most intense. This could be attributed to 
a number of factors, such as the addition of Fx may be perturbing the conformations and 
hence charge state distribution of unbound monomeric species present, either through 
promotion of more extended species or alteration of the solution pH. In order to discount 
this, solution pH was measured after addition of Fx and remains constant, enabling pH 
effects to be disregarded. The promotion of more extended conformations in the presence of 
Fx can be studied via DT IM-MS and is considered in detail below.  
An alternative explanation is that Fx is binding to the species in solution which are capable 
of accepting three protons and hence diminishing their relative intensity; considering the 
charge states of the bound dimers (5+ and 6+) this could indeed hold true. To probe this 
possible explanation, and the stability of the DHBD2+Fx species, CID studies were performed 
on the 5+ and 6+ species. CID experiments showed that the first fragmentation pathway is 
the loss of SO3 groups from Fx, highlighting the stability of this complex (Appendix 5 
Figure A5.1). The complex can, however, be dissociated through increasing the collisional 
energy and [MHBD2+3H]
3+
 species are then observed supporting the hypothesis that these 
species are involved in Fx binding and providing a plausible explanation for the lower 
observed relative intensity of these species in the presence of Fx.    
6.3.1.2 Conformations of HBD2:Fx complexes: insights from DT IM-MS 
Conformations adopted by HBD2 and DHBD2+Fx were then studied using DT IM-MS. In 
both cases CCS were determined by studying samples prepared at a 1:1 ratio of HBD2:Fx. 
Considering first the unbound species, CCS of monomeric HBD2 were determined over the 









Figure 6.3: Average CCS of HBD2, and Fx bound HBD2, calculated from three repeats, error bars 
represent the standard deviation between these values. Unbound species (hollow symbols) were 
determined in the presence of Fx. Fx bound species of dimeric (D) and tetrameric (TE) HBD2 are also 
shown here (filled symbols). Theoretical CCS for monomeric HBD2 and dimeric HBD2+Fx (structure 
shown in insert) are represented by black and grey dashed lines respectively.  
CCS of the monomeric species are very similar, presenting over a narrow conformational 
range increasing from ~582-683 Å
2
, consistent with a single conformational family, with the 
slight increase observed being attributed to Coulombic repulsion of proximal charges. The 
presence of a single, stable conformational family is accredited to the three disulfide bonds 
present within HBD2 which would act as conformational staples, restricting the fold
48
. The 
theoretical CCS was determined for monomeric HBD2 by clipping a single monomer from 
the HBD2 dimer, solved by X-ray crystallography, followed by gas-phase minimisation. The 
resulting theoretical CCS (700 Å
2
) is in excellent agreement with the experimental CCS of 
monomeric HBD2, suggesting that the peptide ions could be adopting conformations similar 
to this.  
In order to determine if the conformations and hence CCS of monomeric HBD2 are altered 
in the presence of Fx, CCS were determined for a single repeat of HBD2 in 20 mM AmAc 
and were found to lie within experimental error of those determined in the presence of Fx 
(Appendix 5 Table A5.2) and in good agreement with previously reported values
28
. This 
signifies that Fx does not alter the conformation of unbound HBD2 and hence the shift in the 




Fx binding to the species in solution which are capable of accepting three net protons and 
hence reducing their relative intensity consistent with findings from CID (Appendix 5 Figure 
A5.1).  
CCS of the GAG-bound complexes (DHBD2+Fx) were then determined over the charge state 
range 5+ to 7+ (Figure 6.3 and Appendix 5 Table A5.3). DHBD2+Fx exists in a small range of 
CCS (~964-1070 Å
2
), suggesting it is in a similar, stable conformation at all charge states, 
which is not greatly affected by increasing charge. The CCS for a single charge state (6+) of 
unbound dimeric HBD2 could be determined here and is smaller by ~10 % than the 
Fx-bound dimers. The similarities in CCS between DHBD2 and DHBD2+Fx indicates specific 
GAG-bound complexes are formed, as non-specific complexes would be expected to present 
with much larger CCS, consistent with the findings from CID which suggested stable, 
specific complexes were formed.  
The structure of the DHBD2+Fx complex has been studied by NMR, identifying a number of 
residues thought to be involved in binding
29
; however, a solved complex structure has not yet 
been reported. In order to further probe the conformation of this complex, detailed molecular 
dynamics (MD) studies were performed in combination with the work presented in this 
thesis, with the aim of predicting the conformation of the bound complex, via theoretical 
CCS comparison.  In this study the initial coordinates for dimeric HBD2 were taken from the 
structure solved by X-ray crystallography (PDB 1FD3) and coordinates of Fx were taken 
from a complex with antithrombin and coagulation factor Xa, (PDB 2GD4). The structure of 
the DHBD2+Fx complex was predicted using Autodock 4.2 software
49
. The docking 
simulations provided a likely candidate complex. The complex was then minimised in vacuo 
and subjected to gas-phase dynamics prior to CCS determination. The resulting candidate 
complex is shown in Figure 6.4, in which the Fx chain binds between two HBD2 monomeric 
units with multiple basic sites of interaction, which would strengthen and stabilise this 
complex. Significantly, the residues which are shown to be involved in binding, compare 
remarkably well to the residues implicated in binding through NMR studies into HBD2 plus 
Fx
29
 (Figure 6.4B).  The CCS of this species (1100 Å
2
) is in excellent agreement with the 
experimental CCS obtained, suggesting the complex formed could indeed be adopting this 





Figure 6.4: Theoretical DHBD2+Fx complex obtained from MD simulations, initial coordinates of 
dimeric HBD2 were obtained from PDB 1FD3. A) No residues labelled B) All basic residues 
identified in the previous study by Seo et al
29
 to interact with Fx are shown in blue. C) All basic 
residues in in HBD2 shown as a surface. All structures for this figure were visualised in VMD.  
In addition, there is evidence from DT IM-MS that HBD2 can form tetrameric complexes 
binding two Fx chains and presenting in a 10+ charge state (Figure 6.3). This species is m/z 
coincident with [DHBD2+Fx+5H]
5+
, however, they can be separated out based on their 
mobility through the buffer gas filled drift cell.  The CCS was determined as 1649 ± 17 Å
2
, 
just under twice the size of the DHBD2+Fx species suggesting it could be a dimer of dimers.  
6.3.1.3 HBD2:GAG binding interface: ECD studies  
Considering DHBD2+Fx in more detail, the previously reported NMR study into interactions 
between HBD2 and Fx
29
 distinguished a number of chemical shift perturbations in HBD2 
including; R22, R23, K25, K39 and K40, all of which fall within the binding interface of the 
gas-phase complex predicted through MD simulations (Figure 6.4B). Interestingly, GAG 
binding in chemokines can involve a binding motif of sequence BBXB (where B is a basic 
amino acid)
50




 sequence implicated in HBD2:GAG 
binding by NMR
29
. Oligomerisation of chemokines and defensins on GAG binding, 
however, can complicate the identification of such regions and hence consideration of purely 
linear sequences alone is not always applicable. In order to probe this interface further in the 
gas-phase, ECD studies were performed with the aim that the high sensitivity of the FT 
ICR-MS instrument used here would enable even low intensity fragmentation to be detected.  
Samples were initially prepared in 20 mM AmAc, enabling DHBD2+Fx at charge states 5+ 
and 6+ to be transferred and detected at high enough intensity to be subsequently isolated 
and subjected to ECD.  For [DHBD2+Fx+5H]
5+
 no fragmentation is observed, attributed to its 
low charge state and compact nature (Appendix 5 Figure A5.2A). [DHBD2+Fx+6H]
6+
 also 
remains mostly intact; however, here limited backbone cleavage occurs (Appendix 5 Figure 




intact. The lack of fragmentation observed at both charge states studied is consistent with a 
compact species (as shown by DT IM-MS), stabilised through numerous interactions. 
Furthermore, the three disulfide bridges in HBD2 would be preferentially cleaved in ECD 
prior to backbone fragmentation, limiting the fragmentation efficiency. The charge state of 
the species also has to be considered as ECD is known to be more effective at higher charge 
states
51
. It is therefore conceivable that here the low charge states of the complexes are 
limiting the fragmentation efficiency.  
In an attempt to further probe the stability of this complex and its binding interface a 
‘supercharging’ reagent known as meta-nitrobenzyl alcohol (m-NBA)
52
 was added to the 
sample solution (1 % in 20 mM AmAc). Addition of m-NBA promotes higher charge states 
of monomeric HBD2 and DHBD2+Fx (Appendix 5 Figure A5.3A). Previous studies have 
shown that addition of m-NBA can disrupt native protein complexes
53
 and perturb the 
conformations of monomeric systems (see Chapter 4 section 4.3.3). Therefore DT IM-MS 
experiments were first performed on the supercharged samples to discern if addition of this 
reagent alters the conformations of the monomeric peptide or the complex. CCS determined 
from the supercharged sample (Appendix 5 Table A5.4) are within experimental error of 
those determined in the buffered sample (Appendix 5 Tables A5.2 and A5.3), highlighting 
that here m-NBA is not altering the conformation of the peptide or the complex.  Addition of 
m-NBA enabled the DHBD2+Fx  complex to be detected in charges state 6-9+ on the DT IM-
MS instrument, whilst in buffered conditions only charge states 5-7+ were observed. The 
CCS for the 8+ and 9+ species are slightly more extended (1175 ± 24 Å
2
 and 1256 ± 15 Å
2
 
respectively) than those of the lower charge states, as expected. These more extended and 
unfolded species therefore present favourable targets for further ECD analysis. Supercharged 
species were then studied on the FT ICR-MS instrument, enabling two higher charge states 





 (Appendix 5 Figure A5.3B). 
[DHBD2+Fx+7H]
7+
 undergoes low intensity ECD fragmentation (Appendix 5 Figure A5.4), 
producing a number of fragment ions, corresponding to the DHBD2+Fx complex fragmenting 
at the first and second amino acids of the N-termini and the last amino acid at the C-termini 
of a HBD2 monomer, with the complex remaining intact. In addition, at this charge state 
there is evidence for complex dissociation to monomer. For [DHBD2+Fx+8H]
8+
 the main 
fragment species observed are due to the complex remaining intact and fragmenting at the 
termini, with the most extensive fragmentation being in the first six amino acids of the 




suggesting this complex is more stable. The buffered DT IM-MS experiments showed 
[DHBD2+Fx+7H]
7+
 adopts two conformations (Figure 6.3); a compact and more extended 
form suggesting it is a key transitional charge state between conformational families.   
This limited complex dissociation and observation that covalent bonds in the termini are the 
favoured cleavage site demonstrates the stability of this complex. The findings for this 
complex are consistent with the complex structure shown in Figure 6.4 which predicts 
multiple interactions with Fx along the backbone of both HBD2 monomers in the dimer 
which would produce a stable, fragmentation-resistant species.  The lack of fragmentation 
along the peptide backbone in all complex species is attributed in part to the stability of 
HBD2, with each monomeric unit in the dimer containing three constraining disulfide bonds 
which stabilise the tertiary fold and hence limit fragmentation. Furthermore, in ECD 
disulfide bonds are preferentially reduced through the addition of the electrons, which 
significantly limits any backbone fragmentation for disulfide bridged proteins. ECD studies 
were also performed on HBD2 monomer and very little fragmentation is observed, with the 
majority of fragmentation occurring in the first 13 amino acids of the N-termini consistent 
with a stable, constrained species (Appendix 5 Figure A5.5). Similar comparisons with 
dimeric HBD2 could not be made due to its low abundance.  The ECD studies, in 
combination with DT IM-MS and CID, suggest that HBD2 forms stable, compact specific 
interactions with Fx to form a dimeric HBD2 plus Fx complex. 
6.3.1.4 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) experiments were then performed with the aim of 
confirming the stoichiometry of this interaction in solution and to determine the dissociation 
constant (Kd) of binding. In all ITC experiments 16 injections were performed, with the first 
being a lower volume, as the error in the first injection is often the highest and therefore this 
injection is routinely discounted for analysis. 
ITC experiments involved injecting Fx into a cell filled with HBD2 and measuring the 
resulting change in heat. Two control experiments were also run; injecting buffer into a cell 
of HBD2 and injecting Fx into a cell filled with buffer. These control experiments enable 
any heat change due to buffer mismatch effects to be identified and accounted for, here each 
control experiment shows no such effects enabling them to be discounted (Figure 6.5). The 
ITC binding study was performed by injecting 88 µM Fx into a cell filled with 10 µM HBD2 
(Figure 6.5). It is clear that there are at least two different physical processes occurring here. 




ratio is increased, the overall reaction is dominated by exothermic events, characterised by 
the switch in peak direction.   
 
Figure 6.5: ITC traces obtained for HBD2 plus Fx reaction, obtained at 15 µM HBD2 concentration 
and 88 µM Fx concentration. Fx plus buffer control (injecting 88 µM Fx into a cell filled with buffer) 
and buffer plus HBD2 control (injecting buffer into a cell filled with 10 µM HBD2). Data processed 
to correct baseline, normalise and subtract controls. Insert shows only exothermic processes.  In all 
cases buffer was 20 mM AmAc. 
A similar effect was detected in experiments in which 175 µM Fx solution was injected into 
a cell filled with 10 µM HBD2, highlighting this observation is repeatable.  One possible 
explanation is that at low molar ratios the process is dominated by electrostatic interactions 
attracting a defensin, or multiple defensins, towards a sugar molecule and disrupting the 
water core around the sugar and/or defensin, and displacement of counter-ions
54
 bound to Fx 




signature. When the molar ratio is increased these forces no longer dominate and the 
molecules bind in greater numbers forming the complex, creating the exothermic signature. 
It is, however, likely that there are many processes occurring at once, complicating this 
signature further and therefore at this point it is not possible to conclusively determine the 
processes occurring.  For example the aggregation occurring upon addition of Fx would also 
complicate these results.  
No standard ITC model can be fitted to this data and hence the Kd and stoichiometry of the 
reaction, as well as determination of the multiple processes occurring here cannot be 
definitively determined. In order to overcome this, highly robust data would be required 
involving multiple repeats, and more injections per repeat. Due to the sample-intensive 
nature of ITC, with each binding study requiring 60 µL of Fx and 350 µL of HBD2 per run 
and the same volume being required for controls which are necessary for each individual run, 
further ITC studies are not feasible here.  
Clearly the binding process between HBD2 and Fx is complex and more experiments are 
needed here to fully characterise these interactions, the ITC observations are repeatable but 
are dissimilar to those made for previous chemokine:GAG binding events which showed 
purely exothermic processes
31
. Despite this, information can still be gleaned from these 
experiments; HBD2 and Fx do bind in solution and an end point can be observed, based on 
the plateau of peaks. Considering only the exothermic processes, and hence the later three 
quarters of the data, fitting to a standard ITC model a binding stoichiometry of ~0.5 is 
determined which is consistent with a dimer of HBD2 binding a single Fx chain, in 
agreement with findings from MS. Fitting only three quarters of the data is evidently not 
robust and therefore additional studies in this area are required, which as discussed earlier 
necessitates substantial material and therefore alternative sources and methods of production 
(such as peptide expression) would be vital to generate the necessary material.   
6.3.1.5 Assessing aggregation: TEM studies 
MS studies into the interactions of HBD2 with Fx highlighted that aggregation can occur 
upon addition of this GAG, as has been observed with chemokines
23,43
 including Ltn 
(Chapter 5). In order to further study this phenomena transmission electron microscopy 
(TEM) studies were performed. A 1:1 mixture with Fx (Figure 6.6), yields large globular 
aggregates, dissimilar in appearance to the ribbon-like species observed for WT and CC3 Ltn 
(Chapter 5 section 5.3.1 and 5.3.3) but similar in morphology to those observed previously 




however, smaller and generally fewer in number then the WT and WT 1-72 Ltn species, 
either due to HBD2 having a lower affinity for the grid or aggregation occurring to a lesser 
extent, which is consistent with results from MS. The observation of these species is 
significant, however, clearly emphasising that aggregation is occurring here.  
 
Figure 6.6: Representative TEM images obtained for 1:1 HBD2 plus Fx (50 μM). 
6.3.2 Ability of HBD3 to bind Fx 
The results from the previous sections demonstrate that HBD2 can bind Fx, producing stable 
specific dimeric complexes and displaying similar traits to the chemokine superfamily of 
proteins. In order to further probe the GAG binding affinity of β-defensins and their 
similarities to chemokines another member of this subfamily of peptides was studied, human 
β-defensin-3 (HBD3). 
6.3.2.1 Stoichiometry of binding: MS studies 
MS studies were performed to determine if HBD3 could bind Fx and to discern the 
stoichiometry of any resulting complexes. The spectrum obtained for HBD3 peptide solution 
showed HBD3 exists mostly in a monomeric form (MHBD3) under the conditions employed 




 with the species 
accepting five charges being the most intense. In solution HBD3 has been shown to exist in a 
dimeric form
3
; however, these studies were performed at 360 µM, and therefore the high 
intensity of monomer observed here is attributed to the substantially lower concentration 
used (50 µM). A low intensity peak was assigned as dimeric HBD3 (DHBD3), in the 7+ charge 
state, demonstrating that dimeric species can form. The expected and observed masses for all 





Figure 6.7: Mass spectrum of HBD3 A) 50 µM HBD3 B) HBD3 plus Fx prepared at a 1:1 ratio at 50 
µM peptide concentration. C) HBD3 plus Fx prepared at a 2:1 ratio at 50 µM HBD3 concentration. 
Previous MS-based studies showed that HBD3 aggregates extensively upon the addition of 
equimolar concentrations of Fx, resulting in an inability to record usable spectra and observe 
binding
28
. In order to overcome this, a number of conditions were tuned to optimise the 
signal of oligomers, including pressure in the source region and tuning of the n-ESI 
capillaries pulled for use in these studies. Through optimisation of these parameters it was 
possible to obtain a mass spectrum for HBD3 plus Fx at a 1:1 ratio at 50 µM concentration, 
as shown in Figure 6.7B. The spectrum shows signs of extensive aggregation as exemplified 
by the raised baseline particularly over the m/z range 1100-3000. Despite the substantial 
aggregation occurring, a number of peaks are distinguished due to HBD3 binding to Fx, 
most notably monomeric HBD3 is observed at high intensity to bind a single Fx chain. The 
complex presented in both 4+ and 5+ charge states and is observed to be the most intense 
species in the spectrum. In addition, two lower intensity peaks could be assigned to dimeric 
HBD3 binding two chains of Fx (DHBD3+2Fx), in 6+ and 7+ charge states. 
[DHBD3+2Fx+6H]
6+
 is mass coincident with [MHBD3+Fx+3H]
3+




due to both species. Previous studies into the GAG binding propensity of HBD3 showed 
tetrameric (heparin degree of polymerisation (dp) 4) and hexameric (dermatan sulfate dp6) 
GAG chains can bind to both monomeric and dimeric HBD3
28
, consistent with the ability of 
Fx to bind in both monomeric and dimeric complexes as observed here.  The presence of 
both monomeric and dimeric bound species was attributed to the distance between the GAG 
binding site on each HBD3 monomer being greater than on HBD2
28
, which only formed 
dimeric GAG bound complexes with the same GAGs.  
In addition to the Fx-bound species, two further low intensity peaks are observed due to 
unbound monomeric HBD3. The peaks present at the low m/z region are due to salts and 
contaminants from the Fx sample. Despite the low quality of the spectrum obtained here, due 
to extensive aggregation, it is clear that HBD3 can bind Fx. In order to obtain a spectrum of 
higher quality, the concentration of Fx was lowered and a sample was prepared at a 2:1 ratio 
of HBD3:Fx at 50 µM peptide concentration (Figure 6.7C and Figure 6.8). Here aggregation 
is limited, enabling a clearer spectrum to be obtained. The most intense species are observed 
to be monomeric HBD3 and interestingly a shift in the charge state distribution of the 
monomer to lower charges is also observed, suggesting Fx is promoting the formation of 
compact monomeric species or that Fx preferentially binds the more extended higher 
charged species in solution resulting in a subsequent reduction in their relative intensity.  
 
Figure 6.8: Enlarged regions of the mass spectrum (shown in Figure 6.7C) obtained for the HBD3 




A number of additional low intensity peaks are present in the spectrum, which are assigned 
as HBD3 plus Fx complexes (Figure 6.7C and Figure 6.8). The most intense complex species 
here is dimeric HBD3 (DHBD3) binding a single Fx chain (DHBD3+Fx), similar to the 
observations made for HBD2 (Figure 6.2B). The 6+ and 7+ species were isolated and 
subjected to CID. The first fragmentation pathway was again found to be loss of SO3 from 
Fx as opposed to complex dissociation (Appendix 5 Figure A5.6), this highlights the stability 
of the complexes. For the 7+ species more extensive complex dissociation was also observed 
but at lower intensity than Fx fragmentation, consistent with the findings for DHBD2+Fx and 
supports specific, stable complex formation.  
Trimeric (THBD3), tetrameric (TEHBD3) and pentameric (PHBD3) HBD3 are also observed in 
complex with Fx, where the trimer binds one (THBD3+Fx) or two (THBD3+2Fx) Fx chains, 
tetrameric HBD3 binds three Fx chains (TEHBD3+3Fx) and pentameric HBD3 binds four Fx 
chains (PHBD3+4Fx). The expected and observed masses of all Fx bound species are in 
agreement and can be found in Appendix 5 Table A5.5. Fx is clearly promoting aggregation 
of HBD3 leading to a range of oligomeric species; however, interestingly no species of 
unbound trimeric or tetrameric HBD3 are observed suggesting under these conditions higher 
order oligomers are only stabilised by binding to Fx. The sequence of HBD3 does not 
contain the ‘BBXB’ amino acid GAG binding motif, suggesting that HBD3 oligomerisation 
may promote GAG binding through the creation of basic patches to which Fx can bind. The 
presence of MHBD3+Fx and high GAG content of the oligomers, however, suggests that this 
motif is not essential for defensin GAG binding and the higher order oligomers are a product 
of extensive, favourable aggregation which allows more species, potentially on pathway to, 
or fragments of, higher order aggregates- to be observed.   
6.3.2.2 Conformations of HBD3:Fx complexes: insights from DT IM-MS 
In samples prepared at a 2:1 HBD3:Fx ratio  a wide range of oligomers is detected and hence 
DT IM-MS studies were performed on these samples allowing CCS to be obtained for a 
range of species. For HBD3 only unbound monomeric species were observed both in the 
presence and the absence of Fx. The CCS for monomeric HBD3 were determined in the 
presence of Fx over the charge state range 4+ to 6+ and found to be ~746-796 Å
2
 (Appendix 
5 Table A5.6). The small CCS range is attributed to the structural rigidity imposed by the 
three disulfide bonds. The slightly larger size in comparison to HBD2 is due to the longer 
sequence of HBD3, four amino acids longer than HBD2. CCS were determined for a single 
repeat of HBD3 in 20 mM AmAc and monomeric species lie within experimental error of 









Figure 6.9: Average CCS of Fx bound HBD3 species, from three repeats, error bars represent the 
standard deviation between these values. Where, monomeric (M), dimeric (D), trimeric (T), tetrameric 
(TE) pentameric (P), hexameric (H), octameric (O) and decameric (DE) HBD3 species are identified 
by letter codes.  A)  species versus CCS B) molecular weight versus CCS. Hollow red symbols 
represent the CCS predicted for a spherical complex of constant protein density, according to the 




Fx-bound species were observed in a range of oligomeric orders composed of up to ten 
HBD3 units and up to six chains of Fx, a number of which were observed as m/z coincident 
species and could only be distinguished using DT IM-MS. The presence and conformations 
of such a range of GAG-bound peptide oligomers have not to-date been reported, possibly 
due in part to the problems associated with the extensive and rapid aggregation. 
Determination of the conformations of these species and their implication in growth 
mechanisms could provide insight into the nature of their formation. DT IM-MS allows these 
species to be separated and also their CCS to be determined (Figure 6.9 and Appendix 5 
Table A5.7). Due to the range of species observed, viewing the data in a plot of charge state 
versus CCS, is not optimum for observing trends (Appendix 5 Figure A5.7). Therefore, the 
data is shown as CCS versus species (Figure 6.9A) and a similar plot of CCS versus 
molecular weight (Figure 6.9B). Due to the range of oligomeric species observed and the 
computationally expensive nature of the MD simulations, no theoretical comparisons are 
made here.  
Considering DHBD2+Fx and DHBD2+2Fx, a compaction in CCS is observed moving from the 
species binding one Fx chain to that binding two at the same charge state (Figure 6.9A; pink, 
green and navy spheres). This compaction upon binding is interesting as the three disulfide 
bonds in HBD3 would limit non-specific collapse, which suggests these species are 
undergoing a conformational constriction or compaction upon binding of additional Fx 
chains and suggesting there is specificity in their formation. A similar observation is made 
for the 9+ trimeric species; however, at all other oligomeric orders the same charge state is 
not observed upon increasing the number of chains of Fx bound so similar comparisons 
cannot be made here. 
The range of CCS covered is expansive, with CCS increasing by over eight times from the 
MHBD3+Fx species to decameric HBD3 binding six Fx chains (DEHBD3+6Fx).  Interestingly, 
growth appears somewhat linear over the range of species observed here, with no major 
plateau region, significant jump or compression in CCS over the full range of species. There 
are a number of growth models which have previously reported to fit to CCS data including: 
the isotropic growth model, single strand fibril growth and steric zipper fibril growth
55
.  
Fibril growth mechanisms are not appropriate here, as TEM studies show the resulting 
species are not fibrillar in nature (see section 6.3.2.3). The isotropic growth model states that 





the monomer cross section. The difficulty with fitting this model to the data presented here is 




where growth occurs through binding of two different species. It is possible, instead of 
considering the monomer as the initial growth state, to consider MHBD3+Fx, however, this 
growth model would then only be appropriate for species in which even numbers of HBD3 
and Fx are binding, which is only the case for three of the observed species namely; 
monomer (MHBD3+Fx), dimer (DHBD3+2Fx) and tetramer (TEHBD3+4Fx). Hence, the isotropic 
growth model is not considered here. 
Benesch et al
56
 have provided a relationship through which the CCS can be estimated, 
assuming species are adopting a perfect spherical conformation as shown in Equation 6.1, 
where Ω is the CCS, m is the mass, ρ is the density and rg is the radius of the buffer gas 
(which for helium is 1.4 Å). Numerous estimates of protein density have been reported in the 
literature
57,58
 and here a value of 0.90 Da Å
-3
 is used, which is based on small globular 
proteins
58
. CCS of all Fx bound species were estimated in this way (Appendix 5 Table A5.7) 
and are shown plotted as hollow red circles in Figure 6.9. These spherical CCS are much 
lower than the experimentally observed species as expected, consistent with the observed 
oligomers existing as specific complexes undergoing a form of linear growth and not 
existing as purely spherical species of constant density, species which would be unlikely to 
form. Oligomers formed, therefore, are non-spherical and are, with respect to size, between 
globular and linear species. 
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6.3.2.3 Assessing aggregation: TEM studies 
From MS it is clear that extensive aggregation occurs when HBD3 and Fx are mixed at a 1:1 
ratio, a finding which is further accentuated through TEM studies (Figure 6.6A). Images 
obtained from TEM show a number of large globular aggregates, similar in appearance to 
those observed for HBD2 in the presence of Fx. HBD3 aggregate species, however, appear 
larger and aggregation is much more extensive, covering a larger proportion of the TEM 
grid. The extent of aggregation occurring is noteworthy considering samples were incubated 
for only 30 minutes prior to grid preparation. The aggregates form large clusters with many 
species overlapping causing the morphology of the species to be difficult to discern. 
In order to further probe the aggregation occurring for HBD3 upon addition of Fx a further 
sample was studied at a 2:1 HBD3:Fx ratio (Figure 6.10B), as MS studies highlighted that at 
this ratio aggregation can be slowed enabling a greater range of oligomers to be observed. 




the 1:1 mixture of HBD3 plus Fx, large globular aggregate clusters of typically of µm length. 
At this 2:1 ratio, as aggregation is slowed, smaller clusters of species are also observable in 
the background. These background species appear of a similar globular nature, however, 
‘networks’ of interconnecting species can be distinguished which presumably go on to form 
the large globular ‘networks’ present in the more aggregated sample. As a control HBD3 in 
the absence of Fx was studied and no evidence for higher order aggregation was observed, 
indicating this is an Fx induced effect (Appendix 5 Figure A5.8). Clearly Fx induces 
aggregation in both HBD2 and HBD3, with both defensins forming aggregates of a globular 
morphology.  
 
Figure 6.10: Representative TEM images obtained for  A) 1:1 HBD3 plus Fx (50 μM) and B) 2:1 
HBD3 plus Fx (50 μM HBD3 concentration). 
6.3.3 Investigating HBD2:HBD3 interactions 
6.3.3.1 Stoichiometry of binding: MS studies 
The results in the previous sections highlight that both HBD2 and HBD3 can bind Fx, here 
the ability of these two β-defensins to interact with each other is investigated. The need for 
such a study is based on the apparent redundancy of the immune system, with many proteins 
interacting with the same receptor; for example HBDs can activate the G protein coupled 
receptor CCR6
19,59
, which is also activated by the chemokine CCL20
60
. Recent studies have 
shown that chemokines can form heterodimers which can also bind GAGs, challenging the 
previously considered redundancy of these systems
37,38,44
 and hence equivalent studies are 
required for β-defensins.  
Initial studies were performed on a 1:1 solution of HBD2 and HBD3 and the resulting 




Additionally, HBD2 forms dimers and trimers and HBD3 is also observed in a dimeric form, 
both of which are consistent with findings for the individual peptides (Figure 6.2 and Figure 
6.7). However, in the case of HBD3 the dimeric species are found to be more intense in this 
mixed sample.  
 
Figure 6.11: Mass spectrum of HBD3 plus HBD3 prepared at a 1:1 ratio at 50 µM concentration A) 
m/z 500-3000 B) Enlargement of m/z 1465-2440. Peptide monomer (M), dimer (D) and trimer are 
described by letter codes. 
A number of additional peaks due to HBD2+HBD3 complexes are also observed (Figure 
6.11). The heterodimeric complex (MHBD2+MHBD3) is present at high intensity demonstrating 
that the formation of this complex is favourable. Furthermore, a heterotrimer composed of 
two HBD2 plus one HBD3 (DHBD2+MHBD3) and heterotetramers composed of three HBD2 
plus one HBD3 (THBD2+MHBD3) are formed. It is proposed that for both these cases HBD3 is 
binding to the HBD2 dimers and trimers already present in solution. A corresponding 
substantial decrease in relative intensity of the unbound HBD2 dimers and trimers is not 
observed, suggesting that the original amount of unbound dimer and trimer are restored by a 
shift in equilibrium, between the monomeric species and these higher order oligomers, 
according to Le Chatelier’s principle. Additionally, heterotrimers are detected at two charge 




formed via the HBD3 dimers binding monomeric HBD2 and hence could explain the 
promoted formation and higher intensity of HBD3 dimers here. The expected and observed 
masses of all heterodefensin complexes are in good agreement and can be found in Appendix 
5 Table A5.8. 
Next the ability of these heterodefensin complexes to bind Fx was studied. Here a 1:1:1 
sample of HBD2 and HBD3 plus Fx was prepared with each component present at 25 µM. 
The most intense peaks in this spectrum (Figure 6.12) are again attributed to the individual 
peptides, however, in this case HBD2 is significantly more intense due to its apparent lower 
binding affinity for Fx, forming fewer observable species in comparison to HBD3. HBD3 
binds Fx in a range of oligomeric orders from monomer to pentamer, consistent with the 
findings for the 2:1 HBD3 plus Fx sample studied earlier (Figure 6.7). Significantly, only 
one low intensity HBD2+Fx complex is observed, trimeric HBD2 binding a single Fx chain 
(THBD2+Fx), in contrast to the high intensity dimeric Fx-bound species observed in the 
absence of HBD3 (Figure 6.2), suggesting HBD3 out-competes formation of this species. 
The intensity of the MHBD2+MHBD3 heterodimer is also significantly reduced, attributed again 
to the rapid and favourable binding of Fx to HBD3.  
 
Figure 6.12: Mass spectrum of HBD3 plus HBD3 plus Fx prepared at a 2:2:1 ratio at 25 µM peptide 
concentration A) m/z 500-3000 B) Enlargement of m/z 1500-3000. Peptide monomeric (M), dimeric 




Interestingly, a number of HBD2+HBD3+Fx species are present, namely a  
MHBD2+MHBD3+Fx complex observed in two charge states (6+ and 7+) and a 
MHBD2+DHBD3+Fx complex detected in the 8+ and 9+ charge states. Both the MHBD2+MHBD3 
and MHBD2+DHBD3 complexes were observed in absence of Fx; however, the charge state 
distribution is lower by a single charge in the unbound form. The higher charge states of the 
Fx-bound species cannot be attributed to the Fx, and instead suggests that these complexes 
are formed from a higher charged monomer of either HBD2 or HBD3 in the presence of Fx. 
An alternative explanation is that the Fx-bound heterodefensin complexes have a different 
binding interface than the heterodefensin complexes themselves and therefore the surface, 
solvent exposed residues are different here leading to more solvent accessible chargeable 
residues, a theory which can be probed further using DT IM-MS and is discussed in detail 
below.  
Control MS experiments were performed with HBD2 and bovine pancreatic trypsin inhibitor 
(BPTI), to discern the specificity of binding of HBD2 and HBD3. BPTI was chosen due to 
its similar tertiary fold to the β-defensins, comprising two β-strands and two helices 
constrained by three disulfide bonds. In this case in a 1:1 mixture no complexes between 
HBD2 and BPTI form, suggesting the binding between HBD2 and HBD3 is specific 
(Appendix 5 Figure A5.9A). Low intensity 1:1:1 (HBD2:BPTI:Fx) complexes were 
observed in the presence of Fx, however, highlighting Fx can promote complex formation 
(Appendix 5 Figure A5.9B). 
The presence of high intensity heterodefensin complexes is, therefore, significant. The 
ability of β-defensins to form complexes between different members of this subclass has not 
previously been investigated and the determination that these complexes can go on to bind 
Fx proposes they could have a functional role within GAG binding and chemotaxis.  
 
Figure 6.13: Representative TEM images obtained for a 1:1:1 mixture of HBD2 plus HBD3 plus Fx.  
It is important to note that upon addition of Fx, the mixed defensin sample was seen to 
aggregate within the n-ESI glass capillary, an observation not made with the HBD2 plus 




were performed (Figure 6.13). From the TEM images it is clear the aggregation occurring in 
the mixed peptide plus Fx sample is similar to that in the individual peptide samples in the 
presence of Fx with networks of large globular aggregates forming. 
6.3.3.2 Conformations of heterodefensin complexes: insights from DT 
IM-MS 
In order to further probe the interactions of HBD2 and HBD3 DT IM-MS experiments were 
performed. CCS were first determined for the heterodefensin complexes and compared to the 
individual monomers and dimers (Figure 6.14 and Appendix 5 Table A5.9). CCS of the 
individual monomers and dimers plotted in Figure 6.14 are those determined in the 
individual peptide plus Fx sample (reported in sections 6.3.1.2 and 6.3.2.2). CCS for the 
monomeric species of HBD2 and HBD3 were also determined from the HBD2 plus HBD3 
mixed sample and remain the same within experimental error (Appendix 5 Table A5.10), 
signifying the presence of the other peptide does not influence the monomeric 
conformations.   
 
Figure 6.14: Average CCS of HBD2, HBD3 and the heterodefensin complexes, calculated from three 
repeats, error bars represent the standard deviation between these values. HBD2 and HBD3 CCS were 
as determined from individual peptide solutions. Where peptide monomeric (M), dimeric (D), trimeric 
(T) and tetrameric (TE) species are identified by letter codes.   
Considering next the heterodimers (MHBD2+ MHBD3), CCS were determined for the 5+ and 6+ 
complexes and were found to increase marginally with charge, lying between those of the 




different heterotrimeric complexes, namely DHBD2+MHBD3 and MHBD2+DHBD3. Interestingly, 
the trimers DHBD2+MHBD3 are significantly smaller than the MHBD2+DHBD3 trimers, furthermore 
these species are seen to become more compact with increasing charge in contrast to 
MHBD2+DHBD3 which becomes more extended with increasing charge. The substantial 
differences in the CCS for these two families of trimeric species suggests that they are 
different in nature, with an excess of HBD2 promoting tighter packing and more compact 
CCS. Interestingly, the THBD2+MHBD3 species also become more compact with increasing 
charge state suggesting this is characteristic of complexes containing more HBD2 than 
HBD3; however, in this case the compaction is much lower, lying within experimental error. 
In addition the DHBD2+DHBD3 complex is very similar in CCS to that of the MHBD2+DHBD3 
complex at the same charge state, proposing similar complexes are formed here.   
Clearly, the conformations of the complexes are diverse; however, a number of trends can be 
recognised here. When HBD2 is in excess, in the complex the species presents with small 
CCS and undergoes compaction with increasing charge. In contrast, when HBD3 is in excess 
species are generally larger. This difference in CCS is greater than that found for the 
individual peptides and is therefore not attributed to the longer chain length of HBD3 and 
instead inferred to be due to differences in the complex conformations and resulting packing 
of subunits.  
Upon addition of Fx, the conformations of the heterodefensin complexes observed in the 
absence and presence of Fx were considered, namely the heterodimers at charge states 5+ 
and 6+, and found to lie within experimental error (Appendix 5 Table A5.9). The 
conformations adopted by the GAG-bound heterodefensin complexes were then determined 
(Figure 6.15 and Appendix 5 Table A5.11). Considering the MHBD2+MHBD3+Fx complex first, 
it is clear two conformational families are present. The more compact conformational family 
presents over a narrow CCS range (~1134-1301 Å
2
) over the charge state range 5+ to 8+, 
whilst the more extended conformational family is observed only at charge states 7+ and 8+ 
over a CCS range of ~1429-1542 Å
2
. CCS of the compact family are marginally larger than 
the MHBD2+MHBD3 complex, suggesting the conformation is not significantly altered upon 
binding, whilst the more extended family is considerably larger than the unbound species 
suggesting the conformations these species are adopting are significantly different than those 
of the unbound heterodimers, and suggests these species may have a different interaction 
interface. The presence of two distinct conformational families suggests there may also be 
two discrete binding sites for this heterodimeric complex, which, considering the nature of 




CCS for MHBD2+DHBD3+Fx were determined for the 9+ charge state and this species was 
found to exist in two conformational families, the more compact of which is similar to that of 
the more extended family of MHBD2+MHBD3+Fx. Significantly, the CCS of this Fx-bound 
trimer was observed to be smaller than that of its unbound counterpart at the 8+ charge state 
but similar in CCS to that of the [MHBD2+DHBD3+7H]
7+
 complex.  This lower CCS suggests 
that Fx confers a conformational tightening, consistent with stable specific binding. The 
second conformation is much more extended and illustrates a significantly different complex 
is formed here, perhaps due to Fx binding to a different, conceivably a less specific, binding 
site. Additionally, the trimerisation interface may be different for this extended complex.  
 
Figure 6.15: Average CCS of heterodefensin complexes unbound and bound to Fx, calculated from 
three repeats, error bars represent the standard deviation between these values. Fx unbound 
heterodefensin complex CCS were determined in the absence of Fx. Where peptide monomeric (M), 
dimeric (D), trimeric (T) and tetrameric (TE) species are identified by letter codes.   
The final Fx-bound heterodefensin complex detected was [DHBD2+DHBD3+2Fx+10H]
10+
, 
which presents at the same m/z as [MHBD2+MHBD3+Fx+5H]
5+
. The CCS of this hexameric 
species is within error of the DHBD2+DHBD3 complex observed at its single charge state (8+). 
As only one charge state is observed for this species in both its Fx-bound and unbound form 
it is difficult to discern any trends; however, the similar CCS suggest that binding of Fx may 
be specific. These results demonstrate that Fx can specifically bind a number of 
heterodefensin complexes, reinforcing the possibility of a functional role. Further in vitro 





β-defensins share a number of structural and functional features with the chemokine 
superfamily of proteins. The studies presented here were designed to further investigate these 
similarities through consideration of GAG binding. Both HBD2 and HBD3 bind the model 
GAG fondparinux forming complexes of a similar nature to those of chemokines, 
particularly in the case of HBD2.  
HBD2 binds in a controlled, specific manner, exclusively binding Fx in a dimeric form, 
consistent with previous studies which have shown a number of chemokines bind GAGs in 
dimeric forms. However, preferential formation of GAG-bound monomers or dimers is 
thought to depend upon the chain length of the GAG
31,33,61
. Hence it would be of interest to 
study HBD2 interactions with GAGs of varying chain length by MS and other biophysical 
techniques. The dimeric HBD2 plus Fx complexes were studied using a variety of 
biophysical techniques. DT IM-MS, in combination with detailed MD simulations, provided 
a likely complex candidate structure. The stability of this complex is illustrated through CID 
and ECD studies in which limited fragmentation and dissociation occurs. Finally, ITC shows 
this binding process is complex, dominated by endothermic processes at low molar ratio and 
exothermic processes at high molar ratios. There are several possible processes which could 
be occurring here and therefore many conceivable explanations for this behaviour; however, 
to better understand these processes more robust data, including numerous repeats, would be 
required which due to limited sample were not possible here.   
HBD3 aggregates extensively upon addition of Fx, resulting in a range of oligomeric species 
(monomer to decamer) binding up to eight chains of Fx. Such a wide range of GAG-bound 
oligomers has not to-date been reported, which could in part be attributed to the difficulty in 
studying such systems due to extensive aggregation. This is exemplified for HBD3 through 
the TEM studies, in which large ‘networks’ of globular aggregates are observed, similar in 
appearance to those observed for WT 1-72 Ltn plus Fx (Chapter 5 section 5.3.2), the Ltn 
construct with the most similar structure to the HBDs. The possible functional relevance of 
aggregating species is of interest; formation could overcome the effects of vascular flow, 
enabling a concentration gradient to be established and it is conceivable that these large 
aggregate species may be more resistant to digestion. The binding of β-defensins with GAGs 
could have implications for the chemotactic activity of these peptides. The results suggest 
that, as with chemokines, interactions with cell surface GAGs may enable a concentration 
gradient along which cells can migrate in vivo. Furthermore, previous studies have 






bacteria could exploit through the induction of GAGs
62
, decreasing the efficacy of host 
defence. Clearly defensin GAG binding is a complex, biologically important process and 
better understanding these interactions at both fundamental in vitro and in vivo levels with 
respect to both antimicrobial and chemotactic activities is essential.  
Furthermore, the interactions between HBD2 and HBD3 were studied. HBD2 and HBD3 are 
shown here to interact forming a range of heterodefensin complexes from dimers to 
hexamers. This finding was not replicated in experiments considering HBD2 and BPTI, 
suggesting heterodefensin complexes are specific. The conformations adopted by all 
heterodefensin complexes were studied using DT IM-MS and a remarkable trend was 
observed whereby the species in which HBD2 is in excess are more compact than HBD3 
counterparts, and become more compact with increasing charge, indicating that HBD2 
promotes the formation of tighter complexes.  The ability of heterodefensin complexes to 
bind Fx was then considered, the resulting data show a clear preference for HBD3:Fx 
binding, in a range of oligomeric orders, as opposed to HBD2 or heterodefensin complexes 
binding Fx, further illustrating the high propensity of HBD3 for GAG binding. Despite this, 
dimeric, trimeric and tetrameric heterodefensin complexes were observed to bind GAGs with 
CCS of all species suggesting that stable, specific complexes are forming.  
The ability of different members of the β-defensin subclass to interact with each other, and to 
go on to interact with other biomolecules, has not to-date been reported. The observation of 
such species at high intensity, forming specific complexes is significant and suggests there 
could be a functional role for such complexes. It is conceivable that hetero-oligomerisation 
could play a role in differentiating between and modulating the activity of specific defensins. 
In-depth studies would be required, however, to determine any effects, to conclude if these 
species can form in vivo and if the functional response is different for the heterodefensin 
mixtures as opposed to the individual samples, an effect which has been previously observed 
for heterochemokines
37,42
. Although it is thought that monomers bind the GPCR, 
dimerisation
23
, and possibly heterodimerisation, is thought to be important for in vivo 
function, possibly to overcome effects of vascular flow or to increase concentration at the 
receptor.   
The processes of GAG binding and the interactions between different members of the 
β-defensin subfamily are intricate and complex. As cells exist in and migrate through 
complex environments the consideration and understanding of possible interactions is vital 
and may contribute to the better understanding of the sophisticated immunological system. 




species to be identified and the conformations of both the initial complexes and the highly 
aggregated samples to be studied.  
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Mass spectrometry (MS) and drift time ion mobility-mass spectrometry (DT IM-MS) in 
combination with additional biophysical techniques have provided valuable insight into the 
dynamic structure and interactions of peptides and proteins. In this chapter the conclusions 














MS and IM-MS are emerging as powerful tools in the study of proteins and peptides, 
enabling complexes and conformations adopted by these species to be probed in a 
solvent-free environment.  These techniques, have lower resolution than traditional 
techniques such as NMR or X-ray crystallography, yet they can still provide detailed insight 
into dynamic systems providing ‘snapshots’ of unfolding and insight into interactions 
occurring between species. In this thesis a combination of biophysical techniques, including 
MS and DT IM-MS, were applied to study the structure of conformationally dynamic 
systems and their interactions with biomolecules.  
Chapter 3 focused on the leucine zipper regions of the aggressive oncoprotein c-MYC and its 
binding partner MAX, considering their interaction in the absence and presence of a 
potential inhibitor ligand, 10058-F4. This conformationally dynamic system undergoes a 
disorder-to-order transition upon binding. DT IM-MS revealed the peptide heterodimers can 
exist in two distinct conformational families; a disordered complex and a more extended 
potentially ‘coiled-coil’ leucine zipper type complex. DT IM-MS reveals the ligand 10058-
F4 preferentially inhibits the formation of the coiled-coil structure, pushing the equilibrium 
towards the disordered from, which is supposedly inactive.  These results demonstrate the 
power of this technique to distinguish between and separate multiple conformations of 
dynamic systems, providing insight which could not have been obtained from solution based 
methods, such as CD spectroscopy. Studies of a shorter c-MYC peptide comprising the 
leucine zipper region but which does not contain the 10058-F4 drug target binding region (c-
MYC-ZipΔDT) showed no significant differences in complex formation, inhibition or 
binding of 10058-F4, demonstrating this ligand is not as specific as initially reported. The 
combination of MS and DT IM-MS can provide a useful ligand screening method in the 
development of more specific compounds designed to disrupt the formation of the c-
MYC:MAX leucine zipper. 
Chapter 4 investigated the conformationally dynamic, metamorphic protein lymphotactin 
(Ltn) using a combination of DT IM-MS and ECD fragmentation. The results propose that 
the distinct monomer and dimer conformations of Ltn can be preserved and studied in the 
gas-phase, suggesting this combination of techniques could be highly beneficial in the study 
of dynamic proteins. The results provided detailed insight into the fold and unfolding of this 
dynamic protein, highlighting the susceptible regions of each fold and demonstrating that the 
intrinsically disordered (ID) tail of Ltn can associate with structural core, which is thought to 
confer stability to the tertiary fold.  Further analysis focused on two specific mutants aimed 




of this fold. The dimer mutant (W55D) however appears less stable as a dimer than the WT 
Ltn, signifying that future studies are required to design a more stable mutant for the dimeric 
fold. In Ltn there is evidence to suggest β-sheets may be preserved in the gas-phase, which 
to-date have remained elusive; Ltn therefore is an excellent candidate for future studies, such 
as gas-phase IR to determine if these secondary structural elements can be preserved in 
gaseous protein ions.  
In Chapter 5 the interactions of the metamorphic chemokine lymphotactin and a model 
pentameric GAG, Fondaparinux (Fx) were studied. The results highlight, that despite its 
metamorphic nature, the functions of WT Ltn are not completely separate and defined in 
vitro and Ltn is capable of binding Fx as both a monomer and a dimer. ECD and DT IM-MS 
suggest the resulting complexes are adopting stable, specific conformations. Furthermore, 
complexes formed between Ltn and Fx appear to be stabilised by the ID tail, suggesting this 
preserved disordered region is functionally important with respect to GAG binding and could 
help explain why this region is conserved. A finding reinforced from the dramatically 
different behaviour of the WT 1-72 construct (which lacks the ID tail). The monomer mutant 
(CC3) displays similar behaviour to the WT Ltn and studies of the dimer mutant (W55D) 
again highlighted the necessity for a better defined mutant.  The results suggest that Fx binds 
to a basic patch of amino acids on both the Ltn10 and Ltn40 folds. Interactions between 
GAGs and a basic region of a protein would enable multiple interactions to occur, 
strengthening and stabilising binding and the corresponding complexes formed. Studies then 
focused on Ltn constructs involving mutation of basic amino acids within this accessible 
region which were found to decrease the GAG binding propensity of Ltn, reinforcing the 
importance of this region for GAG binding. In future studies it would be of interest to study 
the interactions of Ltn with a range of GAGs of varying to chain lengths and sulfonation 
patterns to better understand and characterise the interactions. 
Chapter 6 focused on the interactions of the chemotactic antimicrobial peptides human 
β-defensins (HBD) with Fx, considering HBD2 and HBD3. HBD2 solely binds Fx in a 
dimeric form and the findings from DT IM-MS, ECD, CID and molecular dynamics suggest 
these species are stable and specific. Limited aggregation is also observed upon addition of 
Fx to HBD2. HBD3, however, aggregates extensively in the presence of Fx, resulting in a 
wide range of oligomeric species being observed, with species comprising up to ten HBD3 
monomers and up to eight chains of Fx detected. The binding of β-defensins with GAGs 
could have implications for the chemotactic activity of these peptides. This suggests that, as 




concentration gradient along which cells can migrate in vivo and aggregation may help 
overcome effects of vascular flow. As with Ltn, future studies should investigate the 
interactions of HBDs with a range of GAGs to further characterise these interactions. 
Finally, the interactions between HBD2 and HBD3 were considered and the defensins found 
to form high intensity, specific heterodefensin complexes, ranging from dimers to hexamers. 
Furthermore, dimeric, trimeric and tetrameric heterodefensin complexes were observed to 
bind GAGs. The conformations adopted by the heterodefensin and Fx-bound heterodefensin 
complexes suggest in both cases stable specific complexes are being formed.  This finding is 
significant as the ability of β-defensins to interact with each other, and to go on to bind other 
biomolecules, has not to-date been reported. Further in vitro and in vivo studies would be of 
interest here to determine the functional relevance of the heterodefensin complexes.  
The combination of MS, ECD and DT IM-MS provides a powerful approach to distinguish 
between multiple conformations of dynamic peptide and protein systems, and their 
interactions with other biomolecules, which can be difficult to distinguish in traditional 
solution-phase studies. The advantage of using such techniques becomes evident when 
considering the small sample volumes required, with as little as 25 μg of protein providing 
detailed insight into dynamic conformations or interactions. Furthermore, through the 
combination of biophysical techniques insight can be gained not only into individual proteins 
or peptides but also the interactions of these species and resulting complexes formed, 
enabling all species present to be studied simultaneously and providing insight into 





A1.1 Amino acids 
 






A1.2 ITC analysis 
In ITC for each injection the heat evolved or absorbed is proportional to the change in 
concentration of the ligand, see Equation A1.1, where V is the reaction volume and ΔH
0
 is 
the enthalpy of binding.  
                      [A1.1] 
In a simple model where there exists a single set of identical binding sites on the molecule 
(M) (described by Equation A1.2) the cumulative heat (Q) can be described in terms of total 
ligand concentration ([L]total), as shown in Equation A1.3. Hence, the stoichiometry of 
binding (n), association constant (Ka) and ΔH
0 
 can be determined by fitting to a graph of Q 
versus [L]total, yielding a hyperbolic curve. Alternatively one can plot the 1
st
 derivative of Q 
with respect to [L]total (incremental heat signal)  against the molar ratio ([L]total/[M]total), 
yielding a sigmoidal curve.  
            [A1.2] 
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  [A1.3] 
From Equation A1.4 the magnitudes of the free energy (ΔG
0
) and entropy (ΔS
0
) of binding 
can be determined.  
                      [A1.4] 
The change in heat capacity (ΔCp) can also be determined if two experiments are run at 
difference temperatures, based on Equation A1.5. 
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Appendix 2: c-MYC 
A2.1 c-MYC peptide synthesis details 
In brief, peptide carboxamides were synthesised using the Fmoc-based technique using Rink 
amide MBHA resin. Peptide synthesis was carried out using an ABI 433A (Applied 
Biosystems, Foster City, CA, USA), automated peptide synthesiser. Identity of peptides was 
confirmed using liquid chromatography-mass spectrometry on a Waters uPLC/SQD-LC 
series electrospray mass spectrometer (Waters, Manchester, UK).  LC-MS was performed 
using a gradient of 5-95% acetonitrile containing 0.1% trifluroacetic acid (TFA) over 10 
minutes (flow rate of 0.6 mL/min). Semi-preparative high performance liquid 
chromatography (HPLC) was performed using a Phenomenex LUNA C18 column and a 
gradient of 10-90% acetonitrile containing 0.1% TFA over 50 minutes (flow rate of 4.0 
mL/min). c-MYC-Zip and c-MYC-ZipΔDT were prepared as acetylated peptides and 
MAX-Zip was non-aceteylated. Peptides were supplied as lyophilised samples and stored 
at -20 °C until use.  
A2.2 Molecular dynamics simulations 
All molecular dynamics simulations and theoretical calculations run were performed by Dr 
Massimilano Porrini. The coordinate file for the NMR structure of the 
c-MYC-ZipΔDT:MAX-Zip hetero-dimeric leucinne zipper was downloaded the Research 
Collaboratory for Structural Bioinformatics (RCSB) databank web site, (PDB code 1A93). 
Monomeric and dimeric species were built from these coordinates, by splitting the dimer into 
monomers and adding the four residue stretch (YILS) to create the c-MYC-Zip. The CCS of 
the two heterodimeric leucine zippers, c-MYC-Zip:MAX-Zip and c-MYC-ZipΔDT:MAX-
Zip, were calculated from these initial coordinates files minimised in vacuo, using the 
trajectory method (TM) implemented in MOBCAL code
1
.  
A MD simulation was performed on the c-MYC-Zip:MAX leucine zipper complex to 
determine its stability at 300 K, after the addition of the additional four amino acids to this 
structure. The sandar MD engine of Amber 11 was used to propagate the trajectories, 
utilising the AMBER99SB-ildn force field with a time step of 2 fs. Bonds involving 
hydrogen atoms were constrained at their equilibrium values via the SHAKE algorithm
2
.  
After thermalizing and equilibrating the leucine zipper in a truncated octahedral box of 
explicit water TIP3P (with ca. 9780 water molecules and 2 Cl
−
 ions to neutralize the system) 




molecules were stripped out, 100 sample structures were stored (1 every 100 ps) along the 
obtained trajectory and minimized in vacuo. 
To derive the CCS of the disordered monomeric and dimeric species, the following 
simulated annealing (SA) procedure was used; initial minimisation was performed followed 
by dynamics for 60 ps at 800 K, gradual exponential stepwise cooling from 800 K to 0 K 
was then carried out with 2 ps per step followed by a final minimisation. This procedure was 
carried out 500 times for monomers and 1000 times for dimers. Chirality restraints were used 
to keep the angles at biological equilibrium values, as during the dynamics at 800 K they 
might incur a chirality inversion. 
The molecular dynamics (MD) engine sander of Amber10 software package was utilized to 
propagate trajectories in vacuo, implementing the Amber99SB-ILDN force field
3
. All bonds 
involving hydrogen atoms were kept constrained at their equilibrium values using the 
SHAKE algorithm, and a time step of 1.0 fs was utilised. An “infinite” radial cut off 
(rc = 999 Å) was used to evaluate the non-bonded interactions and the temperature was kept 
constant through the weak-coupling algorithm
4
 during the dynamics propagation. In the case 
of the dimers a potential well was applied between the monomers centres of mass in order to 
prevent complete dissociation during the dynamics. The extent monomers moved was 
confined to a width of 107 Å, which is just larger than the distance between the centres of 
mass of the two monomers in their fully extended conformation and aligned in succession 
along their longitudinal axis. 
A2.3 c-MYC CD studies 
 
Figure A2.1: CD spectra of MAX at pH6.8, showing the fitting from the DICHROWEB server using 





Figure A2.2: CD spectra obtained in 20 mM AmAc at pH 9.8, 6.8 and 2 of A) c-MYC-Zip plus MAX 
B) c-MYC-Zip plus MAX plus 10058-F4 
A2.4 c-MYC mass spectrometry studies 
 
Figure A2.3: Mass spectra for  the c-MYC peptides in the presence of the ligand 10058-F4 at a 1:1 





A2.5 Attempts to observe 10058-F4 peptide complexes. 
 
Figure A2.4: Mass spectra obtained for c-MYC plus MAX plus 10058-F4 at a 1:1:1 ratio at 125 μM 
concentration in 20 mM AmAc, after incubation at room temperature (18 °C) for A) 15 minutes, B) 







Figure A2.5: Mass spectra obtained for c-MYC plus MAX plus 10058-F4 at a 1:1:1 ratio at 125 μM 
concentration in A) 10 mM AmAc B) 40 mM AmAc C) 80 mM AmAc D) 100 mM AmAc. A sphere 







Figure A2.6: Mass spectra obtained for c-MYC plus MAX plus 10058-F4 at a 1:1:1 ratio at 125 μM 
concentration in 20 mM AmAc at A) pH 8.8 B) pH 5.8  and C) pH 2.8 . pH was altered through the 
addition of NaOH (pH 8.8) or formic acid (pH 5.8 and 2.8). A sphere represents a monomeric unit of 







Figure A2.7: Mass spectra obtained for c-MYC plus MAX plus 10058-F4 at a 1:1:1 ratio at 125 μM 
concentration in 20 mM AmAc. Spectra acquired with a capillary voltage of A) 1.3 kV B) 1.7 kV and 







Figure A2.8: Mass spectra obtained for c-MYC plus MAX plus 10058-F4 at a 1:1:1 ratio at 125 μM 
concentration in 20 mM AmAc. Spectra acquired with a cone voltage of A) 15 V B) 25 V and C) 
40 V. A sphere represents a monomeric unit of c-MYC-Zip (black) or MAX-Zip (grey). 
 
Figure A2.9: Mass spectra obtained for c-MYC plus MAX plus 10058-F4 at a 1:1:1 ratio at 125 μM 
concentration in 20 mM AmAc. Spectra acquired during solvent vapour exposure with acetonitrile. A 




A2.6 CCS of c-MYC, MAX homo- and heterodimers in presence of 10058-F4 
Species Experimental CCS, 
Å2 (absence of 
ligand) 
Experimental CCS, 




 565 ± 2 564 ± 8 
 [M+3H]
3+
 554 ± 6 546 ± 2 
 [D+4H]
4+
 857 ± 12 866 ± 5 
c-Myc-ZipΔDT [M+4H]
4+
 629 ± 4 632 ± 8 
 [M+3H]
3+
 595 ± 5 586 ± 4 
 [M+2H]
2+ 
453 ± 11 443 ± 8 
 [D+5H]
5+
 941 ± 8 950 ± 2 
c-Myc-Zip [M+4H]
4+
 711 ± 2 716 ± 9 
 [M+3H]
3+
 649 ± 3 633 ± 4 
 [M+2H]
2+
 479 ± 8 n/a 
 [D+5H]
5+
 1131 ± 5 1122 ± 8 
Figure A2.1: Experimental CCS for c-MYC-Zip, c-MYC-ZipΔDT and MAX-Zip monomers (M) and 


















Appendix 3: Lymphotactin equilibrium studies 
A3.1 Molecular dynamics simulations 
All molecular dynamics simulations were performed by Dr Massimilano Porrini and are 
described in brief below. Two independent MD runs in explicit solvent were conducted for 
the monomer Ltn10 (PDB 1J9O), using different initial velocities and the same starting 
structure coordinates. The simulation protocol implemented was as follows; the monomer 
was immersed in a truncated octahedron box, with minimum distance between one edge of 
the box and one atom of the solute of ~15 Å, the system was minimised, gradually heated up 
to 300 K, with density equilibrated at 300 K and 1 bar, a further 10 ns equilibration was run 
after which the 150 ns production run was carried out.  The force field implemented was 
Amber99SB-ILDN
3
 together with the model TIP3P
5
 for water molecules, the radial cut-off 
for the non-bonded interactions was 8 Å, a time step of 2.0 fs was utilised, with all the bonds 
involving hydrogen atoms kept at their equilibrium distance, and the trajectories were 
propagated with the module pmemd.cuda of Amber12
6
. During the heating and density 
equilibration the solute was kept restrained with a force constant of 0.5 kcal/mol/Å
2
. 
The net charge of Ltn10 at pH=7 is +9 therefore in order to study the species [MWT+7H]
7+
 
two basic residues have to be deprotonated, determined by calculating the pK1/2 values of all 
residues. In order to do this one structure was taken every 10 ns for 50 ns from the first 
simulation in explicit solvent, these were then submitted to the H++ webserver to calculate 
the pK1/2 values, the average for the five structures was then taken and showed that the lowest 
pK1/2 are those of Lys41 and Lys65 and hence these amino acids were deprotonated. Water 
molecules and counter-ions were stripped out from the last snapshot of the second simulation 
in water of Ltn10 and the two protons removed. The resulting [M+7H]
7+
 was firstly 
minimised, then gradually heated up to 300 K after which a constant temperature production 
run of 150 ns was carried out in vacuo. Along the heating and production dynamics a time 
step of 1.0 fs was implemented and an “infinite” (rcut=999 Å) radial cut-off was utilised for 
the non-bonded interactions. 
Next Ltn40 (PDB 2JP1) was considered, as with Ltn10 two independent trajectories in 
explicit solvent were first run. The PDB file contains 20 models as NMR candidate 
structures of the dimer in water. The first and the second model were utilised as starting 
coordinates for the two runs, applying the same simulation protocol as that implemented for 
the monomer, except production runs were 200 ns long. The net charge of the dimer Ltn40 at 




To select which acidic residue is most likely to be protonated, the pK1/2 values of each single 
acidic and basic residue belonging to the dimer were determined from 5 snapshots from the 
first 50 ns of the first simulation in water. This procedure shows that the weakest acidic 
moieties are the Glu3 of the chain A and hence this residue was protonated to form the 
[M+11H]
11+
 species for further study. Water molecules and counter-ions were stripped out 
from the last snapshot of the first simulation in water of Ltn40, following which the proton 
was added to the above glutamic acid. The resulting [D+11H]
11+
 was subjected to the same 
procedure of gas-phase MD as the monomer [M+7H]
7+
. 





. The command utilised was hbond imposing a radial cut-off between 
hydrogen bond donor and acceptor equal to 3 Å. The computation considered only the 
anionic carboxylate of acidic residues (Asp and Glu) and the cationic ammonium of basic 
residues (Lys and Arg). Occupancies of greater than 20 % were reported in each case.  
A3.2 WT Ltn solution studies 
 
Figure A3.1: Mass spectra obtained for 50 μM Ltn in 20 mM AmAc with A) 0 mM NaCl B) 1 mM 
NaCl C) 5 mM NaCl. For top panels all major species are labelled, in all other panels the highest and 








4+ 757 ± 4 
[MWT+5H]
5+ 967 ± 13 
[MWT+6H]
6+ 1021 ± 27 
[MWT+7H]
7+ 1100 ± 63 
[MWT+8H]
8+ 1528 ± 8 
[MWT+9H]
9+ 1560 ± 40 
[MWT+9H]
9+* 1685 
Table A3.1: The experimental CCS for all observed species of monomeric WT Ltn. *represents 
species observed in all repeats but only clearly resolvable in one. The average values obtained from 




4+ 856  ± 4 
[M1-72+5H]
5+ 916 ± 8 
[M1-72+6H]





7+ 1229 ± 12 
[M1-72+8H]
8+ 1416 ± 8 
[D1-72+8H]
8+
 1404 ± 6 
[D1-72+9H]
9+






 1751 ± 10 
[D1-72+11H]
11+
 1872 ± 4 
[D1-72+12H]
12+
 1861 ± 8 
Table A3.2: The experimental CCS for all observed species of monomeric WT 1-72 Ltn. *represents 
species observed in all repeats but only clearly resolvable in one. The average values obtained from 




8+ 1376 ± 25 
[DWT+9H]












Table A3.3: The experimental CCS for all observed species of dimeric WT Ltn. * represents species 
observed in all repeats but only clearly resolvable in one. The average values obtained from three 







A3.4 Ability of the structural core of Ltn (WT 1-72) to bind the ID tail 
(WT 72-93), as shown by mass spectrometry 
 
Figure A3.2: Mass spectra obtained at 50 μM in 20 mM AmAc for A) WT 72-93 B) WT 1-72 and C) 
1:1 mixture of WT 72-93 and WT 1-72 both at 50 μM. In all cases peaks corresponding to WT 72-93 











A3.5 MS spectra for WT Ltn acquired on the FT ICR-MS instrument used for 
ECD studies 
 
Figure A3.3: Mass spectra obtained on a 12T Apex Qe FTICR for WT Ltn A) Acquired from 
electrospray ionisation of 10 μM Ltn  in 100 mM ammonium acetate B) Acquired from nano-
electrospray ionisation of 30 μM Ltn in 100 mM ammonium acetate  
A3.6 Ltn10 salt bridge studies 
Residue 1 Residue 2 Run 1 
occupancy (%)  
Run 2 
occupancy (%) 
Glu30(OE2) Arg56(NH2) 52.15  
Glu30(OE1) Arg56(NH1) 48.53  
Glu30(OE1) Arg56(NH2) 45.17  
Asp6(OD2) Arg8(NH2) 41.52  
Glu30(OE2) Arg56(NH1) 36.65  
Asp6(OD2) Arg8(NE) 33.99  
Asp6(OD1) Arg8(NH2) 33.66  
Asp6(OD1) Arg8(NE) 31.26  
Asp57(OD2) Arg17(NH2) 26.75 32.94 
Asp6(OD1) Arg17(NH2) 23.65  
Asp6(OD2) Arg17(NH1) 21.14  
Glu3(OE2) Arg8(NH2)  48.91 
Glu3(OE1) Arg8(NH2)  45.02 
Glu3(OE1) Arg8(NE)  35.08 
Glu3(OE2) Arg8(NE)  32.05 
Asp57(OD1) Arg17(NH2)  28.83 
Asp57(OD1) Arg60(NH2)  26.40 
Asp57(OD2) Arg17(NH1)  24.93 
Asp57(OD1) Arg17(NH1)  21.07 





Residue 1 Residue 2 Occupancy 
(%) 
Asp63(OD2) Arg64(NE) 95.22 
Glu3(OE1) Arg8(NE) 732.21 
Asp57(OD1) Arg60(NH2) 66.24 
Glu3(OE2) Arg8(NH2) 61.87 
Asp57(OD2) Arg17(NH2) 59.46 
Asp57(OD2) Arg17(NH1) 55.95 
Asp57(OD1) Arg60(NE) 53.35 
Asp63(OD1) Arg64(NH2) 52.67 
Asp57(OD2) Arg60(NH2) 51.85 
Asp63(OD2) Arg64(NH2) 49.76 
Asp57(OD1) Arg17(NH1) 37.73 
Asp57(OD1) Arg17(NH2) 37.26 
Asp57(OD2) Arg60(NE) 35.17 
Glu3(OE1) Arg8(NH2) 34.59 
Table A3.5: Ltn10 [MWT+7H]
7+




Figure A3.4: Snapshots of the structure of Ltn10 taken every 2.5 ns over the 10 ns equilibrium period 
during the second simulation in water. 
 
 
Figure A3.5: A) Ltn10 [M + 7H]
7+
 at the end of the in vacuo simulation B) CCS of [M + 7H]
7+
with 
respect to time evolution along the 150 ns MD in vacuo. 
 
Visual inspection of the PDB file suggests the possibility of formation of an additional 
classical salt bridge between Glu30-Arg34 and Arg34-Asp49 and MD simulations in solvent 
support this possibility (Figure A3.6A) however this is present at lower occupancy (< 10%) 
than those listed in Tables A3.4 and A3.5. However this salt bridge can strengthen in the gas-
phase (Figure A3.6B), determined by selecting two structures one at 60 ns and one at 70 ns 






Figure A3.6: Distance between the centres of mass of the negative moiety of Glu30 side chain and 
positive moiety of Arg34 side chain (grey line) and between the centres of mass of the positive moiety 
of Arg34 side chain and negative moiety of Asp49 side chain (black line), as a function of time. A) 
For the first (bottom) and second (top) simulation in water. B) in vacuo simulations where, the starting 
structure was taken at 60 ns (top graph) and at 70 ns (bottom graph) of the second simulation of Ltn10 
in explicit water 
A3.7 WT Ltn [M+10H]10+ trapping time experiments. 
 
Figure A3.7: Percentage yields calculated for zIc, c and z type fragments as a function of cleavage site 
for [Mwt+10H]
10+




The decreased trapping time for [MWT+10H]
10+
 was enabled using different instrumental 
parameters than those used to obtain the fragmentation maps in Chapter 4 Section 4.3.3, and 
a concentration six times higher therefore differences in fragmentation maps could also be 
due to differences in instrumental settings, other than trapping times.  
A3.8 Ltn40 salt bridge studies 




Intra-chain A    
Asp49(OD1) Arg8(NE) 44.77  
Asp49(OD2) Arg8(NH2) 37.09  
Asp49(OD1) Arg8(NH2) 29.57  
Asp49(OD2) Arg8(NE) 27.12  
Asp49(OD2) Arg34(NH2) 23.87 42.60 
Asp49(OD1) Arg34(NH2)  39.55 
Asp49(OD2) Arg34(NE)  34.71 
Asp49(OD2) Lys7(NZ)  27.58 
Asp49(OD1) Arg34(NE)  27.19 
Intra-chain B    
Asp49(OD2) Arg34(NH2) 58.34 25.25 
Asp49(OD1) Arg8(NE) 51.83 22.99 
Asp49(OD2) Arg34(NE) 34.84 22.00 
Asp49(OD1) Arg8(NH2) 31.48 20.99 
Asp49(OD2) Arg8(NH2) 28.05  
Asp49(OD1) Arg34(NH2)  26.77 
Asp49(OD1) Arg34(NE)  25.67 
Asp49(OD2) Arg34(NE)  23.60 
Asp49(OD2) Arg8(NE)  23.09 
Asp57(OD1) Arg56(NH2)  22.21 
Asp57(OD1) Arg56(NE)  21.12 
Asp57(OD2) Arg56(NE)  20.92 
Asp6(OD1) Lys7(NZ)  20.84 
Inter-chain A,B    
Glu30(OE1) Arg22(NH2) 37.39 24.28 
Arg(NH1) Glu30(OE2) 33.15  
Glu30(OE2) Arg17(NH2) 32.51 76.75 
Glu30(OE2) Arg17(NH1) 32.31 31.40 
Arg22(NH2) Glu30(OE1) 32.05  
Arg22(NH2) Glu30(OE2) 29.24  
Glu30(OE2) Arg22(NE) 23.46  
Glu30(OE1) Arg22(NE) 23.18 54.11 
Glu30(OE2) Arg22(NH2) 21.78 56.46 
Arg22(NH1) Glu30(OE1) 21.68  
Lys24(NZ) Glu30(OE2)  42.60 
Lys24(NZ) Glu30(OE1)  38.28 
Glu30(OE1) Lys24(NZ)  24.35 








Residue 1 Residue 2 Occupancy (%) 
Intra-chain A   
Asp49(OD2) Arg8(NH2) 49.48 
Asp49(OD2) Arg8(NE) 48.80 
Asp49(OD1) Arg34(NH2) 48.62 
Asp49(OD1) Arg8(NE) 48.32 
Asp49(OD2) Arg34(NH2) 48.28 
Asp49(OD1) Arg8(NH2) 45.81 
Asp49(OD1) Arg34(NE) 32.61 
Asp49(OD2) Arg34(NE) 30.81 
Intra-chain B   
Asp49(OD2) Arg34(NH2) 97.52 
Asp49(OD1) Arg8(NH2) 96.67 
Asp57(OD2) Arg56(NH2) 96.65 
Asp49(OD1) Arg8(NE) 95.11 
Asp6(OD2) Lys7(NZ) 93.90 
Asp49(OD2) Arg34(NE) 87.22 
Asp57(OD2) Arg56(NE) 82.91 
Inter-chain A,B   
Arg22(NH2) Glu30(OE1) 97.35 
Arg22(NH1) Glu30(OE2) 94.50 
Glu30(OE1) Lys24(NZ) 92.28 
Arg22(NE) Asp57(OD1) 91.41 
Arg22(NH2) Asp57(OD1) 89.83 
Asp57(OD2) Arg17(NH1) 86.65 
Arg42(NH2) Glu3(OE1) 86.91 
Arg17(NH2) Glu3(OE1) 85.19 
Glu30(OE2) Arg61(NH2) 84.16 
Glu30(OE2) Arg61(NH1) 83.63 
Glu30(OE1) Arg22(NE) 61.25 
Glu30(OE2) Arg22(NE) 50.72 
Arg17(NE) Glu3(OE2) 36.59 
Glu30(OE2) Arg22(NH2) 33.46 
Arg17(NE) Glu3(OE1) 24.75 
Table A3.7: Ltn40 salt bridge occupancies ≥ 20 % along the 200 ns MD trajectory in vacuo 
 
Figure A3.8: CCS of [D + 11H]
11+











CCS /Å2  
[MCC3+5H]
5+ 1012 ± 2 1023 ± 8 
[MCC3+6H]
6+ 1014 ± 3 1046 ± 15 
[MCC3+7H]
7+ 1163 ± 4 1252 ± 30 
[MCC3+8H]
8+ 1243 ± 5 1439 ± 25 
[MCC3+9H]
9+  1498 ± 10 
[MCC3+10H]
10+ 
  1622 ± 17 
[MCC3+11H]
11+  1697 ± 1 
[MCC3+12H]
12+ 
  1757 ± 28 
[MCC3+13H]
13+  1824 ± 6 
[DCC3+9H]
9+ 1611 ± 2  
[DCC3+10H]
10+ 
 1802 ± 5  
Table A3.8: The experimental CCS for all observed species of monomeric CC3, obtained from 
buffered and ‘supercharged’ solution conditions. The average values obtained from three different day 
repeats are reported here and errors are reported as the standard deviation between these. 
 
A3.10: W55D solution studies 
 
Figure A3.9: W55D Ltn mass spectra for 50 μM Ltn. A) buffer strength from 0-150 mM AmAc, B) 20 
mM AmAc at pH 2.8-9.8, altered through addition of formic acid or ammonia. For top panels all 
major species are labelled, in all other panels the highest and lowest charge states for monomer and 








4+ 778 ± 8 
[MW55D+5H]
5+ 839 ± 7 
[MW55D+6H]
6+ 1057 ±12 
[MW55D+7H]
7+
 1150 ± 26 
[MW55D+8H]
8+
 1401 ± 6 
[MW55D+9H]
9+
 1407 ± 9 
[DW55D+8H]
8+ 
 1509 ± 6 
[DW55D+9H]
9+  1641 ± 8 
[DW55D+ 9H]
9+*  1674 
[DW55D+10H]









 2062 ± 8 
[DW55D+13H]
13+  2103 ± 67 
[DW55D+13H]
13+
 2237 ± 95 
[DW55D+14H]




16+ 2519 ± 12 
Table A3.9: The experimental CCS for all observed species of W55D. * represents species observed 
in all repeats but only clearly resolvable in one.  The average values obtained from three repeats are 



















Appendix 4: Ltn:GAG binding studies 
A4.1 Images of n-ESI capillaries 
 
Figure A4.1: Images of n-ESI of 1:1 solutions of Ltn plus Fx at 50 μM concentration in 20 mM 
AmAc. A) W55D and B) WT 1-72 Ltn. 
A4.2 Studies into WT Ltn:GAG binding 
 
Figure A4.2: Spectra obtained for isolated species (top) and after CID (bottom) for A) 
[MWT+Fx+5H]
5+
 and B) [MWT+Fx+6H]
6+
. Acquired from a 1:1 (Ltn:Fx) solution prepared at 50  μM 





WT Ltn Monomer (MWT) 10172.6 10171.4 
WT Ltn Dimer (DWT) 20345.2 20344.6 
WT Ltn Monomer + Fx (MWT+Fx) 11680.8 11680.2 
WT Ltn Dimer + Fx (DWT+Fx) 21853.4 21851.9 
WT Ltn Dimer +2 Fx (DWT+2Fx) 23361.6 23360.7 
Table A4.1: Expected and observed masses for all WT Ltn and WT Ltn+Fx complexes, averaged over 
all observed charge states in the spectra in Chapter 5 Figure 5.2B. The expected mass of fully desalted 









5+ 845 ± 27 
[MWT+Fx+6H]
6+ 1004 ± 8 
[MWT+Fx+7H]
7+ 1247 ± 54 
[DWT+Fx+9H]
9+ 1530 ± 1 
[DWT+Fx+10H]
10+
 1602 ± 7 
[DWT+2Fx+8H]
8+ 1426 ± 31 
[DWT+2Fx+9H]
9+ 1591 ± 37 
[DWT+2Fx+10H]
10+* 1651 
Table A4.2: The experimental CCS for all observed Fx bound species of WT Ltn. 
*
 represents species 
observed in all repeats but only resolvable in one. The average values obtained from three different 
day repeats are reported here and errors are reported as the standard deviation between these. 
 
Figure A4.3: Representative TEM images obtained for A) WT Ltn and B) Foundaparinux. Each 
prepared at 50 µM concentration in 20 mM AmAc. 
A4.3 Studies into WT 1-72 Ltn:GAG binding 
 
Figure A4.4: Spectra obtained for a 1:1 mixture of WT 1-72 plus Fx, at 50 μM protein concentration 









WT 1-72 Ltn Monomer (M1-72) 8111.3 8111.6 
WT 1-72 Ltn Dimer (D1-72) 16222.6 16223.9 
WT 1-72 Ltn Monomer + Fx (M1-72+Fx) 9619.5 19618.2 
WT 1-72 Ltn Dimer + Fx (D1-72+Fx) 17730.8 17730.4 
WT 1-72 Ltn Dimer +2 Fx (D1-72+2Fx) 19239.0 19239.21 
Table A4.3: Expected and observed masses for all WT 1-72 Ltn and WT 1-72 Ltn+Fx complexes, 
averaged over all observed charge states in the spectra in Chapter 5 Figure 5.6B. The expected mass 





 946  
[M1-72+Fx+5H]
5+ 995 ± 16 
[M1-72+Fx+6H]
6+ 1232 ± 46 
[D1-72+Fx+7H]
7+ 1403 ± 25 
[D1-72+Fx+7H]
7+ 1660 ± 12 
[D1-72+Fx+8H]
8+ 1420 ± 19 
[D1-72+Fx+8H]
8+
 1788 ± 5 
[D1-72+Fx+9H]
9+ 1624 ± 20 
[D1-72+Fx+9H]
9+ 1884 ± 48 
[D1-72+Fx+9H]
9+ 2153 ± 24 
Table A4.4: The experimental CCS for all observed Fx bound species of WT 1-72 Ltn. 
*
 represents 
species observed in all repeats but only resolvable in one. The average values obtained from three 
different day repeats are reported here and errors are the standard deviations between these. 
 
Figure A4.5: Spectra obtained for WT 1-72 plus WT 72-93 plus Fx in 20 mM AmAc A) prepared at a 
1:1:1 ratio at 50 µM concentration B) prepared at a 2:2:1 (1-72:72-93:Fx) ratio at 50 µM WT 1-72 
concentration C) prepared at a 2:2:1 (1-72:72-93:Fx) ratio at 25 µM WT 1-72 concentration D) 





Figure A4.6: Zoom in of the 1250-3500 m/z region of the spectra obtained for WT 1-72 plus 
WT 72-93 plus Fx in 20 mM AmAc, as shown in Figure A3.6 A) prepared at a 1:1:1 ratio at 50 µM 
concentration B) prepared at a 2:2:1 (1-72:72-93:Fx) ratio at 50 µM WT 1-72 concentration C) 
prepared at a 2:2:1 (1-72:72-93:Fx) ratio at 25 µM WT 1-72 concentration D) prepared at a 4:4:1 
(1-72:72-93:Fx) ratio at 25 µM WT 1-72 concentration.  





CC3 Monomer (MCC3) 10183.6 10184.1 
CC3 Dimer (DCC3) 20367.2 23068.0 
CC3 Monomer + Fx (MCC3+Fx) 11691.8 11692.7 
CC3 Dimer + Fx (DCC3+Fx) 21875.4 21876.3 
CC3 Dimer +2 Fx (DCC3+2Fx) 23383.6 23384.7 
Table A4.5: Expected and observed masses for CC3 and CC3+Fx complexes, averaged over all 
observed charge states in the spectra in Chapter 5 Figure 5.10B. The expected mass of fully desalted 





 833 ± 7 
[MCC3+Fx+6H]
6+ 1075 ± 21 
[MCC3+Fx+7H]
7+ 1105 ± 13 
[DCC3+Fx+8H]
8+
 1424 ± 28 
[DCC3+Fx+9H]
9+ 1524 ± 16 
[DCC3+Fx+10H]
10+ 1716 ± 4 
[DCC3+2Fx+8H]
8+
 1423  
[DCC3+2Fx+9H]
9+ 1624 ± 13 
[DCC3+2Fx+10H]
10+ 1712 ± 5 
Table A4.6: The experimental CCS for all observed Fx bound species of CC3. The average values 






Figure A4.7: Spectra obtained for isolated species (top) and after CID (bottom) for A) 
[MCC3+Fx+5H]
5+
 and B) [MCC3+Fx+6H]
6+
. Acquired from a 1:1 (Ltn:Fx) solution prepared at 50  μM 
protein concentration in 20 mM AmAc. Where X represents (SO3). 
A4.5 Studies into W55D:GAG binding 
 
Figure A4.8: Spectra obtained for isolated species (top) and after CID (bottom) for [DW55D+Fx+9H]
9+
. 
Acquired from a 1:1 (Ltn:Fx) solution prepared at 50  μM protein concentration in 20 mM AmAc. 






Figure A4.9: Spectra obtained for isolated species (top) and after CID (bottom) for A) 
[MW55D+Fx+5H]
5+
 and B) [MW55D+Fx+6H]
6+
. Acquired from a 1:1 (Ltn:Fx) solution prepared at 





W55D Monomer (MW55D) 10294.7 10295.1 
W55D Ltn Dimer (DW55D) 20589.4 20590.3 
W55D Ltn Monomer + Fx (MW55D+Fx) 11802.9 11803.5 
W55D Ltn Dimer + Fx (DW55D+Fx) 22097.6 22098.9 
W55D Ltn Dimer +2 Fx (DW55D+2Fx) 23605.8 23606.6 
Table A4.7: Expected and observed masses for all W55D and W55D+Fx complexes, averaged over 
all observed charge states in the spectra in Chapter 5 Figure 5.13B. The expected mass of fully 





 1162 ± 22 
[MW55D+Fx+6H]
6+ 1173 ± 37 
[MW55D+Fx+7H]
7+
 1253 ± 31 
[DW55D+Fx+9H]
9+
 1651 ± 35 
[DW55D+Fx+10H]
10+ 1874 ± 26 
[DW55D+Fx+11H]






10+ 1778 ± 39 
[DW55D+2Fx+11H]




Table A4.8: The experimental CCS for all observed Fx bound species of W55D. 
*
 represents species 
observed in all repeats but only resolvable in one. The average values obtained from three different 






A4.6 Studies into arginine Ltn mutants 
 
Figure A4.10: Spectra obtained for A) R23A , B) R43A and C) R23A/R43A. In all cases spectra were 





R23A Monomer (MR23A) 10085.6 10085.4 
R23A Dimer (DR23A)
 20171.2 20170.8 
R23A Monomer+Fx (MR23A+Fx) 11593.8 11593.0 
R23A Dimer+Fx (DR23A+Fx) 21679.4 21679.6 
R23A Dimer+2Fx(DR23A+2Fx)
 23187.6 23187.6 
R43A Monomer (MR43A) 10085.6 10085.7 
R43A Dimer (DR43A)
 20171.2 20170.2 
R43A Monomer+Fx (MR43A+Fx) 11593.8 11594.6 
R43A Dimer+Fx (DR43A+Fx) 21679.4 21680.4 
R43A Dimer+2Fx(DR43A+2Fx)
 23187.6 23189.0 
R23A/R43A Monomer (MR23A/R43A) 10099.5 10099.5 
R23A/R43A Dimer (DR23A/R43A)
 20199.0 20200.4 
R23A/R43A Monomer+Fx (MR23A/R43A+Fx) 11607.19 11608.3 
R23A/R43A Dimer+Fx (DR23A/R43A+Fx) 21707.2 21707.9 
R23A/R43A Dimer+2Fx (DR23A/R43A+2Fx) 23215.4 23216.5 
R23A/R43A Trimer+Fx (TR23A/R43A+Fx) 31806.7 31805.8 
R23A/R43A Trimer+2Fx (TR23A/R43A+2Fx) 33314.9 33315.7 
R23A/R43A Tetramer+2Fx(TER23A/R43A+2Fx)
 43414.4 43414.9 
R23A/R43A Tetramer+3Fx(TER23A/R43A+3Fx) 44922.6 44924.5 
Table A4.9: Expected and observed masses for all arginine mutant complexes, averaged over all 
observed charge states in the spectra in Chapter 5 Figure 5.17. The expected mass of fully desalted 




Appendix 5: HBD:GAG binding studies 
A5.1 Molecular dynamics simulations 
In order to study the conformation adopted by the dimeric HBD2 plus Fx (DHBD2+Fx) 
complex and to determine its theoretical CCS a theoretical study was undertaken, all 
calculations were performed by Dr Massimilano Porrini. The structure of Fx was taken from 
the PDB file of its complex with Antithrombin-S195A factor Xa (PDB 2GD4). Fx 
coordinates were taken from this PDB file and GLYCAM06 force field nomenclature was 
mapped onto them.
8
  Sulfate groups were then attached at the correct N- and O- positions, 
topology paramaters and coordinate files were then created with the tleap module of 
Amber11.
9
 The initial coordinates for HBD2 were taken from the crystal structure of the 
dimer (PDB 1FD3). Hydrogen atoms were added using tleap and the protonation states of 
the acidic and basic residues were assigned based on a solution pH of 7.  
To create the complex the HBD2 dimer and Fx molecule were docked using Autodock 4.2 
software
10
 to predict the initial structure of the carbohydrate-protein complex. Autodock 4.2 
features the implementation of flexible docking, allowing the rotation around diverse bonds. 
In the docking procedure used here all the bonds other than the glycosidic ones were allowed 
to rotate.  
For determination of theoretical CCS monomer, dimer and complex structures were firstly 
minimised in vacuo with an “infinite” (999 Å) radial cut-off for the non-bonded interactions, 
and then gradually heated up to 300K, using a 1 fs time-step. The Amber99SB-ILDN
3
 force 
field was used for the monomeric and dimeric species whilst the GLYCAM06
8
 force field 
was used for pentasaccharide calculations. All MD simulations were run using the NAMD 
2.9
11
 simulation software. In all cases bonds involving hydrogen atoms were constrained at 
their equilibrium values using SHAKE algorithm.  
For the dimeric simulations, in order to prevent the dissociation of the two monomers 
composing the dimer, a restraining harmonic potential was applied between the centres of 
mass of the monomers, with an equilibrium distance value equal to r0=12.93 Å. This 
equilibrium distance is the average distance between the centres of mass of the two 
monomers determined from an 1 ns simulation of the dimer in water. A force constant of 
10 kcal/mol/Å
2 
was applied in order to keep the monomers together but to enable the dimer 
to explore the conformational space.   
In vacuo production runs of 10 ns were carried out at constant temperature (300 K), with a 1 




the trajectory method of MOBCAL
1
 one computation each 100 ps of the simulation time, for 
a total of 100 values. 
A5.2 HBD2 plus Fx 
Species Expected mass (Da) Observed mass (Da) 
HBD2 Monomer (MHBD2) 4328.2 4327.4 
HBD2 Dimer (DHBD2) 8656.5 8657.9 
HBD2 Trimer (THBD2) 12984.6 12987.1 
HBD2 Dimer + Fx (DHBD2+Fx) 10164.7 10165.9 
Table A5.1: Expected and observed masses for all HBD2 and HBD2+Fx complexes, averaged over all 
observed charge states in the spectra in Chapter 6 Figure 6.2. The expected mass of fully desalted and 
protonated Fx is 1508.19 Da.  
 
Figure A5.1: Spectra obtained for isolated species (top) and after CID (bottom) for A) 
[DHBD2+Fx+6H]
6+
 and B) [DHBD2+Fx+5H]
5+
. Acquired from a 1:1 (HBD2:Fx) solution prepared at 50  




(absence of Fx) /Å2 
[MHBD2+3H]
3+
 582 ± 8 590 
[MHBD2+4H]
4+ 589 ± 5 595 
[MHBD2+5H]
5+
 641 ± 7 623 
[MHBD2+6H]
6+
 683 ± 8 675 
[DHBD2+6H]
6+
 928 ± 13 937 
Table A5.2: Experimental CCS for all HBD2 monomeric and dimeric species, determined in the 
presence of Fx. The average values obtained from three different day repeats are reported here and 
errors are the standard deviations between these. Experimental values obtained from the single repeat 








 964 ± 6 
[DHBD2+Fx+6H]
6+
 1023 ± 9 
[DHBD2+Fx+7H]
7+ 1029 ± 3 
[DHBD2+Fx+7H]
7+
 1070 ± 7 
[TEHBD2+2Fx+10H]
7+
 1649 ± 17 
Table A5.3: The experimental CCS for all HBD2+Fx complex species. The average values obtained 
from three different day repeats are reported here and errors are the standard deviations between these. 
 
Figure A5.2: Mass spectra obtained following ECD on the 12T Apex Qe FTICR for HBD2 plus Fx 
expanded view to show ECD fragments, inserts show full range spectra. Acquired using nano-
electrospray ionisation of a 1:1 sample solution of HBD2 plus Fx prepared at 30 μM peptide 
concentration in 20 mM AmAc. A) isolation of [DHBD2+Fx+5H]
5+ 







 593 ± 11 
[MHBD2+5H]
5+
 661 ± 13 
[MHBD2+6H]
6+ 698 ± 10 
[MHBD2+7H]






 1022 ± 7 
[DHBD2+Fx+7H]
7+
 1064 ± 6 
[DHBD2+Fx+8H]
8+
 1175 ± 24 
[DHBD2+Fx+9H]
9+ 1256 ± 15 
Table A5.4: The experimental CCS for all ‘supercharged’ HBD2 monomeric and dimeric species in 
addition to HBD2+Fx complex species. The average values obtained from three different day repeats 
are reported here and errors are the standard deviations between these.
 *
 represents species observed in 





Figure A5.3: Spectra obtained for 1:1 sample solution of HBD2 plus Fx prepared in 20 mM AmAc + 
1% m-NBA. A) 50 µM peptide concentration on the DT IM-MS instrument B) 30 μM peptide 
concentration on the 12T Apex Qe FTICR instrument. 
 
Figure A5.4: Mass spectra obtained following ECD on the 12T Apex Qe FTICR for HBD2 plus Fx 
zoomed in to show ECD fragments, inserts show full range spectra. Acquired using nano-electrospray 
ionisation of a 1:1 sample solution of HBD2 plus Fx prepared at 30 μM peptide concentration in 20 
mM AmAc + 1% m-NBA. A) isolation of [DHBD2+Fx+7H]
7+







Figure A5.5: Percentage yields calculated for zic, c- and z-type ragments as a function of cleavage site 
















HBD3 Monomer (MHBD3) 5155.2 5155.9 
HBD3 Dimer (DHBD3) 10310.4 10311.7 
HBD3 Monomer + Fx (MHBD3+Fx) 6663.4 6664.6 
HBD3 Dimer + Fx (DHBD3+Fx) 11818.6 11820.6 
HBD3 Dimer +2 Fx (DHBD3+2Fx) 13326.8 13327.7 
HBD3 Trimer + Fx (THBD3+Fx) 16973.8 16975.3 
HBD3 Trimer + 2Fx (THBD3+2Fx) 18482.0 18483.6 
HBD3 Tetramer + 3Fx (THBD3+2Fx) 25145.3 25147.7 
HBD3 Pentamer + 4Fx (PHBD3+2Fx) 31808.7 31811.9 
Table A5.5: Expected and observed masses for all HBD3 and HBD3+Fx complexes, averaged over all 
observed charge states in the spectra in Chapter 6 Figures 6.7 and 6.8. The expected mass of fully 
desalted and protonated Fx is 1508.19 Da.  
 
Figure A5.6: Spectra obtained for isolated species (top) and after CID (bottom) for A) 
[DHBD3+Fx+6H]
6+
 and B) [DHBD3+Fx+7H]
7+
. Acquired from a 2:1 (HBD3:Fx) solution prepared at 50 





(absence of Fx) 
[MHBD3+4H]
4+
 746 ± 15 758 
[MHBD3+5H]
5+ 760 ± 9 770 
[MHBD3+6H]
6+* 796 804 
[DHBD3+8H]
8+*
 1164 n/a 
Table A5.6: The experimental CCS for all HBD3 monomeric and dimeric species, determined in the 
presence of Fx. The average values obtained from three different day repeats are reported here and 
errors are the standard deviations between these. Experimental CCS determined from a single repeat 






Theoretical  CCS 




 538 ± 20 571 
[MHBD3+Fx+4H]
4+
 767 ± 27  
[MHBD3+Fx+5H]
5+
 854 ± 4  
[DHBD3+Fx+5H]
5+
 953 ± 21 806 
[DHBD3+Fx+6H]
6+
 1174 ± 27  
[DHBD3+Fx+7H]
7+
 1265 ± 11  
[DHBD3+Fx+8H]
8+
 1330 ± 14  
[DHBD3+2Fx+6H]
6+
 966 ± 22 868 
[DHBD3+2Fx+7H]
7+
 1187 ± 24  
[DHBD3+2Fx+8H]
8+
 1319 ± 89  
[DHBD3+2Fx+10H]
10+
 1470 ± 38  
[THBD3+Fx+7H]
7+
 1415 ± 41 1006 
[THBD3+Fx+8H]
8+
 1544 ± 14  
[THBD3+Fx+9H]
9+
 1707 ± 27  
[THBD3+2Fx+8H]
8+
 1560 ± 66 1060 
[THBD3+2Fx+9H]
9+
 1659  ± 50  
[THBD3+2Fx+10H]
10+
 1734 ± 28  
[TEHBD3+2Fx+10H]
10+
 1729 ± 17 1235 
[TEHBD3+2Fx+12H]
12+
 1941 ± 27  
[TEHBD3+2Fx+14H]
14+
 2218 ± 70  
[TEHBD3+2Fx+16H]
16+ 2256 ± 93  
[TEHBD3+3Fx+11H]
11+
 1932 ± 44 1283 
[TEHBD3+4Fx+14H]
14+
 2171 ± 38 1330 
[PHBD3+3Fx+11H]
11+*
 2289 1441 
[PHBD3+3Fx+12H]
12+
 2496 ± 8  
[PHBD3+4Fx+12H]
12+
 2468 ± 27 1485 
[PHBD3+4Fx+13H]
13+*
 2472  
[HHBD3+2Fx+14H]
14+
 2484 ± 18 1546 
[HHBD3+2Fx+16H]
16+
 2809 ± 93  
[HHBD3+2Fx+18H]
18+
 2886 ± 87  
[HHBD3+4Fx+16H]
16+ 2864 ± 42 1631 
[HHBD3+4Fx+18H]
18+
 3030 ± 73  
[HHBD3+4Fx+20H]
20+
 3083 ± 45  
[OHBD3+6Fx+22H]
22+
 3355 ± 99 1978 
[DEHBD3+6Fx+24H]
24+*
 4808 2225 
[DEHBD3+6Fx+26H]
26+*
 4814 2295 
[DEHBD3+8Fx+24H]
24+
 4465 ± 64  
Table A5.7: The experimental CCS for all HBD3+Fx complex species.
 *
 represents species observed 
in all repeats but only resolvable in one.  The average values obtained from three different day repeats 
are reported here and errors are the standard deviations between these. Theoretical CCS were 
determined as described in Chapter 6 section 6.3.3.3 based on a sphere of constant protein density.   
Where, monomeric (M), dimeric (D), trimeric (T), tetrameric (TE) pentameric (P), hexameric (H), 






Figure A5.7: Average CCS determined for three repeats of all HBD3 plus Fx complexes, plotted as 
charge state versus CCS. Error bars represent the standard deviation between three repeats.  
 
Figure A5.8: Representative TEM images for 65 µM HBD3 in 20 mM AmAc, stained with uranyl 
acetate 





HBD2+HBD3 (MHBD3+MHBD3) 9483.4 9482.2 
2HBD2+HBD3 (DHBD3+MHBD3) 13811.6 13810.3 
3HBD2+HBD3 (THBD3+MHBD3) 18139.8 18138.1 
HBD2+2HBD3 (MHBD3+DHBD3) 14638.6 14637.5 




Table A5.8: Expected and observed masses for all HBD2+HBD3 and HBD2+HBD3+Fx complexes, 
averaged over all observed charge states in the spectra in Chapter 6 Figures 6.11 and 6.12. The 






Figure A5.9: Mass spectrum of HBD2 plus BPTI A) prepared at a 1:1 ratio at 50 µM concentration B) 
HBD2 plus BPTI plus Fx prepared at 1:1:2 ratio at a 50 μM total protein concentration plus 50 μM Fx. 
In both cases samples were prepared in 20 mM AmAc.  
Species Experimental 
CCS /Å2 
Experimental CCS /Å2 
(determined in the 
presence of Fx) 
[MHBD2+MHBD3+4H]
4+*
 1115  
[MHBD2+MHBD3+5H]
5+ 1034 ± 18 1038 ± 23 
[MHBD2+MHBD3+6H]
6+
  1068 ± 5 1059 ± 22 
[MHBD2+DHBD3+7H]
7+
 1527 ± 4  
[MHBD2+DHBD3+8H]
8+
 1639 ± 21  
[DHBD2+MHBD3+6H]
6+
 1362 ± 24  
[DHBD2+MHBD3+7H]
7+
 1252 ± 31  
[THBD2+MHBD3+8H]
8+ 1948 ± 24  
[THBD2+MHBD3+9H]
9+* 1682  
[THBD2+MHBD3+9H]
9+ 1929 ± 16  
[DHBD2+DHBD3+8H]
8+* 1871  
[TEHBD2+DHBD3+12H]
12+
 2421 ± 47  
Table A5.9: The experimental CCS for all HBD2 plus HBD3 complex species. 
*
 represents species 
observed in all repeats but only resolvable in one. The average values obtained from three different 
day repeats are reported here and errors are the standard deviations between these. Peptide monomer 











CCS/ Å2  
Experimental CCS/ 
Å2 (determined from 
mixed peptide 
sample) 
HBD2   
[MHBD2+3H]
3+
 582 ± 8 593±6 
[MHBD2+4H]
4+ 589 ± 5 594±8 
[MHBD2+5H]
5+
 641 ± 7 623±12 
[MHBD2+6H]
6+
 683 ± 8 669±8 
[DHBD2+6H]
6+
 928 ± 13 n/a 
HBD3   
[MHBD3+4H]
4+
 746 ± 15 732±13 
[MHBD3+5H]
5+ 760 ± 9 750±22 
[MHBD3+6H]
6+* 796 799±6 
[DHBD3+8H]
8+*
 1164 n/a 
Table A5.10: The experimental CCS for all HBD2 plus HBD3 complex species. 
*
 represents species 





 1130 ± 29 
[MHBD2+MHBD3+Fx+6H]
6+ 1131 ± 9 
[MHBD2+MHBD3+Fx+7H]
7+ 1428 ± 43 
[MHBD2+MHBD3+Fx+7H]
7+





8+* 1301 ± 5 
[MHBD2+DHBD3+Fx+9H]
9+ 1573 ±35 
[MHBD2+DHBD3+Fx+9H]
9+ 2163 ± 27 
[DHBD2+DHBD3+Fx+10H]
10+ 1859 ± 45 
Table A5.11: The experimental CCS for all HBD2 plus HBD3 plus Fx complex species. The average 
values obtained from three different day repeats are reported here and errors are the standard 
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